


**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2021**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2021

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41th EDITION

**Cumulative Supplement 9
September 2021**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

**CUMULATIVE SUPPLEMENT 9
SEPTEMBER 2021**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

AUROBINDO PHARMA LTD
(AUROBINDO PHARMA LTD)

AKORN INC
(AKORN)

AKORN INC
(AKORN INC)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

EUGIA PHARMA SPECIALITIES LTD
(EUGIA PHARMA)

AKORN OPERATING CO LLC
(AKORN)

AKORN OPERATING CO LLC
(AKORN)

PADDOCK LABORATORIES LLC (PADDOCK LABS LLC)	PADAGIS US LLC (PADAGIS US)
PADDOCK LABORATORIES LLC (PADDOCK LLC)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO OF TENNESSEE INC (PERRIGO CO)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO TENNESSEE INC (PERRIGO CO TENNESSEE)	PADAGIS US LLC (PADAGIS US)
PERRIGO NEW YORK INC (PERRIGO NEW YORK)	PADAGIS US LLC (PADAGIS US)
PERRIGO PHARMA INTERNATIONAL DAC (PERRIGO PHARMA INTL)	PADAGIS US LLC (PADAGIS US)
PERRIGO UK FINCO LTD PARTNERSHIP (PERRIGO UK FINCO)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
PERRIGO ISRAEL PHARMACEUTICALS LTD (PERRIGO ISRAEL)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT)	HIKMA PHARMACEUTICALS USA INC (HIKMA PHARMS)
WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT)	HIKMA PHARMACEUTICALS USA INC (HIKMA PHARMS)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been

² Please consult the Active Section of the Orange Book for information on other strengths.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month

period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2020</u>	<u>MAR</u> <u>2021</u>	<u>JUN</u> <u>2021</u>	<u>SEP</u> <u>2021</u>	<u>DEC</u> <u>2021</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20478 (13.0%)	20726 (12.9%)	20916 (12.8%)	20919 2659 (12.7%)	
MULTISOURCE	17819 (87.0%)	18055 (87.1%)	18241 (87.2%)	18260 (87.3%)	
THERAPEUTICALLY EQUIVALENT	17746 (86.7%)	17990 (86.8%)	18175 (86.9%)	18114 (86.6%)	
NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)	66 (0.3%)	146 (0.7%)	
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)	54 (0.3%)	54 (0.3%)	
NEW MOLECULAR ENTITIES APPROVED	22	29	33	18	
NUMBER OF APPLICANTS	1185	1184	1182	1167	

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET; ORAL		ABIRATERONE ACETATE						
AB	AMNEAL PHARMS	500MG		A208327	002	Dec 23, 2020	Apr	NEWA
AB	QILU	500MG		A212462	002	Jun 25, 2021	Jun	NEWA

ACARBOSE

TABLET; ORAL		ACARBOSE						
AB	EMCURE PHARMS LTD	25MG		A202271	001	Feb 07, 2012	Apr	CMFD
AB		50MG		A202271	002	Feb 07, 2012	Apr	CMFD
AB		100MG		A202271	003	Feb 07, 2012	Apr	CMFD
	@ HANGZHOU ZHONGMEI	25MG		A213821	001	Aug 18, 2020	Aug	DISC
	@	50MG		A213821	002	Aug 18, 2020	Aug	DISC
	@	100MG		A213821	003	Aug 18, 2020	Aug	DISC

ACETAMINOPHEN

POWDER; INTRAVENOUS		ACETAMINOPHEN						
	+ @ MYLAN LABS LTD	1GM/VIAL		N206610	001	Jan 15, 2021	Jan	NEWA
SOLUTION; INTRAVENOUS		ACETAMINOPHEN						
	+! B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)		N204957	001	Feb 18, 2021	Feb	NEWA
	+!	1GM/100ML (10MG/ML)		N204957	002	Feb 18, 2021	Feb	NEWA
>A> AP	BAXTER HLTHCARE CORP	1GM/100ML (10MG/ML)		A214331	001	Sep 17, 2021	Sep	NEWA

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL		CODEINE, ASPIRIN, APAP FORMULA NO. 2						
	+ @ SCHERER LABS	150MG; 180MG; 15MG		A085640	001		Aug	CRLD
		CODEINE, ASPIRIN, APAP FORMULA NO. 3						
	+ @ SCHERER LABS	150MG; 180MG; 30MG		A085639	001		Aug	CRLD

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL		BUTALBITAL AND ACETAMINOPHEN						
AA	ALVOGEN	300MG; 50MG		A207635	001	Jun 05, 2017	Jun	CAHN
AA		325MG; 50MG		A205120	001	Oct 30, 2015	Jun	CAHN
	+ @ WATSON LABS	325MG; 50MG		A087550	001	Oct 19, 1984	Aug	CRLD
		PHRENILIN						
	+ @ VALEANT	325MG; 50MG		A087811	001	Jun 19, 1985	Aug	CRLD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
	+ @ GILBERT LABS	325MG; 50MG; 40MG		A088825	001	Dec 05, 1984	Aug	CRLD
AA	HAVIX	300MG; 50MG; 40MG		A214087	001	Aug 13, 2021	Aug	NEWA
AA		325MG; 50MG; 40MG		A214087	002	Aug 13, 2021	Aug	NEWA
AA	SENORES PHARMS	300MG; 50MG; 40MG		A214087	001	Aug 13, 2021	Aug	CAHN
AA		325MG; 50MG; 40MG		A214087	002	Aug 13, 2021	Aug	CAHN
AA	XSPIRE PHARMA	300MG; 50MG; 40MG		A206615	001	Aug 04, 2017	Feb	CAHN
TABLET; ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
AA	+ ACTAVIS LABS UT INC	325MG; 50MG; 40MG		A088616	001	Nov 09, 1984	Aug	CRLD
AA	ALVOGEN	325MG; 50MG; 40MG		A204984	001	Jan 10, 2017	Jun	CAHN
	@ GRANULES	325MG; 50MG; 40MG		A040864	001	Dec 01, 2008	Apr	CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE						
AB	NOSTRUM LABS INC	325MG; 50MG; 40MG; 30MG		A075929	001	Apr 22, 2002	Jan	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL		TREZIX						
	XSPIRE PHARMA	320.5MG; 30MG; 16MG		A204785	001	Nov 26, 2014	Jul	CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

+ @ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A 085861	001		Aug	CRLD
--------------------------	--------------------	----------	-----	--	-----	------

+ @ ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A 085057	001		Aug	CRLD
------------------------	--------------------	----------	-----	--	-----	------

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	NOSTRUM LABS INC	300MG;15MG	A 088629	002	Mar 06, 1985	Aug	CMS1
AA		300MG;30MG	A 088629	003	Mar 06, 1985	Aug	CMS1
AA	+	300MG;60MG	A 088629	001	Mar 06, 1985	Aug	CRLD
	+ @ PUREPAC PHARM	300MG;30MG	A 086681	001		Aug	CRLD
	+ @ SANDOZ	300MG;15MG	A 087433	001		Aug	CRLD
	+ @	300MG;30MG	A 085917	001		Aug	CRLD
	@ VINTAGE	300MG;15MG	A 089990	001	Sep 30, 1988	Apr	DISC
	@	300MG;30MG	A 089805	001	Sep 30, 1988	Apr	DISC
	@	300MG;60MG	A 089828	001	Sep 30, 1988	Apr	DISC
AA		300MG;60MG	A 089828	001	Sep 30, 1988	Apr	CAHN
	TYLENOL W/ CODEINE NO. 2						
	+ @ JANSSEN PHARMS	300MG;15MG	A 085055	002		Aug	CRLD
	TYLENOL W/ CODEINE NO. 3						
	+ @ JANSSEN PHARMS	300MG;30MG	A 085055	003		Aug	CRLD
	TYLENOL W/ CODEINE NO. 4						
	+ @ JANSSEN PHARMS	300MG;60MG	A 085055	004		Aug	CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

ANEXSIA 5/325

AA	! SPECGX LLC	325MG;5MG	A 040409	001	Oct 20, 2000	Apr	CHRS
----	--------------	-----------	----------	-----	--------------	-----	------

ANEXSIA 7.5/325

AA	! SPECGX LLC	325MG;7.5MG	A 040405	001	Sep 08, 2000	Apr	CHRS
----	--------------	-------------	----------	-----	--------------	-----	------

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ ALVOGEN	300MG;5MG	A 208540	001	Nov 08, 2018	Aug	CAHN
	@	300MG;7.5MG	A 208540	002	Nov 08, 2018	Aug	CAHN
	@	300MG;10MG	A 208540	003	Nov 08, 2018	Aug	CAHN
	@	325MG;2.5MG	A 209958	001	Oct 24, 2018	Aug	CAHN
	@	325MG;5MG	A 209958	002	Oct 24, 2018	Aug	CAHN
	@	325MG;7.5MG	A 209958	003	Oct 24, 2018	Aug	CAHN
	@	325MG;10MG	A 209958	004	Oct 24, 2018	Aug	CAHN
AA	! SPECGX LLC	325MG;10MG	A 040400	001	Jul 26, 2000	Apr	CHRS
	NORCO						
	@ APIL	325MG;2.5MG	A 040148	004	Jul 07, 2014	Apr	DISC
	@	325MG;5MG	A 040099	001	Jun 25, 1997	Apr	DISC
	@	325MG;5MG	A 040148	005	Jul 07, 2014	Apr	DISC
	@	325MG;7.5MG	A 040148	003	Sep 12, 2000	Apr	DISC
	@	325MG;10MG	A 040148	001	Feb 14, 1997	Apr	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE AND ACETAMINOPHEN

AA	! ABHAI LLC	325MG/5ML;5MG/5ML	A 211499	001	Dec 31, 2018	Aug	CTEC
AA	NOSTRUM LABS INC	325MG/5ML;5MG/5ML	A 201448	001	Aug 26, 2021	Aug	NEWA

TABLET;ORAL

OXYCODONE 5/APAP 500

+ @ BRISTOL MYERS SQUIBB	500MG;5MG	A 085911	001		Aug	CRLD
--------------------------	-----------	----------	-----	--	-----	------

OXYCODONE AND ACETAMINOPHEN

AA	CHARTWELL	325MG;5MG	A 207834	001	Aug 15, 2019	Jan	CAHN
AA		325MG;7.5MG	A 207834	002	Aug 15, 2019	Jan	CAHN
AA		325MG;10MG	A 207834	003	Aug 15, 2019	Jan	CAHN

PERCOCET

+ @ VINTAGE PHARMS LLC	325MG;5MG	A 085106	002		Aug	CRLD
------------------------	-----------	----------	-----	--	-----	------

ROXICET

+ @ HIKMA PHARMS	325MG;5MG	A 087003	001		Aug	CRLD
@	325MG;5MG	A 087003	001		Jan	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

AB	ACCORD HLTHCARE	500MG	A 207659	001	Oct 18, 2018	Apr	CMFD
AB	! INDICUS PHARMA	500MG	A 090779	001	Jul 14, 2011	Jun	CAHN

TABLET; ORAL

ACETAZOLAMIDE							
AB	APPCO	125MG	A211372	001	Feb 22, 2021	Feb	NEWA
AB		250MG	A211372	002	Feb 22, 2021	Feb	NEWA
AB	RUBICON	125MG	A215101	001	Aug 19, 2021	Aug	NEWA
AB		250MG	A215101	002	Aug 19, 2021	Aug	NEWA

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS; OTIC

DOMEBORO							
	+ @ BAYER PHARMS	2%;0.79%	A084476	001		Aug	CRLD

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE							
AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Apr	NEWA

ACITRETIN

CAPSULE; ORAL

ACITRETIN							
>D>	AB SIGMAPHARM LABS LLC	25MG	A204633	004	May 22, 2015	Sep	CHRS
>A>	AB !	25MG	A204633	004	May 22, 2015	Sep	CHRS
SORIATANE							
>D>	AB + STIEFEL LABS INC	10MG	N019821	001	Oct 28, 1996	Sep	DISC
>A>	AB + @	10MG	N019821	001	Oct 28, 1996	Sep	DISC
>D>	AB +!	25MG	N019821	002	Oct 28, 1996	Sep	DISC
>A>	AB + @	25MG	N019821	002	Oct 28, 1996	Sep	DISC

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR							
	+! ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012	Feb	CAHN

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION

DUAKLIR PRESSAIR							
	+! ASTRAZENECA	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun	CHRS
	+	0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Jun	CRLD
		0.4MG/INH;0.012MG/INH	N210595	001	Mar 29, 2019	Feb	CAHN

ACYCLOVIR

OINTMENT; TOPICAL

ACYCLOVIR							
	@ ANDA REPOSITORY	5%	A206437	001	Jul 31, 2017	Jun	DISC
AB	MACLEODS PHARMS LTD	5%	A212444	001	May 19, 2021	May	NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM							
AP	NAMIGEN LLC	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun	CAHN
AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan	CHRS
AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan	CPOT

ADAPALENE

GEL; TOPICAL

ADAPALENE							
>D>	AB TOLMAR	0.3%	A200298	001	Jun 14, 2012	Sep	DISC
>A>	AB @	0.3%	A200298	001	Jun 14, 2012	Sep	DISC

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE							
>D>	AB TOLMAR	0.1%;2.5%	A206164	001	May 23, 2018	Sep	DISC
>A>	AB @	0.1%;2.5%	A206164	001	May 23, 2018	Sep	DISC

ADENOSINE

SOLUTION; INTRAVENOUS

ADENOSINE							
AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb	CMFD
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb	CMFD

AIR POLYMER-TYPE AFOAM; INTRAUTERINE
EXEM FOAM KIT

+! GISKIT 10ML N212279 001 Nov 07, 2019 Aug CAHN

ALBENDAZOLETABLET; ORAL
ALBENDAZOLE

AB	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jan	NEWA
	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jan	DISC
AB	MSN	200MG	A213435	001	Jan 21, 2021	Jan	NEWA

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION
ALBUTEROL SULFATE

	@ PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Jul	CAHN
AB1	SANDOZ INC	EQ 0.09MG BASE/INH	A207085	001	Jun 01, 2021	May	NEWA

SOLUTION; INHALATION
ALBUTEROL SULFATE

	@ LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Aug	CAHN
	@	EQ 0.042% BASE	A211888	002	Apr 20, 2020	Aug	CAHN
AN		EQ 0.083% BASE	A206224	001	Oct 17, 2017	Aug	CAHN

TABLET; ORAL

ALBUTEROL SULFATE

>D>	AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep	CAHN
	AB		EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb	CMFD
>D>	AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep	CAHN
	AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb	CMFD
>A>	AB	APPCO	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep	CAHN
>A>	AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep	CAHN
	@ EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020	Apr	DISC	
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Apr	DISC	

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

>D>	AB	MYLAN	EQ 4MG BASE	A078092	002	Jan 29, 2007	Sep	DISC
>A>		@	EQ 4MG BASE	A078092	002	Jan 29, 2007	Sep	DISC
>D>		!	EQ 8MG BASE	A078092	001	Jan 29, 2007	Sep	DISC
>A>		@	EQ 8MG BASE	A078092	001	Jan 29, 2007	Sep	DISC
		VOSPIRE ER						
>D>	AB	DAVA PHARMS INC	EQ 4MG BASE	A076130	002	Sep 26, 2002	Sep	CTEC
>A>			EQ 4MG BASE	A076130	002	Sep 26, 2002	Sep	CTEC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

	@ AUROBINDO PHARMA LTD	EQ 0.083% BASE; 0.017%	A206532	001	Jul 08, 2020	Jan	DISC	
	@ LUOXIN AUROVITAS	EQ 0.083% BASE; 0.017%	A206532	001	Jul 08, 2020	Aug	CAHN	
>D>	AN	NEPHRON	EQ 0.083% BASE; 0.017%	A076749	001	Dec 31, 2007	Sep	CHRS
>A>	AN	!	EQ 0.083% BASE; 0.017%	A076749	001	Dec 31, 2007	Sep	CHRS

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

	@ JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun	DISC
	@	EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun	DISC
	@	EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun	DISC
	@	EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun	DISC
	@ US ANTIBIOTICS	EQ 5MG BASE	A079049	003	Aug 04, 2008	May	CAHN
	@	EQ 10MG BASE	A079049	004	Aug 04, 2008	May	CAHN
	@	EQ 35MG BASE	A079049	001	Aug 04, 2008	May	CAHN
	@	EQ 70MG BASE	A079049	002	Aug 04, 2008	May	CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

+	ORGANON	EQ 70MG BASE; 2,800 IU	N021762	001	Apr 07, 2005	Jun	CAHN
+	!	EQ 70MG BASE; 5,600 IU	N021762	002	Apr 26, 2007	Jun	CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTRUNA HCT

+ @	NODEN PHARMA	EQ 150MG BASE;12.5MG	N022107	001	Jan 18, 2008	May	DISC
+ @		EQ 150MG BASE;25MG	N022107	002	Jan 18, 2008	May	DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	CHARTWELL	100MG	A077353	001	Sep 08, 2005	Jun	CAHN
AB		300MG	A077353	002	Sep 08, 2005	Jun	CAHN

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

@	MYLAN	0.25MG	A074215	001	Jan 27, 1994	Jun	DISC
@		0.5MG	A074215	002	Jan 27, 1994	Jun	DISC
@		1MG	A074215	003	Jan 27, 1994	Jun	DISC
@		2MG	A074215	004	Jan 27, 1994	Jun	DISC
AB	NOVITIUM PHARMA	0.25MG	A074174	001	Oct 19, 1993	Apr	CMFD
AB		0.5MG	A074174	002	Oct 19, 1993	Apr	CMFD
AB		1MG	A074174	003	Oct 19, 1993	Apr	CMFD
AB		2MG	A074174	004	Oct 19, 1993	Apr	CMFD

ALPROSTADIL

INJECTABLE; INJECTION

CAVERJECT

+ @	PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan	CAHN
AP		0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan	CAHN
AP	+	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan	CAHN
AP	+	0.04MG/VIAL	N020379	004	May 19, 1997	Jan	CAHN

CAVERJECT IMPULSE

PFIZER

		0.01MG/VIAL	N021212	001	Jun 11, 2002	Jan	CAHN
--	--	-------------	---------	-----	--------------	-----	------

0.02MG/VIAL

			N021212	002	Jun 11, 2002	Jan	CAHN
--	--	--	---------	-----	--------------	-----	------

PROSTIN VR PEDIATRIC

AP	+	PFIZER	0.5MG/ML	N018484	001		Jan	CAHN
----	---	--------	----------	---------	-----	--	-----	------

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

>D>	AB	STRIDES PHARMA	100MG	A209047	001	Jun 07, 2017	Sep	CTEC
>A>	BX		100MG	A209047	001	Jun 07, 2017	Sep	CTEC

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

>D>	AA	INVATECH	50MG/5ML	A214178	001	Aug 20, 2021	Sep	CAHN
	AA		50MG/5ML	A214178	001	Aug 20, 2021	Aug	NEWA
>A>	AA	NOVELGENIX THERAPS	50MG/5ML	A214178	001	Aug 20, 2021	Sep	CAHN
	@	WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Jan	DISC

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

	@	INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Jan	DISC
>D>	AB	STRIDES PHARMA	100MG	A209035	001	Jun 09, 2017	Sep	CTEC
>A>	BX		100MG	A209035	001	Jun 09, 2017	Sep	CTEC

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+ @	ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan	CAHN
+ @		EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan	CAHN
+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan	CAHN
+ @		EQ 258MG BASE	N209410	003	Feb 16, 2018	May	DISC
+		EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan	CAHN
+ @	ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan	CAHN
+ @		EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan	CAHN
+		EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan	CAHN
+		EQ 258MG BASE	N209410	003	Feb 16, 2018	Jan	CAHN

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

>D>	AB	ANDA REPOSITORY	5MG	A204180	001	Aug 07, 2015	Sep	CAHN
>A>	AB	USPHARMA WINDLAS	5MG	A204180	001	Aug 07, 2015	Sep	CAHN

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ CHARTWELL RX

EQ 5MG ANHYDROUS; 50MG

A 073357 001 Nov 27, 1991 Aug CAHN

AMINOCAPROIC ACID

SOLUTION; ORAL

AMICAR

AA +! AKORN

0.25GM/ML

N 015230 002

Feb CPOT

AA +!

1.25GM/5ML

N 015230 002

Feb CDFR

AMINOCAPROIC ACID

AA AIRIS PHARMA PVT LTD

0.25GM/ML

A 213825 001 Apr 08, 2021

Apr NEWA

AA AMNEAL

0.25GM/ML

A 212780 001 Aug 23, 2019

Feb CPOT

AA 1.25GM/5ML

A 212780 001 Aug 23, 2019

Feb CDFR

AA BELCHER

0.25GM/ML

A 213825 001 Apr 08, 2021

Jul CAHN

AA LEADING PHARMA LLC

0.25GM/ML

A 214140 001 Jan 26, 2021

Feb CPOT

AA 1.25GM/5ML

A 214140 001 Jan 26, 2021

Feb CDFR

AA TULEX PHARMS INC

0.25GM/ML

A 212494 001 Aug 11, 2020

Feb CPOT

AA 1.25GM/5ML

A 212494 001 Aug 11, 2020

Feb CDFR

AA VISTAPHARM

0.25GM/ML

A 212814 001 Feb 26, 2020

Feb CPOT

AA 1.25GM/5ML

A 212814 001 Feb 26, 2020

Feb CDFR

SYRUP; ORAL

AMINOCAPROIC ACID

AA LEADING PHARMA LLC

1.25GM/5ML

A 214140 001 Jan 26, 2021

Jan NEWA

TABLET; ORAL

AMINOCAPROIC ACID

AB EDENBRIDGE PHARMS

500MG

A 212110 001 Jun 14, 2021

Jun NEWA

AB LEADING PHARMA LLC

500MG

A 213928 001 Feb 12, 2021

Feb NEWA

AB 1GM

A 213928 002 Feb 12, 2021

Feb NEWA

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLIN

+ @ GD SEARLE LLC

25MG/ML

A 087243 001 May 24, 1982

Aug CRLD

+ @

25MG/ML

A 087621 001 May 24, 1982

Aug CRLD

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

AP ACELLA

50MG/ML

A 077610 001 Oct 30, 2008

Aug CAHN

AP 50MG/ML

A 077834 001 Oct 30, 2008

Aug CAHN

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB RUBICON

100MG

A 078578 002 Feb 26, 2021

Feb NEWA

AB 400MG

A 078578 003 Feb 26, 2021

Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB MANKIND PHARMA

10MG

A 213999 001 Feb 19, 2021

Feb NEWA

AB 25MG

A 213999 002 Feb 19, 2021

Feb NEWA

AB 50MG

A 213999 003 Feb 19, 2021

Feb NEWA

AB 75MG

A 213999 004 Feb 19, 2021

Feb NEWA

AB 100MG

A 213999 005 Feb 19, 2021

Feb NEWA

AB 150MG

A 213999 006 Feb 19, 2021

Feb NEWA

@ MYLAN

10MG

A 086009 002

Jun DISC

@ 25MG

A 086009 003

Jun DISC

@ 50MG

A 086009 001

Jun DISC

@ 75MG

A 086009 004

Jun DISC

@ 100MG

A 086009 005

Jun DISC

@ 150MG

A 086009 006

Jun DISC

AB + SANDOZ

10MG

A 085968 004

Aug CRLD

AB + 50MG

A 085968 001

Aug CRLD

AB + 75MG

A 085968 006

Aug CRLD

AB + 100MG

A 085968 003

Aug CRLD

AB + 150MG

A 085968 005

Aug CRLD

UNICHEM

10MG

A 214548 001 May 19, 2021

May NEWA

AB 25MG

A 214548 002 May 19, 2021

May NEWA

AB 50MG

A 214548 003 May 19, 2021

May NEWA

AB 75MG

A 214548 004 May 19, 2021

May NEWA

AB 100MG

A 214548 005 May 19, 2021

May NEWA

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB 150MG A214548 006 May 19, 2021 May NEWA

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

@ WOCHKHARDT EQ 2.5MG BASE A078500 001 Sep 06, 2007 Jan DISC
 @ EQ 5MG BASE A078500 002 Sep 06, 2007 Jan DISC
 @ EQ 10MG BASE A078500 003 Sep 06, 2007 Jan DISC

>D> AMLODIPINE BESYLATE; CELECOXIB

>D> TABLET;ORAL

>D> CONSENSI

>D> + COEPTIS EQ 2.5MG BASE;200MG N210045 001 May 31, 2018 Sep DISC
 >A> + @ EQ 2.5MG BASE;200MG N210045 001 May 31, 2018 Sep DISC
 >D> + EQ 5MG BASE;200MG N210045 002 May 31, 2018 Sep DISC
 >A> + @ EQ 5MG BASE;200MG N210045 002 May 31, 2018 Sep DISC
 >D> +! EQ 10MG BASE;200MG N210045 003 May 31, 2018 Sep DISC
 >A> + @ EQ 10MG BASE;200MG N210045 003 May 31, 2018 Sep DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@ JUBILANT GENERICS EQ 5MG BASE;20MG A207450 001 May 15, 2017 Jun DISC
 @ EQ 5MG BASE;40MG A207450 002 May 15, 2017 Jun DISC
 @ EQ 10MG BASE;20MG A207450 003 May 15, 2017 Jun DISC
 @ EQ 10MG BASE;40MG A207450 004 May 15, 2017 Jun DISC

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP METHODIST 3.75mCi-260mCi/ML A215083 001 Jul 09, 2021 Jul NEWA
 AP NUKEMED 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A204455 001 Apr 23, 2015 Jan CAHN

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB CHARTWELL 250MG A062058 001 Jun CAHN
 AB 500MG A062058 002 Jun CAHN

AMOXIL

AB US ANTIBIOTICS 250MG A062216 001 May CAHN
 AB 500MG A062216 004 May CAHN

FOR SUSPENSION;ORAL

AMOXIL

AB US ANTIBIOTICS 50MG/ML A062226 005 May CAHN
 AB 125MG/5ML A062226 001 May CAHN
 + @ 200MG/5ML N050760 001 Apr 15, 1999 May CAHN
 AB 250MG/5ML A062226 002 May CAHN
 + @ 400MG/5ML N050760 002 Apr 15, 1999 May CAHN

LAROTID

AB US ANTIBIOTICS 125MG/5ML A062226 003 May CAHN
 AB 250MG/5ML A062226 004 May CAHN

TABLET;ORAL

AMOXIL

+ @ US ANTIBIOTICS 500MG N050754 002 Jul 10, 1998 May CAHN
 + @ 875MG N050754 001 Jul 10, 1998 May CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

>D> AB HIKMA 125MG A205274 001 Jun 25, 2020 Sep CTEC
 >A> BX 125MG A205274 001 Jun 25, 2020 Sep CTEC
 >D> AB 250MG A205274 002 Jun 25, 2020 Sep CTEC
 >A> BX 250MG A205274 002 Jun 25, 2020 Sep CTEC

AMOXIL

+ @ US ANTIBIOTICS 125MG N050542 002 May CAHN
 @ 200MG N050761 001 Apr 15, 1999 May CAHN
 + @ 250MG N050542 001 May CAHN
 @ 400MG N050761 002 Apr 15, 1999 May CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

		CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL							
		LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)							
	@	ANI PHARMS	500MG;500MG;30MG	A200218	001	Aug 30, 2013	Jul	CTNA	
	@		500MG;500MG;30MG	A200218	001	Aug 30, 2013	Jul	CPOT	
	@		500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A200218	001	Aug 30, 2013	Jul	CDFR	
AB	!	RISING	500MG;500MG;30MG	A206006	001	Oct 07, 2016	Jul	CTNA	
AB	!		500MG;500MG;30MG	A206006	001	Oct 07, 2016	Jul	CPOT	
AB	!		500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A206006	001	Oct 07, 2016	Jul	CDFR	
AB		SANDOZ INC	500MG;500MG;30MG	A202588	001	Mar 04, 2014	Jul	CTNA	
AB			500MG;500MG;30MG	A202588	001	Mar 04, 2014	Jul	CPOT	
AB			500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A202588	001	Mar 04, 2014	Jul	CDFR	
		PREVPAC (COPACKAGED)							
	+	@ TAKEDA PHARMS USA	500MG;500MG;30MG	N050757	001	Dec 02, 1997	Jul	CTNA	
	+	@	500MG;500MG;30MG	N050757	001	Dec 02, 1997	Jul	CPOT	
	+	@	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	N050757	001	Dec 02, 1997	Jul	CDFR	

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL
 OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

	+	@ CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	May	DISC	
--	---	---------------------	--	---------	-----	--------------	-----	------	--

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB		MICRO LABS LTD INDIA	200MG/5ML;EQ 28.5MG BASE/5ML	A205187	001	May 21, 2021	May	NEWA	
AB			400MG/5ML;EQ 57MG BASE/5ML	A205187	002	May 21, 2021	May	NEWA	
		AUGMENTIN '125'							
AB	+	US ANTIBIOTICS	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	May	CAHN	
		AUGMENTIN '200'							
	+	@ US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N050725	001	May 31, 1996	May	CAHN	
		AUGMENTIN '250'							
AB	+	! US ANTIBIOTICS	250MG/5ML;EQ 62.5MG BASE/5ML	N050575	002	Aug 06, 1984	May	CAHN	
		AUGMENTIN '400'							
	+	@ US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N050725	002	May 31, 1996	May	CAHN	
		AUGMENTIN ES-600							
AB	+	US ANTIBIOTICS	600MG/5ML;EQ 42.9MG BASE/5ML	N050755	001	Jun 22, 2001	May	CAHN	
		TABLET;ORAL							
		AUGMENTIN '250'							
	+	@ US ANTIBIOTICS	250MG;EQ 125MG BASE	N050564	001	Aug 06, 1984	May	CAHN	
		AUGMENTIN '500'							
	+	@ US ANTIBIOTICS	500MG;EQ 125MG BASE	N050564	002	Aug 06, 1984	May	CAHN	
		AUGMENTIN '875'							
AB	+	US ANTIBIOTICS	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	May	CAHN	
		TABLET, CHEWABLE;ORAL							
		AUGMENTIN '125'							
	+	@ US ANTIBIOTICS	125MG;EQ 31.25MG BASE	N050597	001	Jul 22, 1985	May	CAHN	
		AUGMENTIN '200'							
	+	@ US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726	001	May 31, 1996	May	CAHN	
		AUGMENTIN '250'							
	+	@ US ANTIBIOTICS	250MG;EQ 62.5MG BASE	N050597	002	Jul 22, 1985	May	CAHN	
		AUGMENTIN '400'							
	+	@ US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726	002	May 31, 1996	May	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		AUGMENTIN XR							
	+	@ US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785	001	Sep 25, 2002	May	CAHN	

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

>D>		ADZENYS ER							
>D>	+	! NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017	Sep	DISC	
>A>	+	@	EQ 1.25MG BASE/ML	N204325	001	Sep 15, 2017	Sep	DISC	

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	2.5MG; 2.5MG; 2.5MG; 2.5MG	A213111	003	Jan 13, 2021	Jan	NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A213111	005	Jan 13, 2021	Jan	NEWA
AB		5MG; 5MG; 5MG; 5MG	A213111	006	Jan 13, 2021	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214959	001	Sep 29, 2021	Sep	NEWA
>A>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Sep	NEWA
>A>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Sep	NEWA
>A>	AB		5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Sep	NEWA
>A>	AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Sep	NEWA
>A>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Sep	NEWA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A213709	001	Apr 22, 2021	Apr	NEWA
AB			1.875MG; 1.875MG; 1.875MG; 1.875MG	A213709	002	Apr 22, 2021	Apr	NEWA
AB			2.5MG; 2.5MG; 2.5MG; 2.5MG	A213709	003	Apr 22, 2021	Apr	NEWA
AB			3.125MG; 3.125MG; 3.125MG; 3.125MG	A213709	004	Apr 22, 2021	Apr	NEWA
AB			3.75MG; 3.75MG; 3.75MG; 3.75MG	A213709	005	Apr 22, 2021	Apr	NEWA
AB			5MG; 5MG; 5MG; 5MG	A213709	006	Apr 22, 2021	Apr	NEWA
AB			7.5MG; 7.5MG; 7.5MG; 7.5MG	A213709	007	Apr 22, 2021	Apr	NEWA
>D>	AB	LIBERTY PHARMA INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210293	001	Apr 03, 2020	Sep	CAHN
	AB		1.25MG; 1.25MG; 1.25MG; 1.25MG	A210293	001	Apr 03, 2020	Aug	CAHN
>D>	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A210293	002	Apr 03, 2020	Sep	CAHN
	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A210293	002	Apr 03, 2020	Aug	CAHN
>D>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210293	003	Apr 03, 2020	Sep	CAHN
	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210293	003	Apr 03, 2020	Aug	CAHN
>D>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210293	004	Apr 03, 2020	Sep	CAHN
	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210293	004	Apr 03, 2020	Aug	CAHN
>D>	AB		5MG; 5MG; 5MG; 5MG	A210293	005	Apr 03, 2020	Sep	CAHN
	AB		5MG; 5MG; 5MG; 5MG	A210293	005	Apr 03, 2020	Aug	CAHN
>D>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210293	006	Apr 03, 2020	Sep	CAHN
	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210293	006	Apr 03, 2020	Aug	CAHN
		@ MYLAN	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206721	001	Nov 10, 2015	Aug	CAHN
		@	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206721	001	Nov 10, 2015	Aug	DISC
		@	1.875MG; 1.875MG; 1.875MG; 1.875MG	A206721	002	Nov 10, 2015	Aug	CAHN
		@	1.875MG; 1.875MG; 1.875MG; 1.875MG	A206721	002	Nov 10, 2015	Aug	DISC
		@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A206721	003	Nov 10, 2015	Aug	CAHN
		@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A206721	003	Nov 10, 2015	Aug	DISC
		@	3.125MG; 3.125MG; 3.125MG; 3.125MG	A206721	004	Nov 10, 2015	Aug	CAHN
		@	3.125MG; 3.125MG; 3.125MG; 3.125MG	A206721	004	Nov 10, 2015	Aug	DISC
		@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A206721	005	Nov 10, 2015	Aug	CAHN
		@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A206721	005	Nov 10, 2015	Aug	DISC
		@	5MG; 5MG; 5MG; 5MG	A206721	006	Nov 10, 2015	Aug	CAHN
		@	5MG; 5MG; 5MG; 5MG	A206721	006	Nov 10, 2015	Aug	DISC
		@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A206721	007	Nov 10, 2015	Aug	CAHN
		@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A206721	007	Nov 10, 2015	Aug	DISC
AB		RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A213111	001	Jan 13, 2021	Jan	NEWA
AB			1.875MG; 1.875MG; 1.875MG; 1.875MG	A213111	002	Jan 13, 2021	Jan	NEWA
AB			3.125MG; 3.125MG; 3.125MG; 3.125MG	A213111	004	Jan 13, 2021	Jan	NEWA
AB			7.5MG; 7.5MG; 7.5MG; 7.5MG	A213111	007	Jan 13, 2021	Jan	NEWA
>A>	AB	USPHARMA WINDLAS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210293	001	Apr 03, 2020	Sep	CAHN
>A>	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A210293	002	Apr 03, 2020	Sep	CAHN
>A>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210293	003	Apr 03, 2020	Sep	CAHN
>A>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210293	004	Apr 03, 2020	Sep	CAHN
>A>	AB		5MG; 5MG; 5MG; 5MG	A210293	005	Apr 03, 2020	Sep	CAHN
>A>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210293	006	Apr 03, 2020	Sep	CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

		@ GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jun	DISC
AA			5MG	A212186	001	Jan 27, 2021	Jan	NEWA
		@	10MG	A212186	002	Jan 27, 2021	Jun	DISC
AA			10MG	A212186	002	Jan 27, 2021	Jan	NEWA
		+ @ LANNETT	5MG	A083901	001	Aug 31, 1984	Aug	CRLD
		+ @	10MG	A083901	002	Aug 31, 1984	Aug	CRLD
		@ MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jan	DISC

TABLET;ORAL

AMPHETAMINE SULFATE

	@	10MG	A213898	002	Jul 14, 2020	Jan	DISC
	@ NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Mar	DISC
	@	10MG	A213763	002	Aug 24, 2020	Mar	DISC
AA	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Aug	NEWA
AA		10MG	A213852	002	Sep 07, 2021	Aug	NEWA
AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Aug	CAHN
AA		10MG	A212901	002	May 22, 2020	Aug	CAHN
AA	SPECGX LLC	5MG	A213583	001	Jan 22, 2021	Jan	NEWA
AA		10MG	A213583	002	Jan 22, 2021	Jan	NEWA
AA	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Jan	NEWA
AA		10MG	A214574	002	Jan 27, 2021	Jan	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

	+ @ ARBOR PHARMS LLC	2.5MG	N209905	005	Apr 16, 2021	Jul	DISC
	+	2.5MG	N209905	005	Apr 16, 2021	Apr	NEWA
	+!	20MG	N209905	004	Jan 30, 2019	Apr	CHRS

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

	@ HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Mar	CAHN
AP		EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Mar	CAHN
AP		EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Mar	CAHN
	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Mar	CAHN
AP		EQ 1GM BASE/VIAL	A062772	001	Apr 15, 1993	Mar	CAHN
	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Mar	CAHN
AP		EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Mar	CAHN
	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Mar	CAHN
AP		EQ 10GM BASE/VIAL	A063142	001	Apr 15, 1993	Mar	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP	HQ SPECLT PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005	Mar	CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005	Mar	CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005	Mar	CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

ANAGRELIDE HYDROCHLORIDE

	@ CHARTWELL RX	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Aug	CAHN
	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Aug	CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

	@ FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Aug	DISC
	@ US ANTIBIOTICS	1MG	A090732	001	Jun 28, 2010	May	CAHN

ANIDULAFUNGIN

POWDER;INTRAVENOUS

ERAXIS

	+! VICURON HOLDINGS	50MG/VIAL	N021632	001	Feb 17, 2006	Jul	CAHN
	+!	100MG/VIAL	N021632	002	Nov 14, 2006	Jul	CAHN

APIXABAN

TABLET;ORAL

APIXABAN

AB	BRECKENRIDGE	2.5MG	A209845	001	Jul 26, 2021	Jul	NEWA
AB		5MG	A209845	002	Jul 26, 2021	Jul	NEWA

APREMILAST

TABLET;ORAL

APREMILAST

>A>	AB	ALKEM LABS LTD	10MG	A211761	001	Sep 21, 2021	Sep	NEWA
>A>	AB		20MG	A211761	002	Sep 21, 2021	Sep	NEWA
>A>	AB		30MG	A211761	003	Sep 21, 2021	Sep	NEWA
	AB	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jun	NEWA
	AB		20MG	A211782	002	Jun 30, 2021	Jun	NEWA

<u>TABLET; ORAL</u>							
<u>APREMILAST</u>							
AB		30MG	A211782	003	Jun 30, 2021	Jun	NEWA
	@ UNICHEM	10MG	A211819	001	Feb 17, 2021	Aug	DISC
AB		10MG	A211819	001	Feb 17, 2021	Feb	NFTG
	@	20MG	A211819	002	Feb 17, 2021	Aug	DISC
AB		20MG	A211819	002	Feb 17, 2021	Feb	NFTG
	@	30MG	A211819	003	Feb 17, 2021	Aug	DISC
AB		30MG	A211819	003	Feb 17, 2021	Feb	NFTG
>A>	AB	ZYDUS PHARMS	10MG	A211859	001	Sep 21, 2021	Sep NEWA
>A>	AB		20MG	A211859	002	Sep 21, 2021	Sep NEWA
>A>	AB		30MG	A211859	003	Sep 21, 2021	Sep NEWA
<u>OTEZLA</u>							
AB	+	AMGEN INC	10MG	N205437	001	Mar 21, 2014	Feb CFTG
AB	+		20MG	N205437	002	Mar 21, 2014	Feb CFTG
AB	+	!	30MG	N205437	003	Mar 21, 2014	Feb CFTG
<u>ARFORMOTEROL TARTRATE</u>							
<u>SOLUTION; INHALATION</u>							
<u>ARFORMOTEROL TARTRATE</u>							
AN		AXAR PHARMS INC	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Jun NFTG
AN		CIPLA	EQ 0.015MG BASE/2ML	A207306	001	Jun 22, 2021	Jun NFTG
AN		GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021	Jun NFTG
<u>BROVANA</u>							
AN	+	SUNOVION	EQ 0.015MG BASE/2ML	N021912	001	Oct 06, 2006	Jun CFTG
<u>ARGATROBAN</u>							
<u>INJECTABLE; INJECTION</u>							
<u>ARGATROBAN</u>							
AP		CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan NFTG
AP	+	HIKMA PHARM CO LTD	50MG/50ML (1MG/ML)	N203049	002	Sep 30, 2016	Jan CFTG
<u>INJECTABLE; INTRAVENOUS</u>							
<u>ARGATROBAN IN SODIUM CHLORIDE</u>							
+	@	EAGLE PHARMS	50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	May DISC
<u>SOLUTION; INTRAVENOUS</u>							
<u>ARGATROBAN IN SODIUM CHLORIDE</u>							
+	!	ACCORD HLTHCARE	50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021	Jun NEWA
<u>ARSENIC TRIOXIDE</u>							
<u>INJECTABLE; INJECTION</u>							
<u>ARSENIC TRIOXIDE</u>							
AP		AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	Aug CMFD
	@		1MG/ML	A210739	001	Jan 25, 2021	May DISC
AP			1MG/ML	A210739	001	Jan 25, 2021	Jan NEWA
AP			2MG/ML	A210739	002	Aug 19, 2021	Aug NEWA
	@	INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb DISC
AP			2MG/ML	A209315	002	Jan 14, 2021	Jan NEWA
<u>ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K</u>							
<u>INJECTABLE; INTRAVENOUS</u>							
<u>INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)</u>							
+	!	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 1.7MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb CAIN
<u>ASENAPINE MALEATE</u>							
<u>TABLET; SUBLINGUAL</u>							
<u>ASENAPINE MALEATE</u>							
AB		ALEMBIC PHARMS LTD	EQ 2.5MG BASE	A206098	003	Jul 19, 2021	Jul NEWA
AB		BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb NEWA
<u>ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE</u>							
<u>TABLET; ORAL</u>							
<u>NORGESIC</u>							
+	@	BAUSCH	385MG; 30MG; 25MG	N013416	003	Oct 27, 1982	May CAHN
<u>NORGESIC FORTE</u>							
+	@	BAUSCH	770MG; 60MG; 50MG	N013416	004	Oct 27, 1982	May CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

PROPOXYPHENE COMPOUND 65

+ @ SANDOZ	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983	Aug CRLD
------------	-------------------	---------	-----	--------------	----------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

! INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul CHRS
	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul CTEC
@ SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jul DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB @ LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019	Apr DISC
MICRO LABS	25MG;200MG	A209929	001	Aug 11, 2021	Jul NEWA
@ SUN PHARM	25MG;200MG	A208572	001	Aug 21, 2018	Aug DISC

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021	May NEWA
------------	-----------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

@ MAYNE PHARMA INC	325MG;4.8355MG	A091670	001	Mar 16, 2011	Jul DISC
--------------------	----------------	---------	-----	--------------	----------

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB LAURUS LABS LTD	EQ 150MG BASE	A212579	001	Apr 30, 2021	Apr NEWA
AB	EQ 200MG BASE	A212579	002	Apr 30, 2021	Apr NEWA
AB	EQ 300MG BASE	A212579	003	Apr 30, 2021	Apr NEWA

>A> ATOGEPAANT

>A> TABLET;ORAL

>A> QULIPTA

>A> + ABBVIE INC	10MG	N215206	001	Sep 28, 2021	Sep NEWA
>A> +	30MG	N215206	002	Sep 28, 2021	Sep NEWA
>A> +!	60MG	N215206	003	Sep 28, 2021	Sep NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar NEWA
AB	18MG	A202682	002	Mar 11, 2021	Mar NEWA
AB	25MG	A202682	003	Mar 11, 2021	Mar NEWA
AB	40MG	A202682	004	Mar 11, 2021	Mar NEWA
AB	60MG	A202682	005	Mar 11, 2021	Mar NEWA
AB	80MG	A202682	006	Mar 11, 2021	Mar NEWA
AB	100MG	A202682	007	Mar 11, 2021	Mar NEWA
@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb DISC
AB	10MG	A079021	001	Feb 18, 2021	Feb NEWA
@	18MG	A079021	002	Feb 18, 2021	Feb DISC
AB	18MG	A079021	002	Feb 18, 2021	Feb NEWA
@	25MG	A079021	003	Feb 18, 2021	Feb DISC
AB	25MG	A079021	003	Feb 18, 2021	Feb NEWA
@	40MG	A079021	004	Feb 18, 2021	Feb DISC
AB	40MG	A079021	004	Feb 18, 2021	Feb NEWA
@	60MG	A079021	005	Feb 18, 2021	Feb DISC
AB	60MG	A079021	005	Feb 18, 2021	Feb NEWA
@	80MG	A079021	006	Feb 18, 2021	Feb DISC
AB	80MG	A079021	006	Feb 18, 2021	Feb NEWA
@	100MG	A079021	007	Feb 18, 2021	Feb DISC
AB	100MG	A079021	007	Feb 18, 2021	Feb NEWA

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan CAHN
AB		EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan CAHN
AB		EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan CAHN
AB		EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan CAHN
AB	AUGUST	EQ 10MG BASE	A214969	001	Sep 02, 2021	Aug NEWA
AB		EQ 20MG BASE	A214969	002	Sep 02, 2021	Aug NEWA
AB		EQ 40MG BASE	A214969	003	Sep 02, 2021	Aug NEWA
AB		EQ 80MG BASE	A214969	004	Sep 02, 2021	Aug NEWA
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A214659	001	Jul 14, 2021	Jul NEWA
AB		EQ 20MG BASE	A214659	002	Jul 14, 2021	Jul NEWA
AB		EQ 40MG BASE	A214659	003	Jul 14, 2021	Jul NEWA
AB		EQ 80MG BASE	A214659	004	Jul 14, 2021	Jul NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

@	SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Jul CAHN
@		EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Jul CAHN
@		EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul CAHN
@		EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul CAHN
	LIPTRUZET					
+	@ ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb CAHN
+	@	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb CAHN
+	@	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb CAHN
+	@	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb CAHN

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

AB	BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar NEWA
----	----------------	-----------	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

AP	ACCORD HLTHCARE	0.25MG/5ML (0.05MG/ML)	A212868	001	Jul 26, 2021	Jul NFTG
AP		0.5MG/5ML (0.1MG/ML)	A212868	002	Jul 26, 2021	Jul NFTG
AP		1MG/10ML (0.1MG/ML)	A212868	003	Jul 26, 2021	Jul NEWA
AP	+! HOSPIRA	0.25MG/5ML (0.05MG/ML)	N021146	002	Jul 09, 2001	Jul CFTG
AP	+!	0.5MG/5ML (0.1MG/ML)	N021146	004	Aug 17, 2017	Jul CFTG
AP	+!	1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Jul CTEC
AP	+!	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar CTEC
AP	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar CTEC

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

AP	ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar NFTG
AP	+! FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Mar CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	AA	ECI PHARMS LLC	0.025MG;2.5MG	A207128	001	Oct 21, 2020	Sep CAHN
>A>	AA	PHARMA LIFE	0.025MG;2.5MG	A207128	001	Oct 21, 2020	Sep CAHN
	AA	WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan NEWA

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+	@ MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan CAHN
---	---------	-------------------	---------	-----	--------------	----------

AVAPRITINIB

TABLET; ORAL

AYVAKIT

+	BLUEPRINT MEDICINES	25MG	N212608	004	Jun 16, 2021	Jun NEWA
+		50MG	N212608	005	Jun 16, 2021	Jun NEWA

AVIBACTAM SODIUM; CEFTAZIDIMEPOWDER; INTRAVENOUS
AVYCAZ

+! ALLERGAN EQ 0.5GM BASE; 2GM/VIAL N206494 001 Feb 25, 2015 Jan CDFR

AZELASTINE HYDROCHLORIDESPRAY, METERED; NASAL
ASTELIN

>A>	AB	+!	MYLAN SPCLT VIATRIS	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Sep	CAHN
>D>	AB	+!	MYLAN SPECIALITY LP	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Sep	CAHN
	AB	+!		0.137MG/SPRAY	N020114	001	Nov 01, 1996	Aug	CPOT

ASTEPRO

		@	MYLAN SPECIALITY LP	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Aug	CPOT
		+ @		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jul	DISC
AB		+!		0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jul	CPOT

AZELASTINE HYDROCHLORIDE

AB			AKORN	0.137MG/SPRAY	A207610	001	May 17, 2019	Aug	CPOT
AB				0.2055MG/SPRAY	A210032	001	Aug 23, 2019	Aug	CPOT
AB			ALKEM LABS LTD	0.137MG/SPRAY	A208156	001	Aug 18, 2017	Aug	CPOT
AB			AMNEAL	0.137MG/SPRAY	A204660	001	Aug 28, 2017	Aug	CPOT
AB				0.2055MG/SPRAY	A208199	001	Dec 15, 2017	Aug	CPOT
AB			APOTEX INC	0.137MG/SPRAY	A077954	001	Apr 30, 2009	Aug	CPOT
AB				0.2055MG/SPRAY	A201846	001	Aug 31, 2012	Aug	CPOT
AB			AUROBINDO PHARMA LTD	0.137MG/SPRAY	A212289	001	May 08, 2020	Aug	CPOT
AB				0.2055MG/SPRAY	A212775	001	Nov 12, 2020	Aug	CPOT
AB			BRECKENRIDGE	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Aug	CPOT
AB			HIKMA PHARMS	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Aug	CPOT
AB				0.2055MG/SPRAY	A207243	001	Sep 22, 2017	Aug	CPOT
AB			SUN PHARM	0.137MG/SPRAY	A090423	001	May 23, 2012	Aug	CPOT
AB			UPSHER SMITH LABS	0.137MG/SPRAY	A202609	001	Mar 17, 2017	Aug	CPOT
AB			ZYDUS PHARMS	0.137MG/SPRAY	A091409	001	Aug 14, 2017	Aug	CPOT

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB			APOTEX	0.137MG/SPRAY; 0.05MG/SPRAY	A207712	001	Apr 28, 2017	Aug	CPOT
AB			PADAGIS ISRAEL	0.137MG/SPRAY; 0.05MG/SPRAY	A208111	001	Feb 18, 2021	Aug	CPOT
AB			PERRIGO UK FINCO	EQ 0.125MG BASE/SPRAY; 0.05MG/SPRAY	A208111	001	Feb 18, 2021	Feb	NEWA
			DYMISTA						
AB		+!	MYLAN SPECIALITY LP	0.137MG/SPRAY; 0.05MG/SPRAY	N202236	001	May 01, 2012	Aug	CPOT

AZITHROMYCINFOR SUSPENSION; ORAL
AZITHROMYCIN

AB TARO EQ 200MG BASE/5ML A211521 001 Dec 11, 2019 Feb CMFD

INJECTABLE; INJECTION

AZITHROMYCIN

@ MYLAN ASI EQ 500MG BASE/VIAL A065506 001 Mar 24, 2009 Feb DISC

TABLET; ORAL

AZITHROMYCIN

AB			ALEMBIC PHARMS LTD	EQ 600MG BASE	A211793	001	Jan 27, 2020	Jul	CMFD
AB			YUNG SHIN PHARM	EQ 500MG BASE	A211318	001	Mar 17, 2021	Mar	NEWA
AB				EQ 600MG BASE	A211068	001	May 08, 2020	Feb	CMFD

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

@ XELLIA PHARMS APS 50,000 UNITS/VIAL A203177 001 Aug 25, 2014 Jun DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL

CORTISPORIN

+ @ MONARCH PHARMS 400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 5,000 UNITS/GM N050168 002 May 04, 1984 Jul DISC

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP			MAIA PHARMS INC	0.05MG/ML	A210777	001	Jan 15, 2021	Jan	NEWA
AP				0.5MG/ML	A210048	001	Sep 11, 2019	Aug	CMFD
AP				2MG/ML	A210048	002	Sep 11, 2019	Aug	CMFD

INJECTABLE; INTRATHECAL

GABLOFEN

AP	+	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Mar	CHRS
AP	+		0.05MG/ML	N022462	001	Nov 19, 2010	Mar	CRLD
AP	+		0.5MG/ML	N022462	002	Nov 19, 2010	Mar	CHRS
AP	+		0.5MG/ML	N022462	002	Nov 19, 2010	Mar	CRLD
AP	+		2MG/ML	N022462	003	Nov 19, 2010	Mar	CHRS
AP	+		2MG/ML	N022462	003	Nov 19, 2010	Mar	CRLD

TABLET; ORAL

BACLOFEN

AB		AUROBINDO PHARMA LTD	10MG	A214099	001	Jul 13, 2021	Jul	NEWA
AB			20MG	A214099	002	Jul 13, 2021	Jul	NEWA
AB		BEXIMCO PHARMS USA	10MG	A214114	001	Jul 16, 2021	Jul	NEWA
AB			20MG	A214114	002	Jul 16, 2021	Jul	NEWA
AB		IMPAX	5MG	A077971	003	Jul 07, 2021	Jun	NEWA
AB			10MG	A077971	001	Oct 26, 2007	Jun	CAHN
AB			20MG	A077971	002	Oct 26, 2007	Jun	CAHN
AB		INNOGENIX	5MG	A212378	003	Apr 30, 2021	Apr	NEWA
AB		KARTHA	5MG	A214374	001	Mar 05, 2021	Feb	NEWA
>D>	AB		10MG	A214374	002	Mar 05, 2021	Sep	DISC
>A>		@	10MG	A214374	002	Mar 05, 2021	Sep	DISC
AB			10MG	A214374	002	Mar 05, 2021	Feb	NEWA
>D>	AB		20MG	A214374	003	Mar 05, 2021	Sep	DISC
>A>		@	20MG	A214374	003	Mar 05, 2021	Sep	DISC
AB			20MG	A214374	003	Mar 05, 2021	Feb	NEWA
>A>	AB	LANNETT CO INC	5MG	A077241	003	Sep 22, 2021	Sep	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

+	@	UCB INC	10MG	N021589	001	Oct 30, 2003	May	CRLD
+	@		20MG	N021589	002	Oct 30, 2003	May	CRLD

BALOXAVIR MARBOXIL

TABLET; ORAL

XOFLUZA

+		GENENTECH INC	80MG	N210854	003	Mar 18, 2021	Mar	NEWA
---	--	---------------	------	---------	-----	--------------	-----	------

BELUMOSUDIL MESYLATE

TABLET; ORAL

REZUROCK

+	!	KADMON PHARMS LLC	EQ 200MG BASE	N214783	001	Jul 16, 2021	Jul	NEWA
---	---	-------------------	---------------	---------	-----	--------------	-----	------

BELZUTIFAN

TABLET; ORAL

WELIREG

+	!	MERCK SHARP DOHME	40MG	N215383	001	Aug 13, 2021	Aug	NEWA
---	---	-------------------	------	---------	-----	--------------	-----	------

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB		CADILA	5MG	A078848	001	May 23, 2008	Aug	CAHN
AB			10MG	A078848	002	May 23, 2008	Aug	CAHN
AB			20MG	A078848	003	May 23, 2008	Aug	CAHN
AB			40MG	A078848	004	May 23, 2008	Aug	CAHN
		LOTENSIN						
AB	+	VALIDUS PHARMS	5MG	N019851	001	Jun 25, 1991	Feb	CAHN
AB	+		10MG	N019851	002	Jun 25, 1991	Feb	CAHN
AB	+		20MG	N019851	003	Jun 25, 1991	Feb	CAHN
AB	+		40MG	N019851	004	Jun 25, 1991	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	MYLAN	5MG; 6.25MG	A076688	001	Feb 11, 2004	Jul	DISC
	@		10MG; 12.5MG	A076688	002	Feb 11, 2004	Jul	DISC
	@		20MG; 12.5MG	A076688	003	Feb 11, 2004	Jul	DISC
	@		20MG; 25MG	A076688	004	Feb 11, 2004	Jul	DISC
		SANDOZ	5MG; 6.25MG	A076631	001	Feb 11, 2004	Jul	CTEC
		LOTENSIN HCT						
+	@	VALIDUS PHARMS	5MG; 6.25MG	N020033	001	May 19, 1992	Feb	CAHN
AB	+		10MG; 12.5MG	N020033	002	May 19, 1992	Feb	CAHN
AB	+		20MG; 12.5MG	N020033	004	May 19, 1992	Feb	CAHN
AB	+		20MG; 25MG	N020033	003	May 19, 1992	Feb	CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC
 FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
 +! BAUSCH LOMB IRELAND 0.4%;0.3%

N211039 001 Mar 09, 2020 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	ENCUBE	5%;1.2%	A212433	001	Apr 28, 2021	Apr	NEWA
>D>	AB	TOLMAR	5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Sep DISC
>A>	@		5%;EQ 1% BASE	A204087	001	Jun 27, 2017	Sep DISC
>D>	AB		5%;1.2%	A203688	001	Aug 25, 2016	Sep DISC
>A>	@		5%;1.2%	A203688	001	Aug 25, 2016	Sep DISC
	DUAC						
AB	+ STIEFEL	5%;1.2%	N050741	001	Aug 26, 2002	Jan	CHRS

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL
 TWYNEO
 +! SOL-GEL TECHNOLOGIES 3%;0.1%

N214902 001 Jul 26, 2021 Jul NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL
 BENZPHETAMINE HYDROCHLORIDE

>A>	@	SCINOPHARM TAIWAN	50MG	A040578	001	Apr 17, 2006	Sep CAHN
>D>	@	TWI PHARMS	50MG	A040578	001	Apr 17, 2006	Sep CAHN

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC
 BEPOTASTINE BESILATE

AT	APOTEX	1.5%	A206066	001	Mar 05, 2019	May	CMFD
AT	MYLAN	1.5%	A206220	001	Mar 18, 2019	May	CMFD
	BEPREVE						
AT	+! BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	May	CTEC

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
 CELESTONE SOLUSPAN

AB	+! ORGANON	3MG/ML;EQ 3MG BASE/ML	N014602	001		Aug	CAHN
----	------------	-----------------------	---------	-----	--	-----	------

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL
 SERNIVO
 +! PRIMUS PHARMS EQ 0.05% BASE/SPRAY

N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	!	TARO	EQ 0.05% BASE;1%	A076493	001	Jul 28, 2004	Feb CHRS
		LOTRISONE					
	+	@ MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
 BETAXOLOL HYDROCHLORIDE

AT	ACELLA	EQ 0.5% BASE	A078694	001	Nov 16, 2009	Aug	CAHN
----	--------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET;ORAL
 BETHANECHOL CHLORIDE

>A>	AA	BIOPHARM	5MG	A040728	002	Oct 26, 2007	Sep CAHN
>A>	AA		10MG	A040728	003	Oct 26, 2007	Sep CAHN
>A>	AA		25MG	A040728	004	Oct 26, 2007	Sep CAHN
>A>	AA		50MG	A040728	001	Oct 26, 2007	Sep CAHN
>D>	AA	DISCOVERY THERAP	5MG	A040728	002	Oct 26, 2007	Sep CAHN
>D>	AA		10MG	A040728	003	Oct 26, 2007	Sep CAHN
>D>	AA		25MG	A040728	004	Oct 26, 2007	Sep CAHN
>D>	AA		50MG	A040728	001	Oct 26, 2007	Sep CAHN
	@	WOCKHARDT	5MG	A040532	001	Sep 29, 2003	Jan DISC
	@		50MG	A040518	001	Sep 29, 2003	Jan DISC

	TABLET;ORAL								
	URECHOLINE								
	+ @ ODYSSEY PHARMS	10MG		A088440	001	May 29, 1984	Aug	CRLD	
	+ @	25MG		A088441	001	May 29, 1984	Aug	CRLD	
	<u>BEXAROTENE</u>								
	CAPSULE;ORAL								
	BEXAROTENE								
AB	TEVA PHARMS USA	75MG		A209931	001	Jan 14, 2021	Jan	NEWA	
	<u>BIMATOPROST</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	BIMATOPROST								
	@ AKORN	0.03%		A203299	001	Nov 08, 2018	Feb	CAHN	
AT	! ALEMBIC PHARMS LTD	0.03%		A210263	001	Apr 12, 2019	Jan	CHRS	
AT	LUPIN LTD	0.03%		A203991	001	Feb 20, 2015	Jan	CHRS	
	<u>BISOPROLOL FUMARATE</u>								
	TABLET;ORAL								
	BISOPROLOL FUMARATE								
AB	UNICHEM	5MG		A078635	001	Aug 18, 2009	Apr	CAHN	
AB	!	10MG		A078635	002	Aug 18, 2009	Apr	CAHN	
	<u>BIVALIRUDIN</u>								
	INJECTABLE;INTRAVENOUS								
	BIVALIRUDIN								
AP	HAINAN POLY PHARM	250MG/VIAL		A213078	001	May 28, 2021	May	NEWA	
	<u>BLEOMYCIN SULFATE</u>								
	INJECTABLE;INJECTION								
	BLEOMYCIN SULFATE								
	@ CIPLA	EQ 15 UNITS BASE/VIAL		A209439	001	Mar 11, 2019	Aug	DISC	
	<u>BORTEZOMIB</u>								
	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS								
	VELCADE								
	+! TAKEDA PHARMS USA	3.5MG/VIAL		N021602	001	May 13, 2003	May	CAHN	
	<u>BOSENTAN</u>								
	TABLET;ORAL								
	BOSENTAN								
	@ ALEMBIC PHARMS LTD	62.5MG		A211461	001	Jan 23, 2020	Aug	DISC	
AB		62.5MG		A211461	001	Jan 23, 2020	May	CMFD	
	@	125MG		A211461	002	Jan 23, 2020	Aug	DISC	
AB		125MG		A211461	002	Jan 23, 2020	May	CMFD	
>D>	AB	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019	Sep	DISC	
>A>		@	62.5MG	A206987	001	Apr 26, 2019	Sep	DISC	
>D>	AB		125MG	A206987	002	Apr 26, 2019	Sep	DISC	
>A>		@	125MG	A206987	002	Apr 26, 2019	Sep	DISC	
	TRACLEER								
AB	+ ACTELION	62.5MG		N021290	001	Nov 20, 2001	Feb	CAHN	
AB	+!	125MG		N021290	002	Nov 20, 2001	Feb	CAHN	
	TABLET, FOR SUSPENSION;ORAL								
	TRACLEER								
	+! ACTELION	32MG		N209279	001	Sep 05, 2017	Feb	CAHN	
	<u>BRIGATINIB</u>								
	TABLET;ORAL								
	ALUNBRIG								
	+ TAKEDA PHARMS USA	30MG		N208772	001	Apr 28, 2017	May	CAHN	
	+	90MG		N208772	002	Apr 28, 2017	May	CAHN	
	+!	180MG		N208772	003	Oct 02, 2017	May	CAHN	
	<u>BRIMONIDINE TARTRATE</u>								
	GEL;TOPICAL								
	BRIMONIDINE TARTRATE								
>A>	AB	PADAGIS ISRAEL	EQ 0.33% BASE	A209158	001	Sep 23, 2021	Sep	NFTG	
		MIRVASO							
>D>	+!	GALDERMA LABS LP	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Sep	CFTG	
>A>	AB	+!	EQ 0.33% BASE	N204708	001	Aug 23, 2013	Sep	CFTG	

BRIMONIDINE TARTRATE; BRINZOLAMIDESUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA

>A>	+	ALCON LABS INC	0.2%;1%	N204251	001	Apr 19, 2013	Sep CAHN
>D>	+	NOVARTIS	0.2%;1%	N204251	001	Apr 19, 2013	Sep CAHN

BRINCIDOFOVIRSUSPENSION;ORAL
TEMBEXA

+	CHIMERIX	10MG/ML	N214460	001	Jun 04, 2021	Jun NEWA
---	----------	---------	---------	-----	--------------	----------

TABLET;ORAL
TEMBEXA

+	CHIMERIX	100MG	N214461	001	Jun 04, 2021	Jun NEWA
---	----------	-------	---------	-----	--------------	----------

BRINZOLAMIDESUSPENSION/DROPS;OPHTHALMIC
BRINZOLAMIDE

AB	BAUSCH	1%	A204884	001	Aug 18, 2021	Aug NEWA
----	--------	----	---------	-----	--------------	----------

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

>A>	@	NOVITIUM PHARMA	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Sep CAHN
>D>	@	VISTAPHARM	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Sep CAHN

BROMOCRIPTINE MESYLATECAPSULE;ORAL
PARLODEL

AB	+	VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb CAHN
----	---	----------------	-------------	---------	-----	--------------	----------

TABLET;ORAL
PARLODEL

AB	+	VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb CAHN
----	---	----------------	---------------	---------	-----	--	----------

BUDESONIDECAPSULE, DELAYED RELEASE;ORAL
BUDESONIDE

	@	ALVOGEN	3MG	A206724	001	Nov 23, 2016	Apr CDFR
AB		AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Apr CDFR
AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Apr CDFR
AB		MYLAN	3MG	A090410	001	May 16, 2011	Apr CDFR
AB		RISING	3MG	A207367	001	Apr 07, 2017	Apr CDFR
AB		SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Apr CDFR
AB		ZYDUS PHARMS	3MG	A206134	001	May 04, 2017	Apr CDFR

SUSPENSION;INHALATION
BUDESONIDE

AN		SUN PHARM	0.25MG/2ML	A211922	001	Apr 14, 2021	Apr NEWA
AN			0.5MG/2ML	A211922	002	Apr 14, 2021	Apr NEWA
AN			1MG/2ML	A211922	003	Apr 14, 2021	Apr NEWA

BUMETANIDETABLET;ORAL
BUMETANIDE

>D>	AB	RISING	0.5MG	A212019	001	Dec 12, 2019	Sep CTEC
>A>	BX		0.5MG	A212019	001	Dec 12, 2019	Sep CTEC
>D>	AB		1MG	A212019	002	Dec 12, 2019	Sep CTEC
>A>	BX		1MG	A212019	002	Dec 12, 2019	Sep CTEC
>D>	AB		2MG	A212019	003	Dec 12, 2019	Sep CTEC
>A>	BX		2MG	A212019	003	Dec 12, 2019	Sep CTEC

BUPIVACAINESOLUTION, EXTENDED RELEASE;INFILTRATION
POSIMIR

+	@	DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Mar DISC
+	!		660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Feb NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A205141	002	Feb 11, 2021	Feb	NEWA
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE							
AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A204842	002	Feb 11, 2021	Feb	NEWA
AP		0.75%	A204842	003	Feb 11, 2021	Feb	NEWA

BUPIVACAINE; MELOXICAMSOLUTION, EXTENDED RELEASE; PERIARTICULAR
ZYNRELEF KIT

+!	HERON THERAPS INC	60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML	N211988	001	May 12, 2021	Jun	NEWA
+!		200MG/7ML (29.25MG/ML); 6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021	Jun	NEWA
+!		300MG/10.5ML (29.25MG/ML); 9MG/10.5ML	N211988	003	May 12, 2021	Jun	NEWA
+!		400MG/14ML (29.25MG/ML); 12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021	Jun	NEWA

BUPRENORPHINEFILM, EXTENDED RELEASE; TRANSDERMAL
BUPRENORPHINE

>A>	AB	AVEVA	5MCG/HR	A210272	001	Sep 23, 2021	Sep	NEWA
>A>	AB		7.5MCG/HR	A210272	002	Sep 23, 2021	Sep	NEWA
>A>	AB		10MCG/HR	A210272	003	Sep 23, 2021	Sep	NEWA
>A>	AB		15MCG/HR	A210272	004	Sep 23, 2021	Sep	NEWA
>A>	AB		20MCG/HR	A210272	005	Sep 23, 2021	Sep	NEWA
	@	MYLAN TECH VIATRIS	5MCG/HR	A210162	001	May 03, 2021	Aug	DISC
	@		5MCG/HR	A210162	001	May 03, 2021	Aug	DISC
	@		7.5MCG/HR	A210162	002	May 03, 2021	Aug	DISC
	@		7.5MCG/HR	A210162	002	May 03, 2021	Aug	DISC
	@		10MCG/HR	A210162	003	May 03, 2021	Aug	DISC
	@		10MCG/HR	A210162	003	May 03, 2021	Aug	DISC
	@		15MCG/HR	A210162	004	May 03, 2021	Aug	DISC
	@		15MCG/HR	A210162	004	May 03, 2021	Aug	DISC
	@		20MCG/HR	A210162	005	May 03, 2021	Aug	DISC
	@		20MCG/HR	A210162	005	May 03, 2021	Aug	DISC
AB		MYLAN TECHNOLOGIES	5MCG/HR	A210162	001	May 03, 2021	Apr	NEWA
AB			7.5MCG/HR	A210162	002	May 03, 2021	Apr	NEWA
AB			10MCG/HR	A210162	003	May 03, 2021	Apr	NEWA
AB			15MCG/HR	A210162	004	May 03, 2021	Apr	NEWA
AB			20MCG/HR	A210162	005	May 03, 2021	Apr	NEWA
AB		WATSON LABS TEVA	7.5MCG/HR	A204937	005	Jun 29, 2021	Jun	NEWA

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

AB	+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Jul	CFTG
AB	+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Jul	CFTG
AB	+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Jul	CFTG
AB	+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Jul	CFTG
AB	+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Jul	CFTG
AB	+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Jul	CFTG
AB	+!		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Jul	CFTG

BUPRENORPHINE HYDROCHLORIDE

AB		ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Aug	CAHN
AB			EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Jul	NFTG
AB			EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Aug	CAHN
AB			EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jul	NFTG
AB			EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Aug	CAHN
AB			EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jul	NFTG
AB			EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Aug	CAHN
AB			EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jul	NFTG
AB			EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Aug	CAHN
AB			EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jul	NFTG
AB			EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Aug	CAHN
AB			EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jul	NFTG
AB			EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Aug	CAHN
AB			EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jul	NFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A214930	001	Jun 15, 2021	Jun	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A214930	002	Jun 15, 2021	Jun	NEWA
	@ MAYNE PHARMA INC	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jan	DISC
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jul	DISC
AB		EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	May	CMFD
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jan	DISC
AB	RHODES PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Jul	CMFD
AB		EQ 8MG BASE;EQ 2MG BASE	A205601	002	Mar 30, 2020	Jul	CMFD

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
+		348MG	N022108	002	Apr 23, 2008	Feb	CAHN
+	!	522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

	@ MYLAN	75MG	A075491	001	Apr 17, 2000	Aug	DISC
	@	100MG	A075491	002	Apr 17, 2000	Aug	DISC

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

	@ IMPAX LABS	150MG	A077415	001	Nov 26, 2008	Aug	DISC
	@	200MG	A076711	001	Dec 03, 2004	Aug	DISC
	@ TORRENT	100MG	A203969	001	Oct 31, 2014	Jan	DISC
	@	150MG	A203969	002	Oct 31, 2014	Jan	DISC
	@	200MG	A203969	003	Oct 31, 2014	Jan	DISC

FORFIVO XL

>A>	+	ALMATICA	450MG	N022497	001	Nov 10, 2011	Sep	CAHN
>D>	+	ALVOGEN	450MG	N022497	001	Nov 10, 2011	Sep	CAHN
		WELLBUTRIN XL						
AB3	+	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb	CAHN
AB3	+	!	300MG	N021515	002	Aug 28, 2003	Feb	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	RUBICON	5MG	A075521	001	Apr 05, 2002	Feb	CMFD
AB		7.5MG	A075521	004	Mar 16, 2021	Mar	NEWA
AB		10MG	A075521	002	Apr 05, 2002	Feb	CMFD
AB		15MG	A075521	003	Apr 05, 2002	Feb	CMFD
AB		30MG	A075521	005	Mar 16, 2021	Mar	NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb	CAHN
----	-----------	--------	---------	-----	--------------	-----	------

BUTABARBITAL SODIUM

TABLET;ORAL

BUTABARBITAL SODIUM

+	@ SANDOZ	15MG	A085938	001		Aug	CRLD
---	----------	------	---------	-----	--	-----	------

CABERGOLINE

TABLET;ORAL

DOSTINEX

+	@ PFIZER	0.5MG	N020664	001	Dec 23, 1996	Jan	CAHN
---	----------	-------	---------	-----	--------------	-----	------

CABOTEGRAVIR SODIUM

TABLET;ORAL

VOCABRIA

+	!	VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021	Jan	NEWA
---	---	---------------	--------------	---------	-----	--------------	-----	------

CABOTEGRAVIR; RILPIVIRINESUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
CABENUVA KIT

+!	VIIV HLTHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	Jan	NEWA
+!		600MG/3ML (200MG/ML); 900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021	Jan	NEWA

CAFFEINE CITRATESOLUTION; INTRAVENOUS
CAFCIT

AP	+!	HIKMA PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Jul	CAHN
AA	+!	HIKMA PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Jul	CAHN

CAFFEINE; ERGOTAMINE TARTRATE

TABLET; ORAL

CAFERGOT

+	@	SANDOZ	100MG; 1MG	A084294	001		Aug	CRLD
	@		100MG; 1MG	A084294	001		Jul	DISC
!		MIKART	100MG; 1MG	A040590	001	Sep 16, 2005	Jul	CHRS
			100MG; 1MG	A040590	001	Sep 16, 2005	Jul	CTEC

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

AP		CUSTOPHARM INC	200 IU/ML	A212416	001	May 14, 2021	May	NFTG
AP	+!	MYLAN IRELAND LTD	200 IU/ML	N017808	002	Mar 29, 1991	May	CFTG

CALCIUM ACETATE

TABLET; ORAL

CALCIUM ACETATE

AB	!	CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Apr	CHRS
----	---	---------------------	-------	---------	-----	--------------	-----	------

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+	@	WARNER CHILCOTT	EQ 500MG BASE; 35MG	N021823	001	Aug 12, 2005	Jul	CPOT
+	@		EQ 500MG BASE, N/A; N/A, 35MG	N021823	001	Aug 12, 2005	Jul	CDFR

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

+	@	ABBOTT	EQ 90MG CALCIUM/5ML	A080001	001		Aug	CRLD
---	---	--------	---------------------	---------	-----	--	-----	------

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS

CALCIUM GLUCONATE IN SODIUM CHLORIDE

+!		FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021	Aug	NEWA
+!			2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021	Aug	NEWA
+!		HQ SPCLT PHARMA	1GM/100ML (10MG/ML)	N210906	003	Jun 04, 2021	Jun	NEWA

CAPREOMYCIN SULFATE

INJECTABLE; INJECTION

CAPASTAT SULFATE

+	@	AKORN	EQ 1GM BASE/VIAL	N050095	001		Jun	DISC
---	---	-------	------------------	---------	-----	--	-----	------

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB		ANNORA PHARMA	12.5MG	A074737	001	Oct 28, 1998	Jul	CMFD
AB			25MG	A074737	002	Oct 28, 1998	Jul	CMFD
AB			50MG	A074737	003	Oct 28, 1998	Jul	CMFD
AB			100MG	A074737	004	Oct 28, 1998	Jul	CMFD
>D>	AB	HIKMA INTL PHARMS	100MG	A074505	004	Feb 13, 1996	Sep	CHRS
>A>	AB	!	100MG	A074505	004	Feb 13, 1996	Sep	CHRS
>D>	AB	MYLAN	12.5MG	A074434	001	Feb 13, 1996	Sep	CAHN
>A>	AB	@	12.5MG	A074434	001	Feb 13, 1996	Sep	CAHN

TABLET;ORAL
CAPTOPRIL

>D>	AB		25MG	A 074434	002	Feb 13, 1996	Sep	CAHN
>A>		@	25MG	A 074434	002	Feb 13, 1996	Sep	CAHN
>D>	AB		50MG	A 074434	003	Feb 13, 1996	Sep	CAHN
>A>		@	50MG	A 074434	003	Feb 13, 1996	Sep	CAHN
>D>	AB	!	100MG	A 074434	004	Feb 13, 1996	Sep	CAHN
>A>		@	100MG	A 074434	004	Feb 13, 1996	Sep	CAHN

CAPTROPIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

		@ MYLAN	25MG;15MG	A 074896	001	Dec 29, 1997	Aug	CAHN
		@	25MG;15MG	A 074896	001	Dec 29, 1997	Aug	DISC
		@	25MG;25MG	A 074896	002	Dec 29, 1997	Aug	CAHN
		@	25MG;25MG	A 074896	002	Dec 29, 1997	Aug	DISC
		@	50MG;15MG	A 074896	004	Dec 29, 1997	Aug	CAHN
		@	50MG;15MG	A 074896	004	Dec 29, 1997	Aug	DISC
		@	50MG;25MG	A 074896	003	Dec 29, 1997	Aug	CAHN
		@	50MG;25MG	A 074896	003	Dec 29, 1997	Aug	DISC

CARBAMAZEPINE

TABLET;ORAL
CARBAMAZEPINE

	AB	VGAAAN	200MG	A 214328	001	Aug 16, 2021	Aug	NEWA
--	----	--------	-------	----------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
CARBAMAZEPINE

>A>	AB	ANBISON LAB	100MG	A 212948	001	Sep 30, 2021	Sep	NEWA
>A>	AB		200MG	A 212948	002	Sep 30, 2021	Sep	NEWA
>A>	AB		400MG	A 212948	003	Sep 30, 2021	Sep	NEWA
	AB	CSPC OUYI	100MG	A 213311	001	Apr 13, 2021	Apr	NEWA
	AB		200MG	A 213311	002	Apr 13, 2021	Apr	NEWA
	AB		400MG	A 213311	003	Apr 13, 2021	Apr	NEWA

CARBIDOPA; LEVODOPA

TABLET;ORAL
CARBIDOPA AND LEVODOPA

	AB	SCIEGEN PHARMS INC	10MG;100MG	A 214092	001	May 07, 2021	Apr	NEWA
	AB		25MG;100MG	A 214092	002	May 07, 2021	Apr	NEWA
	AB		25MG;250MG	A 214092	003	May 07, 2021	Apr	NEWA

SINEMET

	AB	+ ORGANON	10MG;100MG	N 017555	001		Aug	CAHN
	AB	+	25MG;100MG	N 017555	003		Aug	CAHN
	AB	+	25MG;250MG	N 017555	002		Aug	CAHN

TABLET, EXTENDED RELEASE;ORAL
CARBIDOPA AND LEVODOPA

>A>	AB	SCIEGEN PHARMS INC	25MG;100MG	A 214091	001	Oct 05, 2021	Sep	NEWA
>A>	AB		50MG;200MG	A 214091	002	Oct 05, 2021	Sep	NEWA

SINEMET CR

>D>	+	@ MERCK SHARP DOHME	25MG;100MG	N 019856	002	Dec 24, 1992	Sep	CAHN
>D>	+	@	50MG;200MG	N 019856	001	May 30, 1991	Sep	CAHN
>A>	+	@ ORGANON	25MG;100MG	N 019856	002	Dec 24, 1992	Sep	CAHN
>A>	+	@	50MG;200MG	N 019856	001	May 30, 1991	Sep	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
CARBIDOPA AND LEVODOPA

		@ MYLAN	10MG;100MG	A 078893	001	Sep 18, 2008	Aug	CAHN
		@	10MG;100MG	A 078893	001	Sep 18, 2008	Aug	DISC
		@	25MG;100MG	A 078893	002	Sep 18, 2008	Aug	CAHN
		@	25MG;100MG	A 078893	002	Sep 18, 2008	Aug	DISC
		@	25MG;250MG	A 078893	003	Sep 18, 2008	Aug	CAHN
		@	25MG;250MG	A 078893	003	Sep 18, 2008	Aug	DISC
	AB	! SUN PHARM	25MG;250MG	A 078690	003	Jul 31, 2009	Aug	CTEC
	AB	!	25MG;250MG	A 078690	003	Jul 31, 2009	Aug	CHRS

CARBOPLATIN

INJECTABLE; INTRAVENOUS
CARBOPLATIN

	AP	! HOSPIRA	50MG/5ML (10MG/ML)	A 076517	001	Oct 14, 2004	Mar	CHRS
	AP	!	150MG/15ML (10MG/ML)	A 076517	002	Oct 14, 2004	Mar	CHRS
	AP	!	450MG/45ML (10MG/ML)	A 076517	003	Oct 14, 2004	Mar	CHRS
	AP	!	600MG/60ML (10MG/ML)	A 077059	001	Nov 23, 2004	Mar	CHRS
		@ MEITHEAL	50MG/5ML (10MG/ML)	A 077096	001	Jun 14, 2005	Aug	DISC

INJECTABLE; INTRAVENOUS
CARBOPLATIN

	@	150MG/15ML (10MG/ML)	A 077096	002	Jun 14, 2005	Aug	DISC
	@	450MG/45ML (10MG/ML)	A 077096	003	Jun 14, 2005	Aug	DISC
	@	600MG/60ML (10MG/ML)	A 077096	004	Jun 03, 2013	Aug	DISC
AP	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A 077269	001	Oct 14, 2004	Mar	CHRS
AP		150MG/15ML (10MG/ML)	A 077269	002	Oct 14, 2004	Mar	CHRS
AP		450MG/45ML (10MG/ML)	A 077269	003	Oct 14, 2004	Mar	CHRS
AP		600MG/60ML (10MG/ML)	A 077269	004	Dec 28, 2007	Mar	CHRS

CARBOPROST TROMETHAMINEINJECTABLE; INJECTION
CARBOPROST TROMETHAMINE

AP	SUNNY	EQ 0.25MG BASE/ML	A 213118	001	Mar 25, 2021	Mar	NEWA
----	-------	-------------------	----------	-----	--------------	-----	------

CARFILZOMIBPOWDER; INTRAVENOUS
CARFILZOMIB

	@ BRECKENRIDGE	10MG/VIAL	A 209330	001	Jun 11, 2021	Aug	DISC
AP		10MG/VIAL	A 209330	001	Jun 11, 2021	Jun	NFTG
	@	60MG/VIAL	A 209330	002	Jun 11, 2021	Aug	DISC
AP		60MG/VIAL	A 209330	002	Jun 11, 2021	Jun	NEWA
	KYPROLIS						
	+ ONYX THERAP	10MG/VIAL	N 202714	003	Jun 07, 2018	Aug	CTEC
AP	+	10MG/VIAL	N 202714	003	Jun 07, 2018	Jun	CFTG

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

>D>	AA	ALLIED	350MG	A 040245	001	Sep 08, 1997	Sep	CAHN
>A>	AA	MLV	350MG	A 040245	001	Sep 08, 1997	Sep	CAHN
>D>	AB	STRIDES PHARMA	250MG	A 205513	001	Nov 12, 2015	Sep	CTEC
>A>	BX		250MG	A 205513	001	Nov 12, 2015	Sep	CTEC
>D>	AA		350MG	A 205513	002	Nov 12, 2015	Sep	CTEC
>A>	BX		350MG	A 205513	002	Nov 12, 2015	Sep	CTEC

CARMUSTINEINJECTABLE; INJECTION
BICNU

AP	+!	AVET LIFESCIENCES	100MG/VIAL	N 017422	001		Aug	CAHN
		CARMUSTINE						
>D>	AP	HONG KONG	100MG/VIAL	A 213460	001	Aug 02, 2021	Sep	CAHN
	AP		100MG/VIAL	A 213460	001	Aug 02, 2021	Jul	NEWA
	AP	JIANGSU HENGRUI MED	100MG/VIAL	A 211202	001	Mar 12, 2021	Mar	NEWA
>A>	AP	MEITHEAL	100MG/VIAL	A 213460	001	Aug 02, 2021	Sep	CAHN

CARVEDILOLTABLET; ORAL
CARVEDILOL

>A>	@	ACI	3.125MG	A 078786	001	Dec 22, 2009	Sep	CAHN
>A>	@		6.25MG	A 078786	002	Dec 22, 2009	Sep	CAHN
>A>	@		12.5MG	A 078786	003	Dec 22, 2009	Sep	CAHN
>A>	@		25MG	A 078786	004	Dec 22, 2009	Sep	CAHN
>D>	@	AXXELENT PHARMA	3.125MG	A 078786	001	Dec 22, 2009	Sep	CAHN
	@		3.125MG	A 078786	001	Dec 22, 2009	Aug	CAHN
>D>	@		6.25MG	A 078786	002	Dec 22, 2009	Sep	CAHN
	@		6.25MG	A 078786	002	Dec 22, 2009	Aug	CAHN
>D>	@		12.5MG	A 078786	003	Dec 22, 2009	Sep	CAHN
	@		12.5MG	A 078786	003	Dec 22, 2009	Aug	CAHN
>D>	@		25MG	A 078786	004	Dec 22, 2009	Sep	CAHN
	@		25MG	A 078786	004	Dec 22, 2009	Aug	CAHN
		COREG						
AB	+	WOODWARD	3.125MG	N 020297	004	May 29, 1997	Jul	CAHN
AB	+		6.25MG	N 020297	003	Sep 14, 1995	Jul	CAHN
AB	+!		12.5MG	N 020297	002	Sep 14, 1995	Jul	CAHN
AB	+		25MG	N 020297	001	Sep 14, 1995	Jul	CAHN

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE;ORAL
COREG CR

AB	+	WOODWARD	10MG	N022012	001	Oct 20, 2006	Jul	CAHN
AB	+		20MG	N022012	002	Oct 20, 2006	Jul	CAHN
AB	+	!	40MG	N022012	003	Oct 20, 2006	Jul	CAHN
AB	+		80MG	N022012	004	Oct 20, 2006	Jul	CAHN

CASIMERSENSOLUTION;INTRAVENOUS
AMONDYS 45

+	!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021	Feb	NEWA
---	---	---------------------	---------------------	---------	-----	--------------	-----	------

CASPOFUNGIN ACETATEPOWDER;INTRAVENOUS
CASPOFUNGIN ACETATE

>A>	AP	UBI	50MG/VIAL	A211263	001	Oct 01, 2021	Sep	NEWA
>A>	AP		70MG/VIAL	A211263	002	Oct 01, 2021	Sep	NEWA

CEFAZOLIN SODIUMSOLUTION;INTRAVENOUS
CEFAZOLIN IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	Mar	NEWA
+	!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar	CRLD
!			EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar	CHRS

CEFDINIRCAPSULE;ORAL
CEFDINIR

AB		ALKEM LABS LTD	300MG	A210220	001	Feb 19, 2021	Feb	NEWA
		FOR SUSPENSION;ORAL						
		CEFDINIR						
AB		ALKEM LABS LTD	125MG/5ML	A210534	001	Feb 19, 2021	Feb	NEWA
AB			250MG/5ML	A210534	002	Feb 19, 2021	Feb	NEWA

CEFEPIME HYDROCHLORIDEINJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

@		ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Mar	DISC
@			EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Mar	DISC

CEFIXIMEFOR SUSPENSION;ORAL
CEFIXIME

AB		ALKEM LABS LTD	100MG/5ML	A211775	001	Feb 19, 2021	Feb	NEWA
AB			200MG/5ML	A211775	002	Feb 19, 2021	Feb	NEWA

CEFOTAXIME SODIUMINJECTABLE;INJECTION
CLAFORAN

+	@	VALIDUS PHARMS	EQ 500MG BASE/VIAL	N050547	001		Feb	CAHN
+	@		EQ 1GM BASE/VIAL	N050547	002		Feb	CAHN
+	@		EQ 2GM BASE/VIAL	N050547	003		Feb	CAHN
+	@		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Feb	CAHN
		CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
	@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Feb	CAHN
	@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Feb	CAHN
		CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Feb	CAHN
	@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Feb	CAHN

CEFTAROLINE FOSAMILPOWDER;INTRAVENOUS
CEFTAROLINE FOSAMIL

>A>	AP	APOTEX	400MG/VIAL	A208075	001	Sep 21, 2021	Sep	NFTG
>A>	AP		600MG/VIAL	A208075	002	Sep 21, 2021	Sep	NFTG
		TEFLARO						
>D>	+	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010	Sep	CHRS
>A>	AP	+	400MG/VIAL	N200327	001	Oct 29, 2010	Sep	CHRS

POWDER; INTRAVENOUS
TEFLARO

>D>	+	!	600MG/VIAL	N200327	002	Oct 29, 2010	Sep	CFTG
>A>	AP	+	600MG/VIAL	N200327	002	Oct 29, 2010	Sep	CFTG

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

	@	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Feb	CAHN
	+	@	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Feb	CAHN
	+	@	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Feb	CAHN

CEFUROXIME SODIUM

INJECTABLE; INJECTION
ZINACEF

AP	+	!	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb	CAHN
AP	+	!		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb	CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ZINACEF

AB	+	!	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb	CAHN
----	---	---	----------	--------------------	---------	-----	--------------	-----	------

CELECOXIB

CAPSULE; ORAL
CELEBREX

AB	+		UPJOHN	50MG	N020998	004	Dec 15, 2006	Apr	CAHN
AB	+			100MG	N020998	001	Dec 31, 1998	Apr	CAHN
AB	+			200MG	N020998	002	Dec 31, 1998	Apr	CAHN
AB	+	!		400MG	N020998	003	Aug 29, 2002	Apr	CAHN

CELECOXIB

	@	ACIC PHARMS	200MG	A212925	001	Dec 09, 2020	Jun	DISC	
	@		400MG	A212925	002	Dec 09, 2020	Jun	DISC	
>D>	AB		AMNEAL PHARMS	50MG	A208833	001	May 31, 2018	Sep	CTEC
>A>	BX			50MG	A208833	001	May 31, 2018	Sep	CTEC
>D>	AB			100MG	A208833	002	May 31, 2018	Sep	CTEC
>A>	BX			100MG	A208833	002	May 31, 2018	Sep	CTEC
>D>	AB			200MG	A208833	003	May 31, 2018	Sep	CTEC
>A>	BX			200MG	A208833	003	May 31, 2018	Sep	CTEC
>D>	AB			400MG	A208833	004	May 31, 2018	Sep	CTEC
>A>	BX			400MG	A208833	004	May 31, 2018	Sep	CTEC
	@	JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Jun	DISC	
	@		100MG	A207061	002	Apr 04, 2017	Jun	DISC	
	@		200MG	A207061	003	Apr 04, 2017	Jun	DISC	
	@		400MG	A207061	004	Apr 04, 2017	Jun	DISC	
AB		UNICHEM	50MG	A213301	001	Jan 12, 2021	Jan	NEWA	
AB			100MG	A213301	002	Jan 12, 2021	Jan	NEWA	
AB			200MG	A213301	003	Jan 12, 2021	Jan	NEWA	
AB			400MG	A213301	004	Jan 12, 2021	Jan	NEWA	
AB		YILING	50MG	A211412	001	Mar 06, 2020	Jun	CMFD	
AB			100MG	A211412	002	Mar 06, 2020	Jun	CMFD	
AB			200MG	A211412	003	Mar 06, 2020	Jun	CMFD	
AB			400MG	A211412	004	Mar 06, 2020	Jun	CMFD	

SOLUTION; ORAL
ELYXYB

>A>	+	@	BDSI	25MG/ML	N212157	001	May 05, 2020	Sep	CAHN
>D>	+	@	DR REDDYS	25MG/ML	N212157	001	May 05, 2020	Sep	CAHN

CENOBAAMATE

TABLET; ORAL
XCOPRI

	+	!	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Jul	CHRS
	+			200MG	N212839	006	Mar 10, 2020	Jul	CHRS

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

>D>	AB		ALKEM LABS LTD	EQ 750MG BASE	A090836	004	Mar 29, 2013	Sep	CTEC
>A>		!		EQ 750MG BASE	A090836	004	Mar 29, 2013	Sep	CTEC
	AB		YUNG SHIN PHARM	EQ 250MG BASE	A065152	001	Feb 24, 2005	Aug	CMFD
		@		EQ 250MG BASE	A065152	001	Feb 24, 2005	Mar	DISC
	AB			EQ 500MG BASE	A065152	002	Feb 24, 2005	Aug	CMFD
		@		EQ 500MG BASE	A065152	002	Feb 24, 2005	Mar	DISC

CAPSULE;ORAL
 KEFLEX
 + @ PRAGMA EQ 250MG BASE N050405 002 May DISC
 + @ EQ 500MG BASE N050405 003 May DISC
 >D> AB +! EQ 750MG BASE N050405 005 May 12, 2006 Sep DISC
 >A> + @ EQ 750MG BASE N050405 005 May 12, 2006 Sep DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL
 CETIRIZINE HYDROCHLORIDE
 AA MICRO LABS 5MG/5ML A090191 001 Nov 12, 2009 Aug CAHN
 AA ! PADAGIS US 5MG/5ML A078398 001 Jun 17, 2008 Jul CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL
 CHLORDIAZEPOXIDE HYDROCHLORIDE
 @ CHARTWELL RX 5MG A084678 001 Apr CAHN
 @ 10MG A084041 001 Apr CAHN
 @ 25MG A084679 002 Apr CAHN
 + @ UPSHER SMITH LABS 10MG A084920 001 Aug CRLD
 LIBRIUM
 AB +! VALEANT PHARM INTL 25MG A085475 001 Aug CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE
 AB ALKEM LABS LTD 5MG;2.5MG A214065 001 Apr 26, 2021 Apr NEWA
 AB DR REDDYS 5MG;2.5MG A214698 001 May 10, 2021 Apr NEWA
 >D> AB ECI PHARMS LLC 5MG;2.5MG A213530 001 Oct 20, 2020 Sep CAHN
 >A> AB PHARMA LIFE 5MG;2.5MG A213530 001 Oct 20, 2020 Sep CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL
 CHLORHEXIDINE GLUCONATE
 AT BAJAJ 0.12% A075561 001 Nov 14, 2000 Feb CMFD

CHLOROQUINE PHOSPHATE

TABLET;ORAL
 CHLOROQUINE PHOSPHATE
 AA SUVEN PHARMS 500MG A214756 001 Sep 03, 2021 Aug NEWA

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL
 CHLORPROMAZINE HYDROCHLORIDE
 GENUS 30MG/ML A214542 001 Jun 02, 2021 May NEWA
 100MG/ML A214542 002 Jun 02, 2021 May NEWA
 TABLET;ORAL
 CHLORPROMAZINE HYDROCHLORIDE
 >D> AB AMNEAL PHARMS CO 10MG A209755 001 Sep 10, 2018 Sep CTEC
 >A> BX 10MG A209755 001 Sep 10, 2018 Sep CTEC
 >D> AB 25MG A209755 002 Sep 10, 2018 Sep CTEC
 >A> BX 25MG A209755 002 Sep 10, 2018 Sep CTEC
 >D> AB 50MG A209755 003 Sep 10, 2018 Sep CTEC
 >A> BX 50MG A209755 003 Sep 10, 2018 Sep CTEC
 >D> AB 100MG A209755 004 Sep 10, 2018 Sep CTEC
 >A> BX 100MG A209755 004 Sep 10, 2018 Sep CTEC
 >D> AB 200MG A209755 005 Sep 10, 2018 Sep CTEC
 >A> BX 200MG A209755 005 Sep 10, 2018 Sep CTEC
 AB GLENMARK PHARMS LTD 10MG A212144 001 Mar 23, 2021 Mar NEWA
 AB 25MG A212144 002 Mar 23, 2021 Mar NEWA
 AB 50MG A212144 003 Mar 23, 2021 Mar NEWA
 AB 100MG A212144 004 Mar 23, 2021 Mar NEWA
 AB 200MG A212144 005 Mar 23, 2021 Mar NEWA
 AB LANNETT CO INC 10MG A212996 001 Jan 22, 2021 Jan NEWA
 AB 25MG A212996 002 Jan 22, 2021 Jan NEWA
 AB 50MG A212996 003 Jan 22, 2021 Jan NEWA
 AB 100MG A212996 004 Jan 22, 2021 Jan NEWA
 AB 200MG A212996 005 Jan 22, 2021 Jan NEWA
 AB @ MAYNE PHARMA 10MG A213590 001 Aug 31, 2020 Mar DISC
 @ 25MG A213590 002 Aug 31, 2020 Mar DISC
 @ 50MG A213590 003 Aug 31, 2020 Mar DISC
 @ 100MG A213590 004 Aug 31, 2020 Mar DISC

TABLET;ORAL

		CHLORPROMAZINE HYDROCHLORIDE							
	@		200MG	A213590	005	Aug 31, 2020	Mar	DISC	
AB	+	UPSHER SMITH LABS	10MG	A083386	001		Aug	CRLD	
AB	+	!	25MG	A084112	001		Aug	CRLD	
AB	+		50MG	A084113	001		Aug	CRLD	
AB	+	!	100MG	A084114	001		Aug	CRLD	
AB	+		200MG	A084115	001		Aug	CRLD	

CHLORPROPAMIDETABLET;ORAL
CHLORPROPAMIDE

	@	RISING	100MG	A088725	001	Aug 31, 1984	Jan	CAHN	
	@		250MG	A088726	001	Aug 31, 1984	Jan	CAHN	

CHLORTHALIDONETABLET;ORAL
CHLORTHALIDONE

AB	+	MYLAN	25MG	A086831	002		Aug	CRLD	
AB	+	!	50MG	A086831	001		Aug	CRLD	
>A>	AB	NOVAST LABS	25MG	A206904	001	Mar 30, 2017	Sep	CAHN	
>A>	AB		50MG	A206904	002	Mar 30, 2017	Sep	CAHN	
>D>	AB	RICONPHARMA LLC	25MG	A206904	001	Mar 30, 2017	Sep	CAHN	
>D>	AB		50MG	A206904	002	Mar 30, 2017	Sep	CAHN	
>D>	AB	UMEDICA LABS PVT LTD	25MG	A207222	001	May 24, 2018	Sep	CTEC	
>A>	BX		25MG	A207222	001	May 24, 2018	Sep	CTEC	
>D>	AB		50MG	A207222	002	May 24, 2018	Sep	CTEC	
>A>	BX		50MG	A207222	002	May 24, 2018	Sep	CTEC	
		THALITONE							
	+	CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	May	CMFD	
BX	+	!	25MG	N019574	002	Feb 12, 1992	May	CMFD	

CHLORZOXAZONETABLET;ORAL
CHLORZOXAZONE

AA		HAVIX	250MG	A215158	001	Jul 29, 2021	Jul	NEWA	
AA	!	MIKART	250MG	A207483	001	Jun 24, 2016	Jul	CTEC	
AB		PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr	NEWA	
AA		SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Aug	CAHN	

CHOLESTYRAMINEPOWDER;ORAL
CHOLESTYRAMINE

AB		TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb	NEWA	
AB			EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb	NEWA	
		LOCHOLEST LIGHT							
	@	CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr	CAHN	
	@		EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr	CAHN	

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE;ORAL
FENOFIBRIC ACID

AB		ADAPTIS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Aug	CAHN	
AB			EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Aug	CAHN	
	@	YICHANG HUMANWELL	EQ 45MG FENOFIBRIC ACID	A212562	001	Dec 23, 2020	Jun	DISC	
	@		EQ 135MG FENOFIBRIC ACID	A212562	002	Dec 23, 2020	Jun	DISC	

CICLESONIDESPRAY, METERED;NASAL
OMNARIS

	+	COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006	May	CPOT	
--	---	-------	--------------	---------	-----	--------------	-----	------	--

CICLOPIROXGEL;TOPICAL
CICLOPIROX

AB	+	ALVOGEN	0.77%	N020519	001	Jul 21, 1997	Jun	CAHN	
		SOLUTION;TOPICAL							
	@	AKORN	8%	A078975	001	Feb 17, 2010	Apr	DISC	
AT		RISING	8%	A078124	001	Sep 18, 2007	May	CAHN	

CILOSTAZOL

TABLET;ORAL		CILOSTAZOL						
	@ EPIC PHARMA LLC	50MG		A 077022	002	Mar 11, 2005	Jan	CMS1
	@ NOSTRUM LABS INC	50MG		A 077708	001	Sep 28, 2009	Mar	DISC
AB		50MG		A 077708	001	Sep 28, 2009	Jan	CAHN
	@	100MG		A 077708	002	Sep 28, 2009	Mar	DISC
AB		100MG		A 077708	002	Sep 28, 2009	Jan	CAHN

CIMETIDINE

TABLET;ORAL		CIMETIDINE						
	@ NOVITIUM PHARMA	300MG		A 074340	001	Jun 23, 1995	Feb	CAHN
	@	400MG		A 074340	002	Jun 23, 1995	Feb	CAHN
	@	800MG		A 074339	001	Jun 23, 1995	Feb	CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL		CINACALCET HYDROCHLORIDE						
	@ MYLAN	EQ 30MG BASE		A 203422	001	Oct 16, 2018	Aug	CAHN
	@	EQ 30MG BASE		A 203422	001	Oct 16, 2018	Aug	DISC
	@	EQ 60MG BASE		A 203422	002	Oct 16, 2018	Aug	CAHN
	@	EQ 60MG BASE		A 203422	002	Oct 16, 2018	Aug	DISC
	@	EQ 90MG BASE		A 203422	003	Oct 16, 2018	Aug	CAHN
	@	EQ 90MG BASE		A 203422	003	Oct 16, 2018	Aug	DISC

CIPROFLOXACIN

INJECTABLE, SUSPENSION;OTIC		OTIPRIO						
+!	ALK ABELLO	6% (60MG/ML)		N 207986	001	Dec 10, 2015	Jun	CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION		CISATRACURIUM BESYLATE						
	@ SAGENT PHARMS INC	EQ 2MG BASE/ML		A 201851	001	Nov 06, 2020	Jul	DISC
	@ ZYDUS PHARMS	EQ 2MG BASE/ML		A 213527	001	Aug 31, 2020	Feb	DISC

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL		IDKIT:HP						
+!	EXALENZ BIOSCIENCE	4GM;75MG		N 021314	001	Dec 17, 2002	Jul	CPOT

CLARITHROMYCIN

TABLET;ORAL		CLARITHROMYCIN						
	@ WOCKHARDT	250MG		A 065266	001	May 31, 2006	Jan	DISC
	@	500MG		A 065266	002	May 31, 2006	Jan	DISC

CLASCOTERONE

CREAM;TOPICAL		WINLEVI						
>D>	+ @ CASSIOPEA SPA	1%		N 213433	001	Aug 26, 2020	Sep	CMFD
	+ @	1%		N 213433	001	Aug 26, 2020	Mar	DISC
>A>	+! SUN PHARM	1%		N 213433	001	Aug 26, 2020	Sep	CMFD

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL		CLEOCIN HYDROCHLORIDE						
AB	+ PFIZER	EQ 75MG BASE		N 050162	001		Feb	CAHN
AB	+	EQ 150MG BASE		N 050162	002		Feb	CAHN
AB	+!	EQ 300MG BASE		N 050162	003	Apr 14, 1988	Feb	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL		CLEOCIN						
AA	! PFIZER	EQ 75MG BASE/5ML		A 062644	001	Apr 07, 1986	Feb	CAHN

CLINDAMYCIN PHOSPHATE

Code	Manufacturer	Strength	Product ID	Formulation	Approval Date	Approval Agency
AEROSOL, FOAM;TOPICAL						
CLINDAMYCIN PHOSPHATE						
>A> AT	GLENMARK PHARMS LTD	1%	A210778	001 Sep 20, 2021	Sep	NEWA
CREAM;VAGINAL						
CLEOCIN						
	@ PFIZER	EQ 2% BASE	N050680	001 Aug 11, 1992	Feb	CAHN
AB	+	EQ 2% BASE	N050680	002 Mar 02, 1998	Feb	CAHN
GEL;TOPICAL						
CLEOCIN T						
AB1	+	PFIZER	EQ 1% BASE	N050615	001 Jan 07, 1987	Aug CTEC
AB	+		EQ 1% BASE	N050615	001 Jan 07, 1987	Feb CAHN
CLINDAGEL						
AB2	+	BAUSCH	EQ 1% BASE	N050782	001 Nov 27, 2000	Aug CFTG
CLINDAMYCIN PHOSPHATE						
AB1		ENCUBE	EQ 1% BASE	A212438	001 Mar 11, 2021	Aug CTEC
AB			EQ 1% BASE	A212438	001 Mar 11, 2021	Mar NEWA
AB1		FOUGERA PHARMS	EQ 1% BASE	A064160	001 Jan 28, 2000	Aug CTEC
AB1		GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001 Feb 10, 2021	Aug CTEC
AB			EQ 1% BASE	A214251	001 Feb 10, 2021	Jan NEWA
AB1		PADAGIS ISRAEL	EQ 1% BASE	A212104	001 Dec 31, 2020	Aug CTEC
AB		PERRIGO UK FINCO	EQ 1% BASE	A212104	001 Dec 31, 2020	Jan CAHN
AB1		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001 Jul 29, 2020	Aug CTEC
AB2			EQ 1% BASE	A212842	001 Aug 13, 2021	Aug NFTG
AB1		TARO PHARMS	EQ 1% BASE	A214052	001 Nov 10, 2020	Aug CTEC
INJECTABLE;INJECTION						
CLEOCIN PHOSPHATE						
AP		PFIZER	EQ 150MG BASE/ML	A062803	001 Oct 16, 1987	Feb CAHN
AP	+		EQ 150MG BASE/ML	N050441	001	Feb CAHN
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+	@ PFIZER	EQ 6MG BASE/ML	N050639	001 Aug 30, 1989	Feb CAHN
	+	@	EQ 12MG BASE/ML	N050639	002 Aug 30, 1989	Feb CAHN
	+	@	EQ 18MG BASE/ML	N050639	003 Apr 10, 1991	Feb CAHN
CLINDAMYCIN PHOSPHATE						
AP		ALMAJECT	EQ 150MG BASE/ML	A062800	001 Jul 24, 1987	Jul CAHN
	@		EQ 150MG BASE/ML	A062801	001 Jul 24, 1987	Jul CAHN
AP			EQ 150MG BASE/ML	A062943	001 Sep 29, 1988	Jul CAHN
	@	MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001 Oct 10, 2017	Jan DISC
LOTION;TOPICAL						
CLEOCIN T						
AB	+	PFIZER	EQ 1% BASE	N050600	001 May 31, 1989	Feb CAHN
CLINDAMYCIN PHOSPHATE						
AB		TARO PHARMS	EQ 1% BASE	A214526	001 Jun 28, 2021	Jun NEWA
SOLUTION;TOPICAL						
CLEOCIN T						
	+	@ PFIZER	EQ 1% BASE	N050537	001	Feb CAHN
	+	@ PHARMACIA AND UPJOHN	EQ 1% BASE	N050537	001	Jan DISC
SUPPOSITORY;VAGINAL						
CLEOCIN						
	+	PFIZER	100MG	N050767	001 Aug 13, 1999	Feb CAHN
SWAB;TOPICAL						
CLEOCIN						
	+	@ PFIZER	EQ 1% BASE	N050537	002 Feb 22, 1994	Mar DISC
AT	+		EQ 1% BASE	N050537	002 Feb 22, 1994	Feb CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL						
ZIANA						
AB	+	BAUSCH	1.2%;0.025%	N050802	001 Nov 07, 2006	May CAHN

CLOBAZAM

SUSPENSION;ORAL						
CLOBAZAM						
AB		ALKEM LABS LTD	2.5MG/ML	A213039	001 May 06, 2021	Apr NEWA
AB		TARO	2.5MG/ML	A210978	001 Apr 15, 2019	Jul CMFD
TABLET;ORAL						
CLOBAZAM						
	@	CELLTRION	10MG	A211959	001 Dec 09, 2020	Jun DISC
	@		20MG	A211959	002 Dec 09, 2020	Jun DISC
	@	LANNETT CO INC	10MG	A212092	001 Oct 30, 2019	Mar DISC

	TABLET;ORAL						
	CLOBAZAM						
	@	20MG	A212092	002	Oct 30, 2019	Mar	DISC
AB	MSN	10MG	A213404	001	May 11, 2021	Apr	NEWA
AB		20MG	A213404	002	May 11, 2021	Apr	NEWA
	<u>CLOBETASOL PROPIONATE</u>						
	CREAM;TOPICAL						
	CLOBETASOL PROPIONATE						
>D>	AB1	GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Sep CAHN
	AB1		0.05%	A211207	001	Mar 26, 2021	Mar NEWA
>A>	AB1	PAI HOLDINGS PHARM	0.05%	A211207	001	Mar 26, 2021	Sep CAHN
	IMPOYZ						
	+!	PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017	Mar CAHN
	OINTMENT;TOPICAL						
	CLOBETASOL PROPIONATE						
	@	TORRENT	0.05%	A212926	001	Oct 25, 2019	Jan DISC
	SHAMPOO;TOPICAL						
	CLOBETASOL PROPIONATE						
AB	AMNEAL	0.05%	A214895	001	Jun 14, 2021	Jun	NEWA
AB	TARO PHARMS	0.05%	A214867	001	Mar 25, 2021	Mar	NEWA
	SOLUTION;TOPICAL						
	CLOBETASOL PROPIONATE						
AT	PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Jan	NEWA
	SPRAY;TOPICAL						
	CLOBETASOL PROPIONATE						
	@	AKORN	0.05%	A207218	001	Apr 28, 2017	Apr DISC
	<u>CLOFARABINE</u>						
	SOLUTION;INTRAVENOUS						
	CLOFARABINE						
AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan	CAHN
	@	NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar DISC
	<u>CLOMIPRAMINE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	CLOMIPRAMINE HYDROCHLORIDE						
AB	ALEMBIC PHARMS LTD	25MG	A211822	001	Aug 04, 2021	Jul	NEWA
AB		50MG	A211822	002	Aug 04, 2021	Jul	NEWA
AB		75MG	A211822	003	Aug 04, 2021	Jul	NEWA
AB	VGYAAN	25MG	A213221	001	Jun 22, 2020	May	CMFD
AB		50MG	A213221	002	Jun 22, 2020	May	CMFD
AB		75MG	A213221	003	Jun 22, 2020	May	CMFD
	<u>CLONIDINE</u>						
	SYSTEM;TRANSDERMAL						
	CATAPRES-TTS-1						
AB	+	LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan CAHN
AB	+	TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan CAHN
	CATAPRES-TTS-2						
AB	+	LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan CAHN
AB	+	TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan CAHN
	CATAPRES-TTS-3						
AB	+!	LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan CAHN
AB	+!	TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan CAHN
	<u>CLONIDINE HYDROCHLORIDE</u>						
	INJECTABLE;INJECTION						
	CLONIDINE HYDROCHLORIDE						
AP	!	HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar CHRS
	+	@ MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar DISC
	<u>CLOPIDOGREL BISULFATE</u>						
	TABLET;ORAL						
	CLOPIDOGREL BISULFATE						
>D>	AB	ADAPTIS	EQ 75MG BASE	A204359	001	Feb 02, 2017	Sep CAHN
AB		POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb CMFD
AB			EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb CMFD
>A>	AB	RISING	EQ 75MG BASE	A204359	001	Feb 02, 2017	Sep CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

TRANXENE

	+ @ RECORDATI RARE	3.75MG	N017105	001		May	CRLD
	+ @	7.5MG	N017105	002		May	CRLD
	+ @	15MG	N017105	003		May	CRLD

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987	Jan	CAHN
AB		7.5MG	A071858	003	Jul 17, 1987	Jan	CAHN
AB	!	15MG	A071858	001	Jul 17, 1987	Jan	CAHN
	TRANXENE						
	+ @ RECORDATI RARE	3.75MG	N017105	006		May	CRLD
	TRANXENE SD						
	+ @ RECORDATI RARE	11.25MG	N017105	005		May	CRLD
	+ @	22.5MG	N017105	004		May	CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	AKORN	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Feb	CAHN
----	-------	-----------------------------	---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	+!	ACTAVIS MID ATLANTIC	10MG/5ML;6.25MG/5ML	A088763	001	Oct 31, 1984	Aug	CRLD
----	----	----------------------	---------------------	---------	-----	--------------	-----	------

COLCHICINE

TABLET;ORAL

COLCHICINE

AB	HETERO LABS LTD V	0.6MG	A208993	001	Aug 13, 2021	Aug	NEWA
AB	PAR PHARM INC	0.6MG	A203976	001	Aug 12, 2021	Aug	NEWA

COLCHICINE; PROBENECID

TABLET;ORAL

COL-PROBENECID

AB	+!	WATSON LABS	0.5MG;500MG	A084279	001		Aug	CRLD
----	----	-------------	-------------	---------	-----	--	-----	------

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

GLENMARK PHARMS LTD 1.875GM/PACKET

@ WATSON LABS INC 1.875GM/PACKET

@ 3.75GM/PACKET

A202190	001	Jul 16, 2018	Feb	CTEC
A202178	001	Sep 01, 2020	Feb	DISC
A202178	002	Sep 01, 2020	Feb	DISC

TABLET;ORAL

COLESEVELAM HYDROCHLORIDE

@ WATSON LABS INC 625MG

A200830	001	Sep 02, 2020	Feb	DISC
---------	-----	--------------	-----	------

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

COLESTID

AB	+	PFIZER	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Feb	CAHN
AB	+!		5GM/PACKET	N017563	004	Sep 22, 1995	Feb	CAHN
		FLAVORED COLESTID						
	+	PFIZER	5GM/PACKET	N017563	001		Feb	CAHN
	+		5GM/SCOOPFUL	N017563	002		Feb	CAHN

TABLET;ORAL

COLESTID

AB	+!	PFIZER	1GM	N020222	001	Jul 19, 1994	Feb	CAHN
----	----	--------	-----	---------	-----	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

>D>	@	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012	Sep	CMFD
>A>	AP		EQ 150MG BASE/VIAL	A202359	001	Sep 28, 2012	Sep	CMFD

CORTICOTROPIN

		INJECTABLE; INJECTION							
>A>		ACTHAR GEL							
>A>	@	MALLINCKRODT ARD	40 UNITS/ML	N008372	006			Sep	CTNA
>A>	+	!	80 UNITS/ML	N008372	008			Sep	CTNA
>D>		H.P. ACTHAR GEL							
>D>	@	MALLINCKRODT ARD	40 UNITS/ML	N008372	006			Sep	CTNA
>D>	+	!	80 UNITS/ML	N008372	008			Sep	CTNA

CROTAMITON

		CREAM; TOPICAL							
		EURAX							
	+	@	JOURNEY	10%	N006927	001		Jan	CAHN
		LOTION; TOPICAL							
		EURAX							
AT	+	!	JOURNEY	10%	N009112	003		Jan	CAHN

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOS ACID; ZINC SULFATE

SOLUTION; INTRAVENOUS

MULTRY'S

+	!	AM REGENT	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	001	Jul 02, 2020	Aug	CTNA
+	!		(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	001	Jul 02, 2020	Jan	CPOT
+	!		(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	002	Dec 02, 2020	Aug	CTNA
+	!		(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	002	Dec 02, 2020	Jan	NEWA
+	!		(1ML) EQ 0.06MG COPPER/ML; EQ 3MCG BASE/ML; EQ 6MCG BASE/ML; EQ 1MG BASE/ML	N209376	003	Jun 30, 2021	Aug	CTNA
+	!		(1ML) EQ 0.06MG COPPER/ML; EQ 3MCG BASE/ML; EQ 6MCG BASE/ML; EQ 1MG BASE/ML	N209376	003	Jun 30, 2021	Jul	NEWA

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

>D>	AP		XIROMED	1MG/ML	A215046	001	Aug 20, 2021	Sep	DISC
>A>		@		1MG/ML	A215046	001	Aug 20, 2021	Sep	DISC
	AP			1MG/ML	A215046	001	Aug 20, 2021	Aug	NEWA
		VIBISONE							
AP	+	!	FRESENIUS KABI USA	1MG/ML	A080557	003		Aug	CRLD

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

	@	MYLAN PHARMS INC	5MG	A073144	002	Feb 03, 2006	Aug	DISC
	@		7.5MG	A073144	003	Mar 25, 2013	Aug	DISC
	@		10MG	A073144	001	May 30, 1991	Aug	DISC

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

AT			AKORN	2%	A040165	001	Jan 13, 1997	Aug	CMFD
		CYCLOGYL							
AT	+	!	ALCON LABS INC	0.5%	A084109	001		Aug	CRLD
AT	+	!		1%	A084110	001		Aug	CRLD
AT	+	!		2%	A084108	001		Aug	CRLD
AT	!			2%	A084108	001		Aug	CTEC

CYCLOPHOSPHAMIDE

SOLUTION; INTRAVENOUS

CYCLOPHOSPHAMIDE

+	!	AUROMEDICS PHARMA	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021	Aug	NEWA
+	!		1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021	Aug	NEWA

CYCLOSPORINEEMULSION;OPHTHALMIC
VERKAZIA

+! SANTEN 0.1% N214965 001 Jun 23, 2021 Jun NEWA

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

+ @ ACTAVIS MID ATLANTIC 2MG/5ML A086833 001 Aug CRLD

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA +! HERITAGE PHARMA 4MG A087056 001 Aug CRLD

AA QUAGEN 4MG A212491 001 Feb 24, 2021 Feb NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL

PROCYSBI

+ HORIZON EQ 25MG BASE N203389 001 Apr 30, 2013 May CAHN

+! EQ 75MG BASE N203389 002 Apr 30, 2013 May CAHN

CYTARABINE

INJECTABLE;INJECTION

CYTARABINE

>D> AP HONG KONG 20MG/ML A206189 001 Jun 26, 2020 Sep DISC

>A> @ 20MG/ML A206189 001 Jun 26, 2020 Sep DISC

@ MEITHEAL 20MG/ML A206190 001 Nov 09, 2017 Aug DISC

@ MYLAN LABS LTD 20MG/ML A200914 001 Dec 13, 2011 May DISC

DABIGATRAN ETEXILATE MESYLATE

PELLET;ORAL

PRADAXA

+ BOEHRINGER INGELHEIM EQ 20MG BASE/PACKET N214358 001 Jun 21, 2021 Jun NEWA

+ EQ 30MG BASE/PACKET N214358 002 Jun 21, 2021 Jun NEWA

+ EQ 40MG BASE/PACKET N214358 003 Jun 21, 2021 Jun NEWA

+ EQ 50MG BASE/PACKET N214358 004 Jun 21, 2021 Jun NEWA

+ EQ 110MG BASE/PACKET N214358 005 Jun 21, 2021 Jun NEWA

+! EQ 150MG BASE/PACKET N214358 006 Jun 21, 2021 Jun NEWA

PELLETS;ORAL

PRADAXA

+ BOEHRINGER INGELHEIM EQ 20MG BASE/PACKET N214358 001 Jun 21, 2021 Jul CDFR

+ EQ 30MG BASE/PACKET N214358 002 Jun 21, 2021 Jul CDFR

+ EQ 40MG BASE/PACKET N214358 003 Jun 21, 2021 Jul CDFR

+ EQ 50MG BASE/PACKET N214358 004 Jun 21, 2021 Jul CDFR

+ EQ 110MG BASE/PACKET N214358 005 Jun 21, 2021 Jul CDFR

+! EQ 150MG BASE/PACKET N214358 006 Jun 21, 2021 Jul CDFR

DACTINOMYCIN

INJECTABLE;INJECTION

DACTINOMYCIN

AP AUROMEDICS PHARMA 0.5MG/VIAL A203385 001 Nov 09, 2017 Jan CAHN

AP EUGIA PHARMA 0.5MG/VIAL A203385 001 Nov 09, 2017 Aug CAHN

@ HIKMA PHARMS 0.5MG/VIAL A090304 001 Mar 16, 2010 Jul CAHN

AP MEITHEAL 0.5MG/VIAL A213463 001 Nov 13, 2020 Feb CAHN

DAPSONE

TABLET;ORAL

DAPSONE

AB ALVOGEN 25MG A205429 001 Jan 07, 2016 Jun CAHN

AB 100MG A205429 002 Jan 07, 2016 Jun CAHN

AB + JACOBUS 25MG A086841 001 Aug CRLD

AB +! 100MG A086842 001 Aug CRLD

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

AP HISUN PHARM HANGZHOU 500MG/VIAL A212250 001 Apr 21, 2021 Apr NEWA

AP HONG KONG 500MG/VIAL A213623 001 Jun 29, 2021 Jun NEWA

+! HOSPIRA INC 350MG/VIAL N210282 001 Jun 21, 2021 Jun NEWA

+! 500MG/VIAL N210282 002 Jun 21, 2021 Jun NEWA

AP MEITHEAL 500MG/VIAL A213623 001 Jun 29, 2021 Aug CAHN

AP QILU 500MG/VIAL A215316 001 Aug 24, 2021 Aug NEWA

POWDER; IV (INFUSION)

DAPTOMYCIN

AP	HONG KONG	350MG/VIAL	A213786	001	Jun 29, 2021	Jun	NEWA
AP	MEITHEAL	350MG/VIAL	A213786	001	Jun 29, 2021	Aug	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

	@ JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Jun	DISC
	@	EQ 15MG BASE	A205550	002	Oct 12, 2016	Jun	DISC
>D>	AB XIROMED	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Sep	CTEC
>A>	BX	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Sep	CTEC
>D>	AB	EQ 15MG BASE	A209571	001	Oct 22, 2019	Sep	CTEC
>A>	BX	EQ 15MG BASE	A209571	001	Oct 22, 2019	Sep	CTEC

>D> DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

>D> TABLET; ORAL

>D> VIEKIRA PAK (COPACKAGED)

>D>	+!	ABBVIE INC	EQ 250MG BASE; 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Sep	DISC
>A>	+	@	EQ 250MG BASE; 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Sep	DISC
	+	!	EQ 250MG BASE; 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Aug	CPOT

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL

VIEKIRA PAK (COPACKAGED)

+	!	ABBVIE INC	250.0MG; 12.5MG; 75.0MG; EQ 250MG BASE, N/A, N/A, N/A; N/A, 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Aug	CDFR
---	---	------------	--	---------	-----	--------------	-----	------

DASIGLUCAGON HYDROCHLORIDE

SOLUTION; SUBCUTANEOUS

ZEGALOGUE

+	!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May	CAHN
+	!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar	NEWA
			ZEGALOGUE (AUTOINJECTOR)					
+	!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May	CAHN
+	!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar	NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DAUNORUBICIN HYDROCHLORIDE

AP	+	HIKMA PHARMS	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Jul	CAHN
----	---	--------------	----------------	---------	-----	--------------	-----	------

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

	@	APOTEX	50MG/VIAL	A205539	001	Nov 23, 2020	May	DISC
	@	CIPLA	50MG/VIAL	A208601	001	Nov 16, 2017	May	DISC
>A>	AP	EUGIA PHARMA	50MG/VIAL	A214569	001	Sep 20, 2021	Sep	NEWA
	AP	GLAND	50MG/VIAL	A205539	001	Nov 23, 2020	Jul	CMFD
	@		50MG/VIAL	A205539	001	Nov 23, 2020	Jul	CAHN
>D>	AP	HONG KONG	50MG/VIAL	A212959	001	Jul 02, 2021	Sep	CAHN
	AP		50MG/VIAL	A212959	001	Jul 02, 2021	Jun	NEWA
>A>	AP	MEITHEAL	50MG/VIAL	A212959	001	Jul 02, 2021	Sep	CAHN
	AP	QILU	50MG/VIAL	A212826	001	Apr 12, 2021	Apr	NEWA

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

AB		AMNEAL	90MG	A214194	003	Aug 02, 2021	Jul	NEWA
AB			180MG	A214194	001	Feb 09, 2021	Jan	NEWA
AB			360MG	A214194	002	Feb 09, 2021	Jan	NEWA
AB		AUCTA	90MG	A214559	001	Mar 09, 2021	Feb	NEWA
AB			180MG	A214559	002	Mar 09, 2021	Feb	NEWA
AB			360MG	A214559	003	Mar 09, 2021	Feb	NEWA
AB		MSN	180MG	A214650	001	Mar 17, 2021	Mar	NEWA
AB			360MG	A214650	002	Mar 17, 2021	Mar	NEWA

TABLET;ORAL

DEFERASIROX							
AB	ANNORA PHARMA	90MG	A214341	001	May 14, 2021	May	NEWA
AB		180MG	A214341	002	May 14, 2021	May	NEWA
AB		360MG	A214341	003	May 14, 2021	May	NEWA
AB	CELLTRION	90MG	A212669	001	May 27, 2021	May	NEWA
AB		180MG	A212669	002	May 27, 2021	May	NEWA
AB		360MG	A212669	003	May 27, 2021	May	NEWA

DEFERIPRONE

SOLUTION;ORAL							
FERRIPROX							
	+ @ CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Aug	DISC
TABLET;ORAL							
DEFERIPRONE							
AB	HIKMA PHARMS	500MG	A213239	001	Mar 29, 2021	Mar	NEWA
FERRIPROX							
AB	+! CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CTEC

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS							
DEOXYCHOLIC ACID							
AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar	NFTG
KYBELLA							
AP	+! KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Mar	CFTG

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL							
DESIPRAMINE HYDROCHLORIDE							
AB	ALEMBIC PHARMS LTD	10MG	A209785	001	Jul 07, 2021	Jun	NEWA
AB		25MG	A209785	002	Jul 07, 2021	Jun	NEWA
AB		50MG	A209785	003	Jul 07, 2021	Jun	NEWA
AB		75MG	A209785	004	Jul 07, 2021	Jun	NEWA
AB		100MG	A209785	005	Jul 07, 2021	Jun	NEWA
AB		150MG	A209785	006	Jul 07, 2021	Jun	NEWA
NORPRAMIN							
AB	+ VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb	CAHN
AB	+	25MG	N014399	001		Feb	CAHN
AB	+	50MG	N014399	003		Feb	CAHN
AB	+	75MG	N014399	004		Feb	CAHN
AB	+!	100MG	N014399	005		Feb	CAHN
AB	+	150MG	N014399	006		Feb	CAHN

DESLORATADINE

TABLET;ORAL							
CLARINEX							
AB	+! ORGANON	5MG	N021165	001	Dec 21, 2001	Aug	CAHN
DESLORATADINE							
	@ SUN PHARM INDS	5MG	A078359	001	Nov 16, 2010	Aug	DISC

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL							
CLARINEX-D 12 HOUR							
	+! ORGANON	2.5MG;120MG	N021313	001	Feb 01, 2006	Jun	CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL							
NOCTIVA							
>D>	+ @ ROIVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Sep	CAHN
	+ @	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Feb	CAHN
>D>	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Sep	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Feb	CAHN
>A>	+ @ SERENITY PHARMS LLC	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Sep	CAHN
>A>	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Sep	CAHN

DESONIDE

GEL;TOPICAL							
DESONATE							
	+ @ LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Mar	DISC
DESONIDE							
	! CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Mar	CHRS
		0.05%	A202470	001	May 11, 2020	Mar	CTEC

DESOXIMETASONE

	CREAM; TOPICAL								
	DESOXIMETASONE								
	@ AKORN	0.05%	A203787	001	Jan 06, 2017	Apr	DISC		
	@	0.25%	A203234	001	Jun 12, 2015	Apr	DISC		
	OINTMENT; TOPICAL								
	DESOXIMETASONE								
AB	! GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Apr	CHRS		
	TOPICORT								
	@ TARO PHARM INDS LTD	0.25%	A074286	001	Jun 07, 1996	Apr	DISC		

DEXAMETHASONE

	ELIXIR; ORAL								
	DEXAMETHASONE								
AA	+ WOCKHARDT BIO AG	0.5MG/5ML	A088254	001	Jul 27, 1983	Aug	CRLD		
	TABLET; ORAL								
	DEXAMETHASONE								
BP	ALVOGEN	0.5MG	A088481	002	Apr 28, 1983	Jun	CAHN		
BP		0.75MG	A088481	003	Apr 28, 1983	Jun	CAHN		
BP		4MG	A088481	004	Apr 28, 1983	Jun	CAHN		
BP		6MG	A088481	001	Nov 28, 1983	Jun	CAHN		
BP	! HIKMA PHARMS	1MG	A088306	001	Sep 15, 1983	Apr	CHRS		
BP	!	2MG	A087916	001	Aug 26, 1982	Apr	CHRS		

DEXAMETHASONE SODIUM PHOSPHATE

	INJECTABLE; INJECTION								
	DEXAMETHASONE SODIUM PHOSPHATE								
AP	GLAND PHARMA LTD	EQ 4MG PHOSPHATE/ML	A215654	001	Aug 04, 2021	Jul	NEWA		
	+ @ LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Aug	CRLD		

DEXAMETHASONE; TOBRAMYCIN

	SUSPENSION/DROPS; OPHTHALMIC								
	TOBRAMYCIN AND DEXAMETHASONE								
AB	AMNEAL	0.1%; 0.3%	A212991	001	Jul 15, 2021	Jul	NEWA		

DEXCHLORPHENIRAMINE MALEATE

	SYRUP; ORAL								
	DEXCHLORPHENIRAMINE MALEATE								
AA	+! WOCKHARDT BIO AG	2MG/5ML	A088251	001	Mar 23, 1984	Aug	CRLD		
	TABLET; ORAL								
	POLARAMINE								
	+ @ SCHERING	2MG	A086835	001		Aug	CRLD		

DEXMEDETOMIDINE HYDROCHLORIDE

	INJECTABLE; INJECTION								
	DEXMEDETOMIDINE HYDROCHLORIDE								
AP	GLAND	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	May	CAHN		
AP	HIKMA PHARMS	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205046	001	Apr 26, 2017	Jul	CAHN		
AP	HONG KONG	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jun	CMFD		
AP	PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A214794	001	Sep 03, 2021	Aug	NEWA		

DEXMETHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE; ORAL								
	DEXMETHYLPHENIDATE HYDROCHLORIDE								
	@ MYLAN	5MG	A204266	001	Aug 25, 2015	Jul	DISC		
	@	10MG	A204266	002	Aug 25, 2015	Jul	DISC		
	@	15MG	A204266	003	Aug 25, 2015	Jul	DISC		
	@	20MG	A204266	004	Dec 21, 2015	Jul	DISC		
	@	25MG	A204266	005	May 04, 2021	Jul	DISC		
AB		25MG	A204266	005	May 04, 2021	Apr	NEWA		
	@	30MG	A202580	001	Aug 28, 2013	Jul	CAHN		
	@	30MG	A202580	001	Aug 28, 2013	Jul	DISC		
	@	35MG	A204266	006	May 04, 2021	Jul	DISC		
AB		35MG	A204266	006	May 04, 2021	Apr	NEWA		
	@	40MG	A204266	007	Aug 25, 2015	Jul	DISC		

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	@ BIONPHARMA INC	5MG	A209754	001	Mar 24, 2020	Sep CAHN
>A>	@	10MG	A209754	002	Mar 24, 2020	Sep CAHN
>D>	@ USPHARMA	5MG	A209754	001	Mar 24, 2020	Sep CAHN
>D>	@	10MG	A209754	002	Mar 24, 2020	Sep CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE; ORAL

AZSTARYS

+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021	May NEWA
+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021	May NEWA
+	!	EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021	May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

AP	AUROMEDICS PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Jan CAHN
AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Jan CAHN
AP	! EUGIA PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug CHRS
AP		EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug CAHN
AP	!	EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug CHRS
AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug CAHN
	TOTECT					
+	@ CLINIGEN	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Aug DISC
	ZINECARD					
+	@ PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Aug DISC
AP	+	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar CAHN
+	@	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Aug DISC
AP	+	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXEDRINE

+	@ GLAXOSMITHKLINE	5MG	A084935	001		Aug CRLD
	DEXTROAMPHETAMINE SULFATE					
AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	May CTEC
AA		7.5MG	A090533	003	Oct 25, 2011	May CTEC
AA		15MG	A090533	005	Oct 25, 2011	May CTEC
AA		20MG	A090533	006	Oct 25, 2011	May CTEC
AA		30MG	A090533	007	Oct 25, 2011	May CTEC
AA	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	May NEWA
AA		5MG	A212160	002	Jun 07, 2021	May NEWA
AA		7.5MG	A212160	003	Jun 07, 2021	May NEWA
AA		10MG	A212160	004	Jun 07, 2021	May NEWA
AA		15MG	A212160	005	Jun 07, 2021	May NEWA
AA		20MG	A212160	006	Jun 07, 2021	May NEWA
AA		30MG	A212160	007	Jun 07, 2021	May NEWA
	DEXTROSTAT					
+	@ SHIRE	5MG	A084051	001		Aug CRLD
+	@	10MG	A084051	002		Aug CRLD

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

@	FRESENIUS KABI USA	5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020	Mar DISC
	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%					
@	FRESENIUS KABI USA	5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020	Mar DISC
	DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER					
+	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		Mar CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

>D>	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Sep DISC
>A>	@	5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Sep DISC
		5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Jul NFTG
	POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
>D>	AP FRESENIUS KABI USA	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Sep DISC
>A>	@	5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Sep DISC
AP		5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Feb NEWA

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Sep DISC
>A>		@	5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Sep DISC
	AP		5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Jul NFTG
>D>	AP	+ ICU MEDICAL INC	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Sep CTEC
>A>		+	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Sep CTEC
	AP	+	5GM/100ML;149MG/100ML;225MG/100ML	N018365	001		Jul CFTG
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Sep DISC
>A>		@	5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Sep DISC
	AP		5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Feb NEWA
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Sep DISC
>A>		@	5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Sep DISC
	AP		5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Feb NFTG
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Sep DISC
>A>		@	5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Sep DISC
	AP		5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb NEWA
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Sep DISC
>A>		@	5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Sep DISC
	AP		5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb NEWA
		POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
>D>	AP	FRESENIUS KABI USA	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Sep DISC
>A>		@	5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Sep DISC
	AP		5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb NFTG

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
	AP	FRESENIUS KABI USA	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	May CMFD
		DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
	AP	FRESENIUS KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	May CMFD
		@	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb DISC
	AP	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001		May CTEC
		+!	5GM/100ML;300MG/100ML	N017799	001		Feb CTEC
		DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
	AP	FRESENIUS KABI USA	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	May CMFD
		@	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	Mar DISC
		DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
	AP	FRESENIUS KABI USA	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	May CMFD
		@	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	Mar DISC

DIAZEPAM

INJECTABLE; INJECTION

		DIAZEPAM					
	AP	! BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Aug CTEC

DICLOFENAC POTASSIUM

TABLET; ORAL

		CATAFLAM					
>D>		AMICI	25MG	A076561	002	Jul 21, 2021	Sep CTEC
>A>	AB		25MG	A076561	002	Jul 21, 2021	Sep CTEC
			25MG	A076561	002	Jul 21, 2021	Jul NEWA
	AB		50MG	A076561	001	Mar 18, 2004	May CTNA
		DICLOFENAC POTASSIUM					
>A>	AB	RUBICON	25MG	A075229	002	Sep 16, 2021	Sep NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

		DICLOFENAC SODIUM					
	AB	! TARO	3%	A206298	001	Apr 28, 2016	Mar CHRS
		SOLARAZE					
		+ @ FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000	Mar DISC
		SOLUTION; TOPICAL					
		DICLOFENAC SODIUM					
	AT	AKORN	1.5%	A206655	001	Jan 28, 2021	Jan NEWA
		@ RISING	1.5%	A206715	001	Aug 07, 2017	May CAHN

SOLUTION/DROPS;OPHTHALMIC									
DICLOFENAC SODIUM									
AT	!	BAUSCH AND LOMB	0.1%	A 078792	001	Dec 28, 2007	Aug	CHRS	
VOLTAREN									
	+	@ NOVARTIS	0.1%	N 020037	001	Mar 28, 1991	Aug	DISC	
TABLET, DELAYED RELEASE;ORAL									
DICLOFENAC SODIUM									
	@	MICRO LABS	50MG	A 074986	001	Feb 26, 1999	Feb	CAHN	
	@		75MG	A 074986	002	Feb 26, 1999	Feb	CAHN	
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>									
TABLET, DELAYED RELEASE;ORAL									
DICLOFENAC SODIUM AND MISOPROSTOL									
AB		MICRO LABS	50MG;0.2MG	A 204355	001	Jul 15, 2021	Jul	NEWA	
AB			75MG;0.2MG	A 204355	002	Jul 15, 2021	Jul	NEWA	
<u>DICLOXACILLIN SODIUM</u>									
CAPSULE;ORAL									
DICLOXACILLIN SODIUM									
	@	SANDOZ	EQ 125MG BASE	A 061454	002		Jan	DISC	
	@		EQ 250MG BASE	A 061454	001		Jan	DISC	
	@		EQ 500MG BASE	A 061454	003		Jan	DISC	
		TEVA	EQ 250MG BASE	A 062286	001	Jun 03, 1982	Jan	CTEC	
	!		EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan	CTEC	
AB	!		EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan	CHRS	
<u>DICYCLOMINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
DICYCLOMINE HYDROCHLORIDE									
>A>	AP	GENE YORK PHARMS	10MG/ML	A 212058	001	Apr 26, 2019	Sep	CAHN	
>D>	AP	PRAXGEN	10MG/ML	A 212058	001	Apr 26, 2019	Sep	CAHN	
	AP		10MG/ML	A 212058	001	Apr 26, 2019	Jun	CAHN	
SYRUP;ORAL									
DICYCLOMINE HYDROCHLORIDE									
AA		NOVITIUM PHARMA	10MG/5ML	A 214721	001	Apr 23, 2021	Apr	NEWA	
TABLET;ORAL									
DICYCLOMINE HYDROCHLORIDE									
	@	MYLAN	20MG	A 040317	001	Sep 07, 1999	Aug	DISC	
<u>DIDANOSINE</u>									
CAPSULE, DELAYED REL PELLETS;ORAL									
DIDANOSINE									
	@	AUROBINDO PHARMA	125MG	A 090094	001	Sep 24, 2008	Jan	DISC	
	@		200MG	A 090094	002	Sep 24, 2008	Jan	DISC	
	@		250MG	A 090094	003	Sep 24, 2008	Jan	DISC	
	@		400MG	A 090094	004	Sep 24, 2008	Jan	DISC	
<u>DIFELIKEFALIN ACETATE</u>									
SOLUTION;INTRAVENOUS									
KORSUVA									
	+	CARA THERAP	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N 214916	001	Aug 23, 2021	Aug	NEWA	
<u>DIFLORASONE DIACETATE</u>									
CREAM;TOPICAL									
DIFLORASONE DIACETATE									
BX	!	ANI PHARMS	0.05%	A 076263	001	Dec 20, 2002	Apr	CAHN	
OINTMENT;TOPICAL									
DIFLORASONE DIACETATE									
	@	AKORN	0.05%	A 206572	001	Jul 24, 2015	Apr	DISC	
<u>DIFLUNISAL</u>									
TABLET;ORAL									
DIFLUNISAL									
>A>		@ DASTECH INTL	250MG	A 073562	001	Nov 27, 1992	Sep	CAHN	
>A>		@	500MG	A 073563	001	Nov 27, 1992	Sep	CAHN	
>D>		@ SOCORRO	250MG	A 073562	001	Nov 27, 1992	Sep	CAHN	
>D>		@	500MG	A 073563	001	Nov 27, 1992	Sep	CAHN	

DIFLUPREDNATEEMULSION;OPHTHALMIC
DIFLUPREDNATE

AB	CIPLA	0.05%	A211776	001	Aug 09, 2021	Jul	NFTG
AB	+! NOVARTIS	0.05%	N022212	001	Jun 23, 2008	Jul	CFTG

DIGOXINELIXIR;ORAL
DIGOXIN

>A>	AA	NOVITIUM PHARMA	0.05MG/ML	A213000	001	Oct 04, 2019	Sep	CAHN
>D>	AA	VISTAPHARM	0.05MG/ML	A213000	001	Oct 04, 2019	Sep	CAHN

DIHYDROERGOTAMINE MESYLATEINJECTABLE;INJECTION
DIHYDROERGOTAMINE MESYLATE

AP	PROVEPHARM SAS	1MG/ML	A212046	001	Jan 07, 2020	Jan	CAHN	
>A>		SPRAY, METERED;NASAL						
		TRUDHESA						
>A>	+!	IMPEL NEUROPHARMA	0.725MG/SPRAY	N213436	001	Sep 02, 2021	Sep	NEWA

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB1	GLENMARK PHARMS LTD	60MG	A212317	001	Mar 22, 2021	Mar	NEWA
AB1		90MG	A212317	002	Mar 22, 2021	Mar	NEWA
AB1		120MG	A212317	003	Mar 22, 2021	Mar	NEWA
AB1	MYLAN	60MG	A074910	001	May 02, 1997	Mar	CTEC
AB1		90MG	A074910	002	May 02, 1997	Mar	CTEC
AB1	!	120MG	A074910	003	May 02, 1997	Mar	CTEC

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

@	INTL MEDICATION	5MG/ML	A075749	001	Nov 21, 2001	Jan	DISC
---	-----------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

DILTIAZEM HYDROCHLORIDE

@	MYLAN	30MG	A072838	004	Nov 05, 1992	Aug	CAHN
@		30MG	A072838	004	Nov 05, 1992	Aug	DISC
@		60MG	A072838	003	Nov 05, 1992	Aug	CAHN
@		60MG	A072838	003	Nov 05, 1992	Aug	DISC
@		90MG	A072838	002	Nov 05, 1992	Aug	CAHN
@		90MG	A072838	002	Nov 05, 1992	Aug	DISC
@		120MG	A072838	001	Nov 05, 1992	Aug	CAHN
@		120MG	A072838	001	Nov 05, 1992	Aug	DISC

DIMENHYDRINATEINJECTABLE;INJECTION
DIMENHYDRINATE

+ @	WATSON LABS TEVA	50MG/ML	A080615	001		Aug	CRLD
-----	------------------	---------	---------	-----	--	-----	------

TABLET;ORAL

DIMENHYDRINATE

+ @	WATSON LABS	50MG	A085166	001		Aug	CRLD
-----	-------------	------	---------	-----	--	-----	------

DIMETHYL FUMARATECAPSULE, DELAYED RELEASE;ORAL
DIMETHYL FUMARATE

AB	LUPIN	120MG	A210226	001	Oct 05, 2020	Jul	CAHN	
AB		240MG	A210226	002	Oct 05, 2020	Jul	CAHN	
AB	PHARMATHEN	120MG	A210436	001	Mar 26, 2021	Mar	NEWA	
AB		240MG	A210436	002	Mar 26, 2021	Mar	NEWA	
	@ ZYDUS PHARMS	120MG	A210538	001	Sep 24, 2020	Feb	DISC	
	@	240MG	A210538	002	Sep 24, 2020	Feb	DISC	
	TECFIDERA							
AB	+	BIOGEN INC	120MG	N204063	001	Mar 27, 2013	Apr	CAHN
AB	+!		240MG	N204063	002	Mar 27, 2013	Apr	CAHN

DINOPROSTONEGEL; ENDOCERVICAL
PREPIDIL

+! PFIZER 0.5MG/3GM N019617 001 Dec 09, 1992 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE; INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP +! WEST-WARD PHARMS INT 50MG/ML A080817 002 Aug CRLD

DIPYRIDAMOLETABLET; ORAL
DIPYRIDAMOLEAB OXFORD PHARMS 25MG A040542 001 Apr 21, 2006 Jan CMFD
AB 50MG A040542 002 Apr 21, 2006 Jan CMFD
AB 75MG A040542 003 Apr 21, 2006 Jan CMFDDIROXIMEL FUMARATECAPSULE, DELAYED RELEASE; ORAL
VUMERITY

+! BIOGEN INC 231MG N211855 001 Oct 29, 2019 Apr CAHN

DISOPYRAMIDE PHOSPHATECAPSULE; ORAL
DISOPYRAMIDE PHOSPHATE@ MAYNE PHARMA EQ 100MG BASE A070173 001 May 31, 1985 Feb DISC
@ EQ 150MG BASE A070173 002 May 31, 1985 Feb DISCDISULFIRAMTABLET; ORAL
ANTABUSE>D> AB + ODYSSEY PHARMS 250MG A088482 001 Dec 08, 1983 Sep DISC
>A> + @ 250MG A088482 001 Dec 08, 1983 Sep DISC
AB + 250MG A088482 001 Dec 08, 1983 Aug CRLD
>D> AB +! 500MG A088483 001 Dec 08, 1983 Sep DISC
>A> + @ 500MG A088483 001 Dec 08, 1983 Sep DISC
AB +! 500MG A088483 001 Dec 08, 1983 Aug CRLD

DISULFIRAM

>D> AB HIKMA PHARMS 500MG A202652 002 Feb 05, 2014 Sep CHRS
>A> AB ! 500MG A202652 002 Feb 05, 2014 Sep CHRSDIVALPROEX SODIUMCAPSULE, DELAYED REL PELLETS; ORAL
DIVALPROEX SODIUM

@ TEVA PHARMS USA EQ 125MG VALPROIC ACID A211505 001 Nov 17, 2020 May DISC

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

@ ANCHEN PHARMS EQ 500MG VALPROIC ACID A078411 001 Nov 03, 2008 May DISC

TABLET, EXTENDED RELEASE; ORAL
DIVALPROEX SODIUM>D> AB AMTA EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Sep DISC
>A> @ EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Sep DISC
AB EQ 250MG VALPROIC ACID A214462 001 Mar 15, 2021 Mar NEWA
>D> AB EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Sep DISC
>A> @ EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Sep DISC
AB EQ 500MG VALPROIC ACID A214462 002 Mar 15, 2021 Mar NEWADOCETAXELINJECTABLE; INJECTION
DOCETAXELAP EUGIA PHARMA 20MG/2ML (10MG/ML) A214575 001 Jun 25, 2021 Jun NEWA
AP 80MG/8ML (10MG/ML) A214575 002 Jun 25, 2021 Jun NEWA
AP 160MG/16ML (10MG/ML) A214575 003 Jun 25, 2021 Jun NEWA
AP GLAND PHARMA LTD 20MG/2ML (10MG/ML) A213510 001 Jul 01, 2021 Jun NEWA
AP 80MG/8ML (10MG/ML) A213510 002 Jul 01, 2021 Jun NEWA
AP 160MG/16ML (10MG/ML) A213510 003 Jul 01, 2021 Jun NEWA
AP HIKMA 20MG/ML (20MG/ML) A204490 001 Jan 14, 2021 Jan NEWA
AP 80MG/4ML (20MG/ML) A204490 002 Jan 14, 2021 Jan NEWA
AP HONG KONG 20MG/2ML (10MG/ML) A209634 001 Aug 24, 2018 Jun CMFD
AP 80MG/8ML (10MG/ML) A209634 002 Aug 24, 2018 Jun CMFD
AP 160MG/16ML (10MG/ML) A209634 003 Aug 24, 2018 Jun CMFD

INJECTABLE; INJECTION

DOCETAXEL

	@	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Apr	DISC
AP	+	SHILPA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr	CHRS
AP	+		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr	CRLD
AP			20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan	CAHN
AP	+	!	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr	CHRS
AP	+		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr	CRLD
AP			80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan	CAHN
AP	+	!	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr	CHRS
AP	+		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr	CRLD
AP			160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan	CAHN

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

>A>	@	NOVAST LABS	0.125MG	A212410	001	Dec 27, 2019	Sep	CAHN
>A>	@		0.25MG	A212410	002	Dec 27, 2019	Sep	CAHN
>A>	@		0.5MG	A212410	003	Dec 27, 2019	Sep	CAHN
>D>	@	RICONPHARMA LLC	0.125MG	A212410	001	Dec 27, 2019	Sep	CAHN
	@		0.125MG	A212410	001	Dec 27, 2019	Feb	DISC
>D>	@		0.25MG	A212410	002	Dec 27, 2019	Sep	CAHN
	@		0.25MG	A212410	002	Dec 27, 2019	Feb	DISC
>D>	@		0.5MG	A212410	003	Dec 27, 2019	Sep	CAHN
	@		0.5MG	A212410	003	Dec 27, 2019	Feb	DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

	+	@	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Feb	CAHN
	+	@		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Feb	CAHN
		@		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Feb	CAHN

TABLET; ORAL

ANZEMET

	+	@	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Feb	CAHN
	+	@		100MG	N020623	002	Sep 11, 1997	Feb	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT		ALEMBIC PHARMS LTD	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	Apr	NEWA
AT		FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Feb	CMFD

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+	!	HIKMA PHARMS	20MG/ML	N014879	001		Jul	CAHN
----	---	---	--------------	---------	---------	-----	--	-----	------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

>D>	AB		HERITAGE PHARMA	EQ 1MG BASE	A205210	001	Feb 13, 2018	Sep	CTEC
>A>	BX			EQ 1MG BASE	A205210	001	Feb 13, 2018	Sep	CTEC
>D>	AB			EQ 2MG BASE	A205210	002	Feb 13, 2018	Sep	CTEC
>A>	BX			EQ 2MG BASE	A205210	002	Feb 13, 2018	Sep	CTEC
>D>	AB			EQ 4MG BASE	A205210	003	Feb 13, 2018	Sep	CTEC
>A>	BX			EQ 4MG BASE	A205210	003	Feb 13, 2018	Sep	CTEC
>D>	AB			EQ 8MG BASE	A205210	004	Feb 13, 2018	Sep	CTEC
>A>	BX			EQ 8MG BASE	A205210	004	Feb 13, 2018	Sep	CTEC
		@	MYLAN	EQ 1MG BASE	A075509	001	Oct 19, 2000	Jul	DISC
		@		EQ 2MG BASE	A075509	002	Oct 19, 2000	Jul	DISC
		@		EQ 4MG BASE	A075509	003	Oct 19, 2000	Jul	DISC
		@		EQ 8MG BASE	A075509	004	Oct 19, 2000	Jul	DISC

DOXEPIIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIIN HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	EQ 10MG BASE	A215076	001	Apr 21, 2021	Apr	NEWA
AB			EQ 25MG BASE	A215076	002	Apr 21, 2021	Apr	NEWA
AB			EQ 50MG BASE	A215076	003	Apr 21, 2021	Apr	NEWA
AB			EQ 75MG BASE	A215076	004	Apr 21, 2021	Apr	NEWA
AB			EQ 100MG BASE	A215076	005	Apr 21, 2021	Apr	NEWA

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	APPCO	EQ 10MG BASE	A214908	001	Apr 01, 2021	Mar	NEWA
AB		EQ 25MG BASE	A214908	002	Apr 01, 2021	Mar	NEWA
AB		EQ 50MG BASE	A214908	003	Apr 01, 2021	Mar	NEWA
AB		EQ 75MG BASE	A214908	004	Apr 01, 2021	Mar	NEWA
AB		EQ 100MG BASE	A214908	005	Apr 01, 2021	Mar	NEWA
	@ CHARTWELL RX	EQ 10MG BASE	A210268	001	Sep 04, 2020	Aug	CAHN
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Aug	CAHN
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Aug	CAHN
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Aug	CAHN
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Aug	CAHN
AB	LEADING PHARMA LLC	EQ 10MG BASE	A211619	001	Mar 09, 2021	Feb	NEWA
AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Feb	NEWA
AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Feb	NEWA
AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Feb	NEWA
AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Feb	NEWA
AB		EQ 150MG BASE	A211618	001	Mar 01, 2021	Feb	NEWA
	@ UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	May	CAHN
	@	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb	DISC
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	May	CAHN
	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb	DISC
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	May	CAHN
	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb	DISC
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	May	CAHN
	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb	DISC
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	May	CAHN
	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb	DISC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

	@ PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan	DISC
	@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan	DISC
AB	RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	CAHN
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

	@ SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019	Aug	DISC
	@	4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019	Aug	DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

	@ ALMAJECT	2MG/ML	A065515	001	Nov 08, 2012	Jul	CAHN
--	------------	--------	---------	-----	--------------	-----	------

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

	@ MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan	DISC
AB		EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan	NEWA
	@	EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan	DISC
AB		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan	NEWA
	@	EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan	DISC
AB		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan	NEWA
	MONODOX						
AB	+ CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jun	CMFD
AB	+	EQ 75MG BASE	N050641	003	Oct 18, 2006	Jun	CMFD
AB	+	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jun	CMFD

FOR SUSPENSION;ORAL

DOXYCYCLINE

AB	CHARTWELL	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008	Jun	CAHN
----	-----------	------------------	---------	-----	--------------	-----	------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB	CHARTWELL	EQ 50MG BASE	A062500	001	Sep 11, 1984	Jun	CAHN
AB		EQ 100MG BASE	A062500	002	Sep 11, 1984	Jun	CAHN
	@ NOSTRUM LABS INC	EQ 50MG BASE	A209393	001	Dec 10, 2020	Jul	DISC
	@	EQ 100MG BASE	A209393	002	Dec 10, 2020	Jul	DISC

<u>CAPSULE, DELAYED RELEASE;ORAL</u>									
DOXYCYCLINE HYCLATE									
	@ BAUSCH	EQ 75MG BASE	A065281	001	Dec 21, 2005	May	CAHN		
	@	EQ 100MG BASE	A065281	002	Dec 21, 2005	May	CAHN		
<u>INJECTABLE;INJECTION</u>									
DOXYCYCLINE HYCLATE									
AP	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	May	CMFD		
AP		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	May	CMFD		
<u>SYSTEM, EXTENDED RELEASE;PERIODONTAL</u>									
ATRIDOX									
>D>	+!	DEN-MAT	50MG	N050751	001	Sep 03, 1998	Sep	DISC	
>A>	+ @		50MG	N050751	001	Sep 03, 1998	Sep	DISC	
<u>TABLET;ORAL</u>									
DOXYCYCLINE HYCLATE									
>A>	AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A210536	002	Sep 14, 2021	Sep	NEWA	
>A>	@	AMICI	EQ 100MG BASE	A213475	001	Mar 10, 2021	Sep	CAHN	
	AB	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983	Jul	CTEC	
	AB	CHARTWELL	EQ 50MG BASE	A062505	002	Jul 27, 2021	Jul	NEWA	
	AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun	CAHN	
	AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun	CAHN	
	@	MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul	DISC	
>D>	@	ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Sep	CAHN	
	@		EQ 100MG BASE	A213475	001	Mar 10, 2021	Apr	DISC	
	AB		EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb	NEWA	
<u>TABLET, DELAYED RELEASE;ORAL</u>									
DOXYCYCLINE HYCLATE									
	@	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	Aug	CAHN	
	@		EQ 50MG BASE	A090431	003	May 23, 2016	Jul	DISC	
	@		EQ 75MG BASE	A090431	001	Dec 28, 2010	Aug	CAHN	
	@		EQ 80MG BASE	A090431	004	Apr 29, 2016	Aug	CAHN	
	@		EQ 100MG BASE	A090431	002	Dec 28, 2010	Aug	CAHN	
	@		EQ 200MG BASE	A090431	005	May 19, 2016	Aug	CAHN	
<u>DROSPIRENONE; ESTETROL</u>									
TABLET;ORAL									
NEXTSTELLIS									
	+!	MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021	Apr	NEWA	
<u>DROSPIRENONE; ETHINYL ESTRADIOL</u>									
TABLET;ORAL									
DROSPIRENONE AND ETHINYL ESTRADIOL									
AB	HLTHCARE		3MG;0.02MG	A203291	001	Jul 18, 2017	Jun	CAHN	
	@	JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Jun	DISC	
		KYRA							
	@	SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Aug	DISC	
TABLET;ORAL-28									
DROSPIRENONE AND ETHINYL ESTRADIOL									
	@	JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018	Jun	DISC	
		KEMEYA							
	@	SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Aug	DISC	
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM</u>									
TABLET;ORAL									
BEYAZ									
>D>	AB	BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep	CHRS	
>A>	AB	+!	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Sep	CHRS	
<u>DROXIDOPA</u>									
CAPSULE;ORAL									
DROXIDOPA									
AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb	NFTG		
AB		200MG	A214391	002	Feb 18, 2021	Feb	NFTG		
AB		300MG	A214391	003	Feb 18, 2021	Feb	NFTG		
AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb	NFTG		
AB		200MG	A213911	002	Feb 18, 2021	Feb	NFTG		
AB		300MG	A213911	003	Feb 18, 2021	Feb	NFTG		
AB	ANNORA	100MG	A211726	002	Aug 09, 2021	Jul	NEWA		
AB		200MG	A211726	003	Aug 09, 2021	Jul	NEWA		
AB		300MG	A211726	001	Feb 18, 2021	Feb	NFTG		
AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb	NFTG		
AB		200MG	A214387	002	Feb 18, 2021	Feb	NFTG		
AB		300MG	A214387	003	Feb 18, 2021	Feb	NFTG		

CAPSULE;ORAL		DROXIDOPA					
AB	BIONPHARMA INC	100MG	A213033	001	Apr 28, 2021	May	CAHN
AB		200MG	A213033	002	Apr 28, 2021	May	CAHN
AB		300MG	A213033	003	Apr 28, 2021	May	CAHN
AB	BLUEPHARMA	100MG	A214543	001	May 05, 2021	Apr	NEWA
AB		200MG	A214543	002	May 05, 2021	Apr	NEWA
AB		300MG	A214543	003	May 05, 2021	Apr	NEWA
AB	HIKMA PHARMS	100MG	A212835	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A212835	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A212835	003	Feb 18, 2021	Feb	NFTG
AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211652	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211652	003	Feb 18, 2021	Feb	NFTG
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211741	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211741	003	Feb 18, 2021	Feb	NFTG
AB	MYLAN API	100MG	A213033	001	Apr 28, 2021	Apr	NEWA
AB		200MG	A213033	002	Apr 28, 2021	Apr	NEWA
AB		300MG	A213033	003	Apr 28, 2021	Apr	NEWA
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214017	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214017	003	Feb 18, 2021	Feb	NFTG
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214384	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214384	003	Feb 18, 2021	Feb	NFTG
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213661	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213661	003	Feb 18, 2021	Feb	NFTG
AB	@ TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Aug	DISC
AB		100MG	A213162	001	Feb 18, 2021	Feb	NFTG
AB	@	200MG	A213162	002	Feb 18, 2021	Aug	DISC
AB		200MG	A213162	002	Feb 18, 2021	Feb	NFTG
AB	@	300MG	A213162	003	Feb 18, 2021	Aug	DISC
AB		300MG	A213162	003	Feb 18, 2021	Feb	NFTG
AB	TRIS PHARMA INC	100MG	A214543	001	May 05, 2021	Jun	CAHN
AB		200MG	A214543	002	May 05, 2021	Jun	CAHN
AB		300MG	A214543	003	May 05, 2021	Jun	CAHN
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211818	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211818	003	Feb 18, 2021	Feb	NFTG
NORTHERA							
AB	+ LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014	Feb	CFTG
AB	+	200MG	N203202	002	Feb 18, 2014	Feb	CFTG
AB	+!	300MG	N203202	003	Feb 18, 2014	Feb	CFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL		DRIZALMA SPRINKLE					
+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CDFR
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CDFR
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CDFR
+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CDFR
DULOXETINE HYDROCHLORIDE							
AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb	NEWA
AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb	NEWA
AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb	NEWA

DUTASTERIDE

CAPSULE;ORAL		AVODART					
AB	+! WOODWARD	0.5MG	N021319	001	Nov 20, 2001	Jul	CAHN
DUTASTERIDE							
	@ NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015	Apr	CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL		JALYN					
AB	+! WOODWARD	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Jul	CAHN

DYDROGESTERONE

		TABLET; ORAL					
		GYNOREST					
>D>	@	SOLVAY	5MG	N017388	001		Sep CRLD
>A>	+ @		5MG	N017388	001		Sep CRLD
	@		5MG	N017388	001		Jul CRLD
>D>	@		10MG	N017388	002		Sep CRLD
>A>	+ @		10MG	N017388	002		Sep CRLD
	@		10MG	N017388	002		Jul CRLD

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC
PHOSPHOLINE IODIDE

	@	FERA PHARMS LLC	0.03%	N011963	002		Aug CAHN
	@		0.06%	N011963	004		Aug CAHN
	+!		0.125%	N011963	001		Aug CAHN
	@		0.25%	N011963	003		Aug CAHN

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL
ECOZA

	+!	RESILIA PHARMS	1%	N205175	001	Oct 24, 2013	Feb CAHN
--	----	----------------	----	---------	-----	--------------	----------

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION
CALCIUM DISODIUM VERSENATE

	+!	BAUSCH	200MG/ML	N008922	001		May CAHN
	@	BAUSCH	500MG	N008922	002		May CAHN

EFAVIRENZ

TABLET; ORAL
EFAVIRENZ

>D>	AB	MYLAN	600MG	A091471	001	Feb 17, 2016	Sep CTEC
>A>	BX		600MG	A091471	001	Feb 17, 2016	Sep CTEC
	AB	STRIDES PHARMA	600MG	A078509	001	Jun 16, 2021	Jun NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

>A>	AB	MACLEODS PHARMS LTD	600MG; 200MG; 300MG	A204287	001	Sep 13, 2021	Sep NEWA
-----	----	---------------------	---------------------	---------	-----	--------------	----------

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

	+ @	AUROBINDO PHARMA LTD	600MG; 300MG; 300MG	N022343	001	Aug 15, 2018	Feb DISC
--	-----	----------------------	---------------------	---------	-----	--------------	----------

EFINACONAZOLE

SOLUTION; TOPICAL

EFINACONAZOLE

	AB	ACRUX DDS	10%	A211969	001	Jun 21, 2021	Jun NEWA
>D>	AB	AUROBINDO PHARMA LTD	10%	A212066	001	Mar 29, 2021	Sep DISC
>A>	@		10%	A212066	001	Mar 29, 2021	Sep DISC
	AB		10%	A212066	001	Mar 29, 2021	Mar NEWA
	AB	TEVA PHARMS USA	10%	A211827	001	Dec 16, 2020	Feb CTEC
	AB	JUBLIA					
	AB	+! BAUSCH	10%	N203567	001	Jun 06, 2014	Feb CTEC

ELEXACFTOR, IVACAFTOR, TEZACFTOR; IVACAFTOR

TABLET; ORAL

TRIKAFTA (COPACKAGED)

	+!	VERTEX PHARMS INC	50MG, 37.5MG, 25MG; 75MG	N212273	002	Jun 08, 2021	Jun NEWA
	+!		100MG, 75MG, 50MG; 150MG	N212273	001	Oct 21, 2019	Jun CPOT

ELIGLUSTAT TARTRATECAPSULE;ORAL
CERDELGA

AB	+!	GENZYME CORP	EQ 84MG BASE	N205494	001	Aug 19, 2014	Aug CFTG
		ELIGLUSTAT TARTRATE					
>D>	AB	AIZANT	EQ 84MG BASE	A212463	001	Sep 08, 2021	Sep CAHN
	AB		EQ 84MG BASE	A212463	001	Sep 08, 2021	Aug NFTG
>A>	AB	APPCO	EQ 84MG BASE	A212463	001	Sep 08, 2021	Sep CAHN

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB		APOTEX	200MG;300MG	A208740	001	Jun 16, 2021	Jun NEWA
AB		CIPLA	200MG;300MG	A090958	001	Apr 02, 2021	Mar NEWA
AB		LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019	Jan CMFD
AB		LUPIN LTD	200MG;300MG	A204131	001	Jun 04, 2021	May NEWA
AB		MACLEODS PHARMS LTD	200MG;300MG	A203442	001	May 15, 2020	Feb CMFD
AB		MYLAN	200MG;300MG	A206436	001	Apr 09, 2018	Feb CMFD
AB		STRIDES PHARMA	200MG;300MG	A091055	001	Jan 13, 2021	Jan NEWA
AB		ZYDUS PHARMS	100MG;150MG	A212689	002	Jul 01, 2021	Jun NEWA
AB			133MG;200MG	A212689	003	Jul 01, 2021	Jun NEWA
AB			167MG;250MG	A212689	004	Jul 01, 2021	Jun NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB		BIONPHARMA INC	1MG/ML	A212408	001	Aug 10, 2021	Jul NFTG
		EPANED					
AB	+!	AZURITY	1MG/ML	N208686	001	Sep 20, 2016	Jul CFTG

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ MYLAN 5MG;12.5MG
@ 10MG;25MGA075624 001 Sep 18, 2001 Jul DISC
A075624 002 Sep 18, 2001 Jul DISCENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

AB		ACTAVIS LABS FL INC	40MG	A209614	001	May 14, 2021	May NFTG
		XTANDI					
AB	+!	ASTELLAS	40MG	N203415	001	Aug 31, 2012	May CFTG

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

+!	ETON	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun CAHN
+	@	47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun DISC
+!		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun CAHN
+	@	47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun DISC
+!		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun CAHN
+!	SINTETICA SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	Jun NEWA
+!		47MG/ML (47MG/ML)	N213536	002	Jun 14, 2021	Jun NEWA
+!		47MG/5ML (9.4MG/ML)	N213536	003	Jun 14, 2021	Jun NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

AKOVAZ

+!	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Aug NEWA
----	--------------	-------------------	---------	-----	--------------	----------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP		B BRAUN MEDICAL INC	0.005MG/ML;1.5%	A208475	001	Sep 08, 2021	Aug NEWA
----	--	---------------------	-----------------	---------	-----	--------------	----------

EPLERENONE

TABLET;ORAL

EPLERENONE

AB		CHARTWELL RX	25MG	A078482	001	Jul 30, 2008	Apr CAHN
AB			50MG	A078482	002	Jul 30, 2008	Apr CAHN
		@ PIRAMAL HLTHCARE UK	25MG	A212765	001	Aug 10, 2020	Feb DISC

TABLET;ORAL

ERYTHROMYCIN

>D>	AB	ORANGE	250MG	A213628	001	Jun 28, 2021	Sep CAHN
	AB		250MG	A213628	001	Jun 28, 2021	Jun NEWA
>D>	AB		500MG	A213628	002	Jun 28, 2021	Sep CAHN
	AB		500MG	A213628	002	Jun 28, 2021	Jun NEWA
	AB	TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb NEWA
	AB		500MG	A214549	002	Feb 11, 2021	Feb NEWA

TABLET, DELAYED RELEASE;ORAL

ERYTHROMYCIN

	AB	TORRENT	250MG	A211975	001	Jul 26, 2021	Jul NEWA
	AB		500MG	A211975	002	Jul 26, 2021	Jul NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ PAR PHARM INC EQ 200MG BASE/5ML
 @ EQ 400MG BASE/5ML

A211991	001	Oct 23, 2019	May DISC
A211991	002	Oct 23, 2019	May DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

@ ANTRIM PHARMS LLC EQ 5MG BASE/5ML

A203967	001	May 26, 2015	Aug DISC
---------	-----	--------------	----------

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

AB	+	SUNOVION PHARMS INC	200MG	N022416	001	Nov 08, 2013	Jun CFTG
AB	+		400MG	N022416	002	Nov 08, 2013	Jun CFTG
AB	+		600MG	N022416	003	Nov 08, 2013	Jun CFTG
AB	+		800MG	N022416	004	Nov 08, 2013	Jun CFTG

ESLICARBAZEPINE ACETATE

AB		DR REDDYS LABS LTD	200MG	A211238	001	Jun 29, 2021	Jun NFTG
AB			400MG	A211238	002	Jun 29, 2021	Jun NFTG
AB			600MG	A211238	003	Jun 29, 2021	Jun NFTG
AB			800MG	A211238	004	Jun 29, 2021	Jun NFTG

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

@ AMTA EQ 20MG BASE
 @ EQ 40MG BASE

A213859	001	Nov 18, 2020	May DISC
A213859	002	Nov 18, 2020	May DISC

AB		ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Mar NEWA
AB			EQ 40MG BASE	A090841	002	Mar 31, 2021	Mar NEWA
AB		GRAVITI PHARMS	EQ 20MG BASE	A213486	001	Mar 19, 2021	Mar NEWA
AB			EQ 40MG BASE	A213486	002	Mar 19, 2021	Mar NEWA
AB		INDCHEMIE HEALTH	EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB		MYLAN	EQ 20MG BASE;375MG	A204920	001	Jul 20, 2021	Jul NEWA
AB			EQ 20MG BASE;500MG	A204920	002	Jul 20, 2021	Jul NEWA

ESTRADIOL

CREAM;VAGINAL

ESTRACE

AB	+	ALLERGAN	0.01%	A086069	001	Jan 31, 1984	Aug CRLD
----	---	----------	-------	---------	-----	--------------	----------

ESTRADIOL

AB		ALVOGEN	0.01%	A209767	001	Mar 05, 2018	Aug CAHN
AB		PRASCO LABS LLC	0.01%	A212313	001	Jul 15, 2021	Jul NEWA

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

@ ALLERGAN 0.025MG/24HR
 @ 0.05MG/24HR
 @ 0.075MG/24HR
 @ 0.1MG/24HR

N020655	004	Apr 05, 2002	Jul DISC
N020655	001	Dec 20, 1996	Jul DISC
N020655	002	Dec 20, 1996	Jul DISC
N020655	003	Dec 20, 1996	Jul DISC

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

+	!	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996	Jan CAHN
---	---	--------	---------------	---------	-----	--------------	----------

SYSTEM; TRANSDERMAL
ESTRADIOL

>D>	AB1	AMNEAL	0.025MG/24HR	A211293	001	Feb 04, 2019	Sep	CTEC
>A>	BX		0.025MG/24HR	A211293	001	Feb 04, 2019	Sep	CTEC
>D>	AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Sep	CTEC
>A>	BX		0.0375MG/24HR	A211293	002	Feb 04, 2019	Sep	CTEC
>D>	AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Sep	CTEC
>A>	BX		0.05MG/24HR	A211293	003	Feb 04, 2019	Sep	CTEC
>D>	AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Sep	CTEC
>A>	BX		0.075MG/24HR	A211293	004	Feb 04, 2019	Sep	CTEC
>D>	AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Sep	CTEC
>A>	BX		0.1MG/24HR	A211293	005	Feb 04, 2019	Sep	CTEC

TABLET; ORAL
ESTRACE

+	@	BRISTOL MYERS SQUIBB	1MG	A084499	001		Aug	CRLD
+	@		2MG	A084500	001		Aug	CRLD

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL

@	PFIZER	1MG/ML	A085470	001		Mar	CAHN
@		3MG/ML	A085470	002		Mar	CAHN
!		5MG/ML	A085470	003		Mar	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
AMABELZ

>D>	AB	LUPIN LTD	0.5MG; 0.1MG	A203339	001	Jun 20, 2016	Sep	CTEC
>A>	BX		0.5MG; 0.1MG	A203339	001	Jun 20, 2016	Sep	CTEC
>D>	AB		1MG; 0.5MG	A203339	002	Jun 20, 2016	Sep	CTEC
>A>	BX		1MG; 0.5MG	A203339	002	Jun 20, 2016	Sep	CTEC

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET; ORAL
MYFEMBREE

+	!	MYOVANT SCIENCES	1MG; 0.5MG; 40MG	N214846	001	May 26, 2021	May	NEWA
---	---	------------------	------------------	---------	-----	--------------	-----	------

ESTROPIPATE

TABLET; ORAL
OGEN .625

+	@	PFIZER	0.75MG	A083220	001		Aug	CRLD
	@		0.75MG	A083220	001		Jan	CAHN
		OGEN 1.25						
+	@	PFIZER	1.5MG	A083220	002		Aug	CRLD
	@		1.5MG	A083220	002		Jan	CAHN
		OGEN 2.5						
+	@	PFIZER	3MG	A083220	003		Aug	CRLD
	@		3MG	A083220	003		Jan	CAHN
		OGEN 5						
+		PFIZER	6MG	A083220	004		Aug	CRLD
			6MG	A083220	004		Jan	CAHN

ESZOPICLONE

TABLET; ORAL
ESZOPICLONE

@	NOSTRUM LABS INC	1MG	A203087	001	May 08, 2019	Jan	CAHN
@		2MG	A203087	002	May 08, 2019	Jan	CAHN
@		3MG	A203087	003	May 08, 2019	Jan	CAHN

ETHACRYNIC ACID

TABLET; ORAL
ETHACRYNIC ACID

AB	ALVOGEN	25MG	A205709	001	Jul 24, 2018	Jun	CAHN
----	---------	------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL
ETHINYL ESTRADIOL; ETONOGESTREL

AB	TEVA PHARMS USA INC	0.015MG/24HR; 0.12MG/24HR	A204305	001	Jan 13, 2021	Jan	NEWA
----	---------------------	---------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

		TABLET;ORAL							
		SYLEVIA							
		@ SUN PHARM	0.03MG;0.15MG	A202988	001	Feb 06, 2019	Aug	DISC	
		TABLET;ORAL-28							
		CERINTA							
		@ SUN PHARM	0.02MG;0.1MG	A202817	001	Jan 07, 2019	Aug	DISC	
		LEVONORGESTREL AND ETHINYL ESTRADIOL							
>D>	AB1	LUPIN LTD	0.02MG;0.1MG	A091425	001	Jan 18, 2013	Sep	CTEC	
>A>	BX		0.02MG;0.1MG	A091425	001	Jan 18, 2013	Sep	CTEC	
>D>	AB		0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Sep	CTEC	
>A>	BX		0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Sep	CTEC	

ETHINYL ESTRADIOL; NORELGESTROMIN

		FILM, EXTENDED RELEASE;TRANSDERMAL							
		ETHINYL ESTRADIOL AND NORELGESTROMIN							
>D>	AB	AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Sep	CTEC	
>A>	BX		0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Sep	CTEC	
	AB		0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Feb	NEWA	
		ONSURA							
	AB	TEVA PHARMS USA	0.035MG/24HR;0.15MG/24HR	A213977	001	Aug 25, 2021	Aug	NEWA	
		XULANE							
	AB	! MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb	CTEC	

ETHINYL ESTRADIOL; NORETHINDRONE

		TABLET;ORAL-21							
		NORINYL 1+35 21-DAY							
		@ ALLERGAN	0.035MG;1MG	N017565	001		Jul	DISC	
		TABLET;ORAL-28							
		CYCLAFEM 1/35							
		@ VINTAGE PHARMS LLC	0.035MG;1MG	A076337	001	Nov 12, 2010	Aug	DISC	
		CYCLAFEM 7/7/7							
		@ VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A076338	001	Nov 16, 2010	Aug	DISC	
		NORINYL 1+35 28-DAY							
		@ ALLERGAN	0.035MG;1MG	N017565	002		Jul	DISC	
		PIRMELLA 1/35							
>D>	AB	LUPIN LTD	0.035MG;1MG	A201512	001	Apr 24, 2013	Sep	CTEC	
>A>	BX		0.035MG;1MG	A201512	001	Apr 24, 2013	Sep	CTEC	
		PIRMELLA 7/7/7							
>D>	AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013	Sep	CTEC	
>A>	BX		0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013	Sep	CTEC	
		TABLET, CHEWABLE;ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
>D>	AB	LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Sep	CTEC	
>A>	BX		0.035MG;0.4MG	A091332	001	Mar 23, 2016	Sep	CTEC	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

		CAPSULE;ORAL							
		GEMMILY							
	AB	XIROMED	0.02MG;1MG	A213317	001	Nov 09, 2020	Mar	CAHN	
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	AB	AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021	Jul	NEWA	
		TABLET;ORAL							
		FEMHRT							
>D>	AB	APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Sep	CRLD	
>A>	+	@	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Sep	CRLD	
>D>		LOESTRIN 24 FE							
>D>	AB	+ TEVA BRANDED PHARM	0.02MG;1MG	N021871	001	Feb 17, 2006	Sep	DISC	
>A>	+	@	0.02MG;1MG	N021871	001	Feb 17, 2006	Sep	DISC	
		TABLET;ORAL-21							
		GILDESS 1/20							
		@ VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Jul	DISC	
		TABLET;ORAL-28							
		BLISOVI FE 1.5/30							
>D>	AB	LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015	Sep	CTEC	
>A>	BX		0.03MG;1.5MG	A201585	001	Nov 18, 2015	Sep	CTEC	

TABLET;ORAL-28

CHABELINA FE

>D>	AB	NOVAST LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A202962	001	Apr 15, 2020	Sep	CHRS
>A>	AB	!	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A202962	001	Apr 15, 2020	Sep	CHRS
>D>		ESTROSTEP FE						
>D>	AB	+! APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Sep	DISC
>A>		+ @	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Sep	DISC
		GILDESS FE 1/20						
		@ VINTAGE PHARMS LLC	0.02MG;1MG	A077077	001	May 20, 2005	Jul	DISC

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

>D>	AB	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Sep	CTEC
>A>	BX		250MG	A200892	001	Sep 25, 2012	Sep	CTEC
>D>	AB	PURACAP PHARM LLC	250MG	A210654	001	Mar 16, 2020	Sep	CTEC
>A>	BX		250MG	A210654	001	Mar 16, 2020	Sep	CTEC
		SYRUP;ORAL						
		ZARONTIN						
AA		+! PARKE-DAVIS	250MG/5ML	A080258	001		Aug	CRLD

ETODOLAC

TABLET;ORAL

ETODOLAC

AB		BAYSHORE PHARMS LLC	400MG	A210704	001	Dec 16, 2020	Aug	CMFD
		@	400MG	A210704	001	Dec 16, 2020	Jul	DISC
AB			500MG	A210704	002	Dec 16, 2020	Aug	CMFD
		@	500MG	A210704	002	Dec 16, 2020	Jul	DISC

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP		CAPLIN	2MG/ML	A215028	001	Dec 18, 2020	Jul	CMFD
		@	2MG/ML	A215028	001	Dec 18, 2020	Jun	DISC

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

		@ AMNEAL	25MG	A214196	001	Jun 14, 2021	Jul	DISC
AB			25MG	A214196	001	Jun 14, 2021	Jun	NFTG
AB			100MG	A214196	002	Jun 14, 2021	Jun	NFTG
AB			200MG	A214196	003	Jun 14, 2021	Jun	NFTG
		INTELENCE						
		+ JANSSEN R AND D	25MG	N022187	003	Mar 26, 2012	Jul	CTEC
AB		+	25MG	N022187	003	Mar 26, 2012	Jun	CFTG
AB		+	100MG	N022187	001	Jan 18, 2008	Jun	CFTG
AB		+!	200MG	N022187	002	Dec 22, 2010	Jun	CFTG

EVEROLIMUS

TABLET;ORAL

AFINITOR

AB		+ NOVARTIS	10MG	N022334	002	Mar 30, 2009	Feb	CTEC
		EVEROLIMUS						
AB		BIOCON PHARMA	2.5MG	A214182	001	Feb 11, 2021	Aug	CMFD
		@	2.5MG	A214182	001	Feb 11, 2021	Feb	DISC
AB			2.5MG	A214182	001	Feb 11, 2021	Feb	NEWA
AB			5MG	A214182	002	Feb 11, 2021	Aug	CMFD
		@	5MG	A214182	002	Feb 11, 2021	Feb	DISC
AB			5MG	A214182	002	Feb 11, 2021	Feb	NEWA
AB			7.5MG	A214182	003	Feb 11, 2021	Aug	CMFD
		@	7.5MG	A214182	003	Feb 11, 2021	Feb	DISC
AB			7.5MG	A214182	003	Feb 11, 2021	Feb	NEWA
AB			10MG	A214182	004	Feb 11, 2021	Aug	CMFD
		@	10MG	A214182	004	Feb 11, 2021	Feb	DISC
AB			10MG	A214182	004	Feb 11, 2021	Feb	NEWA
AB		BRECKENRIDGE	0.25MG	A205432	001	May 20, 2021	May	NEWA
AB			0.5MG	A205432	002	May 20, 2021	May	NEWA
AB			0.75MG	A205432	003	May 20, 2021	May	NEWA
AB			2.5MG	A205426	001	Mar 05, 2021	Feb	NEWA
AB			5MG	A205426	002	Mar 05, 2021	Feb	NEWA
AB			7.5MG	A205426	003	Mar 05, 2021	Feb	NEWA
AB			10MG	A205426	004	Mar 05, 2021	Feb	NEWA

TABLET;ORAL							
EVEROLIMUS							
AB	MYLAN	10MG	A212936	004	Jun 08, 2020	Aug	CMFD
TABLET, FOR SUSPENSION;ORAL							
AFINITOR DISPERZ							
AB	+ NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012	Aug	CTEC
AB	+	3MG	N203985	002	Aug 29, 2012	Aug	CTEC
AB	+!	5MG	N203985	003	Aug 29, 2012	Aug	CTEC
EVEROLIMUS							
AB	MYLAN	2MG	A210130	001	Apr 19, 2019	Aug	CMFD
AB		3MG	A210130	002	Apr 19, 2019	Aug	CMFD
AB		5MG	A210130	003	Apr 19, 2019	Aug	CMFD
<u>EXEMESTANE</u>							
TABLET;ORAL							
AROMASIN							
AB	+! PFIZER	25MG	N020753	001	Oct 21, 1999	Mar	CAHN
<u>EXENATIDE SYNTHETIC</u>							
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
BYDUREON							
+	@ ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Feb	DISC
BYDUREON PEN							
+	@ ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb	DISC
SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
BYDUREON BCISE							
+	! ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Aug	CAIN
<u>EZETIMIBE</u>							
TABLET;ORAL							
ZETIA							
AB	+! ORGANON	10MG	N021445	001	Oct 25, 2002	Feb	CAHN
<u>EZETIMIBE; ROSUVASTATIN CALCIUM</u>							
TABLET;ORAL							
ROSZET							
+	ALThERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar	NEWA
+		10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar	NEWA
<u>EZETIMIBE; SIMVASTATIN</u>							
TABLET;ORAL							
EZETIMIBE AND SIMVASTATIN							
	@ ANI PHARMS	10MG;10MG	A201890	001	Apr 26, 2017	Jul	DISC
	@	10MG;20MG	A201890	002	Apr 26, 2017	Jul	DISC
	@	10MG;40MG	A201890	003	Apr 26, 2017	Jul	DISC
	@	10MG;80MG	A201890	004	Apr 26, 2017	Jul	DISC
	@ MYLAN	10MG;10MG	A200082	001	Dec 17, 2020	Jan	DISC
	@	10MG;20MG	A200082	002	Dec 17, 2020	Jan	DISC
	@	10MG;40MG	A200082	003	Dec 17, 2020	Jan	DISC
	@	10MG;80MG	A200082	004	Dec 17, 2020	Jan	DISC
VYTORIN							
AB	+ ORGANON	10MG;10MG	N021687	001	Jul 23, 2004	Feb	CAHN
AB	+	10MG;20MG	N021687	002	Jul 23, 2004	Feb	CAHN
AB	+	10MG;40MG	N021687	003	Jul 23, 2004	Feb	CAHN
AB	+!	10MG;80MG	N021687	004	Jul 23, 2004	Feb	CAHN
<u>FAMOTIDINE</u>							
FOR SUSPENSION;ORAL							
FAMOTIDINE							
AB	AKORN	40MG/5ML	A201995	001	May 30, 2014	Feb	CAHN
AB	NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Apr	NEWA

FAMOTIDINE; IBUPROFENTABLET; ORAL
DUEXIS

AB	+!	HORIZON	26.6MG;800MG	N022519	001	Apr 23, 2011	Jul	CFTG
		IBUPROFEN AND FAMOTIDINE						
AB		ALKEM LABS LTD	26.6MG;800MG	A211890	001	Aug 03, 2021	Jul	NFTG

FELBAMATESUSPENSION; ORAL
FELBAMATE

>A>	AB	NOVITIUM PHARMA	600MG/5ML	A211333	001	May 31, 2019	Sep	CAHN
>D>	AB	VISTAPHARM	600MG/5ML	A211333	001	May 31, 2019	Sep	CAHN

FELODIPINETABLET, EXTENDED RELEASE; ORAL
FELODIPINE

	@	JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Jun	DISC
	@		5MG	A203983	002	Aug 19, 2016	Jun	DISC
	@		10MG	A203983	003	Aug 19, 2016	Jun	DISC

FENOFIBRATECAPSULE; ORAL
FENOFIBRATE (MICRONIZED)

>A>	AB	AUROBINDO PHARMA LTD	67MG	A212232	001	Sep 20, 2021	Sep	NEWA
>A>	AB		134MG	A212232	002	Sep 20, 2021	Sep	NEWA
>A>	AB		200MG	A212232	003	Sep 20, 2021	Sep	NEWA

TABLET; ORAL
FENOFIBRATE

AB		ADAPTIS	54MG	A210606	001	Aug 17, 2018	Aug	CAHN
AB			160MG	A210606	002	Aug 17, 2018	Aug	CAHN
AB		AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan	NEWA
AB			145MG	A208476	002	Feb 10, 2021	Jan	NEWA

FENOPROFEN CALCIUMCAPSULE; ORAL
FENOPROFEN CALCIUM

	@	RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988	Jan	CAHN
	@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Jan	CAHN

FENTANYL CITRATEINJECTABLE; INJECTION
FENTANYL CITRATE

AP		FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Jun	CMFD
		@	EQ 0.05MG BASE/ML	A212086	001	Sep 01, 2020	Mar	DISC

SPRAY, METERED; NASAL
LAZANDA

>D>	+	BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep	DISC
>A>	+	@	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep	DISC
>D>	+	!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep	DISC
>A>	+	@	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep	DISC

FERRIC CARBOXYMALTOSSOLUTION; INTRAVENOUS
INJECTAFER

+!		AM REAGENT	1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021	May	NEWA
----	--	------------	------------------------------	---------	-----	--------------	-----	------

FERRIC MALTOLCAPSULE; ORAL
ACCRUFER

+!		SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019	Apr	CMFD
----	--	-----------	-----------	---------	-----	--------------	-----	------

FERRIC OXYHYDROXIDEINJECTABLE; INJECTION
DEXFERRUM

	@	AM REAGENT	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	May	CAIN
AB	+!	SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	N020955	001	Feb 18, 1999	May	CPOT
AB	+!		62.5MG/5ML	N020955	001	Feb 18, 1999	May	CAIN

INJECTABLE; INJECTION							
INFED							
BP	+	ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001		May CAIN
IRON DEXTRAN							
	@	SANOFI AVENTIS US	EQ 50MG IRON/ML	N010787	002		May CAIN
PROFERDEX							
	@	NEW RIVER	EQ 50MG IRON/ML	N017807	001		May CAIN
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE							
AB		WEST-WARD PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)	A078215	001	Mar 31, 2011	May CPOT
AB			62.5MG/5ML	A078215	001	Mar 31, 2011	May CAIN
INJECTABLE; INTRAVENOUS							
VENOFER							
+		AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005	May CPOT
+			EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	May CAIN
@			EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)	N021135	005	Mar 29, 2013	May CPOT
@			EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	May CAIN
@			EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)	N021135	003	Mar 29, 2005	May CPOT
@			EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005	May CAIN
+			EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000	May CPOT
+			EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000	May CAIN
+			EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007	May CPOT
+			EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007	May CAIN
TABLET, CHEWABLE; ORAL							
VELPHORO							
+		VIFOR FRESENIUS	EQ 500MG IRON	N205109	001	Nov 27, 2013	May CPOT
+			500MG	N205109	001	Nov 27, 2013	May CAIN
<u>FERUMOXYTOL</u>							
SOLUTION; INTRAVENOUS							
FERAHEME							
AB	+	AMAG PHARMS INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Jan CFTG
AB	+	COVIS	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	N022180	001	Jun 30, 2009	Mar CAHN
FERUMOXYTOL							
AB		SANDOZ INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)	A206604	001	Jan 15, 2021	Jan NFTG
<u>FEXINIDAZOLE</u>							
TABLET; ORAL							
FEXINIDAZOLE							
+		DNDI	600MG	N214429	001	Jul 16, 2021	Jul NEWA
+		SANOFI	600MG	N214429	001	Jul 16, 2021	Jul CAHN
<u>FINASTERIDE</u>							
TABLET; ORAL							
FINASTERIDE							
	@	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May DISC
<u>FINERENONE</u>							
TABLET; ORAL							
KERENDIA							
+		BAYER HLTHCARE	10MG	N215341	001	Jul 09, 2021	Jul NEWA
+			20MG	N215341	002	Jul 09, 2021	Jul NEWA
<u>FINGOLIMOD HYDROCHLORIDE</u>							
CAPSULE; ORAL							
FINGOLIMOD HYDROCHLORIDE							
	@	ALKEM LABS LTD	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Aug DISC
	@	APOTEX	EQ 0.5MG BASE	A207993	001	Dec 18, 2020	Jun DISC
AB		DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Feb NEWA
	@	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Aug DISC
	@	MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan DISC

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

AB		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan NEWA
	@ STRIDES PHARMA	EQ 0.5MG BASE	A207971	001	Jun 29, 2020	Aug DISC
	@ SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug DISC
	@ ZYDUS PHARMS	EQ 0.5MG BASE	A207994	001	Oct 14, 2020	Mar DISC

FLECAINIDE ACETATE

TABLET;ORAL

TAMBOCOR

	+ @ ALVOGEN	50MG	N018830	004	Aug 23, 1988	Jun CAHN
	+ @	100MG	N018830	001	Oct 31, 1985	Jun CAHN
	+ @	150MG	N018830	003	Jun 03, 1988	Jun CAHN
	@	200MG	N018830	002	Oct 31, 1985	Jun CAHN
	+ @ CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jan DISC
	+ @	100MG	N018830	001	Oct 31, 1985	Jan DISC
	+ @	150MG	N018830	003	Jun 03, 1988	Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	Mar NEWA
	NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Jan CAHN
AP	PHARMALOGIC HLDGS	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan CAHN
AP	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar CTEC

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

AP	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Mar CMFD
AP		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Mar CMFD

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

FLUOCINOLONE ACETONIDE

>A>	@ ALLIED	0.01%	A088047	001	Dec 16, 1982	Sep CAHN
>A>	@	0.025%	A088045	001	Dec 16, 1982	Sep CAHN
>A>	@	0.025%	A088045	001	Dec 16, 1982	Sep CAHN
>D>	@ INVATECH	0.01%	A088047	001	Dec 16, 1982	Sep CAHN
>D>	@	0.025%	A088045	001	Dec 16, 1982	Sep CAHN

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

	@ AKORN	0.01%	A091514	001	Jun 25, 2015	Jul DISC
>A>	AT QUAGEN	0.01%	A212760	001	Apr 02, 2021	Sep CAHN
>A>	AT	0.01%	A212761	001	Apr 02, 2021	Sep CAHN
>D>	AT SOLARIS PHARMA CORP	0.01%	A212760	001	Apr 02, 2021	Sep CAHN
	AT	0.01%	A212760	001	Apr 02, 2021	Mar NEWA
>D>	AT	0.01%	A212761	001	Apr 02, 2021	Sep CAHN
	AT	0.01%	A212761	001	Apr 02, 2021	Mar NEWA

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

	@ AKORN	0.01%	A202705	001	Sep 09, 2016	Jul DISC
>A>	AT QUAGEN	0.01%	A212762	001	Apr 02, 2021	Sep CAHN
>D>	AT SOLARIS PHARMA CORP	0.01%	A212762	001	Apr 02, 2021	Sep CAHN
	AT	0.01%	A212762	001	Apr 02, 2021	Mar NEWA
	AT TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan NEWA

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

>A>	@ ALLIED	0.01%	A088048	001	Dec 16, 1982	Sep CAHN
>D>	@ INVATECH	0.01%	A088048	001	Dec 16, 1982	Sep CAHN

FLUOCINONIDE

CREAM;TOPICAL

LIDEX

	+ @ ALVOGEN	0.05%	N016908	002		Jun CAHN
	LIDEX-E					
AB2	+ ALVOGEN	0.05%	N016908	003		Jun CAHN
	VANOS					
AB	+! BAUSCH	0.1%	N021758	001	Feb 11, 2005	May CAHN

	GEL;TOPICAL						
	FLUOCINONIDE						
AB	+ ALVOGEN	0.05%	N017373	001		Jun	CAHN
	OINTMENT;TOPICAL						
	LIDEX						
AB	+ ALVOGEN	0.05%	N016909	002		Jun	CAHN
	SOLUTION;TOPICAL						
	LIDEX						
AT	+ ALVOGEN	0.05%	N018849	001	Apr 06, 1984	Jun	CAHN

FLUOROURACIL

	CREAM;TOPICAL						
	FLUOROPLEX						
	+ @ ALMIRALL	1%	N016988	001		Aug	DISC
	INJECTABLE;INJECTION						
	FLUOROURACIL						
AP	FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A040279	002	Sep 30, 1998	May	CHRS
AP		1GM/20ML (50MG/ML)	A040279	001	Sep 30, 1998	May	CHRS
AP		2.5GM/50ML (50MG/ML)	A040278	001	Sep 30, 1998	May	CHRS
AP		5GM/100ML (50MG/ML)	A040278	002	Sep 30, 1998	May	CHRS
AP	@ NOVAST LABS	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar	CPOT
AP	TEVA PHARMS USA	500MG/10ML (50MG/ML)	A040333	001	Jan 27, 2000	May	CHRS

FLUOXETINE HYDROCHLORIDE

	CAPSULE;ORAL							
	FLUOXETINE HYDROCHLORIDE							
	@ ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb	DISC	
	@	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb	DISC	
	@	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb	DISC	
	@ GRANULES	EQ 10MG BASE	A078143	001	Jan 16, 2008	Jun	CAHN	
	@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Jun	CAHN	
	@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Jun	CAHN	
AB1	HERITAGE PHARMS INC	EQ 10MG BASE	A201336	001	Oct 01, 2012	Aug	CMFD	
AB1		EQ 20MG BASE	A201336	002	Oct 01, 2012	Aug	CMFD	
AB		EQ 40MG BASE	A201336	003	Oct 01, 2012	Aug	CMFD	
	TABLET;ORAL							
	FLUOXETINE HYDROCHLORIDE							
>A>	AB	+! ALMATICA	EQ 60MG BASE	N202133	001	Oct 06, 2011	Sep	CAHN
>D>	AB	+! ALVOGEN	EQ 60MG BASE	N202133	001	Oct 06, 2011	Sep	CAHN
	AB	! DR REDDYS LABS LTD	EQ 20MG BASE	A076006	002	Apr 23, 2018	Jul	CHRS
		@ MYLAN	EQ 10MG BASE	A075755	001	Aug 02, 2001	Jul	DISC
		@	EQ 20MG BASE	A075755	002	Aug 02, 2001	Jul	DISC
		TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar	CHRS
		!	EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar	CHRS
AB		UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May	CAHN
AB			EQ 20MG BASE	A211696	002	Jan 30, 2019	May	CAHN
	SARAFEM							
	+ @ APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Mar	DISC	
	+ @	EQ 20MG BASE	N021860	003	May 19, 2006	Mar	DISC	

FLUOXYMESTERONE

	TABLET;ORAL						
	FLUOXYMESTERONE						
	@ UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jan	DISC

FLUPHENAZINE HYDROCHLORIDE

	TABLET;ORAL						
	FLUPHENAZINE HYDROCHLORIDE						
AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan	NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan	NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan	NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan	NEWA
AB	NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb	NEWA
AB		2.5MG	A214674	002	Mar 01, 2021	Feb	NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb	NEWA
AB		10MG	A214674	004	Mar 01, 2021	Feb	NEWA
AB	ZYDUS	1MG	A214552	001	May 27, 2021	May	NEWA
AB		2.5MG	A214552	002	May 27, 2021	May	NEWA
AB		5MG	A214552	003	May 27, 2021	May	NEWA
AB		10MG	A214552	004	May 27, 2021	May	NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

FLURBIPROFEN SODIUM

! BAUSCH AND LOMB 0.03%
0.03%A074447 001 Jan 04, 1995 Jan CHRS
A074447 001 Jan 04, 1995 Jan CTEC

OCUFEN

+ @ ALLERGAN 0.03%

N019404 001 Dec 31, 1986 Jan DISC

FLUTAMIDE

CAPSULE;ORAL

FLUTAMIDE

@ CIPLA 125MG
! PAR PHARM 125MG
125MG
! WAYLIS THERAP 125MGA075780 001 Sep 19, 2001 Mar DISC
A075298 001 Sep 18, 2001 Mar CHRS
A075298 001 Sep 18, 2001 Mar CTEC
A075298 001 Sep 18, 2001 Jun CAHNFLUTICASONE PROPIONATE

POWDER;INHALATION

ARMONAIR RESPICLICK

>D> + TEVA PHARM 0.03MG/INH
>A> + @ 0.03MG/INH
+ 0.03MG/INHN208798 007 Jul 09, 2021 Sep DISC
N208798 007 Jul 09, 2021 Sep DISC
N208798 007 Jul 09, 2021 Jul NEWAFLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

AB BEIJING EQ 80MG BASE

A209397 001 Apr 26, 2021 Apr NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

@ BIONPHARMA INC 100MG

A212182 002 Sep 16, 2020 Feb DISC

FOLIC ACID

TABLET;ORAL

FOLIC ACID

AA +! WATSON LABS 1MG

A080680 001 Aug CRLD

FORMOTEROL FUMARATE

SOLUTION;INHALATION

FORMOTEROL FUMARATE

AN TEVA PHARMS USA INC 0.02MG/2ML

A091141 001 Jun 22, 2021 Jun NFTG

PERFOROMIST

AN +! MYLAN SPECLT 0.02MG/2ML

N022007 001 May 11, 2007 Jun CFTG

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

DULERA

+ ORGANON 0.005MG/INH;0.05MG/INH
+! 0.005MG/INH;0.1MG/INH
+! 0.005MG/INH;0.2MG/INHN022518 003 Aug 12, 2019 Jun CAHN
N022518 001 Jun 22, 2010 Jun CAHN
N022518 002 Jun 22, 2010 Jun CAHNFOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP ASPIRO EQ 150MG BASE/VIAL
@ MYLAN LABS LTD EQ 115MG BASE/VIAL
AP PRAXGEN EQ 150MG BASE/VIAL
>A> AP EQ 150MG BASE/VIALA214616 001 Jul 29, 2021 Jul NEWA
A204015 001 Sep 05, 2019 Mar DISC
A211624 001 Sep 05, 2019 Jun CAHN
A213199 001 Oct 04, 2021 Sep NEWAFOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

AP FRESENIUS KABI USA 2.4GM/100ML

A212483 001 Jan 29, 2021 Jan NEWA

AP GLAND PHARMA LTD 2.4GM/100ML

A213001 001 Apr 21, 2021 Apr NEWA

FOSCAVIR

AP +! CLINIGEN HLTHCARE 2.4GM/100ML

N020068 001 Sep 27, 1991 Jan CTEC

FOSDENOPTERIN HYDROBROMIDEPOWDER; INTRAVENOUS
NULIBRY

+! ORIGIN EQ 9.5MG BASE/VIAL N214018 001 Feb 26, 2021 Feb NEWA

FOSINOPRIL SODIUMTABLET; ORAL
FOSINOPRIL SODIUM

AB	CHARTWELL RX	10MG	A076483	001	Apr 23, 2004	Aug	CAHN
AB		20MG	A076483	002	Apr 23, 2004	Aug	CAHN
AB		40MG	A076483	003	Apr 23, 2004	Aug	CAHN

FOSPHENYTOIN SODIUMSOLUTION; INTRAVENOUS
SESQUIENT

+ @	SEDOR PHARMS LLC	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Jul	DISC
+ @		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Jul	DISC

FULVESTRANTINJECTABLE; INTRAMUSCULAR
FULVESTRANT

AO	APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jun	NEWA
AO	AUROMEDICS PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Jan	CAHN
AO	CHEMO RESEARCH SL	50MG/ML	A213553	001	Aug 13, 2021	Aug	NEWA
AO	EUGIA PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Aug	CAHN
AO	XIROMED	50MG/ML	A213553	001	Aug 13, 2021	Aug	CAHN
AO	ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Jul	NEWA

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

AP	ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Apr	CMFD
AP	ATHENEX INC	10MG/ML	A214766	001	Jan 27, 2021	Jan	NEWA
	@ HIKMA	10MG/ML	N018267	001		Jun	CAHN
	@ HIKMA PHARMS	10MG/ML	N018267	001		Jul	CAHN

TABLET; ORAL

LASIX

AB	+ VALIDUS PHARMS	20MG	N016273	002		Feb	CAHN
AB	+	40MG	N016273	001		Feb	CAHN
AB	+!	80MG	N016273	003		Feb	CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB	ASCENT PHARMS INC	100MG	A214956	001	May 10, 2021	Apr	NEWA
AB		300MG	A214956	002	May 10, 2021	Apr	NEWA
AB		400MG	A214956	003	May 10, 2021	Apr	NEWA
AB	GRAVITI PHARMS	100MG	A207099	001	Mar 24, 2017	Jun	CAHN
AB		300MG	A207099	002	Mar 24, 2017	Jun	CAHN
AB		400MG	A207099	003	Mar 24, 2017	Jun	CAHN
AB	ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Apr	CMFD
	@	100MG	A213603	001	Aug 17, 2020	Feb	DISC
AB		300MG	A213603	002	Aug 17, 2020	Apr	CMFD
	@	300MG	A213603	002	Aug 17, 2020	Feb	DISC
AB		400MG	A213603	003	Aug 17, 2020	Apr	CMFD
	@	400MG	A213603	003	Aug 17, 2020	Feb	DISC

SOLUTION; ORAL

GABAPENTIN

>A>	@ NOVITIUM PHARMA	250MG/5ML	A211330	001	Dec 03, 2019	Sep	CAHN
>D>	@ VISTAPHARM	250MG/5ML	A211330	001	Dec 03, 2019	Sep	CAHN

TABLET; ORAL

GABAPENTIN

>A>	AB ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Sep	NEWA
>A>	AB	800MG	A214957	002	Oct 01, 2021	Sep	NEWA

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB	!	YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May	CHRS
		RAZADYNE						
	+	@ JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	May	DISC
	+	@	EQ 8MG BASE	N021169	002	Feb 28, 2001	May	DISC
	+	@	EQ 12MG BASE	N021169	003	Feb 28, 2001	May	DISC

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

	+	@ CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Jul	DISC
		GANCICLOVIR SODIUM						
AP	!	PHARMASCIENCE INC	EQ 500MG BASE/VIAL	A207645	001	Dec 08, 2017	Jul	CHRS

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT		AKORN	0.5%	A203189	001	Sep 03, 2014	Feb	CAHN
		@ MYLAN	0.5%	A206446	001	Jun 08, 2018	Jun	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP		HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	Jun	NEWA
AP			EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	Jun	NEWA
AP	!	JIANGSU HANSOH PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb	CHRS
AP	!		EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb	CHRS
AP		MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan	CAHN
AP			1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan	CAHN
AP			2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan	CAHN
		GEMZAR						
	+	@ LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb	DISC
	+	@	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb	DISC

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021	Jan	NEWA
----	--	-------------------	-------	---------	-----	--------------	-----	------

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

@ HIKMA PHARMS

@

EQ 10MG BASE/ML

EQ 40MG BASE/ML

A062251 002

A062251 001

Jun CAHN

Jun CAHN

GLECAPREVIR; PIBRENTASVIR

PELLETS; ORAL

MAVYRET

	+	! ABBVIE INC	50MG;20MG/PACKET	N215110	001	Jun 10, 2021	Jun	NEWA
--	---	--------------	------------------	---------	-----	--------------	-----	------

GLIPIZIDE

TABLET; ORAL

GLUCOTROL

	+	@ PFIZER	2.5MG	N017783	003	May 11, 1993	Aug	CRLD
--	---	----------	-------	---------	-----	--------------	-----	------

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>A>	AB1	SUNNY	1.25MG	A203581	001	Apr 14, 2016	Sep	CAHN
>A>	AB1		2.5MG	A203581	002	Apr 14, 2016	Sep	CAHN
>A>	AB1		5MG	A203581	003	Apr 14, 2016	Sep	CAHN
>D>	AB1	SWISS PHARM	1.25MG	A203581	001	Apr 14, 2016	Sep	CAHN
>D>	AB1		2.5MG	A203581	002	Apr 14, 2016	Sep	CAHN
>D>	AB1		5MG	A203581	003	Apr 14, 2016	Sep	CAHN
		GLYNASE						
AB	+	PFIZER	1.5MG	N020051	001	Mar 04, 1992	Feb	CAHN
AB	+		3MG	N020051	002	Mar 04, 1992	Feb	CAHN
	+	@	4.5MG	N020051	003	Sep 24, 1993	Feb	CAHN
AB	+	!	6MG	N020051	004	Sep 24, 1993	Feb	CAHN

TABLET;ORAL
MICRONASE

	+ @ PFIZER	1.25MG	N017498	001	May 01, 1984	Feb CAHN
	@	2.5MG	N017498	002	May 01, 1984	Feb CAHN
	+ @	5MG	N017498	003	May 01, 1984	Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION
GLYCOPYRROLATE

AP	ATHENEX INC	0.2MG/ML	A210083	001	Feb 21, 2020	Jan CAHN
>D>	AP HONG KONG	0.2MG/ML	A212802	001	Jul 06, 2021	Sep CAHN
AP		0.2MG/ML	A212802	001	Jul 06, 2021	Jun NEWA
>A>	AP MEITHEAL	0.2MG/ML	A212802	001	Jul 06, 2021	Sep CAHN
AP	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Feb NEWA

ROBINUL

	+ @ HIKMA PHARMS	0.2MG/ML	N017558	001		Jul CAHN
--	------------------	----------	---------	-----	--	----------

SOLUTION;ORAL
CUVPOSA

AA	+! MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010	Jul CFTG
AA	PAR PHARM INC	1MG/5ML	A204438	001	Aug 09, 2021	Jul NFTG

TABLET;ORAL
ROBINUL

AA	+ CASPER PHARMA LLC	1MG	N012827	001		Jun CMFD
AA	+ CASPER PHARMA LLC	2MG	N012827	002		Jun CMFD

GLYCOPYRROLATE

CLOTH;TOPICAL
QBREXZA

	+! JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018	May CAHN
--	------------	--------------	---------	-----	--------------	----------

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION
FACTREL

	@ HIKMA PHARMS	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982	Jul CAHN
	@	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982	Jul CAHN
	@	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982	Jul CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION;ORAL
GRANISOL

	@ INTRA SANA LABS	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jan CAHN
--	-------------------	------------------	---------	-----	--------------	----------

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

	@ CHARTWELL RX	EQ 4MG BASE	A074517	001	Sep 30, 1998	Aug CAHN
	@	EQ 8MG BASE	A074517	002	Sep 30, 1998	Aug CAHN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB	! AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan CHRS
	@ MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan DISC
	@	EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan DISC
AB	UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb NEWA
AB		EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

	@ YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May DISC
	@	EQ 2MG BASE	A213428	002	Nov 25, 2020	May DISC
	@	EQ 3MG BASE	A213428	003	Nov 25, 2020	May DISC
	@	EQ 4MG BASE	A213428	004	Nov 25, 2020	May DISC

HALCINONIDE

CREAM;TOPICAL
HALCINONIDE

AB	GLASSHOUSE PHARMS	0.1%	A214723	001	Sep 08, 2021	Aug NEWA
----	-------------------	------	---------	-----	--------------	----------

SOLUTION;TOPICAL
HALOG

+!	SUN PHARM INDS INC	0.1%		N017823	001		Apr	CRLD
----	--------------------	------	--	---------	-----	--	-----	------

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

@	COSETTE	0.05%		A077721	001	Sep 07, 2006	Mar	DISC
+	@ SUN PHARM INDS INC	0.05%		N019968	001	Dec 17, 1990	Mar	DISC

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB	CYCLE PHARMS LTD	2MG		A071130	001	Feb 17, 1987	Apr	CMFD
AB		5MG		A071131	001	Feb 17, 1987	Apr	CMFD
AB		10MG		A071132	001	May 12, 1987	Apr	CMFD

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

>D>	AO	HONG KONG	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Sep	CAHN
	AO		EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Jul	NEWA
>D>	AO		EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Sep	CAHN
	AO		EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Jul	NEWA
>A>	AO	MEITHEAL	EQ 50MG BASE/ML	A214507	001	Jul 26, 2021	Sep	CAHN
>A>	AO		EQ 100MG BASE/ML	A214507	002	Jul 26, 2021	Sep	CAHN

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALDOL

+	@ ORTHO MCNEIL	EQ 2MG BASE/ML		N015922	001		Mar	CRLD
---	----------------	----------------	--	---------	-----	--	-----	------

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

@	BE PHARMS	1,000 UNITS/ML		A214804	001	Dec 29, 2020	Jun	DISC
@		10,000 UNITS/ML		A214839	001	Dec 29, 2020	Jun	DISC
AP	+!	HIKMA PHARMS	1,000 UNITS/ML	N017037	001		Jul	CAHN
AP	+!		5,000 UNITS/ML	N017037	002		Jul	CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jul	CAHN
AP	+!		10,000 UNITS/ML	N017037	003		Jul	CAHN
	@	NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020	Aug	DISC
		HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020	Apr	CMFD
	@		200 UNITS/100ML	A212441	001	Jul 24, 2020	Jan	DISC
		HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
AP		FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020	Apr	CMFD
	@		200 UNITS/100ML	A212441	002	Jul 24, 2020	Jan	DISC
		HEPARIN SODIUM PRESERVATIVE FREE						
	@	NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020	Aug	DISC
	@	SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Apr	DISC

HISTRELIN ACETATE

IMPLANT;SUBCUTANEOUS

VANTAS

>D>								
>D>	+!	ENDO PHARM	50MG	N021732	001	Oct 12, 2004	Sep	DISC
>A>	+	@	50MG	N021732	001	Oct 12, 2004	Sep	DISC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL

HYCODAN

>D>	+	@ GENUS	1.5MG;5MG	N005213	001	Jul 26, 1988	Sep	CMFD
>A>	AA	+	1.5MG;5MG	N005213	001	Jul 26, 1988	Sep	CMFD

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

AA	+!	PLIVA	25MG	A088467	001	May 01, 1984	Aug	CRLD
AA	+!		50MG	A088468	001	May 01, 1984	Aug	CRLD
	@	UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	Aug	DISC
AA			10MG	A209251	001	Jul 09, 2018	May	CAHN

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE							
	@	25MG	A 209251	002	Jul 09, 2018	Aug	DISC
AA		25MG	A 209251	002	Jul 09, 2018	May	CAHN
	@	50MG	A 209251	003	Jul 09, 2018	Aug	DISC
AA		50MG	A 209251	003	Jul 09, 2018	May	CAHN
	@	100MG	A 209251	004	Jul 09, 2018	Aug	DISC
AA		100MG	A 209251	004	Jul 09, 2018	May	CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

APRESAZIDE

	+ @	NOVARTIS	25MG;25MG	A 084735	001	Aug	CRLD
	+ @		50MG;50MG	A 084810	001	Aug	CRLD

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

MICROZIDE

AB	+!	TEVA BRANDED PHARM	12.5MG	N 020504	001	Dec 27, 1996	Mar	CAHN
----	----	--------------------	--------	----------	-----	--------------	-----	------

SOLUTION;ORAL

HYDROCHLOROTHIAZIDE

	+ @	ROXANE	50MG/5ML	A 088587	001	Jul 02, 1984	Aug	CRLD
--	-----	--------	----------	----------	-----	--------------	-----	------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

AB	+	IVAX SUB TEVA PHARMS	25MG	A 083177	001	Aug	CRLD
AB	+!		50MG	A 083177	002	Aug	CRLD
	+ @		100MG	A 085022	001	Aug	CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

ZESTORETIC

AB	+	ALMATICA	12.5MG;10MG	N 019888	003	Nov 18, 1993	Jan	CAHN
AB	+!		12.5MG;20MG	N 019888	001	Sep 20, 1990	Jan	CAHN
AB	+!		25MG;20MG	N 019888	002	Jul 20, 1989	Jan	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

HYZAAR

AB	+	ORGANON	12.5MG;50MG	N 020387	001	Apr 28, 1995	Aug	CMFD
AB	+		25MG;100MG	N 020387	002	Nov 10, 1998	Aug	CMFD

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		JUBILANT CADISTA	12.5MG;50MG	A 201845	001	Sep 18, 2012	Jun	CAHN
AB			12.5MG;100MG	A 201845	002	Sep 18, 2012	Jun	CAHN
AB			25MG;100MG	A 201845	003	Sep 18, 2012	Jun	CAHN

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>A>	@	CHARTWELL RX	15MG;250MG	A 070182	001	Jan 15, 1986	Sep	CAHN
>A>	@		25MG;250MG	A 070183	001	Jan 15, 1986	Sep	CAHN
>A>	@		30MG;500MG	A 070543	001	Jan 15, 1986	Sep	CAHN
>A>	@		50MG;500MG	A 070544	001	Jan 15, 1986	Sep	CAHN
>D>		MYLAN	15MG;250MG	A 070265	002	Jan 23, 1986	Sep	DISC
>A>	@		15MG;250MG	A 070265	002	Jan 23, 1986	Sep	DISC
>D>	!		25MG;250MG	A 070265	001	Jan 23, 1986	Sep	DISC
>A>	@		25MG;250MG	A 070265	001	Jan 23, 1986	Sep	DISC
>D>	@	YAOPHARMA CO LTD	15MG;250MG	A 070182	001	Jan 15, 1986	Sep	CAHN
>D>	@		25MG;250MG	A 070183	001	Jan 15, 1986	Sep	CAHN
>D>	@		30MG;500MG	A 070543	001	Jan 15, 1986	Sep	CAHN
>D>	@		50MG;500MG	A 070544	001	Jan 15, 1986	Sep	CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

	+ @	CONCORDIA	12.5MG;EQ 25MG TARTRATE	N 021956	001	Aug 28, 2006	Jun	DISC
	+ @		12.5MG;EQ 50MG TARTRATE	N 021956	002	Aug 28, 2006	Jun	DISC
	+ @		12.5MG;EQ 100MG TARTRATE	N 021956	003	Aug 28, 2006	Jun	DISC

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL		LOPRESSOR HCT					
AB	+ VALIDUS PHARMS	25MG; 50MG	N018303	001	Dec 31, 1984	Feb	CAHN
	+ @	25MG; 100MG	N018303	002	Dec 31, 1984	Feb	CAHN
	+ @	50MG; 100MG	N018303	003	Dec 31, 1984	Feb	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL		PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
	@ ANI PHARMS	25MG; 40MG	A070705	002	Oct 01, 1986	Jul	CMS1
	@ MYLAN	25MG; 40MG	A070947	002	Mar 04, 1987	Aug	CAHN
	@	25MG; 40MG	A070947	002	Mar 04, 1987	Aug	DISC
	@	25MG; 80MG	A070947	001	Apr 01, 1987	Aug	CAHN
	@	25MG; 80MG	A070947	001	Apr 01, 1987	Aug	DISC

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL		SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE					
>A>	@ CHARTWELL RX	25MG; 25MG	A086881	001		Sep	CAHN
>D>	@ YAOPHARMA CO LTD	25MG; 25MG	A086881	001		Sep	CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL		VALSARTAN AND HYDROCHLOROTHIAZIDE					
	@ CADILA	12.5MG; 80MG	A203000	001	Mar 15, 2019	Aug	CAHN
	@	12.5MG; 160MG	A203000	002	Mar 15, 2019	Aug	CAHN
	@	12.5MG; 320MG	A203000	003	Mar 15, 2019	Aug	CAHN
	@	25MG; 160MG	A203000	004	Mar 15, 2019	Aug	CAHN
	@	25MG; 320MG	A203000	005	Mar 15, 2019	Aug	CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL		HYDROCODONE BITARTRATE					
AB	ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	Feb	NFTG
AB		30MG	A208269	002	Mar 01, 2021	Feb	NFTG
AB		40MG	A208269	003	Mar 01, 2021	Feb	NFTG
AB		60MG	A208269	004	Mar 01, 2021	Feb	NFTG
AB		80MG	A208269	005	Mar 01, 2021	Feb	NFTG
AB		100MG	A208269	006	Mar 01, 2021	Feb	NFTG
AB		120MG	A208269	007	Mar 01, 2021	Feb	NFTG
		HYSINGLA ER					
AB	+! PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Feb	CFTG
AB	+	30MG	N206627	002	Nov 20, 2014	Feb	CFTG
AB	+	40MG	N206627	003	Nov 20, 2014	Feb	CFTG
AB	+	60MG	N206627	004	Nov 20, 2014	Feb	CFTG
AB	+	80MG	N206627	005	Nov 20, 2014	Feb	CFTG
AB	+	100MG	N206627	006	Nov 20, 2014	Feb	CFTG
AB	+	120MG	N206627	007	Nov 20, 2014	Feb	CFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL		HYDROCODONE BITARTRATE AND IBUPROFEN					
AB	NOSTRUM LABS INC	5MG; 200MG	A077727	001	Nov 06, 2006	Jan	CAHN
AB		7.5MG; 200MG	A077723	001	Nov 06, 2006	Jan	CAHN
		10MG; 200MG	A077723	002	Nov 06, 2006	Mar	CTEC
AB		10MG; 200MG	A077723	002	Nov 06, 2006	Jan	CAHN
		REPREXAIN					
	@ AMNEAL PHARMS NY	2.5MG; 200MG	A076642	003	Oct 19, 2007	Mar	DISC
	@	10MG; 200MG	A076642	004	Oct 19, 2007	Mar	DISC

HYDROCORTISONE

CREAM; TOPICAL		HYTONE					
+	@ VALEANT INTL	1%	A080472	003		Aug	CRLD
+	@	2.5%	A080472	004		Aug	CRLD
		SYNACORT					
	@ BAUSCH	0.5%	A087459	001		May	CAHN
+	@	1%	A087458	001		Aug	CRLD
	@	1%	A087458	001		May	CAHN
+	@	2.5%	A087457	001		Aug	CRLD

	CREAM; TOPICAL							
	SYNACORT							
	@	2.5%		A 087457	001			May CAHN
	ENEMA; RECTAL							
	COLOCORT							
AB	CHARTWELL	100MG/60ML		A 075172	001	Dec 03, 1999		Apr CAHN
	LOTION; TOPICAL							
	HYTONE							
	+ @ VALEANT INTL	1%		A 080473	003			Aug CRLD
	+ @	2.5%		A 080473	004	Nov 30, 1982		Aug CRLD
	OINTMENT; TOPICAL							
	HYDROCORTISONE							
AT	+! FOUGERA PHARMS	1%		A 080692	001			Aug CRLD
	HYTONE							
	+ @ DERMIK LABS	1%		A 080474	003			Aug CRLD
	+ @	2.5%		A 080474	004			Aug CRLD
	SOLUTION; TOPICAL							
	PENECORT							
	+ @ ALLERGAN HERBERT	1%		A 088214	001	Jun 06, 1984		Aug CRLD
	<u>HYDROCORTISONE ACETATE</u>							
	CREAM; TOPICAL							
	CARMOL HC							
	+ @ FOUGERA PHARMS	1%		A 080505	001			Aug CRLD
	HYDROCORTISONE ACETATE							
	+ @ PUREPAC PHARM	1%		A 086052	001			Aug CRLD
	<u>HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
	CREAM; TOPICAL							
	CORTISPORIN							
	+ @ MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM		N 050218	001	Aug 09, 1985		Jul DISC
	<u>HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE</u>							
	AEROSOL, METERED; TOPICAL							
	PROCTOFOAM HC							
BX	+! MYLAN SPECIALITY LP	1%;1%		A 086195	001			Aug CHRS
BX	+	1%;1%		A 086195	001			Aug CRLD
	<u>HYDROCORTISONE PROBUTATE</u>							
	CREAM; TOPICAL							
	PANDEL							
	+! ANI PHARMS	0.1%		N 020453	001	Feb 28, 1997		Apr CAHN
	<u>HYDROCORTISONE SODIUM PHOSPHATE</u>							
	INJECTABLE; INJECTION							
	HYDROCORTONE							
	+ @ MERCK	EQ 50MG BASE/ML		N 012052	001			Feb CRLD
	<u>HYDROCORTISONE VALERATE</u>							
	CREAM; TOPICAL							
	HYDROCORTISONE VALERATE							
AB	COSETTE	0.2%		A 213724	001	Feb 11, 2021		Feb NEWA
	<u>HYDROMORPHONE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	HYDROMORPHONE HYDROCHLORIDE							
	@ LANNETT CO INC	2MG		A 077471	002	Dec 09, 2009		Mar DISC
	@	4MG		A 077471	003	Dec 09, 2009		Mar DISC
	@	8MG		A 077471	001	Dec 09, 2009		Mar DISC
	<u>HYDROXYCHLOROQUINE SULFATE</u>							
	TABLET; ORAL							
	HYDROXYCHLOROQUINE SULFATE							
	ACCORD HLTHCARE	100MG		A 213342	002	Aug 18, 2021		Aug NEWA
		300MG		A 213342	003	Aug 18, 2021		Aug NEWA
		400MG		A 213342	004	Aug 18, 2021		Aug NEWA
>D>	AB	LAURUS LABS LTD	200MG	A 210959	001	Jan 15, 2019		Sep CAHN
>A>	AB	RISING	200MG	A 210959	001	Jan 15, 2019		Sep CAHN
	AB	SENORES PHARMS	200MG	A 212902	001	May 14, 2020		Jul CAHN

HYDROXYPROGESTERONE CAPROATE

		SOLUTION; INTRAMUSCULAR							
		MAKENA							
AP1	+!	COVIS	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Mar	CAHN	
		MAKENA PRESERVATIVE FREE							
AP	+!	COVIS	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Mar	CAHN	
		SOLUTION; SUBCUTANEOUS							
		MAKENA (AUTOINJECTOR)							
	+!	COVIS	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Mar	CAHN	

HYDROXYUREA

		TABLET; ORAL							
		SIKLOS							
	+!	ADDMEDICA SAS	1GM	N208843	002	Dec 21, 2017	Mar	CHRS	

HYDROXYZINE HYDROCHLORIDE

		SYRUP; ORAL							
		HYDROXYZINE HYDROCHLORIDE							
AA	+!	WOCKHARDT BIO AG	10MG/5ML	A087294	001	Apr 12, 1982	Aug	CRLD	
		TABLET; ORAL							
		HYDROXYZINE HYDROCHLORIDE							
>A>	AB	BIOPHARM	10MG	A040804	001	Jun 30, 2008	Sep	CAHN	
>A>	AB		25MG	A040804	002	Jun 30, 2008	Sep	CAHN	
>A>	AB		50MG	A040804	003	Jun 30, 2008	Sep	CAHN	
>D>	AB	DISCOVERY THERAP	10MG	A040804	001	Jun 30, 2008	Sep	CAHN	
>D>	AB		25MG	A040804	002	Jun 30, 2008	Sep	CAHN	
>D>	AB		50MG	A040804	003	Jun 30, 2008	Sep	CAHN	
	AB	+!	PLIVA	A088617	001	Jan 10, 1986	Aug	CRLD	
	AB	+!		A088618	001	Jan 10, 1986	Aug	CRLD	
	AB	+!		A088619	001	Jan 10, 1986	Aug	CRLD	
	AB		PRINSTON INC	A040580	003	May 27, 2005	Feb	CMS1	
	AB			A040580	002	May 27, 2005	Feb	CMS1	

HYDROXYZINE PAMOATE

		CAPSULE; ORAL							
		HYDROXYZINE PAMOATE							
>D>	AB	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Sep	CTEC	
>A>	BX		EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Sep	CTEC	
>D>	AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Sep	CTEC	
>A>	BX		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Sep	CTEC	

IBANDRONATE SODIUM

		INJECTABLE; INTRAVENOUS							
		IBANDRONATE SODIUM							
AP		NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329	001	Jun 16, 2021	Jun	NEWA	

IBREXAFUNGERP CITRATE

		TABLET; ORAL							
		BREXAFEMME							
	+!	SCYNEXIS	EQ 150MG BASE	N214900	001	Jun 01, 2021	Jun	NEWA	

IBRUTINIB

		CAPSULE; ORAL							
		IBRUTINIB							
		@ ZYDUS	70MG	A211344	001	Mar 31, 2021	Jul	DISC	
AB			70MG	A211344	001	Mar 31, 2021	Mar	NFTG	
		@	140MG	A211344	002	Mar 31, 2021	Jul	DISC	
AB			140MG	A211344	002	Mar 31, 2021	Mar	NFTG	
		IMBRUVICA							
	+	PHARMACYCLICS INC	70MG	N205552	002	Dec 20, 2017	Jul	CTEC	
AB	+		70MG	N205552	002	Dec 20, 2017	Mar	CFTG	
	+!		140MG	N205552	001	Nov 13, 2013	Jul	CTEC	
AB	+!		140MG	N205552	001	Nov 13, 2013	Mar	CFTG	

IBUPROFEN

		SUSPENSION; ORAL							
		IBUPROFEN							
AB		PADAGIS US	100MG/5ML	A076925	001	Sep 23, 2004	Jul	CAHN	

TABLET; ORAL

IBUPROFEN

>A>	AB	ALKEM LABS LTD	400MG	A214699	001	Sep 13, 2021	Sep	NEWA
>A>	AB		600MG	A214699	002	Sep 13, 2021	Sep	NEWA
>A>	AB		800MG	A214699	003	Sep 13, 2021	Sep	NEWA
	AB	L PERRIGO CO	400MG	A077114	001	Jul 18, 2005	Jul	CAHN
	AB		600MG	A077114	002	Jul 18, 2005	Jul	CAHN
	AB		800MG	A077114	003	Jul 18, 2005	Jul	CAHN
		@ VINTAGE PHARMS	400MG	A071644	001	Feb 01, 1988	Feb	DISC

IBUTILIDE FUMARATEINJECTABLE; INJECTION
CORVERT

AP	+	PFIZER	0.1MG/ML	N020491	001	Dec 28, 1995	Feb	CAHN
----	---	--------	----------	---------	-----	--------------	-----	------

ICATIBANT ACETATEINJECTABLE; SUBCUTANEOUS
ICATIBANT ACETATE

		@ DR REDDYS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213054	001	Oct 05, 2020	May	DISC
AP		GLENMARK PHARMS LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A213222	001	May 21, 2021	May	NEWA

ICOSAPENT ETHYLCAPSULE; ORAL
ICOSAPENT ETHYL

AB		APOTEX	1GM	A209437	001	Jun 30, 2021	Jun	NEWA
		@ TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Mar	DISC
		@	1GM	A209525	002	Sep 11, 2020	Mar	DISC
		VASCEPA						
	+	AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar	CTEC

ILOPROSTSOLUTION; INHALATION
VENTAVIS

	+	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Feb	CAHN
		@	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Feb	CAHN
	+		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Feb	CAHN

IMIPRAMINE HYDROCHLORIDETABLET; ORAL
IMIPRAMINE HYDROCHLORIDE

AB	+	SPECGX LLC	10MG	A087846	002	May 22, 1984	Aug	CRLD
AB	+		25MG	A087846	003	May 22, 1984	Aug	CRLD
		TOFRANIL						
AB	+	SPECGX LLC	50MG	A087846	001	May 22, 1984	Aug	CRLD

IMIQUIMODCREAM; TOPICAL
IMIQUIMOD

AB		TARO	3.75%	A205971	001	Jan 26, 2021	Jan	NFTG
		ZYCLARA						
AB	+	BAUSCH	3.75%	N022483	001	Mar 25, 2010	Jan	CFTG

INDAPAMIDETABLET; ORAL
INDAPAMIDE

AB	!	ANI PHARMS	2.5MG	A074299	001	Jul 27, 1995	Jul	CHRS
		@ MYLAN	1.25MG	A074461	002	Mar 26, 1997	Jul	DISC
		@	2.5MG	A074461	001	Mar 27, 1996	Jul	DISC

INDOCYANINE GREENINJECTABLE; INJECTION
INDOCYANINE GREEN

AP		RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	Jun	CAHN
----	--	--------------	-----------	---------	-----	--------------	-----	------

INDOMETHACINCAPSULE; ORAL
INDOMETHACIN

		@ JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Jan	DISC
		@	50MG	A205215	002	Aug 25, 2017	Jan	DISC
		TIVORBEX						
	+	@ GENUS	20MG	N204768	001	Feb 24, 2014	Apr	DISC
	+	@	40MG	N204768	002	Feb 24, 2014	Apr	DISC

CAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

@ AUROBINDO PHARMA LTD	75MG	A204243	001	Dec 27, 2016	Jan	DISC
@ JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Jun	DISC

INFIGRATINIB PHOSPHATECAPSULE;ORAL
TRUSELTIQ

>A>	+	HELSINN HLTHCARE	25MG	N214622	001	May 28, 2021	Sep	CAHN
>A>	+	!	100MG	N214622	002	May 28, 2021	Sep	CAHN
>D>	+	QED THERAP	25MG	N214622	001	May 28, 2021	Sep	CAHN
	+		25MG	N214622	001	May 28, 2021	May	NEWA
>D>	+	!	100MG	N214622	002	May 28, 2021	Sep	CAHN
	+	!	100MG	N214622	002	May 28, 2021	May	NEWA

IOPAMIDOLINJECTABLE;INJECTION
ISOVUE-300

+	!	BRACCO	61%	N018735	002	Dec 31, 1985	Jan	CTEC
		ISOVUE-370						
+	!	BRACCO	76%	N018735	003	Dec 31, 1985	Jan	CTEC
		SCANLUX-300						
		@ SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Jan	DISC
		SCANLUX-370						
		@ SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Jan	DISC

IOVERSOLINJECTABLE;INJECTION
OPTIRAY 240

>D>	+	!	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Sep	DISC
>A>	+	@		51%	N019710	002	Dec 30, 1988	Sep	DISC

IPRATROPIUM BROMIDESOLUTION;INHALATION
IPRATROPIUM BROMIDE

AN		LUOXIN AUROVITAS	0.02%	A206543	001	Oct 27, 2016	Aug	CAHN
----	--	------------------	-------	---------	-----	--------------	-----	------

IRBESARTANTABLET;ORAL
IRBESARTAN

@	US ANTIBIOTICS	75MG	A203161	001	Sep 27, 2012	May	CAHN
@		150MG	A203161	002	Sep 27, 2012	May	CAHN
@		300MG	A203161	003	Sep 27, 2012	May	CAHN

IRINOTECAN HYDROCHLORIDEINJECTABLE;INJECTION
IRINOTECAN HYDROCHLORIDE

@	US ANTIBIOTICS	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	May	CAHN
@		100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	May	CAHN

ISOETHARINE HYDROCHLORIDESOLUTION;INHALATION
ISOETHARINE HYDROCHLORIDE

+	@	ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982	Aug	CRLD
+	@		0.125%	A087938	001	Nov 15, 1982	Aug	CRLD
+	@		0.167%	A088470	001	Mar 14, 1984	Aug	CRLD
+	@		0.2%	A088471	001	Mar 14, 1984	Aug	CRLD
+	@		0.25%	A088472	001	Mar 14, 1984	Aug	CRLD
+	@	DEY	1%	A086763	001		Aug	CRLD

ISOFLURANELIQUID;INHALATION
ISOFLURANE

AN		PIRAMAL PHARMA	99.9%	A074502	001	Jun 27, 1995	Aug	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

ISONIAZIDSYRUP;ORAL
ISONIAZID

+	!	CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Aug	CRLD
---	---	----------------	----------	---------	-----	--------------	-----	------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

AP	AMRING PHARMS	0.2MG/ML	A211237	001	May 19, 2021	May NEWA
	@ CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Aug DISC
AP	MICRO LABS	0.2MG/ML	A210845	001	Feb 16, 2021	Feb NEWA

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

AB2	+	SUN PHARM INDS INC	10MG	N021951	001	May 25, 2012	Mar CFTG
AB2	+		20MG	N021951	002	May 25, 2012	Mar CFTG
AB2	+		25MG	N021951	005	Aug 15, 2014	Mar CFTG
AB2	+		30MG	N021951	003	May 25, 2012	Mar CFTG
AB2	+		35MG	N021951	006	Aug 15, 2014	Mar CFTG
AB2	+		40MG	N021951	004	May 25, 2012	Mar CFTG

AMNESTEEM

AB1		MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002	Mar CTEC
AB1			20MG	A075945	002	Nov 08, 2002	Mar CTEC
AB1			40MG	A075945	003	Nov 08, 2002	Mar CTEC

CLARAVIS

AB1		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	Mar CTEC
AB1			20MG	A076135	002	Apr 11, 2003	Mar CTEC
AB1			30MG	A076135	003	May 11, 2006	Mar CTEC
AB1	!		40MG	A076135	001	Apr 11, 2003	Mar CTEC

ISOTRETINOIN

AB2		ACTAVIS LABS FL	10MG	A205063	001	Mar 31, 2021	Mar NFTG
AB2			20MG	A205063	002	Mar 31, 2021	Mar NFTG
AB2			25MG	A205063	003	Mar 31, 2021	Mar NFTG
AB2			30MG	A205063	004	Mar 31, 2021	Mar NFTG
AB2			35MG	A205063	005	Mar 31, 2021	Mar NFTG
AB2			40MG	A205063	006	Mar 31, 2021	Mar NFTG
AB1		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Mar CTEC
AB1			20MG	A207792	002	Sep 29, 2017	Mar CTEC
AB1			30MG	A207792	003	Sep 29, 2017	Mar CTEC
AB1			40MG	A207792	004	Sep 29, 2017	Mar CTEC
>A>	AB2	UPSHER SMITH LABS	10MG	A212333	001	Sep 21, 2021	Sep NEWA
>A>	AB2		20MG	A212333	002	Sep 21, 2021	Sep NEWA
>A>	AB2		30MG	A212333	003	Sep 21, 2021	Sep NEWA
	AB2		40MG	A213571	001	Apr 12, 2021	Apr NEWA

MYORISAN

AB1		DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Mar CTEC
AB1			20MG	A076485	002	Jan 19, 2012	Mar CTEC
AB1			30MG	A076485	004	Aug 25, 2015	Mar CTEC
AB1			40MG	A076485	003	Jan 19, 2012	Mar CTEC

ZENATANE

AB1		DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar CTEC
AB1			20MG	A202099	002	Mar 25, 2013	Mar CTEC
AB1			30MG	A202099	004	Feb 23, 2015	Mar CTEC
AB1			40MG	A202099	003	Mar 25, 2013	Mar CTEC

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

>D>	AB	MYLAN PHARMS INC	100MG	A200463	001	Jul 20, 2012	Sep CTEC
>A>	BX		100MG	A200463	001	Jul 20, 2012	Sep CTEC
>D>	AB	STRIDES PHARMA	100MG	A206410	001	Jul 02, 2019	Sep CTEC
>A>	BX		100MG	A206410	001	Jul 02, 2019	Sep CTEC

TABLET; ORAL

ONMEL

+	@	SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010	Apr DISC
---	---	--------------------	-------	---------	-----	--------------	----------

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET; ORAL

SYMDEKO (COPACKAGED)

+		VERTEX PHARMS INC	75MG; 75MG, 50MG	N210491	002	Jun 21, 2019	Jul CPOT
+			75MG, N/A; 75MG, 50MG	N210491	002	Jun 21, 2019	Jul CDFR
+	!		150MG; 150MG, 100MG	N210491	001	Feb 12, 2018	Jul CPOT
+	!		150MG, N/A; 150MG, 100MG	N210491	001	Feb 12, 2018	Jul CDFR

IVOSIDENIBTABLET; ORAL
TIBSOVO

+! SERVIER 250MG N211192 001 Jul 20, 2018 Apr CAHN

IXAZOMIB CITRATECAPSULE; ORAL
NINLARO+ TAKEDA PHARMS USA EQ 2.3MG BASE N208462 001 Nov 20, 2015 May CAHN
+ EQ 3MG BASE N208462 002 Nov 20, 2015 May CAHN
+! EQ 4MG BASE N208462 003 Nov 20, 2015 May CAHNKETAMINE HYDROCHLORIDEINJECTABLE; INJECTION
KETAMINE HYDROCHLORIDEAP AUROMEDICS PHARMA EQ 10MG BASE/ML A076092 001 Sep 30, 2008 Jan CAHN
AP EQ 50MG BASE/ML A076092 002 Dec 28, 2001 Jan CAHN
AP EQ 100MG BASE/ML A076092 003 Oct 25, 2002 Jan CAHN
AP EUGIA PHARMA EQ 10MG BASE/ML A076092 001 Sep 30, 2008 Aug CAHN
AP EQ 50MG BASE/ML A076092 002 Dec 28, 2001 Aug CAHN
AP EQ 100MG BASE/ML A076092 003 Oct 25, 2002 Aug CAHNKETOCONAZOLEAEROSOL, FOAM; TOPICAL
EXTINA>D> AT +! MYLAN 2% N021738 001 Jun 12, 2007 Sep CTEC
>A> AB +! 2% N021738 001 Jun 12, 2007 Sep CTEC
KETOCONAZOLE
>D> AT PADAGIS ISRAEL 2% A091550 001 Aug 25, 2011 Sep CTEC
>A> AB 2% A091550 001 Aug 25, 2011 Sep CTEC
>D> AT XIROMED 2% A213601 001 May 21, 2021 Sep CTEC
>A> AB 2% A213601 001 May 21, 2021 Sep CTEC
AT 2% A213601 001 May 21, 2021 May NEWACREAM; TOPICAL
KETOCONAZOLEAB ENCUBE 2% A212443 001 May 20, 2021 May NEWA
TABLET; ORAL
KETOCONAZOLE
@ MYLAN 200MG A075597 001 Dec 23, 1999 Mar DISC
AB SENORES PHARMS 200MG A075912 001 Jan 10, 2002 Aug CAHNKETOPROFENCAPSULE; ORAL
KETOPROFEN! HERITAGE PHARMS INC 75MG A074014 003 Jan 29, 1993 Jul CTEC
AB ! 75MG A074014 003 Jan 29, 1993 Jul CHRS
@ RISING 50MG A074024 001 Dec 29, 1995 Jan CAHN
@ 75MG A074024 002 Dec 29, 1995 Jan CAHN
@ TEVA 75MG A073517 001 Dec 22, 1992 Jul DISCKETOROLAC TROMETHAMINEINJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

@ HOSPIRA 15MG/ML A074993 001 Jan 27, 1999 Mar DISC

LABETALOL HYDROCHLORIDEINJECTABLE; INJECTION
LABETALOL HYDROCHLORIDEAP BAXTER HLTHCARE CORP 5MG/ML A076051 001 Jul 05, 2002 Mar CMFD
AP CAPLIN 5MG/ML A214533 001 Sep 07, 2021 Aug NEWA

SOLUTION; INTRAVENOUS

LABETALOL HYDROCHLORIDE IN DEXTROSE

>D> +! HIKMA 200MG/200ML (1MG/ML) N213330 001 Nov 09, 2020 Sep CAHN
>A> +! HIKMA PHARMS 200MG/200ML (1MG/ML) N213330 001 Nov 09, 2020 Sep CAHN
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE
>D> +! HIKMA 100MG/100ML (1MG/ML) N213330 002 Nov 09, 2020 Sep CAHN
>D> +! 200MG/200ML (1MG/ML) N213330 003 Nov 09, 2020 Sep CAHN
>D> +! 300MG/300ML (1MG/ML) N213330 004 Nov 09, 2020 Sep CAHN
>A> +! HIKMA PHARMS 100MG/100ML (1MG/ML) N213330 002 Nov 09, 2020 Sep CAHN
>A> +! 200MG/200ML (1MG/ML) N213330 003 Nov 09, 2020 Sep CAHN
>A> +! 300MG/300ML (1MG/ML) N213330 004 Nov 09, 2020 Sep CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	!	PAR FORM	200MG	A200908	002	Jul 10, 2012	Jul	CHRS
AB		RUBICON	100MG	A211953	001	Aug 18, 2021	Aug	NEWA
AB			200MG	A211953	002	Aug 18, 2021	Aug	NEWA
AB			300MG	A211953	003	Aug 18, 2021	Aug	NEWA

TRANDATE

	+	@	ALVOGEN	100MG	N018716	001	May 24, 1985	Jul	DISC
AB	+			100MG	N018716	001	May 24, 1985	Jul	CAHN
	+	@		200MG	N018716	002	Aug 01, 1984	Jul	DISC
AB	+	!		200MG	N018716	002	Aug 01, 1984	Jul	CAHN
	+	@		300MG	N018716	003	Aug 01, 1984	Jul	DISC
AB	+			300MG	N018716	003	Aug 01, 1984	Jul	CAHN
	+	@		400MG	N018716	004	Aug 01, 1984	Jul	CAHN
AB	+	!	CNTY LINE PHARMS	200MG	N018716	002	Aug 01, 1984	Apr	CHRS

LACTULOSE

SOLUTION;ORAL

LACTULOSE

AA		TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jun	CMFD
		SOLUTION;ORAL, RECTAL						
		LACTULOSE						
AA		TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jun	CMFD

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

>A>	AB	APPCO	150MG	A206974	001	Nov 21, 2016	Sep	CAHN
>A>	AB		300MG	A206974	002	Nov 21, 2016	Sep	CAHN
>D>	AB	ARISE	150MG	A206974	001	Nov 21, 2016	Sep	CAHN
>D>	AB		300MG	A206974	002	Nov 21, 2016	Sep	CAHN
>A>	AB	BRECKENRIDGE	150MG	A203586	001	Nov 21, 2016	Sep	CAHN
>D>	AB	CENTAUR PHARMS PVT	150MG	A203586	001	Nov 21, 2016	Sep	CAHN
	AB		150MG	A203586	001	Nov 21, 2016	Jun	CAHN

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

	+	@	AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Feb	DISC
			TEMIXYS						
	+	@	CELLTRION	300MG;300MG	N211284	001	Nov 16, 2018	Aug	DISC

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

	@	GRANULES	25MG	A078982	001	Jan 27, 2009	Jun	CAHN
	@		100MG	A078982	002	Jan 27, 2009	Jun	CAHN
	@		150MG	A078982	003	Jan 27, 2009	Jun	CAHN
	@		200MG	A078982	004	Jan 27, 2009	Jun	CAHN
>D>	@	PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009	Sep	CAHN
>D>	@		100MG	A078310	002	Feb 04, 2009	Sep	CAHN
>D>	@		150MG	A078310	003	Feb 04, 2009	Sep	CAHN
>D>	@		200MG	A078310	004	Feb 04, 2009	Sep	CAHN
>A>	@	ZENNOVA	25MG	A078310	001	Feb 04, 2009	Sep	CAHN
>A>	@		100MG	A078310	002	Feb 04, 2009	Sep	CAHN
>A>	@		150MG	A078310	003	Feb 04, 2009	Sep	CAHN
>A>	@		200MG	A078310	004	Feb 04, 2009	Sep	CAHN

TABLET, CHEWABLE;ORAL

LAMOTRIGINE

@ JUBILANT GENERICS

@

			5MG	A200220	001	Feb 28, 2011	Jun	DISC
			25MG	A200220	002	Feb 28, 2011	Jun	DISC

TABLET, EXTENDED RELEASE;ORAL

LAMOTRIGINE

AB		ACTAVIS ELIZABETH	250MG	A200672	006	Nov 13, 2013	Jul	CMS1
----	--	-------------------	-------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

AB		AJANTA PHARMA LTD	25MG	A213271	001	Jan 19, 2021	Jan	NEWA
AB			50MG	A213271	002	Jan 19, 2021	Jan	NEWA
AB			100MG	A213271	003	Jan 19, 2021	Jan	NEWA
AB			200MG	A213271	004	Jan 19, 2021	Jan	NEWA

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
PREVACID

+ @ TAKEDA PHARMS USA 15MG

N020406 001 May 10, 1995 Jun DISC

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB DR REDDYS LABS LTD 15MG

A210465 001 Feb 01, 2021 Jan NEWA

AB 30MG

A210465 002 Feb 01, 2021 Jan NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

+ ELI LILLY AND CO EQ 50MG BASE

N211280 001 Jan 31, 2020 May CPOT

+! EQ 100MG BASE

N211280 002 Jan 31, 2020 Aug CHRS

+ EQ 100MG BASE

N211280 002 Jan 31, 2020 May CHRS

+! EQ 100MG BASE

N211280 002 Jan 31, 2020 May CPOT

+ @ EQ 200MG BASE

N211280 003 Dec 18, 2020 Aug DISC

+! EQ 200MG BASE

N211280 003 Dec 18, 2020 May CHRS

+ EQ 200MG BASE

N211280 003 Dec 18, 2020 May CPOT

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

AB AET PHARMA 10MG

A213497 001 May 10, 2021 Jun CAHN

AB 20MG

A213497 002 May 10, 2021 Jun CAHN

AB AUROBINDO PHARMA LTD 10MG

A213652 001 Mar 29, 2021 Mar NEWA

AB 20MG

A213652 002 Mar 29, 2021 Mar NEWA

AB AXUNIO 10MG

A213497 001 May 10, 2021 Apr NEWA

AB 20MG

A213497 002 May 10, 2021 Apr NEWA

LENALIDOMIDE

CAPSULE;ORAL

LENALIDOMIDE

AB ARROW INTL 5MG

A201452 001 May 21, 2021 Jul CAHN

AB 10MG

A201452 002 May 21, 2021 Jul CAHN

AB 15MG

A201452 003 May 21, 2021 Jul CAHN

AB 25MG

A201452 004 May 21, 2021 Jul CAHN

AB NATCO PHARMA LTD 5MG

A201452 001 May 21, 2021 May NFTG

AB 10MG

A201452 002 May 21, 2021 May NFTG

AB 15MG

A201452 003 May 21, 2021 May NFTG

AB 25MG

A201452 004 May 21, 2021 May NFTG

REVLIMID

AB + CELGENE 5MG

N021880 001 Dec 27, 2005 May CFTG

AB + 10MG

N021880 002 Dec 27, 2005 May CFTG

AB + 15MG

N021880 003 Jun 29, 2006 May CFTG

AB +! 25MG

N021880 004 Jun 29, 2006 May CFTG

LETROZOLE

TABLET;ORAL

LETROZOLE

@ APOTEX INC 2.5MG

A091303 001 Apr 19, 2012 Jan DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+! NOVARTIS 2.5MG;EQ 200MG BASE

N209935 001 May 04, 2017 Jul CPOT

+! 2.5MG,N/A;N/A,EQ 200MG BASE

N209935 001 May 04, 2017 Jul CDFR

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP ! HIKMA PHARMS EQ 50MG BASE/VIAL

A089384 001 Sep 14, 1987 Jul CAHN

AP ! EQ 100MG BASE/VIAL

A089717 001 Mar 28, 1988 Jul CAHN

>D> @ INGENUS PHARMS LLC EQ 10MG BASE/ML

A210917 001 Nov 23, 2018 Sep CAHN

>A> @ NOVAST LABS EQ 10MG BASE/ML

A210917 001 Nov 23, 2018 Sep CAHN

TABLET;ORAL

LEUCOVORIN CALCIUM

AB EPIC PHARMA LLC EQ 10MG BASE

A074544 003 May 19, 2021 May NEWA

AB EQ 15MG BASE

A074544 004 May 19, 2021 May NEWA

LEUPROLIDE ACETATEINJECTABLE; INJECTION
LEUPROLIDE ACETATE

AP	VGVAAN	1MG/0.2ML	A213829	001	Aug 13, 2021	Aug NEWA
----	--------	-----------	---------	-----	--------------	----------

LEUPROLIDE ACETATE; NORETHINDRONE ACETATEINJECTABLE, TABLET; INTRAMUSCULAR, ORAL
LUPANETA PACK

	+ @ ABBVIE ENDOCRINE	3.75MG/VIAL, N/A; N/A, 5MG	N203696	001	Dec 14, 2012	Aug DISC
	+ @	11.25MG/VIAL, N/A; N/A, 5MG	N203696	002	Dec 14, 2012	Aug DISC

LEUPROLIDE MESYLATEEMULSION; SUBCUTANEOUS
CAMCEVI KIT

	+! FORESEE PHARMS	EQ 42MG BASE	N211488	001	May 25, 2021	May NEWA
--	-------------------	--------------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDESOLUTION; INHALATION
LEVALBUTEROL HYDROCHLORIDE

AN	LUOXIN AUROVITAS	EQ 0.25% BASE	A207628	001	Jan 31, 2017	Aug CAHN
AN		EQ 0.0103% BASE	A207625	001	Dec 30, 2016	Aug CAHN
AN		EQ 0.021% BASE	A207625	002	Dec 30, 2016	Aug CAHN
AN		EQ 0.042% BASE	A207625	003	Dec 30, 2016	Aug CAHN

LEVETIRACETAMINJECTABLE; INTRAVENOUS
LEVETIRACETAM

	@ JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jun DISC
	LEVETIRACETAM IN SODIUM CHLORIDE					
AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb CDFR
AP	+! HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Feb CPOT
AP	+!	1.5GM/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Feb CPOT
AP	NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb CPOT
AP		1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb CPOT

SOLUTION; ORAL

LEVETIRACETAM

AA	AKORN	100MG/ML	A090601	001	Feb 28, 2012	Feb CAHN
	TABLET; ORAL					
	LEVETIRACETAM					
	@ LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Aug DISC
	@	750MG	A090906	003	Oct 31, 2016	Aug DISC
	@	1GM	A090906	004	Oct 31, 2016	Aug DISC
	@ NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Mar DISC
AB		250MG	A090511	001	Aug 18, 2011	Jan CAHN
	@	500MG	A090511	002	Aug 18, 2011	Mar DISC
AB		500MG	A090511	002	Aug 18, 2011	Jan CAHN
	@	750MG	A090511	003	Aug 18, 2011	Mar DISC
AB		750MG	A090511	003	Aug 18, 2011	Jan CAHN
	@	1GM	A090511	004	Aug 18, 2011	Mar DISC
AB		1GM	A090511	004	Aug 18, 2011	Jan CAHN
AB	SCIEGEN PHARMS INC	750MG	A215069	001	Jun 11, 2021	Jun NEWA
AB		1GM	A215069	002	Jun 11, 2021	Jun NEWA

TABLET, EXTENDED RELEASE; ORAL

ELEPSIA XR

	+ TRIPOINT	1GM	N204417	001	Dec 20, 2018	Jan CAHN
	+!	1.5GM	N204417	002	Dec 20, 2018	Jan CAHN

LEVETIRACETAM

>A>	AB	GENUS LIFESCIENCES	500MG	A204754	001	Aug 26, 2016	Sep CAHN
>A>	AB		750MG	A204754	002	Aug 26, 2016	Sep CAHN
		@ LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	Aug DISC
		@	750MG	A202095	001	Jun 06, 2016	Aug DISC
	AB	OVERSEAS	750MG	A212688	001	Jun 11, 2020	May CMFD
>D>	AB	PHARMA LIFE	500MG	A204754	001	Aug 26, 2016	Sep CAHN
>D>	AB		750MG	A204754	002	Aug 26, 2016	Sep CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

@ AKORN 0.25%

A 074779 001 Oct 29, 1996 Jul DISC

@ 0.5%

A 074780 001 Oct 29, 1996 Jul DISC

BETAGAN

+ @ ALLERGAN 0.25%

N 019814 001 Jun 28, 1989 Jun DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA ! PADAGIS US 2.5MG/5ML

A 091263 001 Nov 07, 2011 Jul CAHN

XYZAL

+ @ SANOFI 2.5MG/5ML

N 022157 001 Jan 28, 2008 Apr DISC

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB ! GLENMARK GENERICS 5MG

A 090385 001 Feb 24, 2011 Apr CHRS

@ GRANULES 5MG

A 090486 001 Mar 26, 2013 Apr CAHN

@ NEOPHARMA 5MG

A 204323 001 Dec 20, 2016 Mar DISC

@ US ANTIBIOTICS 5MG

A 204323 001 Dec 20, 2016 May CAHN

XYZAL

+ @ SANOFI 5MG

N 022064 001 May 25, 2007 Apr DISC

LEVOFLOXACIN

TABLET;ORAL

LEVOFLOXACIN

AB CADILA 250MG

A 077652 001 Sep 07, 2012 Jun CAHN

AB 500MG

A 077652 002 Sep 07, 2012 Jun CAHN

AB 750MG

A 077652 003 Sep 07, 2012 Jun CAHN

@ JUBILANT GENERICS 250MG

A 203613 001 Jun 19, 2015 Jun DISC

@ 500MG

A 203613 002 Jun 19, 2015 Jun DISC

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP HIKMA PHARMS EQ 50MG BASE/VIAL

A 206263 001 Jun 16, 2016 Jul CAHN

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

AB NOVITIUM PHARMA 1MG

A 213479 003 Jul 20, 2021 Jul NEWA

AB 3MG

A 213479 002 Jan 12, 2021 Jan NEWA

AB ! SENTYNL THERAPS INC 3MG

A 074278 003 Jun 18, 2018 Jan CTEC

AB SUN PHARM INDS INC 2MG

A 213906 001 Jun 17, 2021 Jun NEWA

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

@ TEVA PHARMS USA INC 0.075MG

A 211369 001 Oct 28, 2020 Apr DISC

@ 0.088MG

A 213256 001 Jan 06, 2021 Jul DISC

@ 0.1MG

A 213256 002 Jan 06, 2021 Jul DISC

AB 0.112MG

A 211369 003 Apr 16, 2021 Apr NFTG

@ 0.125MG

A 213256 003 Jan 06, 2021 Jul DISC

@ 0.15MG

A 211369 002 Oct 28, 2020 Apr DISC

TIROSINT

+ INSTITUT BIOCHIMIQUE 0.075MG

N 021924 004 Oct 13, 2006 Apr CTEC

+ 0.112MG

N 021924 008 Oct 02, 2009 Apr CFTG

+ 0.15MG

N 021924 007 Oct 13, 2006 Apr CTEC

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

@ DR REDDYS 100MCG/VIAL

A 208837 001 Mar 27, 2020 Feb DISC

SOLUTION;INTRAVENOUS

LEVOTHYROXINE SODIUM

+! CUSTOPHARM INC 100MCG/ML

N 214253 001 May 17, 2021 May NEWA

SOLUTION;ORAL

THYQUIDITY

+! VISTAPHARM 100MCG/5ML

N 214047 001 Nov 30, 2020 Apr CAHN

TIROSINT-SOL

+ INSTITUT BIOCHIMIQUE 37.5MCG/ML

N 206977 013 Jan 13, 2021 Jan NEWA

+ 44MCG/ML

N 206977 014 Jan 13, 2021 Jan NEWA

+ 62.5MCG/ML

N 206977 015 Jan 13, 2021 Jan NEWA

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL
THYRO-TABS

>D>	AB2, + AB4	ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.025MG	N021116	001	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.05MG	N021116	002	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.05MG	N021116	002	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.075MG	N021116	003	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.075MG	N021116	003	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.088MG	N021116	010	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.088MG	N021116	010	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.1MG	N021116	004	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.1MG	N021116	004	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.112MG	N021116	011	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.112MG	N021116	011	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.125MG	N021116	005	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.125MG	N021116	005	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.137MG	N021116	012	Dec 07, 2004	Sep	CAHN
>A>	AB2, + AB4		0.137MG	N021116	012	Dec 07, 2004	Sep	CAHN
>D>	AB2, + AB4		0.15MG	N021116	006	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.15MG	N021116	006	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.175MG	N021116	007	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.175MG	N021116	007	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.2MG	N021116	008	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.2MG	N021116	008	Oct 24, 2002	Sep	CAHN
>D>	AB2, + AB4		0.3MG	N021116	009	Oct 24, 2002	Sep	CAHN
>A>	AB2, + AB4		0.3MG	N021116	009	Oct 24, 2002	Sep	CAHN

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	+!	FOUGERA PHARMS INC	5%	A080198	001		Aug	CRLD
AT		QUAGEN	5%	A212695	001	Apr 20, 2021	Apr	NEWA
	@	RISING	5%	A208604	001	Sep 20, 2017	May	CAHN

PATCH;TOPICAL

LIDOCAINE

AB		NAL PHARM	5%	A205882	001	Apr 29, 2021	Apr	NEWA
	@	NOVEN PHARMS INC	5%	A203265	001	Dec 01, 2020	Jun	DISC

LIDOCAINE HYDROCHLORIDE

JELLY;TOPICAL

XYLOCAINE

+ @ AKORN

2%

N008816 001

Jan DISC

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT		LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Jan	CMFD
----	--	----------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB ACRUX DDS PTY 2.5%;2.5% A212482 001 Jul 27, 2021 Jul NEWA

LINACLOTIDE

CAPSULE; ORAL

LINACLOTIDE

AB @ MYLAN 145MCG A209564 001 Feb 09, 2021 Feb DISC
 AB 145MCG A209564 001 Feb 09, 2021 Jan NFTG
 @ 290MCG A209564 002 Feb 09, 2021 Feb DISC
 AB 290MCG A209564 002 Feb 09, 2021 Jan NFTG

LINZESS

AB +! ALLERGAN 145MCG N202811 001 Aug 30, 2012 Feb CTEC
 AB +! 145MCG N202811 001 Aug 30, 2012 Jan CFTG
 + 290MCG N202811 002 Aug 30, 2012 Feb CTEC
 AB + 290MCG N202811 002 Aug 30, 2012 Jan CFTG

LINAGLIPTIN

TABLET; ORAL

LINAGLIPTIN

AB SUNSHINE 5MG A208335 001 Aug 31, 2021 Aug NFTG
 TRADJENTA
 AB +! BOEHRINGER INGELHEIM 5MG N201280 001 May 02, 2011 Aug CFTG

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

AB + BOEHRINGER INGELHEIM 2.5MG;500MG N201281 001 Jan 30, 2012 Aug CFTG
 AB + 2.5MG;850MG N201281 002 Jan 30, 2012 Aug CFTG
 AB +! 2.5MG;1GM N201281 003 Jan 30, 2012 Aug CFTG

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB SUNSHINE 2.5MG;500MG A208336 001 Aug 30, 2021 Aug NFTG
 AB 2.5MG;850MG A208336 002 Aug 30, 2021 Aug NFTG
 AB 2.5MG;1GM A208336 003 Aug 30, 2021 Aug NFTG

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

AP +! PFIZER EQ 300MG BASE/ML N050317 001 Feb CAHN
 >D> LINCOMYCIN HYDROCHLORIDE
 >D> AP PRAXGEN EQ 300MG BASE/ML A212770 001 Mar 12, 2021 Sep DISC
 >A> @ EQ 300MG BASE/ML A212770 001 Mar 12, 2021 Sep DISC
 AP EQ 300MG BASE/ML A212770 001 Mar 12, 2021 Mar NEWA

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

AB ZYDUS EQ 0.005MG BASE A214803 001 Jan 22, 2021 Jan NEWA
 AB EQ 0.025MG BASE A214803 002 Jan 22, 2021 Jan NEWA
 AB EQ 0.05MG BASE A214803 003 Jan 22, 2021 Jan NEWA

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB YILING 20MG A208920 001 Mar 04, 2021 Feb NEWA
 AB 30MG A208920 002 Mar 04, 2021 Feb NEWA
 AB 40MG A208920 003 Mar 04, 2021 Feb NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

>A> AB EDENBRIDGE PHARMS 2MG A215001 001 Oct 06, 2021 Sep NEWA

LOPINAVIR; RITONAVIR

TABLET; ORAL

KALETRA

AB + ABBVIE 100MG;25MG N021906 002 Nov 09, 2007 May CFTG
 AB +! 200MG;50MG N021906 001 Oct 28, 2005 May CFTG

TABLET;ORAL							
LOPINAVIR AND RITONAVIR							
AB	HETERO LABS LTD III	100MG;25MG	A091677	001	Jun 04, 2021	May	NFTG
AB		200MG;50MG	A091677	002	Jun 04, 2021	May	NFTG
<u>LORAZEPAM</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
LOREEV XR							
+	ALMATICA	1MG	N214826	001	Aug 27, 2021	Aug	NEWA
+		2MG	N214826	002	Aug 27, 2021	Aug	NEWA
+	!	3MG	N214826	003	Aug 27, 2021	Aug	NEWA
CONCENTRATE;ORAL							
LORAZEPAM							
AA	AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb	CAHN
INJECTABLE;INJECTION							
ATIVAN							
AP	+	HIKMA PHARMS	2MG/ML	N018140	001		Jul CAHN
AP	+	!	4MG/ML	N018140	002		Jul CAHN
<u>LOSARTAN POTASSIUM</u>							
TABLET;ORAL							
COZAAR							
AB	+	ORGANON	25MG	N020386	001	Apr 14, 1995	Aug CMFD
AB	+		50MG	N020386	002	Apr 14, 1995	Aug CMFD
LOSARTAN POTASSIUM							
AB		HIKMA PHARMS	25MG	A077459	001	Oct 06, 2010	Jul CMFD
AB			50MG	A077459	002	Oct 06, 2010	Jul CMFD
AB			100MG	A077459	003	Oct 06, 2010	Jul CMFD
AB		JUBILANT CADISTA	25MG	A201170	001	Sep 18, 2012	Jun CAHN
AB			50MG	A201170	002	Sep 18, 2012	Jun CAHN
AB			100MG	A201170	003	Sep 18, 2012	Jun CAHN
<u>LOTEPREDNOL ETABONATE</u>							
GEL;OPHTHALMIC							
LOTEMAX							
AB	+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Jan CFTG
LOTEPREDNOL ETABONATE							
AB		AKORN	0.5%	A212080	001	Feb 10, 2021	Jan NFTG
SUSPENSION/DROPS;OPHTHALMIC							
LOTEPREDNOL ETABONATE							
AB		SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb NEWA
<u>LOXAPINE SUCCINATE</u>							
CAPSULE;ORAL							
LOXAPINE SUCCINATE							
@	MYLAN	EQ 5MG BASE	A076762	001	Nov 01, 2004	Aug	CAHN
@		EQ 5MG BASE	A076762	001	Nov 01, 2004	Jul	DISC
@		EQ 10MG BASE	A076762	002	Nov 01, 2004	Aug	CAHN
@		EQ 10MG BASE	A076762	002	Nov 01, 2004	Jul	DISC
@		EQ 25MG BASE	A076762	003	Nov 01, 2004	Aug	CAHN
@		EQ 25MG BASE	A076762	003	Nov 01, 2004	Jul	DISC
@		EQ 50MG BASE	A076762	004	Nov 01, 2004	Aug	CAHN
@		EQ 50MG BASE	A076762	004	Nov 01, 2004	Jul	DISC
<u>LULICONAZOLE</u>							
CREAM;TOPICAL							
LUZU							
+	!	BAUSCH	1%	N204153	001	Nov 14, 2013	May CAHN
<u>LURASIDONE HYDROCHLORIDE</u>							
TABLET;ORAL							
LURASIDONE HYDROCHLORIDE							
AB		ALEMBIC PHARMS LTD	20MG	A213248	001	May 13, 2021	May NEWA
AB			40MG	A213248	002	May 13, 2021	May NEWA
AB			60MG	A213248	003	May 13, 2021	May NEWA
AB			80MG	A213248	004	May 13, 2021	May NEWA
AB			120MG	A213248	005	May 13, 2021	May NEWA
AB		DR REDDYS LABS LTD	20MG	A208047	001	Aug 24, 2021	Aug NEWA
AB			40MG	A208047	002	Aug 24, 2021	Aug NEWA
AB			60MG	A208047	003	Aug 24, 2021	Aug NEWA
AB			80MG	A208047	004	Aug 24, 2021	Aug NEWA
	@	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28, 2020	Aug DISC

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

	@	40MG	A212091	002	Dec 28, 2020	Aug	DISC	
	@	60MG	A212091	003	Dec 28, 2020	Aug	DISC	
	@	80MG	A212091	004	Dec 28, 2020	Aug	DISC	
	@	120MG	A212091	005	Dec 28, 2020	Aug	DISC	
>D>	AB	WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Sep	DISC
>A>	@		20MG	A208016	001	Feb 02, 2021	Sep	DISC
	AB		20MG	A208016	001	Feb 02, 2021	Jan	NEWA
>D>	AB		40MG	A208016	002	Feb 02, 2021	Sep	DISC
>A>	@		40MG	A208016	002	Feb 02, 2021	Sep	DISC
	AB		40MG	A208016	002	Feb 02, 2021	Jan	NEWA
>D>	AB		60MG	A208016	003	Feb 02, 2021	Sep	DISC
>A>	@		60MG	A208016	003	Feb 02, 2021	Sep	DISC
	AB		60MG	A208016	003	Feb 02, 2021	Jan	NEWA
>D>	AB		80MG	A208016	004	Feb 02, 2021	Sep	DISC
>A>	@		80MG	A208016	004	Feb 02, 2021	Sep	DISC
	AB		80MG	A208016	004	Feb 02, 2021	Jan	NEWA
>D>	AB		120MG	A208016	005	Feb 02, 2021	Sep	DISC
>A>	@		120MG	A208016	005	Feb 02, 2021	Sep	DISC
	AB		120MG	A208016	005	Feb 02, 2021	Jan	NEWA

MACITENTAN

TABLET;ORAL

MACITENTAN

	@	ZYDUS	10MG	A211224	001	Apr 06, 2021	Aug	DISC
AB			10MG	A211224	001	Apr 06, 2021	Mar	NFTG
		OPSUMIT						
	+	ACTELION	10MG	N204410	001	Oct 18, 2013	Aug	CTEC
AB	+		10MG	N204410	001	Oct 18, 2013	Mar	CFTG
	+		10MG	N204410	001	Oct 18, 2013	Feb	CAHN

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP		B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26, 2021	Apr	NEWA
AP			4GM/100ML (40MG/ML)	A207967	002	Apr 26, 2021	Apr	NEWA
AP			4GM/50ML (80MG/ML)	A207967	003	Apr 26, 2021	Apr	NEWA
		MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb	CMFD
		MAGNESIUM SULFATE IN PLASTIC CONTAINER						
AP		BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb	CMFD
AP			4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb	CMFD
AP			4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb	CMFD

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

	@	HERITAGE PHARMA	50MG	A072163	001	Jun 01, 1988	Jun	CAHN
	@	MYLAN	25MG	A072285	002	Oct 03, 1988	Jul	DISC
	@		50MG	A072285	001	Oct 03, 1988	Jul	DISC
	@		75MG	A072285	003	Oct 03, 1988	Jul	DISC
>A>		<u>MARALIXIBAT CHLORIDE</u>						
>A>		SOLUTION;ORAL						
>A>		LIVMARLI						
>A>	+	MIRUM	EQ 9.5MG BASE/ML	N214662	001	Sep 29, 2021	Sep	NEWA

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>D>	@	ANI PHARMS	12.5MG	A084657	002		Sep	CMFD
>A>	AA		12.5MG	A084657	002		Sep	CMFD
>D>	@		25MG	A084657	001		Sep	CMFD
>A>	AA		25MG	A084657	001		Sep	CMFD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

	+	@	PFIZER	100MG/ML	N012541	002		Mar	CAHN
AB	+			150MG/ML	N020246	001	Oct 29, 1992	Mar	CAHN
	+	@		400MG/ML	N012541	003		May	DISC

	INJECTABLE; INJECTION						
	DEPO-PROVERA						
	+!	400MG/ML	N012541	003			Mar CAHN
	INJECTABLE; SUBCUTANEOUS						
	DEPO-SUBQ PROVERA 104						
	+!	PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar CAHN
	TABLET; ORAL						
	PROVERA						
AB	+	PFIZER	2.5MG	N011839	001		Mar CAHN
AB	+		5MG	N011839	003		Mar CAHN
AB	+!		10MG	N011839	004		Mar CAHN
	<u>MEFENAMIC ACID</u>						
	CAPSULE; ORAL						
	MEFENAMIC ACID						
	@	STRIDES PHARMA	250MG	A209209	001	Sep 18, 2020	Mar DISC
	<u>MEFLOQUINE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	MEFLOQUINE HYDROCHLORIDE						
AB	!	BARR	250MG	A076392	001	Dec 29, 2003	Aug CTEC
AB		HIKMA PHARMS	250MG	A076523	001	Oct 01, 2004	Aug CMFD
	<u>MELOXICAM</u>						
	CAPSULE; ORAL						
	MELOXICAM						
AB		LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb CTEC
AB	!		10MG	A209487	002	Jun 01, 2020	Feb CTEC
AB		NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb NEWA
AB			10MG	A211398	002	Mar 09, 2021	Feb NEWA
	<u>MELPHALAN</u>						
	TABLET; ORAL						
	MELPHALAN						
	!	ALVOGEN	2MG	A207809	001	Mar 22, 2017	Jan CAHN
	<u>MELPHALAN FLUFENAMIDE</u>						
	POWDER; INTRAVENOUS						
	PEPAXTO						
	+!	ONCOPEPTIDES AB	20MG/VIAL	N214383	001	Feb 26, 2021	Feb NEWA
	<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE</u>						
	POWDER; INTRAVENOUS						
	PEPAXTO						
	+!	ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021	Mar CPOT
	+!		20MG/VIAL	N214383	001	Feb 26, 2021	Mar CAIN
	<u>MELPHALAN HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	ALKERAN						
	+	@ APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan DISC
	MELPHALAN HYDROCHLORIDE						
AP		ALMAJECT	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	Jul CAHN
AP		HIKMA PHARMS	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Jul CAHN
AP		HONG KONG	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	May NEWA
AP		MEITHEAL	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	Aug CAHN
>A>		@ SCINOPHARM TAIWAN	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep CAHN
>D>		@ TWI PHARMS	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019	Sep CAHN
	<u>MEMANTINE HYDROCHLORIDE</u>						
	CAPSULE, EXTENDED RELEASE; ORAL						
	MEMANTINE HYDROCHLORIDE						
AB		AUROBINDO PHARMA LTD	7MG	A214651	001	Aug 09, 2021	Jul NEWA
AB			14MG	A214651	002	Aug 09, 2021	Jul NEWA
AB			21MG	A214651	003	Aug 09, 2021	Jul NEWA
AB			28MG	A214651	004	Aug 09, 2021	Jul NEWA
	@	MYLAN	7MG	A206032	001	Sep 28, 2016	Jul DISC
	@		14MG	A206032	002	Sep 28, 2016	Jul DISC
	@		21MG	A206032	003	Sep 28, 2016	Jul DISC
	@		28MG	A206032	004	Sep 28, 2016	Jul DISC
AB		YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021	Mar NEWA
AB			14MG	A211100	002	Apr 02, 2021	Mar NEWA

CAPSULE, EXTENDED RELEASE;ORAL
MEMANTINE HYDROCHLORIDE

AB		21MG	A211100	003	Apr 02, 2021	Mar	NEWA
AB		28MG	A211100	004	Apr 02, 2021	Mar	NEWA

SOLUTION;ORAL
MEMANTINE HYDROCHLORIDE

AA	SETON PHARMS	2MG/ML	A210319	001	Aug 31, 2020	May	CAHN
----	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL
MEMANTINE HYDROCHLORIDE

	@ JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Jun	DISC
	@	10MG	A091585	002	Oct 13, 2015	Jun	DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

	@ VALIDUS PHARMS	25MG/ML	N005010	007		Feb	CAHN
	@	50MG/ML	N005010	002		Feb	CAHN
	@	75MG/ML	N005010	009		Feb	CAHN
	@	100MG/ML	N005010	003		Feb	CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

+	@ ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Aug	CRLD
---	-------------------	---------	---------	-----	--------------	-----	------

SYRUP;ORAL

DEMEROL

	@ VALIDUS PHARMS	50MG/5ML	N005010	005		Feb	CAHN
--	------------------	----------	---------	-----	--	-----	------

TABLET;ORAL

DEMEROL

+	@ VALIDUS PHARMS	50MG	N005010	001		Feb	CAHN
+	@	100MG	N005010	004		Feb	CAHN

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA	!	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	Mar	CHRS
AA	!		400MG	A090122	002	Feb 18, 2009	Mar	CHRS
	+	@ WATSON LABS	200MG	A083304	001		Aug	CRLD
		@	200MG	A083304	001		Mar	DISC
	+	@	400MG	A083308	001		Aug	CRLD
		@	400MG	A083308	001		Mar	DISC

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP		EUGIA PHARMA	500MG/VIAL	A205835	001	Mar 27, 2017	Aug	CAHN
AP			1GM/VIAL	A205835	002	Mar 27, 2017	Aug	CAHN

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

+	!	REMPEX	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017	Feb	CAHN
---	---	--------	-------------------	---------	-----	--------------	-----	------

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

MESALAMINE

AB		ALKEM LABS LTD	375MG	A214242	001	Jul 15, 2021	Jul	NEWA
AB		ZYDUS PHARMS	375MG	A208954	001	Aug 12, 2021	Aug	NEWA

SUPPOSITORY;RECTAL

MESALAMINE

>A>	AB	APTAPHARMA INC	1GM	A207448	001	Apr 19, 2019	Sep	CAHN
>D>	AB	PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Sep	CAHN

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

>D>	AB	MYLAN	1.2GM	A203574	001	Nov 20, 2018	Sep	CTEC
>A>	BX		1.2GM	A203574	001	Nov 20, 2018	Sep	CTEC

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

		SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Aug	NEWA
--	--	---------------------	-----------------	---------	-----	--------------	-----	------

METAXALONE

TABLET;ORAL
METAXALONE

>D>	AB	RISING	800MG	A208774	001	Sep 24, 2018	Sep CTEC
>A>	BX		800MG	A208774	001	Sep 24, 2018	Sep CTEC

METFORMIN HYDROCHLORIDE

TABLET;ORAL
METFORMIN HYDROCHLORIDE

AB	CHARTWELL	500MG	A075972	001	Jan 24, 2002	Jun CAHN
		625MG	A075972	005	Jan 24, 2002	Jun CAHN
		750MG	A075972	004	Jan 24, 2002	Jun CAHN
AB		850MG	A075972	002	Jan 24, 2002	Jun CAHN
AB		1GM	A075972	003	Jan 24, 2002	Jun CAHN
	@ INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008	May DISC
	@	850MG	A079148	002	Nov 25, 2008	May DISC
	@	1GM	A079148	003	Nov 25, 2008	May DISC

TABLET, EXTENDED RELEASE;ORAL
METFORMIN HYDROCHLORIDE

AB3	AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb NEWA	
AB3		1GM	A213962	002	Mar 09, 2021	Feb NEWA	
>D>	AB	ALKEM LABS LTD	750MG	A206145	002	Oct 22, 2018	Sep CHRS
>A>	AB	!	750MG	A206145	002	Oct 22, 2018	Sep CHRS
>D>	AB1	AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Sep CTEC
>A>	BX		500MG	A078596	001	Jan 03, 2008	Sep CTEC
>D>	AB	!	750MG	A078596	002	Jan 03, 2008	Sep CHRS
>A>	BX		750MG	A078596	002	Jan 03, 2008	Sep CHRS
AB2	AMTA	500MG	A213394	001	Aug 03, 2021	Jul NEWA	
AB2		1GM	A213394	002	Aug 03, 2021	Jul NEWA	
	@ APOTEX	500MG	A076706	001	Dec 14, 2004	Apr DISC	
AB3	GRANULES	500MG	A213344	001	Jan 12, 2021	Jan NEWA	
AB3		1GM	A213344	002	Jan 12, 2021	Jan NEWA	
AB3	SCIEGEN PHARMS INC	500MG	A213334	001	Apr 16, 2021	Apr NEWA	
AB3		1GM	A213334	002	Apr 16, 2021	Apr NEWA	
>A>	AB2	TWI PHARMS	500MG	A213247	001	Sep 29, 2021	Sep NEWA
>A>	AB2		1GM	A213247	002	Sep 29, 2021	Sep NEWA
AB1	UNICHEM	500MG	A213359	001	Aug 11, 2021	Jul NEWA	
AB		750MG	A213359	002	Aug 11, 2021	Jul NEWA	

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	SANDOZ	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Sep DISC
>A>		@	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Sep DISC
>D>	AB		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Sep DISC
>A>		@	850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Sep DISC
		@ TORRENT PHARMS LTD	500MG;EQ 15MG BASE	A202001	001	Feb 13, 2013	Jan DISC
		@	850MG;EQ 15MG BASE	A202001	002	Feb 13, 2013	Jan DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL
METHADONE HYDROCHLORIDE

AA	@ LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Aug DISC
		10MG/ML	A212094	001	Mar 03, 2021	Feb NEWA

SOLUTION;ORAL
METHADONE HYDROCHLORIDE

AA	+! HIKMA PHARMS	5MG/5ML	A087393	001		Aug CRLD
AA	+!	10MG/5ML	A087997	001	Aug 30, 1982	Aug CRLD

METHENAMINE HIPPURATE

TABLET;ORAL
HIPREX

AB	+ @ VALIDUS PHARMS	1GM	N017681	001		Mar DISC	
	+!	1GM	N017681	001		Feb CAHN	
AB	! AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Mar CHRS	
>A>	AB	NOVAST LABS	1GM	A210068	001	Nov 27, 2020	Sep CAHN
>D>	AB	RICONPHARMA LLC	1GM	A210068	001	Nov 27, 2020	Sep CAHN
AB	ALVOGEN	1GM	N016151	001		Jul CAHN	

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

>A>	AB	BIOPHARM	5MG	A 040547	001	Feb 18, 2005	Sep	CAHN
>A>	AB		10MG	A 040547	002	Feb 18, 2005	Sep	CAHN
>A>		@	20MG	A 040547	004	Feb 18, 2005	Sep	CAHN
>D>	AB	DISCOVERY THERAP	5MG	A 040547	001	Feb 18, 2005	Sep	CAHN
>D>	AB		10MG	A 040547	002	Feb 18, 2005	Sep	CAHN
>D>		@	20MG	A 040547	004	Feb 18, 2005	Sep	CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

AP	+	HIKMA PHARMS	1GM/10ML (100MG/ML)	N 011790	001		Jul	CAHN
----	---	--------------	---------------------	----------	-----	--	-----	------

TABLET; ORAL

METHOCARBAMOL

	@	AUROBINDO PHARMA LTD	750MG	A 213967	001	Aug 12, 2020	Feb	DISC
AA		GRANULATION TECH	500MG	A 212623	001	Apr 30, 2021	Apr	NEWA
AA			750MG	A 212623	002	Apr 30, 2021	Apr	NEWA
AA		MLV	500MG	A 212623	001	Apr 30, 2021	Jun	CAHN
AA			750MG	A 212623	002	Apr 30, 2021	Jun	CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

FOLEX

	+	@	PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A 087695	001	Apr 08, 1983	Aug	CRLD
	+	@		EQ 100MG BASE/VIAL	A 087695	003	Apr 08, 1983	Aug	CRLD

METHOTREXATE SODIUM

AP	!	HIKMA PHARMS	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A 089341	001	Sep 16, 1986	Jul	CAHN
	!		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A 089342	001	Sep 16, 1986	Jul	CAHN

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	!	HIKMA PHARMS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A 089340	001	Sep 16, 1986	Jul	CAHN
AP	!		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A 089343	001	Sep 16, 1986	Jul	CAHN
	@	MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	Aug	CAHN
	@	MYLAN LABS LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A 201529	004	Mar 29, 2012	May	DISC
	@		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A 201530	001	Mar 29, 2012	Aug	DISC

MEXATE

	+	@	BRISTOL	EQ 20MG BASE/VIAL	A 086358	001		Aug	CRLD
	+	@		EQ 50MG BASE/VIAL	A 086358	002		Aug	CRLD
	+	@		EQ 100MG BASE/VIAL	A 086358	003		Aug	CRLD
	+	@		EQ 250MG BASE/VIAL	A 086358	004		Aug	CRLD

TABLET; ORAL

METHOTREXATE SODIUM

AB		LOTUS PHARM CO LTD	EQ 2.5MG BASE	A 209787	001	Apr 23, 2021	Apr	NEWA
----	--	--------------------	---------------	----------	-----	--------------	-----	------

METHYCLOTHIAZIDE

TABLET; ORAL

METHYCLOTHIAZIDE

>A>		@	CHARTWELL RX	2.5MG	A 089835	001	Aug 18, 1988	Sep	CAHN
>A>		@		5MG	A 089837	001	Aug 18, 1988	Sep	CAHN
>D>		@	YAOPHARMA CO LTD	2.5MG	A 089835	001	Aug 18, 1988	Sep	CAHN
>D>		@		5MG	A 089837	001	Aug 18, 1988	Sep	CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

>D>	AB	ACCORD HLTHCARE	250MG	A 070084	001	Oct 15, 1985	Sep	CTEC	
>A>			250MG	A 070084	001	Oct 15, 1985	Sep	CTEC	
>D>	AB		500MG	A 070085	001	Oct 15, 1985	Sep	CHRS	
>A>	!		500MG	A 070085	001	Oct 15, 1985	Sep	CHRS	
>A>		@	CHARTWELL RX	125MG	A 071700	001	Mar 02, 1988	Sep	CAHN
>A>		@		250MG	N 018934	001	Jun 29, 1984	Sep	CAHN
>A>		@		500MG	N 018934	002	Jun 29, 1984	Sep	CAHN
>D>	AB	MYLAN	250MG	A 070076	002	Apr 18, 1985	Sep	DISC	
>A>		@		250MG	A 070076	002	Apr 18, 1985	Sep	DISC
>D>	AB	!		500MG	A 070076	001	Apr 18, 1985	Sep	DISC
>A>		@		500MG	A 070076	001	Apr 18, 1985	Sep	DISC
>D>		@	YAOPHARMA CO LTD	125MG	A 071700	001	Mar 02, 1988	Sep	CAHN

TABLET;ORAL
METHYLDOPA

>D>	@	250MG	N018934	001	Jun 29, 1984	Sep CAHN
>D>	@	500MG	N018934	002	Jun 29, 1984	Sep CAHN

METHYLERGONOVINE MALEATE

TABLET;ORAL
METHYLERGONOVINE MALEATE

AB	RISING	0.2MG	A211919	001	Jan 15, 2021	Jan NEWA
----	--------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AA	ASCENT PHARMS INC	5MG/5ML	A207417	001	Jan 29, 2021	Jan NEWA
AA		10MG/5ML	A207417	002	Jan 29, 2021	Jan NEWA
	@ LANNETT CO INC	5MG/5ML	A207414	001	Dec 16, 2020	Jan DISC
	@	10MG/5ML	A207414	002	Dec 16, 2020	Jan DISC

TABLET;ORAL
METHYLPHENIDATE HYDROCHLORIDE

	@ ALVOGEN	5MG	A206840	001	Sep 15, 2016	Jun CAHN	
	@	10MG	A206840	002	Sep 15, 2016	Jun CAHN	
	@	20MG	A206840	003	Sep 15, 2016	Jun CAHN	
>A>	AB	BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Sep CAHN
>A>	AB		10MG	A209753	002	Mar 02, 2018	Sep CAHN
>A>	AB		20MG	A209753	003	Mar 02, 2018	Sep CAHN
>D>	AB	USPHARMA	5MG	A209753	001	Mar 02, 2018	Sep CAHN
>D>	AB		10MG	A209753	002	Mar 02, 2018	Sep CAHN
>D>	AB		20MG	A209753	003	Mar 02, 2018	Sep CAHN

TABLET, EXTENDED RELEASE;ORAL
METHYLPHENIDATE HYDROCHLORIDE

AB	ALVOGEN	10MG	A204772	001	Feb 29, 2016	Jun CAHN	
AB		18MG	A210818	001	Nov 30, 2018	Aug CAHN	
AB		20MG	A204772	002	Feb 29, 2016	Jun CAHN	
AB		27MG	A210818	002	Nov 30, 2018	Aug CAHN	
AB		36MG	A210818	003	Nov 30, 2018	Aug CAHN	
AB		54MG	A210818	004	Nov 30, 2018	Aug CAHN	
>D>	AB	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Sep CTEC
>A>	BX		18MG	A207515	001	Feb 01, 2018	Sep CTEC
>D>	AB		27MG	A207515	002	Feb 01, 2018	Sep CTEC
>A>	BX		27MG	A207515	002	Feb 01, 2018	Sep CTEC
>D>	AB		36MG	A207515	003	Feb 01, 2018	Sep CTEC
>A>	BX		36MG	A207515	003	Feb 01, 2018	Sep CTEC
>D>	AB		54MG	A207515	004	Feb 01, 2018	Sep CTEC
>A>	BX		54MG	A207515	004	Feb 01, 2018	Sep CTEC

METHYLPREDNISOLONE

TABLET;ORAL
METHYLPREDNISOLONE

>A>	AB	AMNEAL	4MG	A207481	001	Sep 21, 2021	Sep NEWA
>A>	AB		8MG	A207481	002	Sep 21, 2021	Sep NEWA
>A>	AB		16MG	A207481	003	Sep 21, 2021	Sep NEWA
>A>	AB		32MG	A207481	004	Sep 21, 2021	Sep NEWA
	AB	PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENEYORK PHARMS	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Apr NEWA
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Apr NEWA
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Apr NEWA
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Apr NEWA
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Apr NEWA
AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	May CAHN
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	May CAHN
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	May CAHN
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	May CAHN
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	May CAHN

METHYLTESTOSTERONE

CAPSULE; ORAL
TESTRED

+ @ BAUSCH 10MG A083976 001 Aug CRLD

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
REGLAN

@ HIKMA PHARMS EQ 5MG BASE/ML N017862 001 Jul CAHN
@ EQ 10MG BASE/ML N017862 004 May 28, 1987 Jul CAHN

METOLAZONE

TABLET; ORAL
METOLAZONE

AB BAYSHORE PHARMS LLC 2.5MG A214799 001 Mar 30, 2021 Mar NEWA
AB 5MG A214799 002 Mar 30, 2021 Mar NEWA
AB 10MG A214799 003 Mar 30, 2021 Mar NEWA
AB INNOGENIX 2.5MG A213827 001 Mar 30, 2021 Mar NEWA
AB 5MG A213827 002 Mar 30, 2021 Mar NEWA
AB 10MG A213827 003 Mar 30, 2021 Mar NEWA
AB RUBICON 2.5MG A215184 001 Aug 20, 2021 Aug NEWA
AB 5MG A215184 002 Aug 20, 2021 Aug NEWA
AB 10MG A215184 003 Aug 20, 2021 Aug NEWA
AB ! SANDOZ 5MG A076466 001 Dec 19, 2003 May CHRS
AB ! 10MG A076466 002 Dec 19, 2003 May CHRS
ZAROXOLYN
+ @ LANNETT CO INC 2.5MG N017386 001 May DISC
+ @ 5MG N017386 002 May DISC
+ @ 10MG N017386 003 May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

AB ACTAVIS ELIZABETH EQ 25MG TARTRATE A204161 001 Nov 25, 2016 May CMFD
AB EQ 50MG TARTRATE A204161 002 Nov 25, 2016 May CMFD
AB EQ 100MG TARTRATE A204161 003 Nov 25, 2016 May CMFD
AB EQ 200MG TARTRATE A204161 004 Nov 25, 2016 May CMFD
AB YICHANG HUMANWELL EQ 100MG TARTRATE A213854 001 Feb 12, 2021 Feb NEWA
AB EQ 200MG TARTRATE A213854 002 Feb 12, 2021 Feb NEWA

METOPROLOL TARTRATE

TABLET; ORAL
LOPRESSOR

AB + VALIDUS PHARMS 50MG N017963 001 Feb CAHN
AB + 100MG N017963 002 Feb CAHN

METRONIDAZOLE

GEL; TOPICAL
METRONIDAZOLE

AB ALEOR DERMACEUTICALS 1% A212646 001 Sep 03, 2021 Aug NEWA

TABLET; ORAL
METRONIDAZOLE

>A> AB AMICI 250MG A070772 001 Jul 16, 1986 Sep CAHN
>A> AB 500MG A070772 002 Jul 16, 1986 Sep CAHN
>D> AB INNOGENIX 250MG A070772 001 Jul 16, 1986 Sep CAHN
>D> AB 500MG A070772 002 Jul 16, 1986 Sep CAHN

METYROSINE

CAPSULE; ORAL
DEMSER

>D> AB +! BAUSCH 250MG N017871 001 Sep CTEC
>A> +! 250MG N017871 001 Sep CTEC

METYROSINE

>D> AB AMNEAL 250MG A213734 001 Jul 24, 2020 Sep CTEC
>A> BX 250MG A213734 001 Jul 24, 2020 Sep CTEC

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

>A>	AB	HAVIX	150MG	A214089	001	Oct 01, 2021	Sep	NEWA
>A>	AB		200MG	A214089	002	Oct 01, 2021	Sep	NEWA
>A>	AB		250MG	A214089	003	Oct 01, 2021	Sep	NEWA
>A>	AB	NOVAST LABS	150MG	A214352	001	Jan 25, 2021	Sep	CAHN
>A>	AB		200MG	A214352	002	Jan 25, 2021	Sep	CAHN
>A>	AB		250MG	A214352	003	Jan 25, 2021	Sep	CAHN
>D>	AB	RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021	Sep	CAHN
	AB		150MG	A214352	001	Jan 25, 2021	Jan	NEWA
>D>	AB		200MG	A214352	002	Jan 25, 2021	Sep	CAHN
	AB		200MG	A214352	002	Jan 25, 2021	Jan	NEWA
>D>	AB		250MG	A214352	003	Jan 25, 2021	Sep	CAHN
	AB		250MG	A214352	003	Jan 25, 2021	Jan	NEWA

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

AP		HIKMA	EQ 50MG BASE/VIAL	A213261	001	Jul 09, 2021	Jul	NEWA
AP			EQ 100MG BASE/VIAL	A213261	002	Jul 09, 2021	Jul	NEWA
AP		JIANGSU HANSOH PHARM	EQ 50MG BASE/VIAL	A213363	001	Jul 09, 2021	Jul	NEWA
AP			EQ 100MG BASE/VIAL	A213363	002	Jul 09, 2021	Jul	NEWA
AP		XELLIA PHARMS APS	EQ 50MG BASE/VIAL	A211713	001	Jun 02, 2021	May	NEWA
AP			EQ 100MG BASE/VIAL	A211713	002	Jun 02, 2021	May	NEWA

POWDER; INTRAVENOUS

MICAFUNGIN

	+	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021	Jun	NEWA
	+		EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021	Jun	NEWA
>D>	+	TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021	Sep	DISC
>A>	+	@	EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021	Sep	DISC
	+		EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021	Jul	NEWA
>D>	+		EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021	Sep	DISC
>A>	+	@	EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021	Sep	DISC
	+		EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021	Jul	NEWA

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

+	!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Mar	NEWA
+	!		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Mar	NEWA

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

@		HOSPIRA	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002	Aug	DISC
@			EQ 5MG BASE/ML	A075856	002	Jun 13, 2002	Aug	DISC

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan	NEWA
AB			5MG	A214734	002	Jan 21, 2021	Jan	NEWA
AB			10MG	A214734	003	Jan 21, 2021	Jan	NEWA

MIGALASTAT HYDROCHLORIDE

CAPSULE; ORAL

GALAFOLD

>A>	+	AMICUS THERAP US	EQ 123MG BASE	N208623	001	Aug 10, 2018	Sep	CAHN
>D>	+	AMICUS THERAPS US	EQ 123MG BASE	N208623	001	Aug 10, 2018	Sep	CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB	+	PFIZER	25MG	N020682	001	Dec 18, 1996	Feb	CAHN
AB	+		50MG	N020682	002	Dec 18, 1996	Feb	CAHN
AB	+		100MG	N020682	003	Dec 18, 1996	Feb	CAHN

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

>D>	@	LIBERTY PHARMA INC	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
	@		12.5MG	A205071	001	Jan 27, 2016	Aug	CAHN
>D>	@		25MG	A205071	002	Jan 27, 2016	Sep	CAHN
	@		25MG	A205071	002	Jan 27, 2016	Aug	CAHN
>D>	@		50MG	A205071	003	Jan 27, 2016	Sep	CAHN
	@		50MG	A205071	003	Jan 27, 2016	Aug	CAHN
>D>	@		100MG	A205071	004	Jan 27, 2016	Sep	CAHN
	@		100MG	A205071	004	Jan 27, 2016	Aug	CAHN
>A>	@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Sep	CAHN
>A>	@		25MG	A205071	002	Jan 27, 2016	Sep	CAHN
>A>	@		50MG	A205071	003	Jan 27, 2016	Sep	CAHN
>A>	@		100MG	A205071	004	Jan 27, 2016	Sep	CAHN

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP		CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021	Apr	NEWA
----	--	--------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM;TOPICAL

AMZEEQ

+! VYNE EQ 4% BASE

N212379 001 Oct 18, 2019 Mar CAHN

ZILXI

+! VYNE EQ 1.5% BASE

N213690 001 May 28, 2020 Mar CAHN

CAPSULE;ORAL

DYNACIN

AB ALVOGEN EQ 50MG BASE A063067 003 Aug 14, 1990 Jun CAHN

AB EQ 75MG BASE A063067 002 Sep 15, 1999 Jun CAHN

AB EQ 100MG BASE A063067 001 Jul 31, 1990 Jun CAHN

INJECTABLE;INJECTION

MINOCIN

+! REMPEX EQ 100MG BASE/VIAL

N050444 001 May CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

@ BARR LABS INC EQ 65MG BASE

A065485 004 May 18, 2012 May DISC

@ EQ 80MG BASE

A065485 007 Apr 26, 2017 May DISC

@ EQ 105MG BASE

A065485 008 Apr 26, 2017 May DISC

@ EQ 115MG BASE

A065485 005 May 18, 2012 May DISC

MINOLIRA

>D> EPI HLTH EQ 135MG BASE N209269 002 May 08, 2017 Sep CHRS

>A> ! EQ 135MG BASE N209269 002 May 08, 2017 Sep CHRS

SOLODYN

+ @ BAUSCH EQ 45MG BASE

N050808 001 May 08, 2006 May CAHN

AB + EQ 55MG BASE

N050808 008 Aug 27, 2010 May CAHN

AB + EQ 65MG BASE

N050808 004 Jul 23, 2009 May CAHN

AB + EQ 80MG BASE

N050808 007 Aug 27, 2010 May CAHN

+ @ EQ 90MG BASE

N050808 002 May 08, 2006 May CAHN

AB + EQ 105MG BASE

N050808 006 Aug 27, 2010 May CAHN

AB +! EQ 115MG BASE

N050808 005 Jul 23, 2009 May CAHN

+ @ EQ 135MG BASE

N050808 003 May 08, 2006 May CAHN

MINOXIDIL

TABLET;ORAL

LONITEN

+ @ PFIZER 2.5MG

N018154 001 Feb CAHN

+ @ 10MG

N018154 003 Feb CAHN

MIRABEGRON

FOR SUSPENSION, EXTENDED RELEASE;ORAL

MYRBETRIQ GRANULES

+! APGDI 8MG/ML

N213801 001 Mar 25, 2021 Mar NEWA

MISOPROSTOL

TABLET;ORAL

CYTOTEC

>D> AB + PFIZER 0.1MG N019268 003 Sep 21, 1990 Sep CTEC

>A> + 0.1MG N019268 003 Sep 21, 1990 Sep CTEC

>D> AB +! 0.2MG N019268 001 Dec 27, 1988 Sep CTEC

	TABLET;ORAL							
	CYTOTEK							
>A>	+!	0.2MG		N019268	001	Dec 27, 1988	Sep CTEC	
	MISOPROSTOL							
>D>	AB	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012	Sep CTEC	
>A>	BX		0.1MG	A091667	001	Jul 25, 2012	Sep CTEC	
>D>	AB		0.2MG	A091667	002	Jul 25, 2012	Sep CTEC	
>A>	BX		0.2MG	A091667	002	Jul 25, 2012	Sep CTEC	
>A>	<u>MOBOCERTINIB SUCCINATE</u>							
>A>	CAPSULE;ORAL							
>A>	EXKIVITY							
>A>	+!	TAKEDA PHARMS USA	EQ 40MG BASE	N215310	001	Sep 15, 2021	Sep NEWA	
	<u>MODAFINIL</u>							
	TABLET;ORAL							
	MODAFINIL							
	@	MYLAN PHARMS INC	100MG	A076594	001	Jul 16, 2012	Jul DISC	
	@		200MG	A076594	002	Jul 16, 2012	Jul DISC	
	<u>MOMETASONE FUROATE</u>							
	AEROSOL, METERED; INHALATION							
	ASMANEX HFA							
	+	ORGANON	0.05MG/INH	N205641	003	Aug 12, 2019	Jun CAHN	
	+		0.10MG/INH	N205641	001	Apr 25, 2014	Jun CAHN	
	+!		0.20MG/INH	N205641	002	Apr 25, 2014	Jun CAHN	
	OINTMENT; TOPICAL							
	MOMETASONE FUROATE							
	@	TORRENT	0.1%	A207899	001	Jul 13, 2018	Jan DISC	
	POWDER; INHALATION							
	ASMANEX TWISTHALER							
	+	ORGANON	0.11MG/INH	N021067	002	Feb 01, 2008	Jun CAHN	
	+!		0.22MG/INH	N021067	001	Mar 30, 2005	Jun CAHN	
	SPRAY, METERED; NASAL							
	MOMETASONE FUROATE							
AB	!	APOTEX INC	0.05MG/SPRAY	A091161	001	Mar 22, 2016	May CHRS	
		NASONEX						
	+	@ ORGANON	0.05MG/SPRAY	N020762	001	Oct 01, 1997	May DISC	
AB	+!		0.05MG/SPRAY	N020762	001	Oct 01, 1997	Feb CAHN	
	<u>MONTELUKAST SODIUM</u>							
	TABLET;ORAL							
	MONTELUKAST SODIUM							
	@	AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul DISC	
>A>	@	BRECKENRIDGE	EQ 10MG BASE	A205319	001	Oct 30, 2020	Sep CAHN	
>D>	@	LABORATORIOS LIOMONT	EQ 10MG BASE	A205319	001	Oct 30, 2020	Sep CAHN	
	TABLET, CHEWABLE;ORAL							
	MONTELUKAST SODIUM							
	@	AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul DISC	
	@		EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul DISC	
	@	HIKMA PHARMS	EQ 4MG BASE	A091128	001	Aug 03, 2012	Jul DISC	
	@		EQ 5MG BASE	A091128	002	Aug 03, 2012	Jul DISC	
AB		UNICHEM	EQ 4MG BASE	A208621	001	Jul 02, 2018	Aug CMFD	
AB			EQ 5MG BASE	A208621	002	Jul 02, 2018	Aug CMFD	
	<u>MORPHINE SULFATE</u>							
	CAPSULE, EXTENDED RELEASE;ORAL							
	KADIAN							
>D>	AB	+!	ALLERGAN	10MG	N020616	008	Apr 20, 2007	Sep DISC
>A>		+	@	10MG	N020616	008	Apr 20, 2007	Sep DISC
>D>	AB	+		20MG	N020616	001	Jul 03, 1996	Sep DISC
>A>		+	@	20MG	N020616	001	Jul 03, 1996	Sep DISC
>D>	AB	+		30MG	N020616	004	Mar 09, 2001	Sep DISC
>A>		+	@	30MG	N020616	004	Mar 09, 2001	Sep DISC
		+	@	40MG	N020616	009	Jul 09, 2012	May DISC
>D>	AB	+		50MG	N020616	002	Jul 03, 1996	Sep DISC
>A>		+	@	50MG	N020616	002	Jul 03, 1996	Sep DISC
>D>	AB	+		60MG	N020616	005	Mar 09, 2001	Sep DISC
>A>		+	@	60MG	N020616	005	Mar 09, 2001	Sep DISC
		+	@	70MG	N020616	010	Jul 09, 2012	May DISC
>D>	AB	+		80MG	N020616	006	Oct 27, 2006	Sep DISC
>A>		+	@	80MG	N020616	006	Oct 27, 2006	Sep DISC

CAPSULE, EXTENDED RELEASE;ORAL							
KADIAN							
>D>	AB	+!	100MG	N020616	003	Jul 03, 1996	Sep DISC
>A>		+ @	100MG	N020616	003	Jul 03, 1996	Sep DISC
		+ @	130MG	N020616	011	Jul 09, 2012	May DISC
		+ @	150MG	N020616	012	Jul 09, 2012	May DISC
		+ @	200MG	N020616	007	Feb 27, 2007	May DISC
MORPHINE SULFATE							
		IMPAX LABS INC	40MG	A200411	007	Jul 25, 2018	May CTEC
AB		NORTEC DEV ASSOC	20MG	A203158	001	Aug 04, 2021	Jul NEWA
AB			30MG	A203158	002	Aug 04, 2021	Jul NEWA
AB			50MG	A203158	003	Aug 04, 2021	Jul NEWA
AB			60MG	A203158	004	Aug 04, 2021	Jul NEWA
AB			80MG	A203158	005	Aug 04, 2021	Jul NEWA
AB			100MG	A203158	006	Aug 04, 2021	Jul NEWA
>D>	AB	UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013	Sep CHRS
>A>		!	10MG	A202104	001	Jun 03, 2013	Sep CHRS
>D>	AB		100MG	A202104	007	Jun 03, 2013	Sep CHRS
>A>	AB	!	100MG	A202104	007	Jun 03, 2013	Sep CHRS
INJECTABLE;INJECTION							
MORPHINE SULFATE							
		+!	HOSPIRA INC	50MG/ML	N202515	006	Apr 29, 2021
			INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021
							Apr NEWA
							Apr NFTG
SOLUTION;ORAL							
MORPHINE SULFATE							
		@ ANI PHARMS	10MG/5ML	A205509	001	Apr 17, 2018	Jan DISC
		@	20MG/5ML	A205509	002	Apr 17, 2018	Jan DISC
		@	100MG/5ML	A205509	003	Apr 17, 2018	Jan DISC
		@ WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Aug DISC
AA			10MG/5ML	A211454	001	Feb 12, 2021	Feb NEWA
		@	20MG/5ML	A211454	002	Feb 12, 2021	Aug DISC
AA			20MG/5ML	A211454	002	Feb 12, 2021	Feb NEWA
		@	100MG/5ML	A211454	003	Feb 12, 2021	Aug DISC
AA			100MG/5ML	A211454	003	Feb 12, 2021	Feb NEWA
TABLET;ORAL							
MORPHINE SULFATE							
AB		UPSHER SMITH LABS	15MG	A210610	001	Jul 22, 2019	May CAHN
AB			30MG	A210610	002	Jul 22, 2019	May CAHN
<u>MOXIFLOXACIN HYDROCHLORIDE</u>							
SOLUTION/DROPS;OPHTHALMIC							
MOXIFLOXACIN HYDROCHLORIDE							
AT1		UPSHER SMITH LABS	EQ 0.5% BASE	A212616	001	Feb 10, 2021	Jan NEWA
<u>MUPIROCIN CALCIUM</u>							
CREAM;TOPICAL							
MUPIROCIN							
AB		ENCUBE	EQ 2% BASE	A213076	001	Aug 31, 2021	Aug NEWA
<u>MYCOPHENOLATE MOFETIL</u>							
SUSPENSION;ORAL							
MYCOPHENOLATE MOFETIL							
AB		LANNETT CO INC	200MG/ML	A214525	001	Jul 29, 2021	Jul NEWA
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
MYCOPHENOLATE MOFETIL HYDROCHLORIDE							
>D>	AP	AMNEAL	500MG/VIAL	A211374	001	Mar 05, 2021	Sep DISC
>A>		@	500MG/VIAL	A211374	001	Mar 05, 2021	Sep DISC
	AP		500MG/VIAL	A211374	001	Mar 05, 2021	Feb NEWA
AP		MEITHEAL	500MG/VIAL	A212130	001	Jan 15, 2021	Jan CAHN
AP		NANJING KING-FRIEND	500MG/VIAL	A212130	001	Jan 15, 2021	Jan NEWA
<u>MYCOPHENOLIC ACID</u>							
TABLET, DELAYED RELEASE;ORAL							
MYCOPHENOLIC ACID							
>A>	AB	ALKEM LABS LTD	180MG	A208315	001	Sep 23, 2021	Sep NEWA
>A>	AB		360MG	A208315	002	Sep 23, 2021	Sep NEWA
	AB	AMTA	180MG	A214376	001	Feb 10, 2021	Jan NEWA
	AB		360MG	A214376	002	Feb 10, 2021	Jan NEWA

NABUMETONETABLET; ORAL
NABUMETONE

AB	ANNORA PHARMA	500MG	A 090445	001	Jan 12, 2011	Mar	CAHN
AB		750MG	A 090445	002	Jan 12, 2011	Mar	CAHN

NADOLOLTABLET; ORAL
NADOLOL

	@ NOVAST LABS	20MG	A 210786	001	Jun 01, 2018	May	DISC
	@	40MG	A 210786	002	Jun 01, 2018	May	DISC
	@	80MG	A 210786	003	Jun 01, 2018	May	DISC
AB	VGYAAN	20MG	A 212856	001	Sep 13, 2019	May	CMFD
AB		40MG	A 212856	002	Sep 13, 2019	May	CMFD
AB		80MG	A 212856	003	Sep 13, 2019	May	CMFD

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION
NALOXONE HYDROCHLORIDE

AP	@ BAXTER HLTHCARE CORP	0.4MG/ML	A 214785	001	Jan 29, 2021	Jul	DISC
		0.4MG/ML	A 214785	001	Jan 29, 2021	Jan	NEWA
	SPRAY; NASAL KLOXXADO						
	+! HIKMA PHARMS	8MG/SPRAY	N 212045	001	Apr 29, 2021	Apr	NEWA

NALTREXONE HYDROCHLORIDETABLET; ORAL
REVIA

	+ @ TEVA WOMENS	50MG	N 018932	001	Nov 20, 1984	Jul	CRLD
--	-----------------	------	----------	-----	--------------	-----	------

NANDROLONE DECANOATEINJECTABLE; INJECTION
NANDROLONE DECANOATE

	+ @ WATSON LABS	200MG/ML	A 088128	001	Dec 05, 1983	Aug	CRLD
--	-----------------	----------	----------	-----	--------------	-----	------

NAPHAZOLINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
NAPHCN FORTE

	+ @ ALCON	0.1%	A 080229	001		Aug	CRLD
--	-----------	------	----------	-----	--	-----	------

NAPROXENSUSPENSION; ORAL
NAPROXEN

AB	NOVITIUM PHARMA	25MG/ML	A 211910	001	Mar 10, 2021	Feb	NEWA
----	-----------------	---------	----------	-----	--------------	-----	------

TABLET; ORAL
NAPROXEN

AB	GRANULES	250MG	A 074140	001	Dec 21, 1993	Feb	CMFD
AB		375MG	A 074140	002	Dec 21, 1993	Feb	CMFD
AB		500MG	A 074140	003	Dec 21, 1993	Feb	CMFD
AB	L PERRIGO CO	250MG	A 077339	001	Apr 27, 2005	Jul	CAHN
AB		375MG	A 077339	002	Apr 27, 2005	Jul	CAHN
AB		500MG	A 077339	003	Apr 27, 2005	Jul	CAHN

NEBIVOLOL HYDROCHLORIDETABLET; ORAL
NEBIVOLOL HYDROCHLORIDE

AB	ANI PHARMS	EQ 2.5MG BASE	A 203659	001	Apr 16, 2015	Jul	CMFD
AB		EQ 5MG BASE	A 203659	002	Apr 16, 2015	Jul	CMFD
AB		EQ 10MG BASE	A 203659	003	Apr 16, 2015	Jul	CMFD
AB		EQ 20MG BASE	A 203659	004	Apr 16, 2015	Jul	CMFD
AB	INDCHEMIE HEALTH	EQ 2.5MG BASE	A 203828	001	Jul 29, 2015	Jul	CMFD
AB		EQ 5MG BASE	A 203828	002	Jul 29, 2015	Jul	CMFD
AB		EQ 10MG BASE	A 203828	003	Jul 29, 2015	Jul	CMFD
AB		EQ 20MG BASE	A 203828	004	Jul 29, 2015	Jul	CMFD
AB	TORRENT	EQ 2.5MG BASE	A 203966	001	Mar 02, 2018	Aug	CMFD
AB		EQ 5MG BASE	A 203966	002	Mar 02, 2018	Aug	CMFD
AB		EQ 10MG BASE	A 203966	003	Mar 02, 2018	Aug	CMFD
AB		EQ 20MG BASE	A 203966	004	Mar 02, 2018	Aug	CMFD

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	CAPLIN	5MG/10ML (0.5MG/ML)	A213074	001	Apr 20, 2021	Apr	NEWA
AP		10MG/10ML (1MG/ML)	A213074	002	Apr 20, 2021	Apr	NEWA
AP	HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar	NEWA
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar	NEWA
>A>	INDOCO	5MG/10ML (0.5MG/ML)	A210652	001	Oct 01, 2021	Sep	NEWA
>A>		10MG/10ML (1MG/ML)	A210652	002	Oct 01, 2021	Sep	NEWA
AP	MEITHEAL	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr	CAHN
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr	CAHN

NIACIN

TABLET;ORAL

NICOLAR

+ @ SANOFI AVENTIS US 500MG

A083823 001

Aug CRLD

TABLET, EXTENDED RELEASE;ORAL

NIACIN

@ JUBILANT GENERICS 500MG

A209156 001 May 14, 2018 Jun DISC

@ 750MG

A209156 002 May 14, 2018 Jun DISC

@ 1GM

A209156 003 May 14, 2018 Jun DISC

AB ! SUN PHARM 750MG

A201273 001 Apr 23, 2014 Aug CHRS

AB ! 1GM

A200484 002 Apr 23, 2014 Aug CHRS

NIASPAN

+ @ ABBVIE 500MG

N020381 002 Jul 28, 1997 Aug DISC

+ @ 750MG

N020381 003 Jul 28, 1997 Aug DISC

+ @ 1GM

N020381 004 Jul 28, 1997 Aug DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB ANI PHARMS 20MG

A074670 001 Oct 28, 1996 May CMFD

AB 30MG

A074670 002 Oct 28, 1996 May CMFD

AB EPIC PHARMA 20MG

A074928 001 Mar 19, 1998 May CTEC

AB ! 30MG

A074928 002 Mar 19, 1998 May CTEC

INJECTABLE;INJECTION

NICARDIPINE HYDROCHLORIDE

AP ! AM REGENT 25MG/10ML (2.5MG/ML)

A090534 001 Nov 17, 2009 Apr CTEC

! 25MG/10ML (2.5MG/ML)

A090534 001 Nov 17, 2009 Feb CHRS

AP SUN PHARM 25MG/10ML (2.5MG/ML)

N078405 001 Nov 17, 2009 Jun CMFD

@ 25MG/10ML (2.5MG/ML)

N078405 001 Nov 17, 2009 Jun CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

ADALAT CC

>D> + @ ALVOGEN 30MG

N020198 001 Apr 21, 1993 Sep CAHN

>D> + @ 60MG

N020198 002 Apr 21, 1993 Sep CAHN

>D> + @ 90MG

N020198 003 Apr 21, 1993 Sep CAHN

>A> + @ NORWICH 30MG

N020198 001 Apr 21, 1993 Sep CAHN

>A> + @ 60MG

N020198 002 Apr 21, 1993 Sep CAHN

>A> + @ 90MG

N020198 003 Apr 21, 1993 Sep CAHN

NIFEDIPINE

AB1 AUROBINDO PHARMA LTD 30MG

A213361 001 Jul 19, 2021 Jul NEWA

AB1 60MG

A213361 002 Jul 19, 2021 Jul NEWA

AB1 90MG

A213361 003 Jul 19, 2021 Jul NEWA

>D> @ ELITE 90MG

A212016 001 Nov 18, 2020 Sep CAHN

@ 90MG

A212016 001 Nov 18, 2020 Jun DISC

>A> @ ELITE PHARM SOLUTION 90MG

A212016 001 Nov 18, 2020 Sep CAHN

@ MYLAN 30MG

A201071 001 Dec 03, 2010 Jul DISC

@ 60MG

A201071 002 Dec 03, 2010 Jul DISC

@ 90MG

A201071 003 Dec 03, 2010 Jul DISC

@ PAR PHARM 30MG

A077899 001 Dec 13, 2006 Apr DISC

@ 60MG

A077899 002 Dec 13, 2006 Apr DISC

@ 90MG

A077899 003 May 25, 2012 Apr DISC

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

>D> AB SOFGEN PHARMS 30MG

A201832 001 Jul 24, 2015 Sep CTEC

>A> BX 30MG

A201832 001 Jul 24, 2015 Sep CTEC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL
NISOLDIPINE

!	MYLAN	20MG	A 079051	001	Jul 25, 2008	Jan	CHRS
		30MG	A 079051	002	Jul 25, 2008	Jan	CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN

AB	ALEMBIC PHARMS LTD	25MG	A 211935	001	Jun 25, 2021	Jun	NEWA
AB		50MG	A 211935	002	Jun 25, 2021	Jun	NEWA
AB		100MG	A 211935	003	Jun 25, 2021	Jun	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
@ MYLAN 75MG;25MG

A 076648	001	Mar 22, 2004	Jul	DISC
----------	-----	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

@ BAUSCH	0.4MG/HR	A 089773	001	Aug 30, 1996	May	CAHN
NITRO-DUR						
+! USPHARMA	0.1MG/HR	N 020145	001	Apr 04, 1995	Aug	CTEC
+!	0.2MG/HR	N 020145	002	Apr 04, 1995	Aug	CTEC
+!	0.4MG/HR	N 020145	004	Apr 04, 1995	Aug	CTEC
+!	0.6MG/HR	N 020145	005	Apr 04, 1995	Aug	CTEC

>D> POWDER;SUBLINGUAL

>D> GONITRO

>D>	+!	POHL BOSKAMP	0.4MG/PACKET	N 208424	001	Jun 08, 2016	Sep	DISC
>A>	+ @		0.4MG/PACKET	N 208424	001	Jun 08, 2016	Sep	DISC
	+!		0.4MG/PACKET	N 208424	001	Jun 08, 2016	Jul	CMFD
	+ @		0.4MG/PACKET	N 208424	001	Jun 08, 2016	Jun	DISC

TABLET;SUBLINGUAL
NITROGLYCERIN

AB	RUBICON	0.3MG	A 209779	001	May 03, 2021	Apr	NEWA
AB		0.4MG	A 209779	002	May 03, 2021	Apr	NEWA
AB		0.6MG	A 209779	003	May 03, 2021	Apr	NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP	ANDERSEN GLOBAL	EQ 1MG BASE/ML	A 214455	001	Jan 22, 2021	Jan	NEWA
AP	BRECKENRIDGE	EQ 1MG BASE/ML	A 214455	001	Jan 22, 2021	Mar	CAHN
AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A 214323	001	May 06, 2021	Apr	NEWA
AP	SUN PHARM	EQ 1MG BASE/ML	A 211980	001	Jan 29, 2021	Jan	NEWA

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

>D>	+ @	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N 214313	001	Jan 15, 2021	Sep	CMFD
>A>	+!		EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N 214313	001	Jan 15, 2021	Sep	CMFD
	+ @		EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N 214313	001	Jan 15, 2021	Jul	DISC
	+!		EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N 214313	001	Jan 15, 2021	Jan	NEWA
>D>	+ @		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N 214313	002	Jan 15, 2021	Sep	CMFD
>A>	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N 214313	002	Jan 15, 2021	Sep	CMFD
	+ @		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N 214313	002	Jan 15, 2021	Jul	DISC
	+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N 214313	002	Jan 15, 2021	Jan	NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

@ ZYDUS	EQ 10MG BASE	A 213441	001	Feb 24, 2021	Aug	DISC
AB	EQ 10MG BASE	A 213441	001	Feb 24, 2021	Feb	NEWA
@	EQ 25MG BASE	A 213441	002	Feb 24, 2021	Aug	DISC
AB	EQ 25MG BASE	A 213441	002	Feb 24, 2021	Feb	NEWA
@	EQ 50MG BASE	A 213441	003	Feb 24, 2021	Aug	DISC

CAPSULE;ORAL								
NORTRIPTYLINE HYDROCHLORIDE								
AB		EQ 50MG BASE		A213441	003	Feb 24, 2021	Feb NEWA	
	@	EQ 75MG BASE		A213441	004	Feb 24, 2021	Aug DISC	
AB		EQ 75MG BASE		A213441	004	Feb 24, 2021	Feb NEWA	
<u>NYSTATIN</u>								
CREAM;TOPICAL								
NYSTATIN								
AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213566	001	Aug 10, 2021	Jul NEWA	
OINTMENT;TOPICAL								
NYSTATIN								
AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021	Jan NEWA	
POWDER;TOPICAL								
NYSTATIN								
AT		ZYDUS PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	Jul CAHN	
SUSPENSION;ORAL								
NYSTATIN								
AA		NIVAGEN PHARMS INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun CAHN	
<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>								
CREAM;TOPICAL								
NYSTATIN AND TRIAMCINOLONE ACETONIDE								
AT		ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar NEWA	
OINTMENT;TOPICAL								
NYSTATIN AND TRIAMCINOLONE ACETONIDE								
AT		MACLEODS PHARMS LTD	100,000 UNITS/GM;0.1%	A214751	001	Aug 17, 2021	Aug NEWA	
<u>ODEVIXIBAT</u>								
CAPSULE;ORAL								
BYLVAY								
	+	ALBIREO	0.4MG	N215498	002	Jul 20, 2021	Jul NEWA	
	+	!	1.2MG	N215498	004	Jul 20, 2021	Jul NEWA	
CAPSULE, PELLETS;ORAL								
BYLVAY								
	+	ALBIREO	0.2MG	N215498	001	Jul 20, 2021	Jul NEWA	
	+	!	0.6MG	N215498	003	Jul 20, 2021	Jul NEWA	
<u>OFLOXACIN</u>								
SOLUTION/DROPS;OPHTHALMIC								
OFLOXACIN								
	@	ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Jun CAHN	
	@		0.3%	A076830	001	Aug 31, 2004	Jan DISC	
SOLUTION/DROPS;OTIC								
OFLOXACIN								
	@	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Jun CAHN	
TABLET;ORAL								
FLOXIN								
	+	@	JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990	Jan CRLD
	+	@		300MG	N019735	002	Dec 28, 1990	Jan CRLD
	+	@		400MG	N019735	003	Dec 28, 1990	Jan CRLD
OFLOXACIN								
AB		LARKEN LABS	400MG	A076093	003	Sep 02, 2003	May CMFD	
<u>OLANZAPINE</u>								
TABLET;ORAL								
OLANZAPINE								
	@	HISUN PHARM HANGZHOU	2.5MG	A206924	001	Dec 31, 2020	Jul DISC	
AB			2.5MG	A206924	001	Dec 31, 2020	Feb CAHN	
	@		5MG	A206924	002	Dec 31, 2020	Jul DISC	
AB			5MG	A206924	002	Dec 31, 2020	Feb CAHN	
	@		7.5MG	A206924	003	Dec 31, 2020	Jul DISC	
AB			7.5MG	A206924	003	Dec 31, 2020	Feb CAHN	
	@		10MG	A206924	004	Dec 31, 2020	Jul DISC	
AB			10MG	A206924	004	Dec 31, 2020	Feb CAHN	
	@		15MG	A206924	005	Dec 31, 2020	Jul DISC	
AB			15MG	A206924	005	Dec 31, 2020	Feb CAHN	
	@		20MG	A206924	006	Dec 31, 2020	Jul DISC	
AB			20MG	A206924	006	Dec 31, 2020	Feb CAHN	

<u>TABLET, ORALLY DISINTEGRATING;ORAL</u>						
<u>OLANZAPINE</u>						
	@ HISUN PHARM HANGZHOU	5MG		A206892	001	Dec 31, 2020 Jul DISC
AB		5MG		A206892	001	Dec 31, 2020 Feb CAHN
	@	10MG		A206892	002	Dec 31, 2020 Jul DISC
AB		10MG		A206892	002	Dec 31, 2020 Feb CAHN
	@	15MG		A206892	003	Dec 31, 2020 Jul DISC
AB		15MG		A206892	003	Dec 31, 2020 Feb CAHN
	@	20MG		A206892	004	Dec 31, 2020 Jul DISC
AB		20MG		A206892	004	Dec 31, 2020 Feb CAHN
AB	TORRENT	5MG		A091415	001	Oct 25, 2011 Aug CAHN
AB		10MG		A091415	002	Oct 25, 2011 Aug CAHN
AB		15MG		A091415	003	Oct 25, 2011 Aug CAHN
AB		20MG		A091415	004	Oct 25, 2011 Aug CAHN

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET;ORAL

LYBALVI

+	ALKERMES INC	5MG;EQ 10MG BASE		N213378	001	May 28, 2021 May NEWA
+		10MG;EQ 10MG BASE		N213378	002	May 28, 2021 May NEWA
+		15MG;EQ 10MG BASE		N213378	003	May 28, 2021 May NEWA
+		20MG;EQ 10MG BASE		N213378	004	May 28, 2021 May NEWA

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

	@ LUPIN LTD	5MG		A206631	001	Apr 27, 2017 Aug DISC
	@	20MG		A206631	002	Apr 27, 2017 Aug DISC
	@	40MG		A206631	003	Apr 27, 2017 Aug DISC
	@ MYLAN	5MG		A078276	001	Oct 26, 2016 Jul DISC
	@	20MG		A078276	002	Oct 26, 2016 Jul DISC
	@	40MG		A078276	003	Oct 26, 2016 Jul DISC

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

	AKORN	EQ 0.2% BASE		A204723	001	Dec 05, 2017 Mar CTEC
	SOMERSET THERAPS LLC	EQ 0.1% BASE		A206306	001	Dec 07, 2015 Jul CTEC
	@ WOCKHARDT LTD	EQ 0.1% BASE		A200810	001	Jun 28, 2017 Jul DISC

SPRAY, METERED;NASAL

OLOPATADINE HYDROCHLORIDE

AB	AMNEAL	0.665MG/SPRAY		A210901	001	Jan 28, 2020 Mar CMFD
	@	0.665MG/SPRAY		A210901	001	Jan 28, 2020 Jan DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

LOVAZA

AB	+	WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004 Feb CAHN
----	---	----------	--	---------	-----	-----------------------

ONDANSETRON

FILM;ORAL

ZUPLENZ

+	@ AQUESTIVE	4MG		N022524	001	Jul 02, 2010 Feb CAHN
+	@	8MG		N022524	002	Jul 02, 2010 Feb CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

	@ HOSPIRA	EQ 2MG BASE/ML		A077840	001	Jan 19, 2007 Jun DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE				
	@ EMCURE PHARMS LTD	EQ 2MG BASE/ML		A078945	001	Jan 03, 2013 May DISC

ORITAVANCIN DIPHOSPHATE

POWDER;INTRAVENOUS

KIMYRSA

+	MELINTA THERAP	EQ 1.2GM BASE/VIAL		N214155	001	Mar 12, 2021 Mar NEWA
+	ORBACTIV					
+	MELINTA THERAP	EQ 400MG BASE/VIAL		N206334	001	Aug 06, 2014 May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE;ORAL
NORFLEX

+ @ BAUSCH	100MG		N012157	001			May CAHN
ORPHENADRINE CITRATE							
@ IMPAX PHARMS	100MG		A040368	001	Jun 23, 2000		Jan DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL
OSELTAMIVIR PHOSPHATE

>A> AB	EPIC PHARMA LLC	EQ 30MG BASE	A215208	001	Oct 01, 2021		Sep NEWA
>A> AB		EQ 45MG BASE	A215208	002	Oct 01, 2021		Sep NEWA
>A> AB		EQ 75MG BASE	A215208	003	Oct 01, 2021		Sep NEWA
	@ MYLAN	EQ 30MG BASE	A210157	001	Jan 21, 2021		Jan DISC
AB		EQ 30MG BASE	A210157	001	Jan 21, 2021		Jan NEWA
	@	EQ 45MG BASE	A210157	002	Jan 21, 2021		Jan DISC
AB		EQ 45MG BASE	A210157	002	Jan 21, 2021		Jan NEWA
	@	EQ 75MG BASE	A210157	003	Jan 21, 2021		Jan DISC
AB		EQ 75MG BASE	A210157	003	Jan 21, 2021		Jan NEWA
	FOR SUSPENSION;ORAL						
	OSELTAMIVIR PHOSPHATE						
AB	APTAPHARMA INC	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021		Aug NEWA

OXALIPLATIN

INJECTABLE;INTRAVENOUS
OXALIPLATIN

	@ CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017		May DISC
	@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017		May DISC
>D> AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018		Sep CAHN
>D> AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018		Sep CAHN
>A> AP	NOVAST LABS	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018		Sep CAHN
>A> AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018		Sep CAHN
AP	QILU PHARM HAINAN	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016		Aug CAHN
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016		Aug CAHN
	!	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016		Aug CAHN

OXCARBAZEPINE

SUSPENSION;ORAL
OXCARBAZEPINE

AB	AKORN	300MG/5ML	A211420	001	Jul 09, 2021		Jul NEWA
AB	GLASSHOUSE PHARMS	300MG/5ML	A212428	001	Jun 21, 2021		Jun NEWA

OXICONAZOLE NITRATE

LOTION;TOPICAL
OXISTAT

+!	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992		Apr CAHN
----	------------	------------	---------	-----	--------------	--	----------

OXYBUTYNIN CHLORIDE

TABLET;ORAL
OXYBUTYNIN CHLORIDE

AB	APPCO	5MG	A209025	001	Dec 21, 2017		Jan CAHN
>D> AB	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019		Sep CTEC
>A> BX		5MG	A211682	001	May 10, 2019		Sep CTEC
>D> AB	EYWA	5MG	A211062	001	Feb 06, 2019		Sep CTEC
>A> BX		5MG	A211062	001	Feb 06, 2019		Sep CTEC
	@ STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020		Jun DISC

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL
OXYCODONE HYDROCHLORIDE

	@ LANNETT CO INC	5MG	A203823	001	Aug 01, 2014		Apr DISC
--	------------------	-----	---------	-----	--------------	--	----------

SOLUTION;ORAL
OXYCODONE HYDROCHLORIDE

AA	QUAGEN	5MG/5ML	A213761	001	Jun 02, 2021		May NEWA
AA		100MG/5ML	A213761	002	Jun 02, 2021		May NEWA

TABLET;ORAL
OXAYDO

+	ZYLA	5MG	N202080	001	Jun 17, 2011		Mar CRLD
+		7.5MG	N202080	002	Jun 17, 2011		Mar CRLD

TABLET;ORAL

OXYCODONE HYDROCHLORIDE							
AB	ALVOGEN	5MG	A202116	001	Dec 30, 2011	Apr	CAHN
AB		15MG	A202116	002	Dec 30, 2011	Apr	CAHN
AB		30MG	A202116	003	Dec 30, 2011	Apr	CAHN

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

OXYMETAZOLINE HYDROCHLORIDE							
>A>	TARO PHARMS	1%	A213584	001	Oct 04, 2021	Sep	NFTG
	RHOFADE						
>D>	+! EPI HLTH	1%	N208552	001	Jan 18, 2017	Sep	CFTG
>A>	+!	1%	N208552	001	Jan 18, 2017	Sep	CFTG

OXYMETHOLONE

TABLET;ORAL

ANADROL-50							
	+ @ MYLAN SPECIALITY LP	50MG	N016848	001		Apr	DISC

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN							
AP	+! HIKMA PHARMS	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Jul	CAHN
AP	+!	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Jul	CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA							
	+ CELGENE INTL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	May	CPOT
	+!	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	May	CPOT
	+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	May	CPOT

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL							
AP	ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	May	CMFD
	@ MYLAN LABS LTD	6MG/ML	A091540	001	Sep 29, 2011	Mar	DISC

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE							
>D>	AMNEAL PHARMS	1.5MG	A204707	001	Sep 23, 2019	Sep	CTEC
>A>	BX	1.5MG	A204707	001	Sep 23, 2019	Sep	CTEC
>D>	AB	3MG	A204707	002	Sep 23, 2019	Sep	CTEC
>A>	BX	3MG	A204707	002	Sep 23, 2019	Sep	CTEC
>D>	AB	6MG	A204707	003	Sep 23, 2019	Sep	CTEC
>A>	BX	6MG	A204707	003	Sep 23, 2019	Sep	CTEC
>D>	AB	9MG	A204707	004	Sep 23, 2019	Sep	CTEC
>A>	BX	9MG	A204707	004	Sep 23, 2019	Sep	CTEC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA HAFYERA							
>A>	+ JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021	Sep	NEWA
>A>	+!	1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021	Sep	NEWA
INVEGA SUSTENNA							
AB	+ JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jul	CTEC
AP	+!	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun	CFTG
AB	+!	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jul	CTEC
AP	+!	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun	CFTG
AB	+!	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jul	CTEC
AP	+!	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun	CFTG
AB	+!	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jul	CTEC
AP	+!	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun	CFTG
AB	+!	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jul	CTEC
AP	+!	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun	CFTG
PALIPERIDONE PALMITATE							
AB	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jul	CTEC
AP		39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jun	NFTG
AB		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jul	CTEC
AP		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jun	NFTG
AB		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jul	CTEC

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
PALIPERIDONE PALMITATE

AP		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jun	NFTG
AB		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jul	CTEC
AP		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jun	NFTG
AB		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jul	CTEC
AP		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jun	NFTG

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
ALOXI

+ @	HEL SINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Apr	DISC
+ @		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Apr	DISC

PALONOSETRON HYDROCHLORIDE

>D>	AP	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Sep	DISC
>A>	@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Sep	DISC
	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Mar	NEWA
	AP	! DR REDDYS LABS LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	CHRS
		EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jun	NEWA
	AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jun	NEWA
	@	HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Apr	DISC
	@	QILU	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Apr	DISC
	@	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Apr	DISC

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

+ @	FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017	May	DISC
-----	--------------------	--	---------	-----	--------------	-----	------

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP	+!	HIKMA PHARMS	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Jul	CAHN
AP	+!		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Jul	CAHN

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

AP		ACIC PHARMS	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Aug	NEWA
			TABLET, DELAYED RELEASE;ORAL					
			PANTOPRAZOLE SODIUM					
	@	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jun	DISC
	@		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jun	DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAROXETINE HYDROCHLORIDE

AB		NOVITIUM PHARMA	EQ 10MG BASE/5ML	A215003	001	Sep 03, 2021	Aug	NEWA
			PAXIL					
AB	+!	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Aug	CTEC
			TABLET, EXTENDED RELEASE;ORAL					
			PAROXETINE HYDROCHLORIDE					
AB		CADILA PHARMS LTD	EQ 12.5MG BASE	A212645	001	Aug 27, 2021	Aug	NEWA
AB			EQ 25MG BASE	A212645	002	Aug 27, 2021	Aug	NEWA
AB			EQ 37.5MG BASE	A212645	003	Aug 27, 2021	Aug	NEWA
AB		CSPC OUYI	EQ 12.5MG BASE	A213485	001	Feb 16, 2021	Feb	NEWA
AB			EQ 25MG BASE	A213485	002	Feb 16, 2021	Feb	NEWA
AB			EQ 37.5MG BASE	A213485	003	Feb 16, 2021	Feb	NEWA
AB		SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A213612	001	Aug 11, 2021	Jul	NEWA
AB			EQ 25MG BASE	A213612	002	Aug 11, 2021	Jul	NEWA

PATROMER SORBITEX CALCIUMPOWDER; ORAL
VELTASSA

+	VIFOR PHARMA	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Jun	CAHN
+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Jun	CAHN
+	!	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Jun	CAHN

PEGCETACOPLANSOLUTION; SUBCUTANEOUS
EMPAVELI

+	APELLIS PHARMS	1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021	May	NEWA
---	----------------	-----------------------	---------	-----	--------------	-----	------

PEMETREXEDSOLUTION; INTRAVENOUS
PEMETREXED

+	@ ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Jan	DISC
+	@	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Jan	DISC
+	@	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Jan	DISC

PENICILLAMINECAPSULE; ORAL
PENICILLAMINE

>D>	AB	AGGREGA	250MG	A215409	001	Aug 23, 2021	Sep	CAHN
	AB		250MG	A215409	001	Aug 23, 2021	Aug	NEWA
>A>	AB	BRECKENRIDGE	250MG	A215409	001	Aug 23, 2021	Sep	CAHN
	AB	INVAGEN PHARMS	250MG	A213293	001	Aug 19, 2021	Aug	NEWA

PENICILLIN G POTASSIUMINJECTABLE; INJECTION
PENICILLIN G POTASSIUM

		HQ SPECTL PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar	CAHN
AP			5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar	CAHN
AP			20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar	CAHN

PENICILLIN V POTASSIUMFOR SOLUTION; ORAL
PENICILLIN V POTASSIUM

	@	DAVA PHARMS INC	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar	DISC
	@		EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar	DISC
		PENICILLIN-VK						
		TEVA	EQ 125MG BASE/5ML	A060456	001		Mar	CTEC
	!		EQ 250MG BASE/5ML	A060456	002		Mar	CTEC

PENTAMIDINE ISETHIONATEINJECTABLE; INJECTION
PENTAMIDINE ISETHIONATE

AP		EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan	NEWA
----	--	-------------------	------------	---------	-----	--------------	-----	------

PENTOBARBITAL SODIUMINJECTABLE; INJECTION
NEMBUTAL SODIUM

AP	+	AKORN	50MG/ML	A083246	001		Aug	CRLD
----	---	-------	---------	---------	-----	--	-----	------

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIL

	@	UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999	May	DISC
	+	@ VALIDUS PHARMS	400MG	N018631	001	Aug 30, 1984	Feb	CAHN

PERAMPANELTABLET; ORAL
FYCOMPA

	+	EISAI INC	2MG	N202834	001	Oct 22, 2012	Jun	CTEC
AB	+		2MG	N202834	001	Oct 22, 2012	May	CFTG
	+		4MG	N202834	002	Oct 22, 2012	Jun	CTEC
AB	+		4MG	N202834	002	Oct 22, 2012	May	CFTG
	+		6MG	N202834	003	Oct 22, 2012	Jun	CTEC
AB	+		6MG	N202834	003	Oct 22, 2012	May	CFTG
	+		8MG	N202834	004	Oct 22, 2012	Jun	CTEC
AB	+		8MG	N202834	004	Oct 22, 2012	May	CFTG

	TABLET;ORAL							
	FYCOMPA							
	+	10MG		N202834	005	Oct 22, 2012	Jun	CTEC
AB	+	10MG		N202834	005	Oct 22, 2012	May	CFTG
	+	12MG		N202834	006	Oct 22, 2012	Jun	CTEC
AB	+	12MG		N202834	006	Oct 22, 2012	May	CFTG
	<u>PERMETHRIN</u>							
	CREAM;TOPICAL							
	ELIMITE							
>D>	+ @	MYLAN	5%	N019855	001	Aug 25, 1989	Sep	CAHN
>A>	+ @		5%	N019855	001	Aug 25, 1989	Sep	CAHN
	<u>PHENDIMETRAZINE TARTRATE</u>							
	TABLET;ORAL							
	BONTRIL PDM							
AA	+	VALEANT	35MG	A085272	001		Aug	CRLD
	<u>PHENTERMINE HYDROCHLORIDE</u>							
	CAPSULE;ORAL							
	ADIPEX-P							
AA	+	TEVA	37.5MG	A088023	001	Aug 02, 1983	Aug	CRLD
	PHENTERMINE HYDROCHLORIDE							
AA	+	SANDOZ	15MG	A087190	002		Aug	CRLD
AA	+		30MG	A086945	001	Jul 20, 1983	Aug	CRLD
	TABLET;ORAL							
	ADIPEX-P							
AA	+	TEVA	37.5MG	A085128	001		Aug	CRLD
	PHENTERMINE HYDROCHLORIDE							
>A>	AA	MERRO PHARM USA	37.5MG	A206342	001	Nov 18, 2016	Sep	CAHN
>D>	AA	POLYGEN PHARMS	37.5MG	A206342	001	Nov 18, 2016	Sep	CAHN
	+ @	USL PHARMA	8MG	A083804	001		Aug	CRLD
	<u>PHENYLEPHRINE HYDROCHLORIDE</u>							
	SOLUTION;INTRAVENOUS							
	BIORPHEN							
	+	ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb	CPOT
	+ @		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Apr	DISC
	+		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Mar	NEWA
	PHENYLEPHRINE HYDROCHLORIDE							
AP1		CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020	Jul	CMFD
AP1			50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020	Jul	CMFD
AP1			100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020	Jul	CMFD
AP1		GLAND PHARMA LTD	10MG/ML (10MG/ML)	A211920	003	Apr 08, 2021	Apr	NEWA
AP2	+	HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jan	CAHN
AP2	+		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jan	CAHN
AP2	+		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jan	CAHN
AP1		PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jan	CAHN
AP1			50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jan	CAHN
AP1			100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jan	CAHN
	<u>PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>							
	SYRUP;ORAL							
	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE							
AA		AKORN	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Feb	CAHN
	PROMETH VC PLAIN							
	+ @	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Aug	CRLD
	<u>PHENYTOIN</u>							
	TABLET, CHEWABLE;ORAL							
	DILANTIN							
AB	+	PHARMACIA	50MG	A084427	001		Aug	CRLD
	<u>PHENYTOIN SODIUM</u>							
	CAPSULE;ORAL							
	DILANTIN							
	+	UPJOHN	30MG EXTENDED	A084349	001		Aug	CRLD
AB	+		100MG EXTENDED	A084349	002		Aug	CRLD
	INJECTABLE;INJECTION							
	PHENYTOIN SODIUM							
AP	+	WEST-WARD PHARMS INT	50MG/ML	A084307	001		Aug	CRLD

PHYTONADIONEINJECTABLE; INJECTION
PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722	001		May	CRLD
AB	+	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	Aug	CRLD

PIFLUFOLASTAT F-18SOLUTION; INTRAVENOUS
PYLARIFY

+	PROGENICS PHARMS INC	50ML (1-80mCi/ML)	N214793	001	May 26, 2021	May	NEWA
---	----------------------	-------------------	---------	-----	--------------	-----	------

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

>A>	AB	AMICI	5MG	A076963	001	Dec 22, 2004	Sep	CAHN
>A>	AB		7.5MG	A076963	002	Feb 27, 2007	Sep	CAHN
>D>	AB	INNOGENIX	5MG	A076963	001	Dec 22, 2004	Sep	CAHN
	AB		5MG	A076963	001	Dec 22, 2004	Aug	CAHN
>D>	AB		7.5MG	A076963	002	Feb 27, 2007	Sep	CAHN
	AB		7.5MG	A076963	002	Feb 27, 2007	Aug	CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014	Jan	CAHN
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Jan	CAHN
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Jan	CAHN
AB	SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jan	NEWA
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jan	NEWA
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

@	MYLAN LABS LTD	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Apr	DISC	
@		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar	DISC	
@		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Jul	DISC	
AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	CAHN	
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	CAHN	
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	CAHN	
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	CAHN	
AP		EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Jan	CAHN	
AP	SAGENT PHARMS INC	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021	Feb	NEWA	
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021	Feb	NEWA	
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021	Feb	NEWA	
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021	Feb	NEWA	
AP	SANDOZ INC	EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A203557	002	Jul 08, 2021	Jul	NEWA	
AP	!	WOCKHARDT BIO AG	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Jan	CHRS
AP	!		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan	CHRS
AP	!		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan	CHRS
AP	!		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CHRS
		ZOSYN						
+	@	WYETH PHARMS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Jan	DISC
+	@		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Jan	DISC
+	@		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Jan	DISC

INJECTABLE; INJECTION
ZOSYN

+ @		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Jan DISC
-----	--	---	---------	-----	--------------	----------

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION
MAXAIR

@ BAUSCH		EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	May CAHN
----------	--	-------------------	---------	-----	--------------	----------

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan CMS1
>D>	AB UNICHEM	10MG	A208340	001	Apr 13, 2017	Sep CTEC
>A>	BX	10MG	A208340	001	Apr 13, 2017	Sep CTEC
>D>	AB	20MG	A208340	002	Apr 13, 2017	Sep CTEC
>A>	BX	20MG	A208340	002	Apr 13, 2017	Sep CTEC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL
LAX-LYTE WITH FLAVOR PACKS

AA	L PERRIGO CO	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A079232	001	Feb 25, 2010	Aug CAHN
----	--------------	--	---------	-----	--------------	----------

POLYMYXIN B SULFATE

INJECTABLE; INJECTION
POLYMYXIN B SULFATE

	@ GLAND	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	May DISC
AP	! XELLIA PHARMS APS	EQ 500,000 UNITS BASE/VIAL	A202766	001	Jan 15, 2014	May CHRS

POMALIDOMIDE

CAPSULE; ORAL
POMALIDOMIDE

@ BRECKENRIDGE		1MG	A210111	001	Oct 30, 2020	Feb DISC
@		2MG	A210111	002	Oct 30, 2020	Feb DISC
@		3MG	A210111	003	Oct 30, 2020	Feb DISC
@		4MG	A210111	004	Oct 30, 2020	Feb DISC
@ EUGIA PHARMA		1MG	A210249	001	Oct 30, 2020	Apr DISC
@		2MG	A210249	002	Oct 30, 2020	Apr DISC
@		3MG	A210249	003	Oct 30, 2020	Apr DISC
@		4MG	A210249	004	Oct 30, 2020	Apr DISC
	POMALYST					
+ CELGENE		1MG	N204026	001	Feb 08, 2013	Apr CTEC
+		2MG	N204026	002	Feb 08, 2013	Apr CTEC
+		3MG	N204026	003	Feb 08, 2013	Apr CTEC
+!		4MG	N204026	004	Feb 08, 2013	Apr CTEC

PONATINIB HYDROCHLORIDE

TABLET; ORAL
ICLUSIG

+ TAKEDA PHARMS USA		EQ 10MG BASE	N203469	004	Dec 18, 2020	May CAHN
+		EQ 15MG BASE	N203469	001	Dec 14, 2012	May CAHN
+		EQ 30MG BASE	N203469	003	Apr 23, 2015	May CAHN
+!		EQ 45MG BASE	N203469	002	Dec 14, 2012	May CAHN

PONESIMOD

TABLET; ORAL
PONVORY

+ JANSSEN PHARMS		2MG	N213498	001	Mar 18, 2021	Mar NEWA
+		3MG	N213498	002	Mar 18, 2021	Mar NEWA
+		4MG	N213498	003	Mar 18, 2021	Mar NEWA
+		5MG	N213498	004	Mar 18, 2021	Mar NEWA
+		6MG	N213498	005	Mar 18, 2021	Mar NEWA
+		7MG	N213498	006	Mar 18, 2021	Mar NEWA
+		8MG	N213498	007	Mar 18, 2021	Mar NEWA
+		9MG	N213498	008	Mar 18, 2021	Mar NEWA
+		10MG	N213498	009	Mar 18, 2021	Mar NEWA
+!		20MG	N213498	010	Mar 18, 2021	Mar NEWA

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL
NOXAFIL POWDERMIX KIT

+! MSD MERCK CO 300MG

N214770 001 May 31, 2021 May NEWA

TABLET, DELAYED RELEASE;ORAL

POSACONAZOLE

AB AET PHARMA 100MG

A213454 001 Feb 01, 2021 Jan NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB GRANULES 8MEQ

A214686 001 Feb 16, 2021 Feb NEWA

AB 10MEQ

A214686 002 Feb 16, 2021 Feb NEWA

FOR SOLUTION;ORAL

POTASSIUM CHLORIDE

@ STRIDES PHARMA 20MEQ

A211667 001 Mar 11, 2021 Aug DISC

AA 20MEQ

A211667 001 Mar 11, 2021 Mar NEWA

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

+ @ ABRAXIS PHARM 2MEQ/ML

A080204 001

Aug CRLD

AP + FRESENIUS KABI USA 2MEQ/ML

A080225 001

Aug CRLD

POTASSIUM CHLORIDE 10MEQ

@ FRESENIUS KABI USA 14.9MG/ML

A211087 001 Sep 09, 2020 Mar DISC

@ 746MG/100ML

A211087 002 Sep 09, 2020 Mar DISC

AP NEXUS PHARMS 14.9MG/ML

A214727 001 Mar 18, 2021 Mar NFTG

AP 745MG/100ML

A214727 002 Mar 18, 2021 Mar NFTG

POTASSIUM CHLORIDE 20MEQ

@ FRESENIUS KABI USA 29.8MG/ML

A211087 003 Sep 09, 2020 Mar DISC

AP 1.49GM/100ML

A211087 005 May 07, 2021 Apr NEWA

AP NEXUS PHARMS 29.8MG/ML

A214727 003 Mar 18, 2021 Mar NFTG

AP 1.49GM/100ML

A214727 004 Mar 18, 2021 Mar NFTG

POTASSIUM CHLORIDE 40MEQ

@ FRESENIUS KABI USA 2.98GM/100ML

A211087 004 Sep 09, 2020 Mar DISC

AP NEXUS PHARMS 2.98GM/100ML

A214727 005 Mar 18, 2021 Mar NFTG

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA GRANULES 20MEQ/15ML

A213392 001 Jan 29, 2021 Jan NEWA

AA 40MEQ/15ML

A213392 002 Jan 29, 2021 Jan NEWA

AA SAPTALIS PHARMS 20MEQ/15ML

A211648 001 May 21, 2021 May NEWA

AA 40MEQ/15ML

A211648 002 May 21, 2021 May NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

@ AMTA 10MEQ

A214395 001 Jan 28, 2021 Jul DISC

AB1 10MEQ

A214395 001 Jan 28, 2021 Jan NEWA

@ 20MEQ

A214395 002 Jan 28, 2021 Jul DISC

AB1 20MEQ

A214395 002 Jan 28, 2021 Jan NEWA

>D> AB1 AUROBINDO PHARMA LTD 10MEQ

A214728 001 Mar 31, 2021 Sep DISC

>A> @ 10MEQ

A214728 001 Mar 31, 2021 Sep DISC

AB1 10MEQ

A214728 001 Mar 31, 2021 Mar NEWA

>D> AB1 15MEQ

A214728 002 Mar 31, 2021 Sep DISC

>A> @ 15MEQ

A214728 002 Mar 31, 2021 Sep DISC

AB1 15MEQ

A214728 002 Mar 31, 2021 Mar NEWA

>D> AB1 20MEQ

A214728 003 Mar 31, 2021 Sep DISC

>A> @ 20MEQ

A214728 003 Mar 31, 2021 Sep DISC

AB1 20MEQ

A214728 003 Mar 31, 2021 Mar NEWA

>A> @ BRECKENRIDGE 10MEQ

A213588 001 Aug 21, 2020 Sep CAHN

>A> @ 20MEQ

A213588 002 Aug 21, 2020 Sep CAHN

>D> @ CENTAUR PHARMS PVT 10MEQ

A213588 001 Aug 21, 2020 Sep CAHN

@ 10MEQ

A213588 001 Aug 21, 2020 Mar DISC

>D> @ 20MEQ

A213588 002 Aug 21, 2020 Sep CAHN

@ 20MEQ

A213588 002 Aug 21, 2020 Mar DISC

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

+! BAXTER HLTHCARE 150MG/100ML;450MG/100ML

N017648 005 Nov 26, 2002 Mar CTNA

+! 150MG/100ML;450MG/100ML

N017648 005 Nov 26, 2002 Mar CTEC

@ FRESENIUS KABI USA 150MG/100ML;450MG/100ML

A212347 001 Sep 17, 2020 Mar DISC

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%

AP +! BAXTER HLTHCARE 150MG/100ML;900MG/100ML

N017648 001

Mar CTNA

AP +! 150MG/100ML;900MG/100ML

N017648 001

Mar CHRS

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%						
AP	FRESENIUS KABI USA	150MG/100ML; 900MG/100ML	A212347	003	Jun 02, 2021	May NEWA
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%						
+!	BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648	002		Mar CTNA
+!		300MG/100ML; 900MG/100ML	N017648	002		Mar CHRS
+		300MG/100ML; 900MG/100ML	N017648	002		Mar CTEC
@	FRESENIUS KABI USA	300MG/100ML; 900MG/100ML	A212347	002	Sep 17, 2020	Mar DISC
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%						
@	BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004		Mar CTNA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE						
AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan NEWA
AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Apr CMFD
@		10MEQ	A212799	001	Jun 29, 2020	Feb DISC
AB		15MEQ	A212799	002	Jun 29, 2020	Apr CMFD
@		15MEQ	A212799	002	Jun 29, 2020	Feb DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb NEWA

PRALSETINIB

CAPSULE; ORAL

GAVRETO						
+!	GENENTECH INC	100MG	N213721	001	Sep 04, 2020	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE						
@	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Jul DISC
AB		0.125MG	A091450	001	Oct 08, 2010	Apr CAHN
@		0.25MG	A091450	002	Oct 08, 2010	Jul DISC
AB		0.25MG	A091450	002	Oct 08, 2010	Apr CAHN
@		0.5MG	A091450	003	Oct 08, 2010	Jul DISC
AB		0.5MG	A091450	003	Oct 08, 2010	Apr CAHN
@		1MG	A091450	004	Oct 08, 2010	Jul DISC
AB		1MG	A091450	004	Oct 08, 2010	Apr CAHN
@		1.5MG	A091450	005	Oct 08, 2010	Jul DISC
AB		1.5MG	A091450	005	Oct 08, 2010	Apr CAHN
TABLET, EXTENDED RELEASE; ORAL						
PRAMIPEXOLE DIHYDROCHLORIDE						
AB	XIAMEN LP PHARM CO	0.375MG	A212797	001	Jun 11, 2021	Jun NEWA
AB		0.75MG	A212797	002	Jun 11, 2021	Jun NEWA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL						
>D>	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018	Sep CTEC
>A>	BX	EQ 5MG BASE	A205913	001	Jun 19, 2018	Sep CTEC
>D>	AB	EQ 10MG BASE	A205913	002	Jun 19, 2018	Sep CTEC
>A>	BX	EQ 10MG BASE	A205913	002	Jun 19, 2018	Sep CTEC
>D>	AB	EQ 5MG BASE	A205790	001	Oct 16, 2017	Sep CAHN
>D>	AB	EQ 10MG BASE	A205790	002	Oct 16, 2017	Sep CAHN
@	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan DISC
@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan DISC
AB	PANACEA	EQ 5MG BASE	A205897	001	Oct 16, 2017	Jul CAHN
AB		EQ 10MG BASE	A205897	002	Oct 16, 2017	Jul CAHN
>A>	AB	EQ 5MG BASE	A205790	001	Oct 16, 2017	Sep CAHN
>A>	AB	EQ 10MG BASE	A205790	002	Oct 16, 2017	Sep CAHN

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL						
+	@ BRISTOL MYERS SQUIBB	20MG	N019898	003	Oct 31, 1991	Jun DISC
+	@	40MG	N019898	004	Mar 22, 1993	Jun DISC
+	@	80MG	N019898	008	Dec 18, 2001	Jun DISC
PRAVASTATIN SODIUM						
AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan CAHN

TABLET;ORAL							
PRAVASTATIN SODIUM							
AB		20MG	A209869	002	Apr 13, 2018	Jan	CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan	CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan	CAHN
	@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan	DISC
	@	40MG	A206061	002	Nov 23, 2018	Jan	DISC
	@	80MG	A206061	003	Nov 23, 2018	Jan	DISC
AB	! TEVA PHARMS	80MG	A077793	001	Jan 15, 2008	Jun	CHRS
<u>PRAZOSIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
PRAZOSIN HYDROCHLORIDE							
AB	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Feb	CMFD
AB		EQ 2MG BASE	A072577	001	May 16, 1989	Feb	CMFD
AB		EQ 5MG BASE	A072577	003	May 16, 1989	Feb	CMFD
<u>PREDNISOLONE</u>							
SYRUP;ORAL							
PREDNISOLONE							
AA	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Mar	CMFD
TABLET;ORAL							
PREDNISOLONE							
	@ RISING	5MG	A084773	001		Jan	CAHN
<u>PREDNISOLONE SODIUM PHOSPHATE</u>							
SOLUTION;ORAL							
PREDNISOLONE SODIUM PHOSPHATE							
	@ BAUSCH	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	May	CAHN
SOLUTION/DROPS;OPHTHALMIC							
INFLAMASE FORTE							
+	@ NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002		Aug	CRLD
INFLAMASE MILD							
+	@ NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001		Aug	CRLD
TABLET, ORALLY DISINTEGRATING;ORAL							
ORAPRED ODT							
+	CONCORDIA PHARMS INC	EQ 10MG BASE	N021959	001	Jun 01, 2006	Jul	CTEC
+		EQ 15MG BASE	N021959	002	Jun 01, 2006	Jul	CTEC
+	!	EQ 30MG BASE	N021959	003	Jun 01, 2006	Jul	CTEC
PREDNISOLONE SODIUM PHOSPHATE							
	@ MYLAN PHARMS INC	EQ 10MG BASE	A202179	001	Apr 10, 2013	Jul	DISC
	@	EQ 15MG BASE	A202179	002	Apr 10, 2013	Jul	DISC
	@	EQ 30MG BASE	A202179	003	Apr 10, 2013	Jul	DISC
<u>PREDNISON</u>							
TABLET;ORAL							
PREDNISON							
AB	! HIKMA PHARMS	1MG	A087800	001	Apr 22, 1982	Aug	CRLD
AB	!	10MG	A084122	001		Aug	CRLD
AB	!	20MG	A087342	001		Aug	CRLD
AB	NOVITIUM PHARMA	1MG	A215246	001	Jul 06, 2021	Jun	NEWA
	@ RISING	10MG	A089983	001	Jan 12, 1989	Jan	CAHN
	@	20MG	A085813	001		Jan	CAHN
	@	50MG	A089984	001	Jan 12, 1989	Jan	CAHN
AB	STRIDES PHARMA	10MG	A208412	001	Feb 11, 2021	Feb	NEWA
AB		20MG	A208412	002	Feb 11, 2021	Feb	NEWA
TABLET, DELAYED RELEASE;ORAL							
RAYOS							
+	HORIZON	1MG	N202020	001	Jul 26, 2012	Apr	CAHN
+		2MG	N202020	002	Jul 26, 2012	Apr	CAHN
+	!	5MG	N202020	003	Jul 26, 2012	Apr	CAHN
<u>PREGABALIN</u>							
CAPSULE;ORAL							
LYRICA							
AB	+ UPJOHN	25MG	N021446	001	Dec 30, 2004	Apr	CAHN
AB	+	50MG	N021446	002	Dec 30, 2004	Apr	CAHN
AB	+	75MG	N021446	003	Dec 30, 2004	Apr	CAHN
AB	+	100MG	N021446	004	Dec 30, 2004	Apr	CAHN
AB	+	150MG	N021446	005	Dec 30, 2004	Apr	CAHN
AB	+	200MG	N021446	006	Dec 30, 2004	Apr	CAHN
AB	+	225MG	N021446	007	Dec 30, 2004	Apr	CAHN

CAPSULE;ORAL
LYRICA

AB	+	!		300MG	N021446	008	Dec 30, 2004	Apr	CAHN
PREGABALIN									
AB			ALKEM LABS LTD	25MG	A207799	007	Sep 30, 2019	Feb	CMS1
AB				50MG	A207799	008	Sep 30, 2019	Feb	CMS1
AB			APOTEX	25MG	A211685	001	Jul 07, 2021	Jun	NEWA
AB				50MG	A211685	002	Jul 07, 2021	Jun	NEWA
AB				75MG	A211685	003	Jul 07, 2021	Jun	NEWA
AB				100MG	A211685	004	Jul 07, 2021	Jun	NEWA
AB				150MG	A211685	005	Jul 07, 2021	Jun	NEWA
AB				200MG	A211685	006	Jul 07, 2021	Jun	NEWA
AB				225MG	A211685	007	Jul 07, 2021	Jun	NEWA
AB				300MG	A211685	008	Jul 07, 2021	Jun	NEWA
AB			CHANGZHOU PHARM	50MG	A214322	001	Jul 15, 2021	Jul	NEWA
AB				75MG	A214322	002	Jul 15, 2021	Jul	NEWA
AB				100MG	A214322	003	Jul 15, 2021	Jul	NEWA
AB				150MG	A214322	004	Jul 15, 2021	Jul	NEWA
AB				200MG	A214322	005	Jul 15, 2021	Jul	NEWA
AB				225MG	A214322	006	Jul 15, 2021	Jul	NEWA
AB				300MG	A214322	007	Jul 15, 2021	Jul	NEWA

SOLUTION;ORAL
LYRICA

AA	+	!	UPJOHN	20MG/ML	N022488	001	Jan 04, 2010	Apr	CAHN
TABLET, EXTENDED RELEASE;ORAL									
LYRICA CR									
AB	+		PFIZER	82.5MG	N209501	001	Oct 11, 2017	Apr	CFTG
AB	+			165MG	N209501	002	Oct 11, 2017	Apr	CFTG
AB	+	!		330MG	N209501	003	Oct 11, 2017	Apr	CFTG
AB	+		UPJOHN	82.5MG	N209501	001	Oct 11, 2017	Apr	CAHN
AB	+			165MG	N209501	002	Oct 11, 2017	Apr	CAHN
AB	+	!		330MG	N209501	003	Oct 11, 2017	Apr	CAHN
PREGABALIN									
AB			ALVOGEN	82.5MG	A211687	001	Jul 06, 2021	Jun	NEWA
AB				165MG	A211687	002	Jul 06, 2021	Jun	NEWA
AB				330MG	A211687	003	Jul 06, 2021	Jun	NEWA
AB			ALVOGEN PINE BROOK	82.5MG	A211593	001	Apr 13, 2021	Apr	NFTG
AB				165MG	A211593	002	Apr 13, 2021	Apr	NFTG
AB				330MG	A211593	003	Apr 13, 2021	Apr	NFTG
AB			APOTEX	165MG	A213313	001	Apr 13, 2021	Apr	NFTG
AB				330MG	A213313	002	Apr 13, 2021	Apr	NFTG
AB			MSN	82.5MG	A213226	001	Apr 13, 2021	Apr	NFTG
AB				165MG	A213226	002	Apr 13, 2021	Apr	NFTG
AB				330MG	A213226	003	Apr 13, 2021	Apr	NFTG
AB			MYLAN	82.5MG	A211948	001	Apr 13, 2021	Apr	NFTG
AB				330MG	A211431	001	Jul 02, 2021	Jun	NEWA
AB			SUN PHARM	82.5MG	A211889	001	Apr 13, 2021	Apr	NFTG
AB				165MG	A211889	002	Apr 13, 2021	Apr	NFTG
AB				330MG	A211889	003	Apr 13, 2021	Apr	NFTG

PROBENECID

TABLET;ORAL									
PROBENECID									
			@ MYLAN	500MG	A084211	002		Aug	CAHN
			@	500MG	A084211	002		Aug	DISC
AB	!		WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	Aug	CTEC

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL									
PROCAN SR									
	+	@	PARKE DAVIS	250MG	A086468	001		Aug	CRLD
	+	@	PARKEDALE	500MG	A086065	001		Aug	CRLD
	+	@		750MG	A087510	001	Apr 01, 1982	Aug	CRLD

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION									
PROCHLORPERAZINE EDISYLATE									
AP			CAPLIN	EQ 5MG BASE/ML	A214379	001	Apr 22, 2021	Apr	NEWA
>A>	AP		GLAND PHARMA LTD	EQ 5MG BASE/ML	A214107	001	Sep 22, 2021	Sep	NEWA
			@ HIKMA PHARMS	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jul	CAHN
	AP			EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jul	CAHN
>A>	AP		VIWIT PHARM	EQ 5MG BASE/ML	A213626	001	Sep 28, 2021	Sep	NEWA

PROGESTERONECAPSULE; ORAL
PROGESTERONE

>D>	AB	SOFGEN PHARMS	100MG	A200456	001	Sep 28, 2012	Sep CTEC
>A>	BX		100MG	A200456	001	Sep 28, 2012	Sep CTEC
>D>	AB		200MG	A200456	002	Sep 28, 2012	Sep CTEC
>A>	BX		200MG	A200456	002	Sep 28, 2012	Sep CTEC

PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE

AA		AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Aug CMFD
		@	6.25MG/5ML	A040882	001	Dec 30, 2009	Feb DISC
AA		QUAGEN	6.25MG/5ML	A213890	001	Jul 12, 2021	Jul NEWA

PROMETHAZINE PLAIN

AA	+!	WOCKHARDT BIO AG	6.25MG/5ML	A087953	001	Nov 15, 1982	Aug CRLD
----	----	------------------	------------	---------	-----	--------------	----------

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	+	SANDOZ	25MG	A084176	003		Aug CRLD
AB	+!		50MG	A084176	001		Aug CRLD

PROPAFENONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
PROPAFENONE HYDROCHLORIDE

		@ MYLAN	225MG	A203803	001	Apr 29, 2016	Jul DISC
		@	325MG	A203803	002	Apr 29, 2016	Jul DISC
		@	425MG	A203803	003	Apr 29, 2016	Jul DISC
>D>	AB	SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	Sep CTEC
>A>	BX		225MG	A210339	001	Jan 04, 2019	Sep CTEC
>D>	AB		325MG	A210339	002	Jan 04, 2019	Sep CTEC
>A>	BX		325MG	A210339	002	Jan 04, 2019	Sep CTEC
>D>	AB		425MG	A210339	003	Jan 04, 2019	Sep CTEC
>A>	BX		425MG	A210339	003	Jan 04, 2019	Sep CTEC
	AB	ZYDUS	225MG	A214184	001	Apr 21, 2021	Apr NEWA
	AB		325MG	A214184	002	Apr 21, 2021	Apr NEWA
	AB		425MG	A214184	003	Apr 21, 2021	Apr NEWA

PROPANTHELINE BROMIDETABLET; ORAL
PROPANTHELINE BROMIDE

		@ HIKMA PHARMS	15MG	A080927	002		Apr DISC
--	--	----------------	------	---------	-----	--	----------

PROPRANOLOL HYDROCHLORIDETABLET; ORAL
PROPRANOLOL HYDROCHLORIDE

>D>		@ IMPAX LABS INC	10MG	A071972	001	Apr 06, 1988	Sep CMFD
>A>	AB		10MG	A071972	001	Apr 06, 1988	Sep CMFD
>D>		@	20MG	A071972	002	Apr 06, 1988	Sep CMFD
>A>	AB		20MG	A071972	002	Apr 06, 1988	Sep CMFD
	AB		40MG	A071972	003	Apr 06, 1988	Aug CMFD
		@ WATSON LABS	60MG	A070178	002	Apr 23, 2018	Apr DISC

PROPYLTHIOURACILTABLET; ORAL
PROPYLTHIOURACIL

BD		QUAGEN	50MG	A080154	001		Mar CMFD
----	--	--------	------	---------	-----	--	----------

PROTAMINE SULFATEINJECTABLE; INJECTION
PROTAMINE SULFATE

		@ HIKMA PHARMS	10MG/ML	A089474	001	Nov 05, 1986	Jul CAHN
		@	10MG/ML	A089475	001	Nov 05, 1986	Jul CAHN

PYRAZINAMIDETABLET; ORAL
PYRAZINAMIDE

AB	+	NOVITIUM PHARMA	500MG	A080157	001		Aug CRLD
AB			500MG	A080157	001		Apr CMFD

PYRIDOXINE HYDROCHLORIDEINJECTABLE; INJECTION
PYRIDOXINE HYDROCHLORIDE

+! FRESENIUS KABI USA 100MG/ML A080618 001 Aug CRLD

PYRIMETHAMINETABLET; ORAL
PYRIMETHAMINE

AB	ALVOGEN	25MG	A211271	001	Jul 27, 2021	Aug CAHN
AB	FERA PHARMS LLC	25MG	A211271	001	Jul 27, 2021	Jul NEWA
AB	TEVA PHARMS	25MG	A215506	001	Aug 13, 2021	Aug NEWA

QUETIAPINE FUMARATETABLET; ORAL
QUETIAPINE FUMARATE

@ JUBILANT GENERICS EQ 25MG BASE A203150 001 Nov 26, 2013 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

	@ ANCHEN PHARMS	EQ 150MG BASE	A090757	001	Dec 01, 2017	Jun DISC	
	@	EQ 200MG BASE	A090757	002	Dec 01, 2017	Jun DISC	
	@	EQ 300MG BASE	A090757	003	Dec 01, 2017	Jun DISC	
	@	EQ 400MG BASE	A090757	004	Dec 01, 2017	Jun DISC	
	@ MYLAN	EQ 50MG BASE	A202228	001	Feb 02, 2021	Feb DISC	
AB	@	EQ 50MG BASE	A202228	001	Feb 02, 2021	Jan NEWA	
	@	EQ 150MG BASE	A202228	002	Feb 02, 2021	Feb DISC	
AB	@	EQ 150MG BASE	A202228	002	Feb 02, 2021	Jan NEWA	
	@	EQ 200MG BASE	A202228	003	Feb 02, 2021	Feb DISC	
AB	@	EQ 200MG BASE	A202228	003	Feb 02, 2021	Jan NEWA	
	@	EQ 300MG BASE	A202228	004	Feb 02, 2021	Feb DISC	
AB	@	EQ 300MG BASE	A202228	004	Feb 02, 2021	Jan NEWA	
	@	EQ 400MG BASE	A202228	005	Feb 02, 2021	Feb DISC	
AB	@	EQ 400MG BASE	A202228	005	Feb 02, 2021	Jan NEWA	
>D>	AB	SCIEGEN PHARMS INC	EQ 50MG BASE	A209635	005	Nov 16, 2018	Sep CTEC
>A>	BX		EQ 50MG BASE	A209635	005	Nov 16, 2018	Sep CTEC
>D>	AB		EQ 150MG BASE	A209635	001	Nov 29, 2017	Sep CTEC
>A>	BX		EQ 150MG BASE	A209635	001	Nov 29, 2017	Sep CTEC
>D>	AB		EQ 200MG BASE	A209635	002	Nov 29, 2017	Sep CTEC
>A>	BX		EQ 200MG BASE	A209635	002	Nov 29, 2017	Sep CTEC
>D>	AB		EQ 300MG BASE	A209635	003	Nov 29, 2017	Sep CTEC
>A>	BX		EQ 300MG BASE	A209635	003	Nov 29, 2017	Sep CTEC
>D>	AB		EQ 400MG BASE	A209635	004	Nov 29, 2017	Sep CTEC
>A>	BX		EQ 400MG BASE	A209635	004	Nov 29, 2017	Sep CTEC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

>A>	AB	EYWA	324MG	A212589	001	Sep 17, 2021	Sep NEWA
		@ RISING	324MG	A089894	001	Dec 15, 1988	Jan CAHN
>D>		! SUN PHARM INDUSTRIES	324MG	A089338	001	Feb 11, 1987	Sep CTEC
>A>	AB	!	324MG	A089338	001	Feb 11, 1987	Sep CTEC

QUINIDINE SULFATE

TABLET; ORAL

CIN-QUIN

+ @ SOLVAY 100MG A085299 001 Aug CRLD

+ @ 200MG A084932 001 Aug CRLD

QUINORA

+ @ SCHERING 300MG A085222 001 Aug CRLD

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

	+ @ WOODWARD	10MG	N020973	001	May 29, 2002	Jul CAHN
AB	+!	20MG	N020973	002	Aug 19, 1999	Jul CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 150MG BASE A211058 001 Jul 16, 2018 Jun DISC

@ EQ 300MG BASE A211058 002 Jul 16, 2018 Jun DISC

SYRUP;ORAL									
RANITIDINE HYDROCHLORIDE									
@	AUROBINDO PHARMA LTD	EQ 15MG BASE/ML	A 090623	001	Jul 28, 2010	Jun	DISC		
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
@	WOCKHARDT LTD	EQ 150MG BASE	A 075208	001	Dec 17, 1998	Jan	DISC		
@		EQ 300MG BASE	A 075208	002	Dec 17, 1998	Jan	DISC		
<u>RANOLAZINE</u>									
TABLET, EXTENDED RELEASE;ORAL									
RANOLAZINE									
AB	ACCORD HLTHCARE	500MG	A 212930	001	May 18, 2021	May	NEWA		
AB		1GM	A 212930	002	May 18, 2021	May	NEWA		
@	AMNEAL	500MG	A 207690	001	Mar 11, 2021	Apr	DISC		
AB		500MG	A 207690	001	Mar 11, 2021	Mar	NEWA		
@		1GM	A 207690	002	Mar 11, 2021	Apr	DISC		
AB		1GM	A 207690	002	Mar 11, 2021	Mar	NEWA		
AB	GRAVITI PHARMS	500MG	A 212889	001	Jan 28, 2021	Jan	NEWA		
AB		1GM	A 212889	002	Jan 28, 2021	Jan	NEWA		
AB	PRAXGEN	500MG	A 212781	001	Mar 23, 2020	Feb	CAHN		
AB		1GM	A 212781	002	Mar 23, 2020	Feb	CAHN		
<u>REPAGLINIDE</u>									
TABLET;ORAL									
REPAGLINIDE									
AB	PADAGIS US	0.5MG	A 201189	001	Jul 17, 2013	Jul	CAHN		
AB		0.5MG	A 201189	001	Jul 17, 2013	Jul	CAHN		
AB		1MG	A 201189	002	Jan 22, 2014	Jul	CAHN		
AB		1MG	A 201189	002	Jan 22, 2014	Jul	CAHN		
AB		2MG	A 201189	003	Jan 22, 2014	Jul	CAHN		
AB		2MG	A 201189	003	Jan 22, 2014	Jul	CAHN		
<u>RIFAXIMIN</u>									
TABLET;ORAL									
XIFAXAN									
+	SALIX PHARMS	550MG	N 021361	002	Mar 24, 2010	Aug	CMS1		
<u>RILUZOLE</u>									
FILM;ORAL									
EXSERVAN									
+	mitsubishi holdings	50MG	N 212640	001	Nov 22, 2019	Feb	CAHN		
<u>RIMEGEPANT SULFATE</u>									
TABLET, ORALLY DISINTEGRATING;ORAL									
NURTEC ODT									
+	BIOHAVEN IRELAND	EQ 75MG BASE	N 212728	001	Feb 27, 2020	Jul	CAHN		
<u>RISPERIDONE</u>									
TABLET, ORALLY DISINTEGRATING;ORAL									
RISPERDAL									
+	@ JANSSEN PHARMS	0.5MG	N 021444	001	Apr 02, 2003	Feb	DISC		
+	@	1MG	N 021444	002	Apr 02, 2003	Feb	DISC		
+	@	2MG	N 021444	003	Apr 02, 2003	Feb	DISC		
+	@	3MG	N 021444	004	Dec 23, 2004	Feb	DISC		
+	@	4MG	N 021444	005	Dec 23, 2004	Feb	DISC		
RISPERIDONE									
AB	! JUBILANT GENERICS	1MG	A 090839	002	Nov 04, 2011	Feb	CHRS		
<u>RITONAVIR</u>									
CAPSULE;ORAL									
RITONAVIR									
@	HIKMA PHARMS	100MG	A 205801	001	Dec 03, 2020	Mar	DISC		
<u>RIZATRIPTAN BENZOATE</u>									
TABLET, ORALLY DISINTEGRATING;ORAL									
RIZATRIPTAN BENZOATE									
@	JUBILANT GENERICS	EQ 5MG BASE	A 203334	001	Oct 16, 2015	Jun	DISC		
@		EQ 10MG BASE	A 203334	002	Oct 16, 2015	Jun	DISC		
AB	PANACEA	EQ 5MG BASE	A 204722	001	Jan 11, 2017	Jul	CAHN		
AB		EQ 10MG BASE	A 204722	002	Jan 11, 2017	Jul	CAHN		

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

REQUIP

	+ @	GLAXOSMITHKLINE LLC	EQ 0.25MG BASE	N020658	001	Sep 19, 1997	Jul	DISC
	+ @		EQ 0.5MG BASE	N020658	002	Sep 19, 1997	Jul	DISC
	+ @		EQ 1MG BASE	N020658	003	Sep 19, 1997	Jul	DISC
	+ @		EQ 2MG BASE	N020658	004	Sep 19, 1997	Jul	DISC
	+ @		EQ 3MG BASE	N020658	006	Jan 27, 1999	Jul	DISC
	+ @		EQ 4MG BASE	N020658	007	Jan 27, 1999	Jul	DISC
	+ @		EQ 5MG BASE	N020658	005	Sep 19, 1997	Jul	DISC

ROPINIROLE HYDROCHLORIDE

AB	!	PRINSTON INC	EQ 0.25MG BASE	A078110	001	May 05, 2008	Jul	CHRS
----	---	--------------	----------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

	+ @	GLAXOSMITHKLINE LLC	EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun	DISC
AB	+		EQ 2MG BASE	N022008	001	Jun 13, 2008	Jun	CHRS
	+ @		EQ 6MG BASE	N022008	006	Apr 10, 2009	Jun	DISC
	+ @		EQ 12MG BASE	N022008	005	Oct 31, 2008	Jun	DISC

ROPINIROLE HYDROCHLORIDE

AB	!	DR REDDYS LABS LTD	EQ 2MG BASE	A201576	001	Jun 06, 2012	Jun	CHRS
----	---	--------------------	-------------	---------	-----	--------------	-----	------

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

	+ @	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	Mar	CRLD
	+ @		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Mar	CRLD

ROPIVACAINE HYDROCHLORIDE

	@	MYLAN ASI	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Jan	DISC
	@		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Jan	DISC

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

	+	WOODWARD	EQ 2MG BASE	N021071	002	May 25, 1999	Jul	CAHN
	+		EQ 4MG BASE	N021071	003	May 25, 1999	Jul	CAHN
	+ @		EQ 8MG BASE	N021071	004	May 25, 1999	Jul	CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB	+	IPR	EQ 5MG BASE	N021366	002	Aug 12, 2003	Apr	CPOT
AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Apr	CPOT
AB	+!		EQ 40MG BASE	N021366	005	Aug 12, 2003	Apr	CPOT

ROSUVASTATIN CALCIUM

AB		ACCORD HLTHCARE	EQ 5MG BASE	A206434	001	Oct 31, 2016	Apr	CPOT
AB			EQ 10MG BASE	A206434	002	Oct 31, 2016	Apr	CPOT
AB			EQ 20MG BASE	A206434	003	Oct 31, 2016	Apr	CPOT
AB			EQ 40MG BASE	A206434	004	Oct 31, 2016	Apr	CPOT
AB		ALKEM LABS LTD	EQ 5MG BASE	A206465	001	Mar 21, 2017	Apr	CPOT
AB			EQ 10MG BASE	A206465	002	Mar 21, 2017	Apr	CPOT
AB			EQ 20MG BASE	A206465	003	Mar 21, 2017	Apr	CPOT
AB			EQ 40MG BASE	A206465	004	Mar 21, 2017	Apr	CPOT
>D>	AB	ALLIED	EQ 5MG BASE	A079168	001	Jul 19, 2016	Sep	CAHN
	AB		EQ 5MG BASE	A079168	001	Jul 19, 2016	Apr	CPOT
>D>	AB		EQ 10MG BASE	A079168	002	Jul 19, 2016	Sep	CAHN
	AB		EQ 10MG BASE	A079168	002	Jul 19, 2016	Apr	CPOT
>D>	AB		EQ 20MG BASE	A079168	003	Jul 19, 2016	Sep	CAHN
	AB		EQ 20MG BASE	A079168	003	Jul 19, 2016	Apr	CPOT
>D>	AB		EQ 40MG BASE	A079168	004	Jul 19, 2016	Sep	CAHN
	AB		EQ 40MG BASE	A079168	004	Jul 19, 2016	Apr	CPOT
		@ AMNEAL PHARMS CO	EQ 5MG BASE	A208850	001	Oct 16, 2018	Apr	CPOT
		@	EQ 10MG BASE	A208850	002	Oct 16, 2018	Apr	CPOT
		@	EQ 20MG BASE	A208850	003	Oct 16, 2018	Apr	CPOT
		@	EQ 40MG BASE	A208850	004	Oct 16, 2018	Apr	CPOT
		@ APOTEX INC	EQ 5MG BASE	A079145	001	Jul 19, 2016	Apr	CPOT
		@	EQ 10MG BASE	A079145	002	Jul 19, 2016	Apr	CPOT
		@	EQ 20MG BASE	A079145	003	Jul 19, 2016	Apr	CPOT
		@	EQ 40MG BASE	A079145	004	Jul 19, 2016	Apr	CPOT
AB		AUROBINDO PHARMA LTD	EQ 5MG BASE	A079170	001	Jul 19, 2016	Apr	CPOT
AB			EQ 10MG BASE	A079170	002	Jul 19, 2016	Apr	CPOT
AB			EQ 20MG BASE	A079170	003	Jul 19, 2016	Apr	CPOT
AB			EQ 40MG BASE	A079170	004	Jul 19, 2016	Apr	CPOT

TABLET;ORAL

ROSUVASTATIN CALCIUM

AB	BIOCON LTD	EQ 5MG BASE	A207752	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Apr	CPOT
AB	BIOCON PHARMA	EQ 5MG BASE	A207752	001	Oct 31, 2016	Jul	CAHN
AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Jul	CAHN
AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Jul	CAHN
AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Jul	CAHN
AB	CADILA PHARMS LTD	EQ 5MG BASE	A207453	001	Nov 23, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207453	002	Nov 23, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207453	003	Nov 23, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207453	004	Nov 23, 2016	Apr	CPOT
AB	CHANGZHOU PHARM	EQ 5MG BASE	A207408	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207408	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207408	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207408	004	Oct 31, 2016	Apr	CPOT
>A>	AB	EQ 5MG BASE	A079168	001	Jul 19, 2016	Sep	CAHN
>A>	AB	EQ 10MG BASE	A079168	002	Jul 19, 2016	Sep	CAHN
>A>	AB	EQ 20MG BASE	A079168	003	Jul 19, 2016	Sep	CAHN
>A>	AB	EQ 40MG BASE	A079168	004	Jul 19, 2016	Sep	CAHN
AB	GLENMARK PHARMS	EQ 5MG BASE	A079172	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079172	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079172	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079172	004	Jul 19, 2016	Apr	CPOT
AB	HETERO LABS LTD V	EQ 5MG BASE	A207616	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207616	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207616	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207616	004	Oct 31, 2016	Apr	CPOT
AB	@ INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021	May	DISC
AB		EQ 5MG BASE	A207653	001	Feb 05, 2021	Apr	CPOT
AB		5MG	A207653	001	Feb 05, 2021	Jan	NEWA
AB	@	EQ 10MG BASE	A207653	002	Feb 05, 2021	May	DISC
AB		EQ 10MG BASE	A207653	002	Feb 05, 2021	Apr	CPOT
AB		10MG	A207653	002	Feb 05, 2021	Jan	NEWA
AB	@	EQ 20MG BASE	A207653	003	Feb 05, 2021	May	DISC
AB		EQ 20MG BASE	A207653	003	Feb 05, 2021	Apr	CPOT
AB		20MG	A207653	003	Feb 05, 2021	Jan	NEWA
AB	@	EQ 40MG BASE	A207653	004	Feb 05, 2021	May	DISC
AB		EQ 40MG BASE	A207653	004	Feb 05, 2021	Apr	CPOT
AB		40MG	A207653	004	Feb 05, 2021	Jan	NEWA
AB	LUPIN	EQ 5MG BASE	A205587	001	Jul 31, 2017	Apr	CPOT
AB		EQ 10MG BASE	A205587	002	Jul 31, 2017	Apr	CPOT
AB		EQ 20MG BASE	A205587	003	Jul 31, 2017	Apr	CPOT
AB		EQ 40MG BASE	A205587	004	Jul 31, 2017	Apr	CPOT
AB	MSN	EQ 5MG BASE	A208898	001	Nov 22, 2017	Apr	CPOT
AB		EQ 10MG BASE	A208898	002	Nov 22, 2017	Apr	CPOT
AB		EQ 20MG BASE	A208898	003	Nov 22, 2017	Apr	CPOT
AB		EQ 40MG BASE	A208898	004	Nov 22, 2017	Apr	CPOT
AB	@ MYLAN	EQ 5MG BASE	A079161	001	Jul 19, 2016	Apr	CPOT
AB	@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Apr	CPOT
AB	@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Apr	CPOT
AB	@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Apr	CPOT
AB	RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Apr	CPOT
AB		EQ 10MG BASE	A207062	002	Oct 31, 2016	Apr	CPOT
AB		EQ 20MG BASE	A207062	003	Oct 31, 2016	Apr	CPOT
AB		EQ 40MG BASE	A207062	004	Oct 31, 2016	Apr	CPOT
AB	SANDOZ INC	EQ 5MG BASE	A079171	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079171	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079171	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079171	004	Jul 19, 2016	Apr	CPOT
AB	@ SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019	Apr	CPOT
AB	@	EQ 10MG BASE	A206381	002	Apr 24, 2019	Apr	CPOT
AB	@	EQ 20MG BASE	A206381	003	Apr 24, 2019	Apr	CPOT
AB	@	EQ 40MG BASE	A206381	004	Apr 24, 2019	Apr	CPOT
AB	SHANDONG	EQ 5MG BASE	A207375	001	May 07, 2019	Apr	CPOT
AB		EQ 10MG BASE	A207375	002	May 07, 2019	Apr	CPOT
AB		EQ 20MG BASE	A207375	003	May 07, 2019	Apr	CPOT
AB		EQ 40MG BASE	A207375	004	May 07, 2019	Apr	CPOT
AB	SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Apr	CPOT
AB		EQ 10MG BASE	A079169	002	Jul 19, 2016	Apr	CPOT
AB		EQ 20MG BASE	A079169	003	Jul 19, 2016	Apr	CPOT
AB		EQ 40MG BASE	A079169	004	Jul 19, 2016	Apr	CPOT

SELEGILINE HYDROCHLORIDE

	CAPSULE; ORAL						
	SELEGILINE HYDROCHLORIDE						
AB	NOVITIUM PHARMA	5MG		A075352	001	Nov 30, 1998	Apr CMFD

SELENIOS ACID

SOLUTION; INTRAVENOUS
SELENIOS ACID

+!	AM REGENT	EQ 12MCG BASE/2ML (EQ 6MCG BASE/ML)		N209379	003	Aug 30, 2021	Aug NEWA
+!		EQ 60MCG BASE/ML (EQ 60MCG BASE/ML)		N209379	002	Jan 25, 2021	Jan NEWA

SELEXIPAG

POWDER; INTRAVENOUS
UPTRAVI

+!	ACTELION	1.8MG/VIAL		N214275	001	Jul 29, 2021	Jul NEWA
----	----------	------------	--	---------	-----	--------------	----------

TABLET; ORAL
UPTRAVI

+	ACTELION	0.2MG		N207947	001	Dec 21, 2015	Feb CAHN
+!		0.4MG		N207947	002	Dec 21, 2015	Feb CAHN
+		0.6MG		N207947	003	Dec 21, 2015	Feb CAHN
+		0.8MG		N207947	004	Dec 21, 2015	Feb CAHN
+		1MG		N207947	005	Dec 21, 2015	Feb CAHN
+		1.2MG		N207947	006	Dec 21, 2015	Feb CAHN
+		1.4MG		N207947	007	Dec 21, 2015	Feb CAHN
+		1.6MG		N207947	008	Dec 21, 2015	Feb CAHN

SELINEXOR

TABLET; ORAL
XPOVIO

+	KARYOPHARM THERAPS	40MG		N212306	002	Apr 15, 2021	Apr NEWA
+		50MG		N212306	003	Apr 15, 2021	Apr NEWA
+		60MG		N212306	004	Apr 15, 2021	Apr NEWA

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS
WEGOVY

+!	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)		N215256	001	Jun 04, 2021	Jun NEWA
+!		0.5MG/0.5ML (0.5MG/0.5ML)		N215256	002	Jun 04, 2021	Jun NEWA
+!		1MG/0.5ML (1MG/0.5ML)		N215256	003	Jun 04, 2021	Jun NEWA
+!		1.7MG/0.75ML (1.7MG/0.75ML)		N215256	004	Jun 04, 2021	Jun NEWA
+!		2.4MG/0.75ML (2.4MG/0.75ML)		N215256	005	Jun 04, 2021	Jun NEWA

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	ACI	EQ 25MG BASE		A076881	001	Feb 06, 2007	Jan CMFD
AB		EQ 50MG BASE		A076881	002	Feb 06, 2007	Jan CMFD
AB		EQ 100MG BASE		A076881	003	Feb 06, 2007	Jan CMFD
AB	ASCENT PHARMS INC	EQ 25MG BASE		A214790	001	May 03, 2021	Apr NEWA
AB		EQ 50MG BASE		A214790	002	May 03, 2021	Apr NEWA
AB		EQ 100MG BASE		A214790	003	May 03, 2021	Apr NEWA
>D>	AUSTARPHARMA LLC	EQ 25MG BASE		A078677	001	Mar 04, 2009	Sep CAHN
>D>		EQ 50MG BASE		A078677	002	Mar 04, 2009	Sep CAHN
>D>		EQ 100MG BASE		A078677	003	Mar 04, 2009	Sep CAHN
AB	GRANULES	EQ 25MG BASE		A078403	001	Jan 08, 2008	May CAHN
AB		EQ 50MG BASE		A078403	002	Jan 08, 2008	May CAHN
AB		EQ 100MG BASE		A078403	003	Jan 08, 2008	May CAHN
>A>	HANGZHOU BINJIANG	EQ 25MG BASE		A078677	001	Mar 04, 2009	Sep CAHN
>A>		EQ 50MG BASE		A078677	002	Mar 04, 2009	Sep CAHN
>A>		EQ 100MG BASE		A078677	003	Mar 04, 2009	Sep CAHN
AB	SCIEGEN PHARMS INC	EQ 25MG BASE		A076442	001	Apr 30, 2007	Apr CMFD
AB		EQ 50MG BASE		A076442	002	Apr 30, 2007	Apr CMFD
AB		EQ 100MG BASE		A076442	003	Apr 30, 2007	Apr CMFD

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

SEVELAMER CARBONATE

AB	BIONPHARMA INC	800MG/PACKET		A209374	001	May 17, 2021	May NEWA
AB	IMPAX	800MG/PACKET		A211316	001	Nov 20, 2020	Aug CMFD
	@	800MG/PACKET		A211316	001	Nov 20, 2020	Mar DISC

FOR SUSPENSION;ORAL						
SEVELAMER CARBONATE						
AB		2.4GM/PACKET	A211316	002	Nov 20, 2020	Aug CMFD
	@	2.4GM/PACKET	A211316	002	Nov 20, 2020	Mar DISC
TABLET;ORAL						
SEVELAMER CARBONATE						
AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar CMFD
AB	LUPIN LTD	800MG	A204600	001	Jan 14, 2021	Jan NEWA
<u>SEVELAMER HYDROCHLORIDE</u>						
TABLET;ORAL						
SEVELAMER HYDROCHLORIDE						
AB	LUPIN LTD	400MG	A213145	001	Jun 16, 2021	Jun NEWA
AB		800MG	A213145	002	Jun 16, 2021	Jun NEWA
<u>SILDENAFIL CITRATE</u>						
FOR SUSPENSION;ORAL						
SILDENAFIL CITRATE						
AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Apr NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE/ML	A213014	001	May 11, 2021	Apr NEWA
TABLET;ORAL						
SILDENAFIL CITRATE						
AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar CAHN
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar CAHN
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar CAHN
AB	UMEDICA LABS PVT LTD	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun NEWA
	@ WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020	May DISC
	@	EQ 50MG BASE	A202506	002	Nov 25, 2020	May DISC
	@	EQ 100MG BASE	A202506	003	Nov 25, 2020	May DISC
<u>SIMVASTATIN</u>						
TABLET;ORAL						
SIMVASTATIN						
AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar CAHN
AB		10MG	A078034	002	Dec 20, 2006	Mar CAHN
AB		20MG	A078034	003	Dec 20, 2006	Mar CAHN
AB		40MG	A078034	004	Dec 20, 2006	Mar CAHN
AB		80MG	A078034	005	Dec 20, 2006	Mar CAHN
AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Apr CMFD
AB		20MG	A206557	002	Nov 13, 2017	Apr CMFD
AB		40MG	A206557	003	Nov 13, 2017	Apr CMFD
AB		80MG	A206557	004	Nov 13, 2017	Apr CMFD
AB	! LUPIN	80MG	A078103	004	May 11, 2007	Jun CHRS
ZOCOR						
AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb CAHN
AB	+	10MG	N019766	002	Dec 23, 1991	Feb CAHN
AB	+	20MG	N019766	003	Dec 23, 1991	Feb CAHN
AB	+	40MG	N019766	004	Dec 23, 1991	Feb CAHN
	+ @	80MG	N019766	005	Jul 10, 1998	Jun DISC
AB	+!	80MG	N019766	005	Jul 10, 1998	Feb CAHN
<u>SINECATECHINS</u>						
OINTMENT;TOPICAL						
VEREGEN						
	+! ANI PHARMS	15%	N021902	001	Oct 31, 2006	Apr CAHN
<u>SIPONIMOD FUMARIC ACID</u>						
TABLET;ORAL						
MAYZENT						
	+ NOVARTIS	EQ 1MG BASE	N209884	003	Aug 24, 2021	Aug NEWA
<u>SIROLIMUS</u>						
TABLET;ORAL						
SIROLIMUS						
AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar NEWA
AB		1MG	A214753	002	Mar 12, 2021	Mar NEWA
AB		2MG	A214753	003	Mar 12, 2021	Mar NEWA

SODIUM ACETATEINJECTABLE; INJECTION
SODIUM ACETATE

AP	+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Apr	CFTG
AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Apr	NFTG

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; INTRAVENOUS
SODIUM PHENYLACETATE AND SODIUM BENZOATE

+	!	MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021	Jun	NEWA
---	---	-----------------	-----------------------------	---------	-----	--------------	-----	------

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

AP		HIKMA PHARMS	9MG/ML	A201833	001	Sep 24, 2013	Jul	CAHN
			9MG/ML	A201850	001	Jan 20, 2012	Jul	CAHN
	+	@ MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Aug	DISC
	+	@	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Aug	DISC
	+	@	22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Aug	DISC
	+	@	27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Aug	DISC
	+	@	45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Aug	DISC

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Jun	DISC
		FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021	Apr	NFTG

SOLUTION; INTRAVENOUS
SODIUM CHLORIDE 14.6%

AP		FRESENIUS KABI USA	50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021	Apr	NFTG
AP			100MEQ/40ML (2.5MEQ/ML)	A212070	002	Apr 28, 2021	Apr	NFTG
AP	+	HOSPIRA	100MEQ/40ML (2.5MEQ/ML)	N018897	002	Jul 20, 1984	Apr	CFTG

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985	Jul	CHRS
+			900MG/100ML	N019319	002	May 17, 1985	Jul	CRLD

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP		@ DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Aug	DISC
		NUKEMED	10-200mCi/ML	A203912	001	Apr 22, 2015	Jan	CAHN

SODIUM NITROPRUSSIDEINJECTABLE; INJECTION
SODIUM NITROPRUSSIDE

AP		BE PHARMS	25MG/ML	A214971	001	Jul 12, 2021	Jul	NEWA
	@	CIPLA	25MG/ML	A210855	001	Jul 16, 2018	Aug	DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB		NOVEL LABS INC	0.398GM;1.102GM	A079247	001	Dec 30, 2011	Jan	CMFD
		OSMOPREP						

AB	+	SALIX PHARMS	0.398GM;1.102GM	N021892	001	Mar 16, 2006	Jan	CTEC
----	---	--------------	-----------------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KIONEX

AA		ANI PHARMS	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN
AA		L PERRIGO CO	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN

SODIUM POLYSTYRENE SULFONATE

>A>	AA	BIOPHARM	453.6GM/BOT	A090313	001	Dec 21, 2011	Sep	CAHN
>A>	AA	CHARTWELL RX	454GM/BOT	A206815	001	Feb 18, 2016	Sep	CAHN
>D>	AA	DISCOVERY THERAP	453.6GM/BOT	A090313	001	Dec 21, 2011	Sep	CAHN
>D>	AA	NOVELGENIX THERAPS	454GM/BOT	A206815	001	Feb 18, 2016	Sep	CAHN
	+	@ WOCKHARDT	453.6GM/BOT	A088786	001	Sep 11, 1984	Aug	CRLD

SUSPENSION; ORAL, RECTAL

KIONEX

	@	ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN
	@	L PERRIGO CO	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN

SUSPENSION;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

	@ ANI PHARMS	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN
	@ L FERRIGO CO	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN
	SPS						
+!	CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Aug	CRLD

SOFOSBUVIR; VELPATASVIR

PELLETS;ORAL
EPCLUSA

+	GILEAD SCIENCES INC	150MG;37.5MG/PACKET	N214187	001	Jun 10, 2021	Jun	NEWA
+!		200MG;50MG/PACKET	N214187	002	Jun 10, 2021	Jun	NEWA

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

	@ AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	Jun	DISC
	@	10MG	A205483	002	May 20, 2019	Jun	DISC
>A> AB	AUSTARPHARMA	5MG	A210281	001	May 20, 2019	Sep	CAHN
>A> AB	@	10MG	A210281	002	May 20, 2019	Sep	CAHN
	@ BRECKENRIDGE	5MG	A209818	001	May 20, 2019	Aug	DISC
	@	10MG	A209818	002	May 20, 2019	Aug	DISC
>D> AB	JIANGXI BOYA SEEHOT	5MG	A210281	001	May 20, 2019	Sep	CAHN
>D> AB	@	10MG	A210281	002	May 20, 2019	Sep	CAHN
	@ ZYDUS PHARMS	5MG	A207721	001	Oct 19, 2020	Mar	DISC
	@	10MG	A207721	002	Oct 19, 2020	Mar	DISC

SORAFENIB TOSYLATE

TABLET;ORAL
NEXAVAR

+!	BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	May	CTEC
	SORAFENIB TOSYLATE						
	@ TEVA PHARMS USA INC	EQ 200MG BASE	A209567	001	Nov 12, 2020	May	DISC

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

	@ MYLAN	80MG	A077616	001	Feb 07, 2007	Feb	DISC
	@	120MG	A077616	002	Feb 07, 2007	Feb	DISC
	@	160MG	A077616	003	Feb 07, 2007	Feb	DISC

SOTORASIB

TABLET;ORAL
LUMAKRAS

+!	AMGEN INC	120MG	N214665	001	May 28, 2021	May	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

	@ OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Aug	DISC
	@	50MG	A040750	002	Aug 29, 2006	Aug	DISC
	@	100MG	A040750	003	Aug 29, 2006	Aug	DISC

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP	HIKMA PHARMS	100% (10ML)	A206369	001	Sep 02, 2015	Jul	CAHN
	@	100% (20ML)	A206369	002	Sep 02, 2015	Jul	CAHN
	! NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Jan	NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

SUCCINYLCHOLINE CHLORIDE

AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	Mar	CMFD
AP	HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Apr	CMFD
	@	20MG/ML	A213229	001	Jun 12, 2020	Feb	DISC
AP	SAGENT PHARMS INC	20MG/ML	A215022	001	Mar 29, 2021	Mar	NEWA
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
	SUCCINYLCHOLINE CHLORIDE						
+!	HIKMA PHARMS	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Aug	NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC
BLEPH-10

AT	+!	ALLERGAN	10%	A 080028	001			Aug	CRLD
----	----	----------	-----	----------	-----	--	--	-----	------

SULFAMETHOXAZOLE

TABLET;ORAL
SULFAMETHOXAZOLE

	@	RISING	500MG	A 085844	001			Jan	CAHN
--	---	--------	-------	----------	-----	--	--	-----	------

SULFASALAZINE

TABLET;ORAL
AZULFIDINE

AB	+!	PFIZER	500MG	N 007073	001			Mar	CAHN
----	----	--------	-------	----------	-----	--	--	-----	------

SULFASALAZINE

AB		CHARTWELL	500MG	A 080197	001			Jun	CMFD
----	--	-----------	-------	----------	-----	--	--	-----	------

TABLET, DELAYED RELEASE;ORAL
AZULFIDINE EN-TABS

AB	+!	PFIZER	500MG	N 007073	002	Apr 06, 1983		Mar	CAHN
----	----	--------	-------	----------	-----	--------------	--	-----	------

SULFISOXAZOLE

TABLET;ORAL
SULFISOXAZOLE

	@	RISING	500MG	A 085628	001			Jan	CAHN
--	---	--------	-------	----------	-----	--	--	-----	------

SULINDAC

TABLET;ORAL
SULINDAC

	@	MYLAN	150MG	A 073039	002	Jun 22, 1993		Aug	CAHN
	@		150MG	A 073039	002	Jun 22, 1993		Aug	DISC
	@		200MG	A 073039	001	Jun 22, 1993		Aug	CAHN
	@		200MG	A 073039	001	Jun 22, 1993		Aug	DISC

SUMATRIPTAN

SPRAY;NASAL
SUMATRIPTAN

AB		CIPLA	20MG/SPRAY	A 214209	001	Feb 22, 2021		Feb	NEWA
AB		FLORIDA	20MG/SPRAY	A 208967	001	Feb 17, 2021		Mar	CAHN
AB		PHARMASERVE NW	20MG/SPRAY	A 208967	001	Feb 17, 2021		Feb	NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

AP		CAPLIN	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 213998	001	Jul 13, 2021		Jul	NEWA
	@	MYLAN ASI	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 090314	001	Jun 10, 2010		May	DISC
	@		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A 090641	001	Jul 28, 2010		Jan	DISC

SUNITINIB MALATE

CAPSULE;ORAL
SUNITINIB MALATE

AB		SUN PHARM	EQ 12.5MG BASE	A 213914	001	Aug 16, 2021		Aug	NFTG
AB			EQ 25MG BASE	A 213914	002	Aug 16, 2021		Aug	NFTG
AB			EQ 37.5MG BASE	A 213914	003	Aug 16, 2021		Aug	NFTG
AB			EQ 50MG BASE	A 213914	004	Aug 16, 2021		Aug	NFTG
		SUTENT							
AB	+	CPPI CV	EQ 12.5MG BASE	N 021938	001	Jan 26, 2006		Aug	CTEC
AB	+		EQ 25MG BASE	N 021938	002	Jan 26, 2006		Aug	CTEC
AB	+		EQ 37.5MG BASE	N 021938	004	Mar 31, 2009		Aug	CTEC
AB	+!		EQ 50MG BASE	N 021938	003	Jan 26, 2006		Aug	CTEC

TACROLIMUS

CAPSULE;ORAL
TACROLIMUS

	@	CONCORD BIOTECH LTD	EQ 0.5MG BASE	A 213112	001	Nov 10, 2020		Apr	DISC
AB		PANACEA	EQ 0.5MG BASE	A 090802	001	Sep 28, 2012		Jul	CAHN
AB			EQ 1MG BASE	A 090802	002	Sep 28, 2012		Jul	CAHN
AB			EQ 5MG BASE	A 090802	003	Sep 28, 2012		Jul	CAHN

TADALAFIL

TABLET; ORAL

CIALIS

AB1	+	LILLY	2.5MG	N021368	004	Jan 07, 2008	Feb CTEC
AB1	+		5MG	N021368	001	Nov 21, 2003	Feb CTEC
AB1	+		10MG	N021368	002	Nov 21, 2003	Feb CTEC

TADALAFIL

AB1		ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209167	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209167	003	Oct 23, 2019	Feb CTEC
AB1		AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209654	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209654	003	Mar 26, 2019	Feb CTEC
AB1		ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A204809	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A204809	003	Mar 26, 2019	Feb CTEC
AB1		AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209744	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209744	003	Mar 26, 2019	Feb CTEC
AB1		AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A206285	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A206285	003	Mar 26, 2019	Feb CTEC
AB1		CIPLA	2.5MG	A209539	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209539	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209539	003	Mar 26, 2019	Feb CTEC
AB1		DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A210069	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A210069	003	Mar 26, 2019	Feb CTEC
	@	GLENMARK PHARMS LTD	2.5MG	A210716	001	Dec 29, 2020	Feb DISC
	@		5MG	A210716	002	Dec 29, 2020	Feb DISC
	@		10MG	A210716	003	Dec 29, 2020	Feb DISC
	@		20MG	A210716	004	Dec 29, 2020	Feb DISC
AB1		HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A209908	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A209908	003	Mar 26, 2019	Feb CTEC
AB1		LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A210567	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A210567	003	Mar 26, 2019	Feb CTEC
AB1		MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Feb CTEC
AB1			5MG	A207244	002	Oct 07, 2019	Feb CTEC
AB1			10MG	A207244	003	Oct 07, 2019	Feb CTEC
	@	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Aug CAHN
	@		2.5MG	A206956	001	Apr 29, 2019	Aug DISC
AB1			2.5MG	A206956	001	Apr 29, 2019	Feb CTEC
	@		5MG	A206957	001	Apr 29, 2019	Aug CAHN
	@		5MG	A206957	001	Apr 29, 2019	Aug DISC
AB1			5MG	A206957	001	Apr 29, 2019	Feb CTEC
	@		10MG	A206956	002	Apr 29, 2019	Aug CAHN
	@		10MG	A206956	002	Apr 29, 2019	Aug DISC
AB1			10MG	A206956	002	Apr 29, 2019	Feb CTEC
	@		20MG	A206956	003	Apr 29, 2019	Aug CAHN
	@		20MG	A206956	003	Apr 29, 2019	Aug DISC
AB1		QILU	2.5MG	A210420	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A210420	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A210420	003	Mar 26, 2019	Feb CTEC
AB1		SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A208934	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A208934	003	Mar 26, 2019	Feb CTEC
AB1		SUNSHINE	2.5MG	A211335	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A211335	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A211335	003	Mar 26, 2019	Feb CTEC
AB1		TEVA PHARMS USA	2.5MG	A090141	001	May 22, 2018	Feb CTEC
AB1			5MG	A090141	002	May 22, 2018	Feb CTEC
AB1			10MG	A090141	003	May 22, 2018	Feb CTEC
AB1		TORRENT	2.5MG	A211839	001	Mar 26, 2019	Feb CTEC
AB1			5MG	A211839	002	Mar 26, 2019	Feb CTEC
AB1			10MG	A211839	003	Mar 26, 2019	Feb CTEC
AB1		UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
AB1			5MG	A211298	002	Oct 23, 2020	Feb CTEC
AB1			10MG	A211298	003	Oct 23, 2020	Feb CTEC
>D>	AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Sep CTEC
>A>	BX		2.5MG	A209250	001	Mar 26, 2019	Sep CTEC
	AB1		2.5MG	A209250	001	Mar 26, 2019	Feb CTEC

TABLET;ORAL
TADALAFIL

>D>	AB1		5MG	A209250	002	Mar 26, 2019	Sep	CTEC
>A>	BX		5MG	A209250	002	Mar 26, 2019	Sep	CTEC
	AB1		5MG	A209250	002	Mar 26, 2019	Feb	CTEC
>D>	AB1		10MG	A209250	003	Mar 26, 2019	Sep	CTEC
>A>	BX		10MG	A209250	003	Mar 26, 2019	Sep	CTEC
	AB1		10MG	A209250	003	Mar 26, 2019	Feb	CTEC
>D>	AB1		20MG	A209250	004	Mar 26, 2019	Sep	CTEC
>A>	BX		20MG	A209250	004	Mar 26, 2019	Sep	CTEC
	AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb	CTEC
	AB1		5MG	A208824	002	Oct 27, 2020	Feb	CTEC
	AB1		10MG	A208824	003	Oct 27, 2020	Feb	CTEC
	AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb	CTEC
	AB1		5MG	A206693	002	Mar 26, 2019	Feb	CTEC
	AB1		10MG	A206693	003	Mar 26, 2019	Feb	CTEC

TALC

AEROSOL; INTRAPLEURAL
SCLEROSOL

>D>	+	LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997	Sep	CAHN
>A>	+	SCIARRA LABS	4GM/SPRAY	N020587	001	Dec 24, 1997	Sep	CAHN
			POWDER; INTRAPLEURAL TALC					
>D>	+	LYMOL MEDCL	5GM/BOT	N021388	001	Dec 15, 2003	Sep	CAHN
>A>	+	SCIARRA LABS	5GM/BOT	N021388	001	Dec 15, 2003	Sep	CAHN

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

			TAMSULOSIN HYDROCHLORIDE					
AB		ANBISON LAB	0.4MG	A211885	001	Oct 17, 2019	Aug	CMFD
	@	ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013	Jun	DISC

TAVABOROLE

SOLUTION;TOPICAL

TAVABOROLE

AB		CIPLA	5%	A212224	001	Feb 09, 2021	Jan	NEWA
AB		FLATWING	5%	A211963	001	Feb 03, 2021	Feb	CPOT
AB			5.0%	A211963	001	Feb 03, 2021	Jan	NEWA
>D>	AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Sep	DISC
>A>	@		5%	A211963	001	Feb 03, 2021	Sep	DISC
	AB		5%	A211963	001	Feb 03, 2021	Feb	CAHN
	AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan	NEWA
	AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

			CIS-MDP					
AP		SUN PHARM INDS INC	N/A	N018124	001		Jul	CTEC
			TECHNETIUM TC-99M MEDRONATE KIT					
AP		CARDINAL HEALTH 414	N/A	N018107	001		Jul	CTNA
AP			N/A	N018107	001		Jul	CMFD

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE; INJECTION

MPI DMSA KIDNEY REAGENT

>D>	@	GE HEALTHCARE	N/A	N017944	001	May 18, 1982	Sep	CRLD
>A>	+ @		N/A	N017944	001	May 18, 1982	Sep	CRLD

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB		CELLTRION	20MG	A078710	001	Jan 08, 2014	Feb	CMFD
AB			40MG	A078710	002	Jan 08, 2014	Feb	CMFD
AB			80MG	A078710	003	Jan 08, 2014	Feb	CMFD
AB		MYLAN	20MG	A202397	001	Jul 07, 2014	Aug	CAHN
AB			40MG	A202397	002	Jul 07, 2014	Aug	CAHN
AB			80MG	A202397	003	Jul 07, 2014	Aug	CAHN

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

>D>	AB	MYLAN	7.5MG	A 070920	002	May 21, 2010	Sep CAHN
>A>		@	7.5MG	A 070920	002	May 21, 2010	Sep CAHN
>D>	AB		15MG	A 070920	004	Jul 07, 1986	Sep CAHN
>A>		@	15MG	A 070920	004	Jul 07, 1986	Sep CAHN
>D>	AB		22.5MG	A 070920	003	Jun 12, 2009	Sep CAHN
>A>		@	22.5MG	A 070920	003	Jun 12, 2009	Sep CAHN
>D>	AB		30MG	A 070920	001	Jul 10, 1986	Sep CAHN
>A>		@	30MG	A 070920	001	Jul 10, 1986	Sep CAHN

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

@	HERITAGE	5MG	A 078879	001	Mar 01, 2010	Feb CAHN
@		20MG	A 078879	002	Mar 01, 2010	Feb CAHN
@		100MG	A 078879	003	Mar 01, 2010	Feb CAHN
@		140MG	A 078879	005	Mar 01, 2010	Feb CAHN
@		180MG	A 078879	006	Mar 01, 2010	Feb CAHN
@		250MG	A 078879	004	Mar 01, 2010	Feb CAHN
@	WATSON LABS TEVA	5MG	A 203959	001	Apr 18, 2017	Jan DISC
@		20MG	A 203959	002	Apr 18, 2017	Jan DISC
@		100MG	A 203959	003	Apr 18, 2017	Jan DISC
@		140MG	A 203959	004	Apr 18, 2017	Jan DISC
@		250MG	A 203959	005	Apr 18, 2017	Jan DISC

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL

TEPMETKO

+	!	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021	Feb NEWA
---	---	----------------	---------------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB		HERITAGE PHARMA	EQ 1MG BASE	A 075614	002	Jan 30, 2001	May CMFD
AB			EQ 2MG BASE	A 075614	001	Jan 30, 2001	May CMFD
AB			EQ 5MG BASE	A 075614	003	Jan 30, 2001	May CMFD
AB			EQ 10MG BASE	A 075614	004	Jan 30, 2001	May CMFD
		@ MYLAN	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Aug CAHN
		@	EQ 1MG BASE	A 075140	002	Feb 11, 2000	Aug DISC
		@	EQ 2MG BASE	A 075140	003	Feb 11, 2000	Aug CAHN
		@	EQ 2MG BASE	A 075140	003	Feb 11, 2000	Aug DISC
		@	EQ 5MG BASE	A 075140	001	Feb 11, 2000	Aug CAHN
		@	EQ 5MG BASE	A 075140	001	Feb 11, 2000	Aug DISC
		@	EQ 10MG BASE	A 075140	004	Feb 11, 2000	Aug CAHN
		@	EQ 10MG BASE	A 075140	004	Feb 11, 2000	Aug DISC

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

LAMISIL

>D>	AB	+	!	NOVARTIS	EQ 250MG BASE	N 020539	001	May 10, 1996	Sep DISC
>A>		+	@		EQ 250MG BASE	N 020539	001	May 10, 1996	Sep DISC
				TERBINAFINE HYDROCHLORIDE					
>D>	AB			AUROBINDO PHARMA	EQ 250MG BASE	A 078297	001	Jul 02, 2007	Sep CHRS
>A>	AB		!		EQ 250MG BASE	A 078297	001	Jul 02, 2007	Sep CHRS

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

>A>	AB			BRECKENRIDGE	7MG	A 209583	001	Sep 24, 2021	Sep NEWA
>A>	AB				14MG	A 209583	002	Sep 24, 2021	Sep NEWA
			@	IMPAX	14MG	A 209677	001	Jun 17, 2020	Feb DISC

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

AB2		ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A 204570	002	Jul 17, 2020	Feb NEWA
AB2			1.62% (40.5MG/2.5GM PACKET)	A 204570	003	Jul 17, 2020	Feb NEWA

	GEL, METERED;TRANSDERMAL								
	TESTOSTERONE								
>D>	AB	ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Sep	DISC	
>A>		@	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Sep	DISC	
	AB		1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Feb	NEWA	
	SOLUTION, METERED;TRANSDERMAL								
	TESTOSTERONE								
	AT	ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A212882	001	Jun 14, 2021	Jun	NEWA	
		@ APOTEX	30MG/1.5ML ACTUATION	A209181	001	Nov 25, 2020	May	DISC	
	AT	DASH PHARMS	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	May	CAHN	
	AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan	NEWA	
	AT	TWI PHARMS	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021	Aug	NEWA	
	<u>TESTOSTERONE CYPIONATE</u>								
	INJECTABLE;INJECTION								
	DEPO-TESTOSTERONE								
		@ PFIZER	50MG/ML	A085635	001		Mar	CAHN	
AO	+	!	100MG/ML	A085635	002		Aug	CRLD	
AO	!		100MG/ML	A085635	002		Mar	CAHN	
AO	+	!	200MG/ML	A085635	003		Aug	CRLD	
AO	!		200MG/ML	A085635	003		Mar	CAHN	
	TESTOSTERONE CYPIONATE								
AO		HIKMA PHARMS	100MG/ML	A090387	001	Jul 15, 2010	Jul	CAHN	
AO			200MG/ML	A090387	002	Jul 15, 2010	Jul	CAHN	
	<u>TETRABENAZINE</u>								
	TABLET;ORAL								
	TETRABENAZINE								
		@ AJANTA PHARMA LTD	12.5MG	A213621	001	Dec 04, 2020	May	DISC	
		@	25MG	A213621	002	Dec 04, 2020	May	DISC	
	<u>TETRACAINE HYDROCHLORIDE</u>								
	SOLUTION;OPHTHALMIC								
	TETRACAINE HYDROCHLORIDE								
	+	!	BAUSCH LOMB IRELAND	0.5%	N210821	001	Mar 12, 2019	May	CAHN
	<u>THALLOUS CHLORIDE TL-201</u>								
	INJECTABLE;INJECTION								
	THALLOUS CHLORIDE TL 201								
	+	@	GE HEALTHCARE	1mCi/ML	N018110	002	Feb 27, 1996	Jun	DISC
	<u>THEOPHYLLINE</u>								
	CAPSULE, EXTENDED RELEASE;ORAL								
	SLO-PHYLLIN								
	+	@	SANOFI AVENTIS US	125MG	A085203	001	May 24, 1982	Aug	CRLD
			SOMOPHYLLIN-CRT						
	+	@	GRAHAM DM	250MG	A087193	001		Aug	CRLD
			THEO-24						
	+		AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Aug	CRLD
	ELIXIR;ORAL								
	THEOPHYLLINE								
	+	@	PRECISION DOSE	80MG/15ML	A085863	001		Aug	CRLD
	SOLUTION;ORAL								
	THEOPHYLLINE								
	+	@	ROXANE	80MG/15ML	A087449	001	Sep 15, 1983	Aug	CRLD
	SOLUTION, ELIXIR;ORAL								
	ELIXOPHYLLIN								
AA	+	!	NOSTRUM LABS INC	80MG/15ML	A085186	001		Aug	CRLD
	SYRUP;ORAL								
	THEOPHYLLINE								
	+	@	ALPHARMA US PHARMS	150MG/15ML	A086545	001		Aug	CRLD
	TABLET, EXTENDED RELEASE;ORAL								
	THEO-DUR								
	+	@	SCHERING	200MG	A086998	001		Aug	CRLD
>D>		@		300MG	A085328	002		Sep	CRLD
>A>		+	@	300MG	A085328	002		Sep	CRLD
	THEOPHYLLINE								
AB			ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May	CTEC
AB	!			450MG	A090430	002	Oct 27, 2010	May	CTEC
AB			GLENMARK PHARMS LTD	300MG	A212184	001	Jun 03, 2021	May	NEWA
AB				450MG	A212184	002	Jun 03, 2021	May	NEWA

<u>TABLET, EXTENDED RELEASE;ORAL</u>							
<u>THEOPHYLLINE</u>							
	@	HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990	Jul DISC
	@		200MG	A089808	001	Apr 30, 1990	Jul DISC
AB	+	RHODES PHARMS	400MG	A040086	002	Sep 01, 1982	Aug CRLD
<u>THIAMINE HYDROCHLORIDE</u>							
<u>INJECTABLE; INJECTION</u>							
<u>BETALIN S</u>							
	+	@ LILLY	100MG/ML	A080853	001		Aug CRLD
<u>THIAMINE HYDROCHLORIDE</u>							
AP	+	! FRESENIUS KABI USA	100MG/ML	A080556	001		Aug CRLD
AP		WEST-WARD PHARMS INT	100MG/ML	A080575	001		Apr CMFD
<u>THIORIDAZINE HYDROCHLORIDE</u>							
<u>TABLET;ORAL</u>							
<u>THIORIDAZINE HYDROCHLORIDE</u>							
		MYLAN	10MG	A088004	002	Mar 15, 1983	Jan CTEC
			25MG	A088004	003	Mar 15, 1983	Jan CTEC
			50MG	A088004	004	Mar 15, 1983	Jan CTEC
	!		100MG	A088004	001	Nov 18, 1983	Jan CTEC
	@	SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Jan DISC
	@		25MG	A089953	003	Aug 01, 1986	Jan DISC
	@		50MG	A089953	002	Aug 01, 1986	Jan DISC
	@		100MG	A089953	001	Oct 07, 1988	Jan DISC
<u>THIOTEPA</u>							
<u>POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL</u>							
<u>THIOTEPA</u>							
AP		GLAND PHARMA LTD	15MG/VIAL	A214222	001	Mar 08, 2021	Feb NEWA
<u>TIAGABINE HYDROCHLORIDE</u>							
<u>TABLET;ORAL</u>							
<u>TIAGABINE HYDROCHLORIDE</u>							
	@	WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Jan DISC
	@		4MG	A206857	002	Oct 13, 2017	Jan DISC
	@		12MG	A206857	003	Oct 13, 2017	Jan DISC
	@		16MG	A206857	004	Oct 13, 2017	Jan DISC
<u>TICAGRELOR</u>							
<u>TABLET;ORAL</u>							
<u>BRILINTA</u>							
AB	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Jul CFTG
<u>TICAGRELOR</u>							
AB		MYLAN	60MG	A208597	001	Jul 09, 2021	Jul NFTG
AB			90MG	A208597	002	Jul 09, 2021	Jul NEWA
<u>TICLOPIDINE HYDROCHLORIDE</u>							
<u>TABLET;ORAL</u>							
<u>TICLOPIDINE HYDROCHLORIDE</u>							
	@	CHARTWELL RX	250MG	A075318	001	Aug 20, 1999	Aug CAHN
	@		250MG	A075326	001	Aug 20, 1999	Aug CAHN
<u>TIGECYCLINE</u>							
<u>POWDER;INTRAVENOUS</u>							
<u>TIGECYCLINE</u>							
AP		HONG KONG	50MG/VIAL	A214020	001	May 13, 2021	May NEWA
AP		MEITHEAL	50MG/VIAL	A214020	001	May 13, 2021	Aug CAHN
<u>TIMOLOL MALEATE</u>							
<u>SOLUTION, GEL FORMING/DROPS;OPHTHALMIC</u>							
<u>TIMOLOL MALEATE</u>							
AB	!	ALEMBIC PHARMS LTD	EQ 0.25% BASE	A212942	001	Oct 22, 2020	Apr CHRS
AB	!		EQ 0.5% BASE	A212942	002	Oct 22, 2020	Apr CHRS
<u>TIMOPTIC-XE</u>							
AB	+	VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr CHRS
AB	+		EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr CHRS
<u>SOLUTION/DROPS;OPHTHALMIC</u>							
<u>TIMOLOL MALEATE</u>							
AT		MANKIND PHARMA	EQ 0.25% BASE	A078771	001	Sep 28, 2009	Apr CAHN
AT1			EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CAHN

TIOPRONINTABLET;ORAL
THIOLA

AB	+!	MISSION PHARMA	100MG	N019569	001	Aug 11, 1988	Apr	CFTG
AB		TEVA PHARMS USA INC	100MG	A214326	001	Apr 26, 2021	Apr	NFTG

TIOTROPIUM BROMIDESPRAY, METERED; INHALATION
SPIRIVA RESPIMAT

	+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Mar	CHRS
--	----	----------------------	-----------------------	---------	-----	--------------	-----	------

TIROFIBAN HYDROCHLORIDESOLUTION; INTRAVENOUS
AGGRASTAT

	+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr	CDFR
AP	+!		EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	N020913	003	Apr 20, 2000	Apr	CFTG
	@		EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr	CDFR
AP		GLAND PHARMA LTD	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A206888	001	Apr 08, 2021	Apr	NFTG

TIVOZANIB HYDROCHLORIDECAPSULE;ORAL
FOTIVDA

	+	AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021	Mar	NEWA
	+!		EQ 1.34MG BASE	N212904	002	Mar 10, 2021	Mar	NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

	@	PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	Jun	DISC
	@		EQ 4MG BASE	A207199	002	Mar 14, 2017	Jun	DISC
	@		EQ 6MG BASE	A207199	003	Mar 14, 2017	Jun	DISC

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB		CADILA	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	CAHN
AB			EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	CAHN
	@	MYLAN	EQ 2MG BASE	A076354	001	Mar 28, 2003	Jan	DISC
	@		EQ 4MG BASE	A076354	002	Mar 28, 2003	Feb	DISC

TOBRAMYCINSOLUTION; INHALATION
TOBRAMYCIN

AN		ALKEM LABS LTD	300MG/5ML	A212848	001	Apr 01, 2021	Mar	NEWA
	@	AUROBINDO PHARMA LTD	300MG/5ML	A210871	001	Jan 22, 2021	Jul	DISC
AN			300MG/5ML	A210871	001	Jan 22, 2021	Jan	NEWA
	@	LUOXIN AUROVITAS	300MG/5ML	A210871	001	Jan 22, 2021	Aug	CAHN

SOLUTION/DROPS;OPHTHALMIC
TOBRAMYCIN

AT		GLAND PHARMA LTD	0.3%	A212628	001	Mar 09, 2021	Feb	NEWA
----	--	------------------	------	---------	-----	--------------	-----	------

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP		GLAND PHARMA LTD	EQ 10MG BASE/ML	A209621	001	Feb 11, 2021	Feb	NEWA
AP			EQ 40MG BASE/ML	A209621	002	Feb 11, 2021	Feb	NEWA
AP			EQ 1.2GM BASE/VIAL	A211189	001	May 18, 2021	May	NEWA
			TOBRAMYCIN SULFATE (PHARMACY BULK)					
AP	!	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jan	CTEC
AP		GLAND PHARMA LTD	EQ 40MG BASE/ML	A209346	001	Feb 09, 2021	Jan	NEWA

TOFACITINIB CITRATESOLUTION;ORAL
XELJANZ

	+!	PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Feb	CMS1
--	----	--------	----------------	---------	-----	--------------	-----	------

TABLET;ORAL

AB	TOFACITINIB CITRATE							
	AJANTA PHARMA LTD	EQ 10MG BASE	A212943	001	Jun 01, 2021	May	NFTG	
	XELJANZ							
AB	+! PF PRISM CV	EQ 10MG BASE	N203214	002	May 30, 2018	May	CFTG	
	TABLET, EXTENDED RELEASE;ORAL							
	TOFACITINIB							
AB	ZYDUS PHARMS	EQ 11MG BASE	A214264	001	Aug 19, 2021	Aug	NFTG	
AB		EQ 22MG BASE	A214264	002	Aug 19, 2021	Aug	NFTG	
	XELJANZ XR							
AB	+ PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	Aug	CFTG	
AB	+!	EQ 22MG BASE	N208246	002	Dec 12, 2019	Aug	CFTG	

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

	@ CHARTWELL RX	100MG	A071633	001	Dec 09, 1987	Aug	CAHN	
	@	250MG	A070289	001	Mar 13, 1986	Aug	CAHN	
	@	500MG	A070290	001	Mar 13, 1986	Aug	CAHN	

TOLBUTAMIDE

TABLET;ORAL

TOLBUTAMIDE

	@ CHARTWELL RX	500MG	A086574	001		Aug	CAHN	
--	----------------	-------	---------	-----	--	-----	------	--

TOLCAPONE

TABLET;ORAL

TOLCAPONE

	@ ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jan	DISC	
>D> AB	MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019	Sep	DISC	
>A>	@	100MG	A210095	001	Aug 01, 2019	Sep	DISC	

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

	@ MYLAN	EQ 400MG BASE	A073393	001	May 27, 1993	Aug	DISC	
	@ TEVA	EQ 400MG BASE	A073290	001	Nov 27, 1991	Aug	DISC	

TABLET;ORAL

TOLMETIN SODIUM

	@ MYLAN	EQ 600MG BASE	A074473	001	Aug 30, 1994	Aug	DISC	
--	---------	---------------	---------	-----	--------------	-----	------	--

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

TOLTERODINE TARTRATE

AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan	CMFD	
AB		4MG	A213397	002	May 19, 2020	Jan	CMFD	
AB	AMTA	2MG	A213858	001	Feb 02, 2021	Jan	NEWA	
AB		4MG	A213858	002	Feb 02, 2021	Jan	NEWA	
	@ MYLAN	2MG	A201486	001	Oct 31, 2013	Jul	DISC	
	@	4MG	A201486	002	Oct 31, 2013	Jul	DISC	

TABLET;ORAL

TOLTERODINE TARTRATE

AB	HETERO LABS LTD V	1MG	A204397	001	Aug 02, 2021	Jul	NEWA	
AB		2MG	A204397	002	Aug 02, 2021	Jul	NEWA	

TOLVAPTAN

TABLET;ORAL

SAMSCA

	+ OTSUKA	15MG	N022275	001	May 19, 2009	Feb	CAHN	
AB	+!	30MG	N022275	002	May 19, 2009	Feb	CAHN	
	+ @	60MG	N022275	003	May 19, 2009	Feb	CAHN	

TOLVAPTAN

	ALKEM LABS LTD	60MG	A211891	002	May 19, 2020	Jul	CTEC	
AB	APOTEX	30MG	A207605	001	May 19, 2020	Aug	CMFD	
AB	HETERO LABS LTD V	30MG	A205646	001	Jul 16, 2021	Jul	NEWA	

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR

AB2	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Jan CFTG
AB2	+		50MG	N205122	002	Mar 11, 2014	Jan CFTG
AB2	+		100MG	N205122	003	Mar 11, 2014	Jan CFTG
AB2	+		150MG	N205122	004	Mar 11, 2014	Jan CFTG
AB2	+		200MG	N205122	005	Mar 11, 2014	Jan CFTG

TOPIRAMATE

AB2		GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2			50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2			100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2			150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2			200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1		ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1			50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1			100MG	A207382	003	Nov 24, 2017	Jan CTEC

TROKENDI XR

AB1	+	SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+		50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+		100MG	N201635	003	Aug 16, 2013	Jan CTEC

TABLET;ORAL

TOPIRAMATE

AB		ASCENT PHARMS INC	25MG	A215414	001	Aug 26, 2021	Aug NEWA
AB			50MG	A215414	002	Aug 26, 2021	Aug NEWA
AB			100MG	A215414	003	Aug 26, 2021	Aug NEWA
AB			200MG	A215414	004	Aug 26, 2021	Aug NEWA

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE
@ MEITHEAL EQ 4MG BASE/VIAL

A201166	001	Aug 08, 2012	Aug DISC
---------	-----	--------------	----------

TORSEMIDE

TABLET;ORAL
SOANZ

+	!	SARFE PHARMS	20MG	N213218	001	Jun 14, 2021	Jul CHRS
+			20MG	N213218	001	Jun 14, 2021	Jun NEWA
+			60MG	N213218	002	Jun 14, 2021	Jul CHRS
+	!		60MG	N213218	002	Jun 14, 2021	Jun NEWA

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE
@ GRAVITI PHARMS 50MG

>A>	AB	MERRO PHARM USA	50MG	A206706	001	Jul 02, 2019	Sep CAHN
>D>	AB	POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Sep CAHN
	AB		50MG	A206706	001	Jul 02, 2019	Feb CMFD
		@ RISING	50MG	A075968	001	Jun 25, 2002	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE
@ ANCHEN PHARMS 100MG
@ 200MG
@ 300MG

A200491	001	Jun 27, 2012	Apr DISC
A200491	002	Jun 27, 2012	Apr DISC
A200491	003	Jun 27, 2012	Apr DISC

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
TARKA

+	@	ABBVIE	2MG;180MG	N020591	001	Oct 22, 1996	Aug DISC
+	@		2MG;240MG	N020591	004	Oct 22, 1996	Aug DISC
+	@		4MG;240MG	N020591	002	Oct 22, 1996	Aug DISC

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

		GLENMARK GENERICS	2MG;180MG	A079135	001	May 26, 2010	Aug CTEC
			2MG;240MG	A079135	002	May 26, 2010	Aug CTEC
	!		4MG;240MG	A079135	003	May 05, 2010	Aug CTEC
AB	!		4MG;240MG	A079135	003	May 05, 2010	Aug CHRS

TRANEXAMIC ACID

		INJECTABLE; INJECTION		CYKLOKAPRON	
AP	+!	PFIZER	100MG/ML	N019281 001	Dec 30, 1986 Mar CAHN
		TRANEXAMIC ACID			
AP		CAPLIN	100MG/ML	A212360 001	Jul 17, 2019 Jun CMFD
AP		PROVEPHARM SAS	100MG/ML	A212676 001	Jul 17, 2019 Jan CAHN
		@ ZYDUS PHARMS	100MG/ML	A205228 001	Jul 17, 2017 Apr DISC
		TABLET; ORAL		TRANEXAMIC ACID	
AB		ANI PHARMS	650MG	A203256 001	Jul 25, 2016 Jun CMFD
		@ APOTEX INC	650MG	A202286 001	Jan 27, 2014 Mar DISC

TRANLYCYPROMINE SULFATE

		TABLET; ORAL		TRANLYCYPROMINE SULFATE	
AB		NOVITIUM PHARMA	EQ 10MG BASE	A206856 001	Apr 17, 2018 Apr CAHN

TRAVOPROST

		SOLUTION/DROPS; OPHTHALMIC		TRAVOPROST	
AT		MICRO LABS	0.004%	A203767 001	Mar 19, 2021 Mar NEWA

TRAZODONE HYDROCHLORIDE

		TABLET; ORAL		TRAZODONE HYDROCHLORIDE	
		@ ALVOGEN	50MG	A071636 001	Apr 18, 1988 Jun DISC
		@	100MG	A071514 001	Apr 18, 1988 Jun DISC
AB		AUROLIFE PHARMA LLC	50MG	A204852 001	Feb 05, 2020 Feb CMFD
AB			100MG	A204852 002	Feb 05, 2020 Feb CMFD
AB			150MG	A204852 003	Feb 05, 2020 Feb CMFD
AB			300MG	A204852 004	Feb 05, 2020 Feb CMFD
		@ RISING	50MG	A072484 001	Apr 30, 1990 Jan CAHN

TREPROSTINIL

		INJECTABLE; IV (INFUSION), SUBCUTANEOUS		REMODULIN	
	+!	UNITED THERAP	20MG/ML	N021272 005	Jul 30, 2021 Aug NEWA
		TREPROSTINIL			
AP		ALEMBIC GLOBAL	1MG/ML	A211574 001	Feb 11, 2021 Feb NEWA
AP			2.5MG/ML	A211574 002	Feb 11, 2021 Feb NEWA
AP			5MG/ML	A211574 003	Feb 11, 2021 Feb NEWA
AP			10MG/ML	A211574 004	Feb 11, 2021 Feb NEWA
		SOLUTION; INTRAVENOUS, SUBCUTANEOUS		REMODULIN	
		@ UNITED THERAP	20MG/20ML (1MG/ML)	N208276 001	Jul 30, 2018 Jun DISC
		@	50MG/20ML (2.5MG/ML)	N208276 002	Jul 30, 2018 Jun DISC
		@	100MG/20ML (5MG/ML)	N208276 003	Jul 30, 2018 Jun DISC
		@	200MG/20ML (10MG/ML)	N208276 004	Jul 30, 2018 Jun DISC

TRETINOIN

		CREAM; TOPICAL		RENOVA	
>D>	AB2	+!	VALEANT PHARMS NORTH	0.05%	N019963 001 Dec 29, 1995 Sep CTEC
>A>		+!		0.05%	N019963 001 Dec 29, 1995 Sep CTEC
		TRETINOIN			
>D>	AB2		ZO SKIN HEALTH	0.05%	A076498 001 Sep 15, 2005 Sep DISC
>A>		@		0.05%	A076498 001 Sep 15, 2005 Sep DISC

TRIAMCINOLONE ACETONIDE

		CREAM; TOPICAL		ARISTOCORT	
		+ @	ASTELLAS	0.5%	A083015 002 Aug CRLD
		+ @	DELCOR ASSET CORP	0.5%	A083943 001 Aug CRLD
		TRIAMCINOLONE ACETONIDE			
AT	+!	FOUGERA PHARMS	0.025%	A085692 001	Aug CRLD
AT	+!		0.1%	A085692 003	Aug CRLD
AT	+!		0.5%	A085692 002	Aug CRLD
AT		MICRO LABS	0.025%	A040671 001	Jun 09, 2006 Aug CAHN
AT			0.1%	A040671 002	Jun 09, 2006 Aug CAHN

CREAM; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan CAHN
AT			0.1%	A040671	002	Jun 09, 2006	Jan CAHN
INJECTABLE; INJECTION							
TRIAMCINOLONE ACETONIDE							
>D>	AB	AMNEAL	40MG/ML	A207550	001	Dec 11, 2017	Sep CTEC
>A>	BX		40MG/ML	A207550	001	Dec 11, 2017	Sep CTEC
LOTION; TOPICAL							
TRIAMCINOLONE ACETONIDE							
AT		MICRO LABS	0.1%	A040672	002	Dec 13, 2006	Aug CAHN
OINTMENT; TOPICAL							
ARISTOCORT							
	+	@ ASTELLAS	0.5%	A080745	002		Aug CRLD
		ARISTOCORT A					
	+	@ ASTELLAS	0.5%	A080745	003		Aug CRLD
		KENALOG					
	+	@ DELCOR ASSET CORP	0.5%	A083944	001		Aug CRLD
TRIAMCINOLONE ACETONIDE							
AT	+	! PADAGIS US	0.025%	A087385	002		Aug CRLD
AT	+	!	0.1%	A087385	003		Aug CRLD
AT	+	!	0.5%	A087385	001		Aug CRLD
SPRAY, METERED; NASAL							
TRIAMCINOLONE ACETONIDE							
		@ PERRIGO	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Jul CAHN
<u>TRIAZOLAM</u>							
TABLET; ORAL							
HALCION							
AB	+	PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb CAHN
AB	+	!	0.25MG	N017892	001	Nov 15, 1982	Feb CAHN
		@	0.5MG	N017892	002	Nov 15, 1982	Feb CAHN
TRIAZOLAM							
>A>	AB	NOVAST LABS	0.125MG	A214219	001	Oct 20, 2020	Sep CAHN
>A>	AB		0.25MG	A214219	002	Oct 20, 2020	Sep CAHN
>D>	AB	RICONPHARMA LLC	0.125MG	A214219	001	Oct 20, 2020	Sep CAHN
>D>	AB		0.25MG	A214219	002	Oct 20, 2020	Sep CAHN
<u>TRIENTINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
CLOVIQUE							
		@ CHARTWELL RX	250MG	A209731	001	Oct 21, 2019	Jun DISC
AB			250MG	A209731	001	Oct 21, 2019	Mar CAHN
TRIENTINE HYDROCHLORIDE							
AB		ACCORD HLTHCARE	250MG	A212929	001	Aug 30, 2021	Aug NEWA
>D>	AB	AMNEAL	250MG	A210619	001	Feb 08, 2019	Sep DISC
>A>		@	250MG	A210619	001	Feb 08, 2019	Sep DISC
		@ CHARTWELL RX	250MG	A209415	001	Sep 16, 2019	Jun DISC
AB			250MG	A209415	001	Sep 16, 2019	Mar CAHN
>D>	AB	ECI PHARMS LLC	250MG	A209945	001	Aug 13, 2021	Sep CAHN
AB			250MG	A209945	001	Aug 13, 2021	Aug NEWA
>D>	AB	MSN	250MG	A211134	001	May 22, 2019	Sep CTEC
>A>	BX		250MG	A211134	001	May 22, 2019	Sep CTEC
>A>	AB	PHARMA LIFE	250MG	A209945	001	Aug 13, 2021	Sep CAHN
<u>TRILACICLIB DIHYDROCHLORIDE</u>							
POWDER; INTRAVENOUS							
COSELA							
	+	! G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Feb NEWA
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
TIGAN							
	+	@ KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	Apr DISC
TRIMETHOBENZAMIDE HYDROCHLORIDE							
AB	!	SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Apr CHRS

TROPICAMIDESOLUTION/DROPS;OPHTHALMIC
MYDRIACYL

AT	+	ALCON LABS INC	1%	A 084306	001		Aug	CRLD
AT	+	SANDOZ INC	0.5%	A 084305	001		Aug	CRLD

TROSPIMUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
TROSPIMUM CHLORIDE

AB		AMTA	60MG	A 214760	001	Apr 30, 2021	Apr	NEWA
----	--	------	------	----------	-----	--------------	-----	------

UMBRALISIB TOSYLATETABLET;ORAL
UKONIQ

	+	TG THERAPS	EQ 200MG BASE	N 213176	001	Feb 05, 2021	Feb	NEWA
--	---	------------	---------------	----------	-----	--------------	-----	------

URSODIOLCAPSULE;ORAL
URSODIOL

AB		STRIDES PHARMA	300MG	A 210344	001	Jan 22, 2021	Jan	NEWA
AB		VGYAAN	300MG	A 214329	001	Jul 28, 2021	Jul	NEWA

VALACYCLOVIR HYDROCHLORIDETABLET;ORAL
VALACYCLOVIR HYDROCHLORIDE

AB		CADILA	EQ 500MG BASE	A 079137	001	Dec 29, 2017	Aug	CAHN
AB			EQ 1GM BASE	A 079137	002	Dec 29, 2017	Aug	CAHN

VALBENZAZINE TOSYLATECAPSULE;ORAL
INGREZZA

	+	NEUROCRINE	EQ 60MG BASE	N 209241	003	Apr 23, 2021	May	NEWA
--	---	------------	--------------	----------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDETABLET;ORAL
VALGANCICLOVIR HYDROCHLORIDE

AB		MYLAN	EQ 450MG BASE	A 205151	001	Mar 03, 2021	Feb	NEWA
----	--	-------	---------------	----------	-----	--------------	-----	------

VALPROIC ACIDCAPSULE;ORAL
VALPROIC ACID

>D>	AB	EYWA	250MG	A 207611	001	Aug 05, 2019	Sep	CTEC
>A>	BX		250MG	A 207611	001	Aug 05, 2019	Sep	CTEC

SYRUP;ORAL
VALPROIC ACID

>A>	AA	BIOPHARM	250MG/5ML	A 090517	001	May 28, 2010	Sep	CAHN
	AA	CHARTWELL RX	250MG/5ML	A 075782	001	Dec 22, 2000	Mar	CMFD
>D>	AA	PHARMA LIFE	250MG/5ML	A 090517	001	May 28, 2010	Sep	CAHN

VALSARTANTABLET;ORAL
VALSARTAN

>A>	AB	DR REDDYS	40MG	A 201618	001	Oct 05, 2021	Sep	NEWA
>A>	AB		80MG	A 201618	002	Oct 05, 2021	Sep	NEWA
>A>	AB		160MG	A 201618	003	Oct 05, 2021	Sep	NEWA
>A>	AB		320MG	A 201618	004	Oct 05, 2021	Sep	NEWA

VANCOMYCINSOLUTION;INTRAVENOUS, ORAL
VANCOMYCIN

	+	XELLIA PHARMS APS	5GM/100ML (50MG/ML)	N 213895	001	Aug 26, 2021	Aug	NEWA
--	---	-------------------	---------------------	----------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDEINJECTABLE;INJECTION
VANCOMYCIN HYDROCHLORIDE

	@	HIKMA	EQ 500MG BASE/VIAL	A 203300	001	Aug 11, 2020	Feb	DISC
	@		EQ 1GM BASE/VIAL	A 203300	002	Aug 11, 2020	Feb	DISC
	!	HOSPIRA	EQ 1.5GM BASE/VIAL	A 062912	003	Jul 10, 2020	May	CMFD

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+ @	BAYER HLTHCARE	EQ 5MG BASE	N021400	001	Aug 19, 2003	Apr	DISC
+ @		EQ 10MG BASE	N021400	002	Aug 19, 2003	Apr	DISC

VARENICLINE

TABLET;ORAL

VARENICLINE

>D>							
>D>	AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Sep CTNA
	AB		EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Jul NFTG
>D>	AB		EQ 1MG BASE	A201785	002	Aug 11, 2021	Sep CTNA
	AB		EQ 1MG BASE	A201785	002	Aug 11, 2021	Jul NFTG

VARENICLINE TARTRATE

TABLET;ORAL

CHANTIX

	AB	+ PF PRISM CV	EQ 0.5MG BASE	N021928	001	May 10, 2006	Jul CFTG
	AB	+	EQ 1MG BASE	N021928	002	May 10, 2006	Jul CFTG
>A>		VARENICLINE TARTRATE					
>A>	AB	PAR PHARM INC	EQ 0.5MG BASE	A201785	001	Aug 11, 2021	Sep CTNA
>A>	AB		EQ 1MG BASE	A201785	002	Aug 11, 2021	Sep CTNA

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

+	!	PAR STERILE PRODUCTS	20UNITS/100ML (0.2UNITS/ML)	N204485	005	Apr 21, 2021	Apr NEWA
---	---	----------------------	-----------------------------	---------	-----	--------------	----------

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

	AB	TORRENT	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	Aug CAHN
	AB		EQ 75MG BASE	A090899	002	Jun 01, 2011	Aug CAHN
	AB		EQ 150MG BASE	A090899	003	Jun 01, 2011	Aug CAHN
	AB	YICHANG HUMANWELL	EQ 37.5MG BASE	A214654	001	Aug 06, 2021	Jul NEWA
	AB		EQ 75MG BASE	A214654	002	Aug 06, 2021	Jul NEWA
	AB		EQ 150MG BASE	A214654	003	Aug 06, 2021	Jul NEWA

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

		@ MYLAN	EQ 25MG BASE	A077166	001	Jun 13, 2008	Jan DISC
		@	EQ 37.5MG BASE	A077166	002	Jun 13, 2008	Jan DISC
		@	EQ 50MG BASE	A077166	003	Jun 13, 2008	Jan DISC
		@	EQ 75MG BASE	A077166	004	Jun 13, 2008	Jan DISC
		@	EQ 100MG BASE	A077166	005	Jun 13, 2008	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

	AB	ALKEM LABS LTD	EQ 37.5MG BASE	A214127	001	Jun 10, 2021	Jun NEWA
	AB		EQ 75MG BASE	A214127	002	Jun 10, 2021	Jun NEWA
	AB		EQ 150MG BASE	A214127	003	Jun 10, 2021	Jun NEWA
	AB		EQ 225MG BASE	A214127	004	Jun 10, 2021	Jun NEWA
	AB	APPCO	EQ 150MG BASE	A214609	001	Jun 30, 2021	Jun NEWA
	AB		EQ 225MG BASE	A214609	002	Jun 30, 2021	Jun NEWA
	AB	DEXCEL PHARMA	EQ 75MG BASE	A213927	001	Jan 21, 2021	Jan NEWA

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

>D>	AB	MYLAN	120MG	A074587	002	Feb 21, 1997	Sep CAHN
>A>		@	120MG	A074587	002	Feb 21, 1997	Sep CAHN
>D>	AB		180MG	A074587	003	Sep 09, 1997	Sep CAHN
>A>		@	180MG	A074587	003	Sep 09, 1997	Sep CAHN
>D>	AB		240MG	A074587	001	Mar 23, 1996	Sep CAHN
>A>		@	240MG	A074587	001	Mar 23, 1996	Sep CAHN

VERICIGUAT

TABLET;ORAL

VERQUVO

+		MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021	Jan NEWA
+			5MG	N214377	002	Jan 19, 2021	Jan NEWA
+	!		10MG	N214377	003	Jan 19, 2021	Jan NEWA

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA	ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan	NEWA	
>A>	AA	AUROBINDO PHARMA LTD	500MG/PACKET	A213899	001	Sep 29, 2021	Sep	NEWA
AA	DEXCEL PHARMA	500MG/PACKET	A214992	001	May 13, 2021	May	NEWA	
AA	NAVISCI	500MG/PACKET	A213390	001	Jul 29, 2021	Jul	NEWA	
AA	SPECGX LLC	500MG/PACKET	A212626	001	Jul 28, 2021	Jul	NEWA	

TABLET;ORAL

VIGABATRIN

>A>	AB	DEXCEL PHARMA	500MG	A215109	001	Sep 23, 2021	Sep	NEWA
AB	DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan	NEWA	

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A208209	001	Apr 27, 2021	Apr	NEWA
AB		20MG	A208209	002	Apr 27, 2021	Apr	NEWA
AB		40MG	A208209	003	Apr 27, 2021	Apr	NEWA
AB	INVAGEN PHARMS	10MG	A208200	001	Apr 07, 2021	Mar	NEWA
AB		40MG	A208200	002	Apr 07, 2021	Mar	NEWA

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

QELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021	Apr	NEWA
+		EQ 150MG BASE	N211964	002	Apr 02, 2021	Apr	NEWA
+	!	EQ 200MG BASE	N211964	003	Apr 02, 2021	Apr	NEWA

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

!	HIKMA PHARMS	10MG/VIAL	A089395	001	Apr 09, 1987	Jul	CAHN
---	--------------	-----------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

@ FRESENIUS KABI USA

EQ 10MG BASE/ML

A076849	001	Apr 18, 2005	Jan	DISC
---------	-----	--------------	-----	------

VOCLOSPORIN

CAPSULE;ORAL

LUPKYNIS

+	!	AURINIA	7.9MG	N213716	001	Jan 22, 2021	Jan	NEWA
---	---	---------	-------	---------	-----	--------------	-----	------

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VORICONAZOLE

AP	ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016	Feb	CAHN
----	----------	------------	---------	-----	--------------	-----	------

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

>D>	+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Sep	CFTG
>A>	AB	+	EQ 5MG BASE	N204447	001	Sep 30, 2013	Sep	CFTG
>D>	+		EQ 10MG BASE	N204447	002	Sep 30, 2013	Sep	CFTG
>A>	AB	+	EQ 10MG BASE	N204447	002	Sep 30, 2013	Sep	CFTG
>D>	+	!	EQ 20MG BASE	N204447	004	Sep 30, 2013	Sep	CFTG
>A>	AB	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Sep	CFTG
>A>		VORTIOXETINE HYDROBROMIDE						
>A>	AB	ZYDUS PHARMS	EQ 5MG BASE	A211146	001	Sep 17, 2021	Sep	NFTG
>A>	AB		EQ 10MG BASE	A211146	002	Sep 17, 2021	Sep	NFTG
>A>	AB		EQ 20MG BASE	A211146	003	Sep 17, 2021	Sep	NFTG

ZIDOVUDINE

INJECTABLE;INJECTION

RETROVIR

>D>	AP	+	VIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990	Sep	CTEC
>A>		+		10MG/ML	N019951	001	Feb 02, 1990	Sep	CTEC

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL

ZILEUTON

>D>	AB	AIZANT	600MG	A211390	001	Oct 23, 2020	Sep CAHN
>A>	AB	DASH PHARMS	600MG	A211390	001	Oct 23, 2020	Sep CAHN
>D>	AB	LUPIN LTD	600MG	A211972	001	Nov 05, 2019	Sep CTEC
>A>	BX		600MG	A211972	001	Nov 05, 2019	Sep CTEC

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

AP		EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021	May NFTG
		ZINC CHLORIDE IN PLASTIC CONTAINER					
AP	+!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986	May CFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB		CHARTWELL RX	EQ 20MG BASE	A090348	001	Sep 05, 2012	Jul CAHN
AB			EQ 40MG BASE	A090348	002	Sep 05, 2012	Jul CAHN
AB			EQ 60MG BASE	A090348	003	Sep 05, 2012	Jul CAHN
AB			EQ 80MG BASE	A090348	004	Sep 05, 2012	Jul CAHN

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

		@ EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Aug DISC
--	--	---------------------	-----------------	---------	-----	--------------	----------

ZOLMITRIPTAN

SPRAY;NASAL

ZOLMITRIPTAN

>A>							
>A>	AB	PADAGIS ISRAEL	2.5MG/SPRAY	A212469	001	Sep 30, 2021	Sep NFTG
>A>	AB		5MG/SPRAY	A212469	002	Sep 30, 2021	Sep NFTG
		ZOMIG					
>D>	+	ASTRAZENECA	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Sep CFTG
>A>	AB	+	2.5MG/SPRAY	N021450	003	Sep 16, 2013	Sep CFTG
>D>	+	!	5MG/SPRAY	N021450	004	Sep 30, 2003	Sep CFTG
>A>	AB	!	5MG/SPRAY	N021450	004	Sep 30, 2003	Sep CFTG

ZOLPIDEM TARTRATE

TABLET, ORALLY DISINTEGRATING;ORAL

TOVALT ODT

		+ @ BIOVAIL LABS INTL	5MG	N021412	001	Apr 25, 2007	Apr CRLD
		+ @	10MG	N021412	002	Apr 25, 2007	Apr CRLD

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	+	CONCORDIA	25MG	N020789	003	Aug 22, 2003	Mar CAHN
		+ @	50MG	N020789	002	Aug 22, 2003	Mar CAHN
AB	+	!	100MG	N020789	001	Mar 27, 2000	Mar CAHN

ZONISAMIDE

AB		CADILA	25MG	A077625	001	Oct 16, 2006	Jul CAHN
AB			50MG	A077625	002	Oct 16, 2006	Jul CAHN
AB			100MG	A077625	003	Oct 16, 2006	Jul CAHN
AB		GRANULES	25MG	A077636	003	Jul 27, 2006	Jun CAHN
AB			50MG	A077636	002	Jul 27, 2006	Jun CAHN
AB			100MG	A077636	001	Dec 22, 2005	Jun CAHN
AB		UNICHEM	25MG	A214492	001	Jan 26, 2021	Jan NEWA
AB			50MG	A214492	002	Jan 26, 2021	Jan NEWA
AB			100MG	A214492	003	Jan 26, 2021	Jan NEWA

ACETAMINOPHEN

	SUPPOSITORY;RECTAL						
>D>	NEOPAP						
>D>	POLYMEDICA	120MG	N016401	001			Sep DISC
>A>	@	120MG	N016401	001			Sep DISC
	TABLET, EXTENDED RELEASE;ORAL						
	ACETAMINOPHEN						
	MARKSANS PHARMA	650MG	A215486	001	Aug 25, 2021		Aug NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

	TABLET;ORAL						
	ACETAMINOPHEN, ASPIRIN AND CAFFEINE						
	GRANULES	250MG;250MG;65MG	A214039	001	Feb 23, 2021		Feb NEWA

ASPIRIN

	CAPSULE;ORAL						
	VAZALORE						
+	PLX PHARMA	81MG	N203697	002	Feb 26, 2021		Jun NEWA

AZELASTINE HYDROCHLORIDE

	SPRAY, METERED;NASAL						
	ASTEPRO ALLERGY						
+	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	001	Jun 17, 2021		Jun NEWA
	CHILDREN'S ASTEPRO ALLERGY						
+	BAYER HLTHCARE	0.2055MG/SPRAY	N213872	002	Jun 17, 2021		Jun NEWA

BUDESONIDE

	SPRAY, METERED;NASAL						
	RHINOCORT ALLERGY						
+	J AND J CONSUMER INC	0.032MG/SPRAY	N020746	003	Mar 23, 2015		Mar CAHN

CETIRIZINE HYDROCHLORIDE

	CAPSULE;ORAL						
	CETIRIZINE HYDROCHLORIDE ALLERGY						
	APOTEX	10MG	A207235	001	Aug 12, 2016		Mar CMFD
	@	10MG	A207235	001	Aug 12, 2016		Jan DISC
	SYRUP;ORAL						
	CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY						
>D>	ATHEM	5MG/5ML	A091327	001	Oct 17, 2011		Sep CAHN
>A>	MICRO LABS	5MG/5ML	A091327	001	Oct 17, 2011		Sep CAHN
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
>D>	ATHEM	5MG/5ML	A091327	002	Oct 17, 2011		Sep CAHN
>A>	MICRO LABS	5MG/5ML	A091327	002	Oct 17, 2011		Sep CAHN
	TABLET;ORAL						
	CETIRIZINE HYDROCHLORIDE ALLERGY						
	@ CIPLA LTD	5MG	A077318	001	Jul 25, 2013		May DISC
	@	10MG	A077318	002	Jul 25, 2013		May DISC
	TABLET, CHEWABLE;ORAL						
	CHILDREN'S ZYRTEC ALLERGY						
+	@ J AND J CONSUMER INC	2.5MG	N021621	007	Nov 30, 2020		Apr DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

	TABLET, EXTENDED RELEASE;ORAL						
	GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE						
	SUN PHARM	30MG;600MG	A214781	001	Jul 01, 2021		Jun NEWA
		60MG;1.2GM	A214781	002	Jul 01, 2021		Jun NEWA

DICLOFENAC SODIUM

	GEL;TOPICAL						
	DICLOFENAC SODIUM						
	AUROLIFE PHARMA LLC	1%	A204306	001	May 06, 2019		May CAHN
	PERRIGO	1%	A211253	001	May 16, 2019		Jun CAHN
	PERRIGO PHARMA INTL	1%	A211253	001	May 16, 2019		Jul CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

TARO 30MG/5ML

A208123 001 Nov 09, 2017 Jun CMFD

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

TARO 30MG/5ML

A208123 002 Nov 09, 2017 Jun CMFD

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

L PERRIGO CO 60MG

A212971 001 Feb 24, 2020 Jun CMFD

180MG

A212971 002 Feb 24, 2020 Jun CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY

N205434 001 Jul 23, 2014 Apr CHRS

FLUTICASONE PROPIONATE

! HIKMA PHARMS 0.05MG/SPRAY

A207957 001 May 26, 2016 Apr CHRS

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

OHM LABS INC 600MG

A209254 001 Jul 16, 2018 Aug CMFD

1.2GM

A209254 002 Jul 16, 2018 Aug CMFD

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

GUARDIAN DRUG 100MG/5ML

A210149 001 Aug 17, 2018 Jan CMFD

@ STRIDES PHARMA 100MG/5ML

A211666 001 Feb 22, 2021 Aug DISC

100MG/5ML

A211666 001 Feb 22, 2021 Feb NEWA

TABLET;ORAL

IBUPROFEN

@ YICHANG HUMANWELL 200MG

A214003 001 Oct 19, 2020 Apr DISC

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL

ZURAGARD

+ @ ZUREX PHARMA 70%

N210872 001 Apr 26, 2019 Jul CPOT

IVERMECTIN

LOTION;TOPICAL

IVERMECTIN

TARO 0.5%

A210720 001 May 06, 2020 May CMKT

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL ANTI-DANDRUFF

+! KRAMER 1%

N020310 001 Oct 10, 1997 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX 5MG

A211443 001 Apr 21, 2021 Apr NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

STRIDES PHARMA 2MG

A213070 001 Aug 11, 2021 Jul NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

BIONPHARMA INC 2MG;125MG

A213484 001 Sep 10, 2021 Sep NEWA

GUARDIAN DRUG 2MG;125MG

A214541 001 May 27, 2021 May NEWA

HETERO LABS LTD V 2MG;125MG

A211438 001 Jun 17, 2021 Jun NEWA

>A>

LORATADINE

SYRUP;ORAL

LORATADINE

HETERO LABS LTD III 1MG/ML

A210409 001 May 07, 2021 Apr NEWA

TABLET;ORAL

LORATADINE

>A> APPCO 10MG

A207569 001 Mar 12, 2019 Sep CAHN

>D> GUARDIAN DRUG 10MG

A207569 001 Mar 12, 2019 Sep CAHN

UNIQUE PHARM 10MG

A214684 001 Jan 07, 2021 Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

@ GLAXOSMITHKLINE 10MG

A075822 001 Feb 10, 2003 Jan DISC

TENSHI 5MG

A212795 001 Sep 18, 2020 Jun CMFD

@ 5MG

A212795 001 Sep 18, 2020 Mar DISC

10MG

A213294 001 Oct 30, 2020 Jun CMFD

@ 10MG

A213294 001 Oct 30, 2020 Mar DISC

MICONAZOLE NITRATE

CREAM, INSERT;TOPICAL, VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM

A079114 001 Jun 02, 2010 Jul CDFR

MONISTAT 1 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,1.2GM

N021308 001 Jun 29, 2001 Jul CDFR

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MICONAZOLE NITRATE COMBINATION PACK

>A> L PERRIGO CO 2%,200MG

A075329 001 Apr 20, 1999 Sep CAHN

>D> PERRIGO 2%,200MG

A075329 001 Apr 20, 1999 Sep CAHN

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

PERRIGO 5%

A091344 001 Apr 28, 2011 Jul CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE EQ 2MG BASE

N022360 001 May 18, 2009 Mar CAHN

+! EQ 4MG BASE

N022360 002 May 18, 2009 Mar CAHN

NICOTINE POLACRILEX

AUROBINDO PHARMA LTD EQ 2MG BASE

A213266 001 Aug 03, 2021 Jul NEWA

EQ 4MG BASE

A213266 002 Aug 03, 2021 Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN EQ 0.1% BASE

A204532 001 Jan 10, 2017 Jun CMKT

EQ 0.2% BASE

A204723 001 Dec 05, 2017 Jun CMKT

ALEMBIC PHARMS LTD EQ 0.1% BASE

A209919 001 Dec 07, 2018 Feb CMKT

EQ 0.2% BASE

A209420 001 Apr 29, 2019 Jan CMKT

APOTEX INC EQ 0.2% BASE

A090918 001 Dec 05, 2017 Jan CMKT

BARR LABS INC EQ 0.2% BASE

A090848 001 Jul 13, 2015 Feb CMKT

@ BAUSCH EQ 0.1% BASE

A206046 001 Jul 26, 2017 Jun CAHN

@ CIPLA EQ 0.2% BASE

A206087 001 Dec 05, 2017 Mar CMKT

MYLAN EQ 0.1% BASE

A204392 001 Mar 21, 2018 Feb CMKT

EQ 0.2% BASE

A204620 001 Jun 16, 2020 Jun CAHN

USV EQ 0.1% BASE

A203152 001 Dec 07, 2015 Apr CMKT

@ WOCKHARDT LTD EQ 0.1% BASE

A200810 001 Jun 28, 2017 Aug CMKT

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

APOTEX 20MG

A210070 001 Feb 11, 2019 May CMFD

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

ANNORA PHARMA 17GM/SCOOPFUL

A214990 001 Apr 14, 2021 Apr NEWA

POTASSIUM IODIDE

TABLET; ORAL

THYROSAFE

>A>	!	BTG INTL	65MG	A076350	001	Sep 10, 2002	Sep CAHN
>D>	!	RECIP	65MG	A076350	001	Sep 10, 2002	Sep CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	EQ 75MG BASE	A207579	001	Nov 13, 2017	Jun DISC
@		EQ 150MG BASE	A207578	001	Nov 13, 2017	Jun DISC
@	WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006	Jan DISC
	ZANTAC 150					
+	@ SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Apr DISC
+	@	EQ 150MG BASE	N021698	002	Mar 13, 2007	Apr DISC
	ZANTAC 75					
+	@ SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Apr DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

	PERRIGO	0.055MG/SPRAY	A078104	002	Nov 14, 2014	Jul CAHN
--	---------	---------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 09 SEPTEMBER 2021

NO SEPTEMBER 2021 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2021 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	10996208	Apr 30, 2038	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	11000517	Mar 13, 2029	DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	11000517	Mar 13, 2029	DP U-2513			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	9592195	Dec 05, 2031	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	11060128	Jun 29, 2032	U-2956			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-3163			
	11077192	Jan 12, 2038	U-3163			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037	U-185			
	10894039	Oct 06, 2037	U-3			
	10952998	Oct 06, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10959991	Oct 06, 2037	U-158			
	10959991	Oct 06, 2037	U-39			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10925835	Jun 14, 2038	U-2410			
	10945960	Jun 14, 2038	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 005	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	>A> 11096983	Dec 18, 2034	U-3211			
	>A> 11096983	Dec 18, 2034	U-3212			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	>A> 11096983	Dec 18, 2034	U-3211			
	>A> 11096983	Dec 18, 2034	U-3212			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036	U-2825			
	11077068	Feb 14, 2022	DP			
<u>APREPITANT - CINVANTI</u>						
N 209296 001	10953018	Sep 18, 2035	U-2161			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENUVU</u>						
N 209381 001	10918723	Sep 10, 2033	U-2310			
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001					CGT	Sep 21, 2021
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		ODE-356	Jun 16, 2028
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		ODE-356	Jun 16, 2028
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 003					ODE-356	Jun 16, 2028
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 004	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
<u>AVAPRITINIB - AYPVAKIT</u>						
N 212608 005	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036	U-3044			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036	U-3044			
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY</u>						
N 213872 001	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-3166			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY</u>						
N 213872 001	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY</u>						
N 213872 002	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-3166			
	9919050	Nov 22, 2025	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
	10633397	Apr 27, 2036	U-2816		NCE	Oct 24, 2023
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					NCE	Oct 24, 2023
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Aug 10, 2026	DS DP U-1544			
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001					NCE	Jul 16, 2026
					>A> ODE-362	Jul 16, 2028
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	>A> 9908845	Sep 05, 2034	DS DP U-3201		>A> NCE	Aug 13, 2026
	>A> 9969689	Sep 05, 2034	DS DP U-3201		>A> ODE-364	Aug 13, 2028
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10941095	Dec 23, 2023	U-2747			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10941095	Dec 23, 2023	U-2746			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902 001	11071878	Dec 30, 2030	DP		>A> NC	Jul 26, 2024
	9868103	Aug 08, 2028	DP U-3194			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
					ODE-333	Dec 03, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
					ODE-333	Dec 03, 2027
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					M-82	Feb 24, 2024
<u>BOSENTAN - TRACLEER</u>						
N 021290 001					ODE*	Sep 05, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSENTAN - TRACLEER</u>						
N 021290 002					ODE*	Sep 05, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	>A> 11103497	Feb 28, 2034	U-3216			
	>A> 11103497	Feb 28, 2034	U-3217			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	>A> 11103497	Feb 28, 2034	U-3216			
	>A> 11103497	Feb 28, 2034	U-3217			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	>A> 11103497	Feb 28, 2034	U-3216			
	>A> 11103497	Feb 28, 2034	U-3217			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	6794489	Jun 28, 2025	DS DP			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10940156	Mar 08, 2037	U-2552			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144 001	9259425	Jul 14, 2030	U-2222			
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214460 001	9303051	Aug 31, 2031	DS DP U-3165		NP ODE-354	Jun 04, 2024 Jun 04, 2028
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214461 001	10112909	Oct 10, 2034	U-3165		NP	Jun 04, 2024
	10487061	Oct 10, 2034	DP U-3165		ODE-354	Jun 04, 2028
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003					NPP	May 10, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	004				NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	005				NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838	001				NPP	May 10, 2021
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866	001	11000522	Apr 30, 2032	U-3119		
		11000522	Apr 30, 2032	U-3120		
		11000522	Apr 30, 2032	U-3121		
		11000522	Apr 30, 2032	U-3122		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001	11033495	Jan 22, 2041	DP U-3182	NPP	Mar 22, 2024
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	002	11033495	Jan 22, 2041	DP U-3182	NPP	Mar 22, 2024
<u>BUPIVACAINE - POSIMIR</u>						
N 204803	001	8153149	Sep 15, 2025	DP	NP	Feb 01, 2024
		8153661	Sep 15, 2025	U-3074		
		8753665	Sep 15, 2025	DP U-3074		
		8846072	Sep 15, 2025	DP U-3074		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	001	10098957	Apr 20, 2035	U-3118	NP	May 12, 2024
		10213510	Apr 20, 2035	DP U-3118		
		10398686	Mar 13, 2034	DP		
		10632199	Apr 20, 2035	DP U-3118		
		10898575	Apr 20, 2035	DP U-3118		
		10980886	Apr 20, 2035	DP		
		11083730	Apr 20, 2035	DP U-3118		
		11083797	Apr 20, 2035	DP U-3118		
		9592227	Mar 13, 2034	DP U-3118		
		9694079	Apr 20, 2035	DP U-3118		
		9744163	Mar 13, 2034	DP		
		9801945	Apr 20, 2035	DP U-3118		
		9913909	Mar 13, 2034	U-3118		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	002	10098957	Apr 20, 2035	U-3118	NP	May 12, 2024
		10213510	Apr 20, 2035	DP U-3118		
		10398686	Mar 13, 2034	DP		
		10632199	Apr 20, 2035	DP U-3118		
		10898575	Apr 20, 2035	DP U-3118		
		10980886	Apr 20, 2035	DP		
		11083730	Apr 20, 2035	DP U-3118		
		11083797	Apr 20, 2035	DP U-3118		
		9592227	Mar 13, 2034	DP U-3118		
		9694079	Apr 20, 2035	DP U-3118		
		9744163	Mar 13, 2034	DP		
		9801945	Apr 20, 2035	DP U-3118		
		9913909	Mar 13, 2034	U-3118		
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	003	10098957	Apr 20, 2035	U-3118	NP	May 12, 2024
		10213510	Apr 20, 2035	DP U-3118		
		10398686	Mar 13, 2034	DP		
		10632199	Apr 20, 2035	DP U-3118		
		10898575	Apr 20, 2035	DP U-3118		
		10980886	Apr 20, 2035	DP		
		11083730	Apr 20, 2035	DP U-3118		
		11083797	Apr 20, 2035	DP U-3118		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	11000520	Nov 06, 2035	U-3111			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	>A> 11033543	Jan 10, 2031	U-1583			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	>A> 8927592	Oct 27, 2030	U-3200		M-128	Dec 18, 2023
	>A> 8927592*PED	Apr 27, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3061			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
<u>CALCITONIN SALMON - CALCITONIN-SALMON</u>						
A 212416 001					CGT	Nov 10, 2021
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017		>A> I-870	Aug 12, 2024
	8772306	Mar 15, 2033	U-1532		ODE-361	Jul 21, 2027
	8772306	Mar 15, 2033	U-3198			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 14, 2035	U-3071		ODE-326	Jul 31, 2027
	10918608	Oct 14, 2035	U-3072		ODE-332	Jul 31, 2027
	10918608	Oct 14, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 14, 2035	U-3071			
	>A> 11096905	Oct 14, 2035	DS DP U-2780			
	>A> 11096905	Oct 14, 2035	DS DP U-2781			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					ODE-345	Jan 22, 2028
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10533174	May 04, 2021	DP		ODE-347	Feb 25, 2028
	10781450	Nov 12, 2030	U-3089			
	8524880	Apr 02, 2026	DS DP U-3087			
	8524880	Apr 02, 2026	DS DP U-3088			
	9228187	Nov 12, 2030	DS DP			
	9416361	May 04, 2021	DS			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					ODE*	Apr 29, 2021
					ODE*	May 26, 2024
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 003					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 004					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 005					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542 001					CGT	Jan 29, 2022
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542 002					CGT	Jan 29, 2022
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001					>A> NCE	Jul 16, 2024
					>A> GAIN	Jul 16, 2029
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	11040004	Nov 12, 2037	U-2252			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2022	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001					NPP	Aug 15, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	11103490	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	11103490	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	11103490	Oct 10, 2031	DP			
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10786518	Jul 19, 2038	U-2978			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	>A> 10039718	Oct 06, 2032	DP			
	>A> 10039718*PED	Apr 06, 2033				
	>A> 7176220	Aug 27, 2026	DS DP U-257			
	>A> 7176220*PED	Feb 27, 2027				
	>A> 7390791	Apr 17, 2025	DS DP			
	>A> 7390791*PED	Oct 17, 2025				
	>A> 7635704	Oct 26, 2026	DS DP U-257			
	>A> 7635704*PED	Apr 26, 2027				
	>A> 8148374	Sep 03, 2029	DS DP U-1279			
	>A> 8148374*PED	Mar 03, 2030				
	>A> 8633219	Apr 24, 2030	DP U-257			
	>A> 8633219*PED	Oct 24, 2030				
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 8754065*PED	Feb 15, 2033				
	>A> 8981103	Oct 26, 2026	DS DP			
	>A> 8981103*PED	Apr 26, 2027				
	>A> 9296769	Aug 15, 2032	DS DP U-257			
	>A> 9296769*PED	Feb 15, 2033				
	>A> 9891239	Sep 03, 2029	DP U-257			
	>A> 9891239*PED	Mar 03, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	11087354	Jun 22, 2034	U-1776			
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001					NCE NP	Dec 14, 2022 Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-2226			
	10987347	Feb 07, 2037	U-2225			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOS ACID; ZINC SULFATE - MULTRY5</u>						
N 209376 002					NCE	Apr 30, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOS ACID; ZINC SULFATE - MULTRY5</u>						
N 209376 003					NCE	Apr 30, 2024
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735 001	9662342	Jun 26, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735 002	9662342	Jun 26, 2035	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 001	10993952	Feb 15, 2036	DP			
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501 002	10993952	Feb 15, 2036	DP			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10918694	Feb 28, 2037	DP			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	7973081	Jan 27, 2026	DP		>A> NP	Jun 23, 2023
	8298568	Nov 03, 2027	DP		ODE-358	Jun 23, 2028
	8524779	Jan 27, 2026	DP			
	9132071	Jun 02, 2029	DP			
	9220694	Jan 27, 2026	DP			
	9956289	Jan 27, 2026	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10905662	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Sep 29, 2034	DP U-3149		NPP	Mar 30, 2024
	10028912	Sep 29, 2034	DP U-3150		ODE-350	Mar 30, 2028
	10166184	Oct 15, 2032	DP U-3149			
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 001	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 002	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 003	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 004	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 005	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 006	6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033	U-3185			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033	U-3185			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					NPP	Jul 22, 2024
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					I-857	Apr 30, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		I-857	Apr 30, 2024
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282 001	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282 002	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	11046713	Oct 27, 2030	DS			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DEFERIPRONE - DEFERIPRONE</u>						
A 208800 001					PC	Mar 27, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
	7049328	Jun 28, 2021	U-3083			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11085043	Jun 22, 2032	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10973870	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10973870	Feb 10, 2029	U-1978			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	11020448	May 21, 2029	U-2327			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	10959996	Mar 07, 2036		U-3055	M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	10959996	Mar 07, 2036		U-3055	M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10799642	May 11, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037		U-3094		
	10954213	Dec 09, 2037		U-3094		
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037		U-3094		
	10954213	Dec 09, 2037		U-3094		
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037		U-3094		
	10954213	Dec 09, 2037		U-3094		
	9079928	Jul 27, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001				NPP	May 25, 2024
<u>DIFELIKEFALIN ACETATE - KORSUVA</u>						
N 214916	001	>A> 10017536	Nov 12, 2027	DS U-3204	>A> NCE	Aug 23, 2026
		>A> 10138270	Nov 12, 2027	U-3204		
		>A> 10793596	Nov 12, 2027	DS DP U-3204		
		>A> 7402564	Nov 12, 2027	DS DP U-3204		
		>A> 7713937	Nov 12, 2027	DS DP U-3204		
		>A> 7727963	Nov 12, 2027	DS DP U-3204		
		>A> 8217007	Nov 12, 2027	U-3204		
		>A> 8236766	Nov 12, 2027	U-3204		
		>A> 8486894	Nov 12, 2027	U-3204		
		>A> 8536131	Nov 12, 2027	DS DP U-3204		
		>A> 9334305	Nov 12, 2027	U-3204		
		>A> 9359399	Nov 12, 2027	U-3204		
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436	001	>A> 10507295	Dec 25, 2032	DP		
		>A> 10940278	Jan 23, 2033	DP		
		>A> 9550036	Sep 05, 2032	DP		
		>A> 9919117	Mar 17, 2033	DP U-3218		
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	001				CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	002				CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	003				CGT	Sep 26, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	10391160	Mar 13, 2035	U-3148		
		10555993	Mar 13, 2035	U-3148		
		10959972	Nov 16, 2035	U-1384		
		10994003	Mar 13, 2035	U-3148		
		11007166	Nov 16, 2035	U-1384		
		11007167	Nov 16, 2035	U-1384		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	10391160	Mar 13, 2035	U-3148		
		10555993	Mar 13, 2035	U-3148		
		10959972	Nov 16, 2035	U-1384		
		10994003	Mar 13, 2035	U-3148		
		11007166	Nov 16, 2035	U-1384		
		11007167	Nov 16, 2035	U-1384		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	001	10842770	Aug 07, 2031	DP U-2998		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	002	10842770	Aug 07, 2031	DP U-2998		
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934	003	10842770	Aug 07, 2031	DP U-2998		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001	>A> 11096920	Apr 11, 2028	U-620		
		>A> 11110074	Jul 20, 2027	U-620		
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002	>A> 11096920	Apr 11, 2028	U-620		
		>A> 11110074	Jul 20, 2027	U-620		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	>A> 11096920	Apr 11, 2028	U-620			
	>A> 11110074	Jul 20, 2027	U-620			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	>A> 11123299	Jun 28, 2031	DP			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	7732430	Mar 02, 2025	DP U-3152		NCE	Apr 15, 2026
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10959982	Apr 13, 2037	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					ODE*	May 05, 2024
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Apr 18, 2027	DS			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	10864274	Oct 02, 2034	U-2720			
	7214506	Feb 22, 2026	U-281			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	10881659	Mar 14, 2034	U-2842			
	11045470	Mar 14, 2034	U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		NPP	Jun 08, 2024
	10022352	Apr 09, 2027	DP U-3156		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-2652		ODE-357	Jun 08, 2028
	10081621	Mar 25, 2031	DP U-3032			
	10081621	Mar 25, 2031	DP U-3157			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-3157		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-3158		NPP	Jun 08, 2024
	10646481	Aug 13, 2029	DP		ODE-357	Jun 08, 2028
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001					ODE*	Nov 16, 2025
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002					ODE*	Aug 26, 2021
					ODE*	Nov 16, 2025
					PED	Feb 26, 2022
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	11090323	Apr 03, 2034	U-3191		>A> I-869	Aug 18, 2024
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	11090323	Apr 03, 2034	U-3192			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	11090323	Apr 03, 2034	U-3193			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	11090323	Apr 03, 2034	U-3193			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002					PC	Mar 09, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721	003				PC	Mar 09, 2021
<u>ENALAPRIL MALEATE - ENALAPRIL MALEATE</u>						
A 212408	001				PC	Feb 13, 2022
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686	001	11040023	Mar 25, 2036	DP		
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725	001	>A> 11091469	May 18, 2037	U-2617		
		>A> 11091469	May 18, 2037	U-2618		
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725	002	>A> 11091469	May 18, 2037	U-2617		
		>A> 11091469	May 18, 2037	U-2618		
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407	001	11090278	May 16, 2040	U-3183		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	001	10960155	Jun 25, 2026	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	002	10842938	Dec 21, 2037	DP U-2980		
		10960155	Jun 25, 2026	DP		
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739	003	10842938	Dec 21, 2037	DP U-2980		
		10960155	Jun 25, 2026	DP		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	001	10898482	Feb 09, 2036	DP U-2518		
		10898482	Feb 09, 2036	DP U-3065		
		10898482	Feb 09, 2036	DP U-3066		
		10898482	Feb 09, 2036	DP U-3067		
		11077106	Feb 02, 2038	U-3196		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	002	10898482	Feb 09, 2036	DP U-2518		
		10898482	Feb 09, 2036	DP U-3065		
		10898482	Feb 09, 2036	DP U-3066		
		10898482	Feb 09, 2036	DP U-3067		
		11077106	Feb 02, 2038	U-3196		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	003	10898482	Feb 09, 2036	DP U-2518		
		10898482	Feb 09, 2036	DP U-3065		
		10898482	Feb 09, 2036	DP U-3066		
		10898482	Feb 09, 2036	DP U-3067		
		11077106	Feb 02, 2038	U-3196		
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243	001	10869844	Sep 10, 2035	U-3034		
		10869844	Sep 10, 2035	U-3035		
		10869844	Sep 10, 2035	U-3036		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	001	10912781	Oct 23, 2028	DP		
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416	002	10912781	Oct 23, 2028	DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	>A> 11116717	Jun 18, 2033	DP			
	>A> 11123283	Jun 18, 2033	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	>A> 11116717	Jun 18, 2033	DP			
	>A> 11123283	Jun 18, 2033	DP			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMREE</u>						
N 214846 001	11033551	Sep 29, 2037	U-3129		NCE	Dec 18, 2025
	7300935	Jan 28, 2024	DS		NP	May 26, 2024
	8058280	Jan 28, 2024	DS DP			
	9346822	Feb 17, 2024	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11033626	Nov 21, 2032	DP U-2439			
	>A> 11103513	Nov 21, 2032	U-2439			
	>A> 11103516	Nov 21, 2032	DP			
	>A> 11110099	Nov 21, 2032	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u>						
N 209405 001					NDF	Mar 30, 2023
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					CGT	Aug 25, 2021
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	7456254	Jun 30, 2025	DP U-2588		PED	Aug 15, 2023
	7456254	Jun 30, 2025	DP U-2589		PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7612176	Apr 13, 2025	DP U-2588			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			PED	Jan 22, 2025
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	U-2588			
	8501698*PED	Dec 20, 2027				
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033	Oct 04, 2030	DP U-3188			
	8895033	Oct 04, 2030	DP U-3189			
	8895033	Oct 04, 2030	DP U-3190			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001 >A>	10452815	Jun 29, 2038	U-2859			
	10947183	Dec 20, 2036	DS DP			
	10950331	Sep 28, 2035	U-3098			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	11040018	Aug 02, 2037	U-2861			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2024	DS DP		NS	Apr 28, 2024
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 001	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030 002	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXINIDAZOLE - FEXINIDAZOLE</u>						
N 214429	001				NCE ODE-359	Jul 16, 2026 Jul 16, 2028
<u>FINERENONE - KERENDIA</u>						
N 215341	001	8436180	Apr 12, 2029	DS DP	NCE	Jul 09, 2026
<u>FINERENONE - KERENDIA</u>						
N 215341	002	8436180	Apr 12, 2029	DS DP	NCE	Jul 09, 2026
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054	001	10933147	Dec 30, 2035	U-2450		
		10953112	Nov 28, 2026	U-1879		
		10967077	Dec 30, 2035	U-2450		
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482	001	>A> 11090294	Nov 29, 2030	U-3202		
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	001	10022510	May 18, 2031	DP		
		10022510*PED	Nov 18, 2031			
		10124131	May 18, 2031	DP		
		10124131*PED	Nov 18, 2031			
		10195375	Feb 14, 2031	DP		
		10195375*PED	Aug 14, 2031			
		10561808	Jan 01, 2032	DP		
		10561808*PED	Jul 01, 2032			
		10765820	May 19, 2025	DP		
		10765820*PED	Nov 19, 2025			
		7540282	May 06, 2023	DP		
		7540282*PED	Nov 06, 2023			
		8651103	Mar 26, 2028	DP		
		8651103*PED	Sep 26, 2028			
		8714149	Feb 25, 2032	DP		
		8714149*PED	Aug 25, 2032			
		8978966	Jan 13, 2032	DP		
		8978966*PED	Jul 13, 2032			
		9216260	Jun 28, 2031	DP		
		9216260*PED	Dec 28, 2031			
		9463288	May 19, 2025	DP		
		9463288*PED	Nov 19, 2025			
		9616024	Sep 01, 2024	DP		
		9616024*PED	Mar 01, 2025			
		9731087	May 18, 2031	DP		
		9731087*PED	Nov 18, 2031			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798	002	10022510	May 18, 2031	DP		
		10022510*PED	Nov 18, 2031			
		10124131	May 18, 2031	DP		
		10124131*PED	Nov 18, 2031			
		10195375	Feb 14, 2031	DP		
		10195375*PED	Aug 14, 2031			
		10561808	Jan 01, 2032	DP		
		10561808*PED	Jul 01, 2032			
		10765820	May 19, 2025	DP		
		10765820*PED	Nov 19, 2025			
		7540282	May 06, 2023	DP		
		7540282*PED	Nov 06, 2023			
		8651103	Mar 26, 2028	DP		
		8651103*PED	Sep 26, 2028			
		8714149	Feb 25, 2032	DP		
		8714149*PED	Aug 25, 2032			
		8978966	Jan 13, 2032	DP		
		8978966*PED	Jul 13, 2032			
		9216260	Jun 28, 2031	DP		
		9216260*PED	Dec 28, 2031			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	10022510	May 18, 2031	DP		NS	Jul 09, 2024
	10124131	May 18, 2031	DP		PED	Jan 09, 2025
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10765820	May 19, 2025	DP			
	7540282	May 06, 2023	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	11033696	May 20, 2033	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FOSCARNET SODIUM - FOSCARNET SODIUM</u>						
A 213001 001					CGT	Dec 28, 2021
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		NCE ODE-342	Feb 26, 2026 Feb 26, 2028
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE W	Dec 01, 2025 Dec 01, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643	001				NCE W	Dec 01, 2025 Dec 01, 2025
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394	001	10028937	Jun 10, 2030	U-2141	D-175	Sep 26, 2022
		10028937	Jun 10, 2030	U-2532	M-259	Apr 10, 2023
		10028937*PED	Dec 10, 2030		NCE	Aug 03, 2022
		10039754	Jun 10, 2030	U-2141	NPP	Apr 30, 2022
		10039754	Jun 10, 2030	U-2532	ODE-232	Apr 30, 2026
		10039754*PED	Dec 10, 2030		ODE-233	Apr 30, 2026
		10286029	Mar 14, 2034	U-2532	PED	Oct 30, 2022
		10286029*PED	Sep 14, 2034		PED	Feb 03, 2023
		8648037	Jan 19, 2032	DS DP U-2141	PED	Mar 26, 2023
		8648037	Jan 19, 2032	DS DP U-2532	PED	Oct 10, 2023
		8648037*PED	Jul 19, 2032		PED	Oct 30, 2026
		8937150	May 18, 2032	DS DP	PED	Oct 30, 2026
		8937150*PED	Nov 18, 2032			
		9321807	Jun 05, 2035	DS		
		9321807*PED	Dec 05, 2035			
		9586978	Jun 10, 2030	U-2141		
		9586978	Jun 10, 2030	U-2532		
		9586978*PED	Dec 10, 2030			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110	001	10028937	Jun 10, 2030	U-3167		
		10028937*PED	Dec 10, 2030			
		10039754	Jun 10, 2030	U-3167		
		10039754*PED	Dec 10, 2030			
		10286029	Mar 14, 2034	U-3167		
		10286029*PED	Sep 14, 2034			
		8648037	Jan 19, 2032	DS DP U-3167		
		8648037*PED	Jul 19, 2032			
		8937150	May 18, 2032	DS DP		
		8937150*PED	Nov 18, 2032			
		9321807	Jun 05, 2035	DS DP		
		9321807*PED	Dec 05, 2035			
		9586978	Jun 10, 2030	U-3167		
		9586978*PED	Dec 10, 2030			
<u>GLUCAGON - BAOSIMI</u>						
N 210134	001	10894133	Jan 03, 2038	DP		
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284	001				NPP	Dec 21, 2021
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437	001	10940110	Feb 26, 2029	DP U-1773		
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970	001	10968450	Jun 28, 2025	DS DP		
		10995337	Jun 28, 2025	DP U-2675		
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566	001	10857159	Nov 30, 2036	DP		
		10857159*PED	May 30, 2037			
		11020407	Nov 30, 2036	DP U-3143		
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876	001	9649280	May 12, 2034	DP U-3075		
		9675559	Jan 10, 2033	U-3075		
		9717740	Nov 19, 2032	U-3075		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	10174074	Jan 19, 2035	DS DP		NCE	Jun 01, 2026
	10370406	Jan 19, 2035	U-3159		GAIN	Jun 01, 2031
	10927142	Jan 19, 2035	DS			
	8188085	Aug 28, 2030	DS DP U-3159			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10961251	Jun 03, 2033	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	>A> 11103477	Apr 29, 2030	U-3209			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	>A> 11103477	Apr 29, 2030	U-3209			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 001	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		ODE-353	May 28, 2028
	9067896	Aug 06, 2028	DS			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		ODE-353	May 28, 2028
	9067896	Aug 06, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	8552002	Aug 25, 2029	DS DP		ODE-353	May 28, 2028
	9067896	Aug 06, 2028	DS			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10980795	Jun 12, 2033		U-1848		
	10993914	Oct 15, 2036		DP		
>A>	8329213	Jan 06, 2027	DS DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001	10688291	Dec 20, 2034	DP U-1397		M-268	Jun 24, 2024
	8226971	May 06, 2025	DP			
	8389583	Aug 09, 2029		U-1397		
	8703828	May 23, 2028	DP			
	9011897	Feb 08, 2025	DP			
	9629368	May 23, 2028		U-1397		
	9844654	Apr 24, 2036	DP U-1397			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033		U-2399	ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033		U-2572		
	10058546	Jul 15, 2033		U-3022		
	10058546	Jul 15, 2033		U-3023		
	10081621	Mar 25, 2031	DP	U-2420		
	10081621	Mar 25, 2031	DP	U-2571		
	10081621	Mar 25, 2031	DP	U-3024		
	10081621	Mar 25, 2031	DP	U-3025		
	10206877	Apr 14, 2035	DP	U-2498		
	10206877	Apr 14, 2035	DP	U-2570		
	10206877	Apr 14, 2035	DP	U-3026		
	10206877	Apr 14, 2035	DP	U-3027		
	8354427	Jul 06, 2026		U-3021		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033		U-2399	ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033		U-2572		
	10058546	Jul 15, 2033		U-3022		
	10058546	Jul 15, 2033		U-3023		
	10081621	Mar 25, 2031	DP	U-2420		
	10081621	Mar 25, 2031	DP	U-2571		
	10081621	Mar 25, 2031	DP	U-3024		
	10081621	Mar 25, 2031	DP	U-3025		
	10206877	Apr 14, 2035	DP	U-2498		
	10206877	Apr 14, 2035	DP	U-2570		
	10206877	Apr 14, 2035	DP	U-3026		
	10206877	Apr 14, 2035	DP	U-3027		
	8354427	Jul 06, 2026		U-3021		
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11052075	Dec 04, 2028	DP U-3181			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11052075	Dec 04, 2028	DP U-3181			
<u>IVERMECTIN - IVERMECTIN</u>						
A 210720 001					PC	May 29, 2021
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	11033565	Apr 22, 2024	DP			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	>A> 10717764	Jan 18, 2033	U-3215			
	>A> 10980788	Jun 07, 2039	U-3112			
	>A> 10980788	Jun 07, 2039	U-3113			
	>A> 10980788	Jun 07, 2039	U-3214			
	>A> 9474779	Aug 19, 2033	DS DP U-2350			
	>A> 9474779	Aug 19, 2033	DS DP U-2533			
	>A> 9474779	Aug 19, 2033	DS DP U-2534			
	>A> 9474779	Aug 19, 2033	DS DP U-3213			
	>A> 9850277	Jan 18, 2033	DS DP U-2350			
	>A> 9850277	Jan 18, 2033	DS DP U-2533			
	>A> 9850277	Jan 18, 2033	DS DP U-2534			
	>A> 9850277	Jan 18, 2033	DS DP U-3213			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11077055	Apr 21, 2036	DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002					ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 24, 2025	DS DP		>A> I-868 >A> M-269	Aug 10, 2024 Jul 21, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 24, 2025	DS DP		>A> I-868 >A> M-269	Aug 10, 2024 Jul 21, 2024
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	10646572	Jan 16, 2027	DP		NP	May 25, 2024
	9572857	Jan 16, 2027	DP			
	9744207	Jan 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	>A> 11090186	Oct 24, 2033		U-2348		
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	10987244	Apr 01, 2031	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	>A> 11096913	Feb 28, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	>A> 11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	>A> 11096913	Feb 28, 2037	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	11058677	Dec 18, 2033	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11033552	May 04, 2027	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10973827	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	>A> 11097063	Jul 17, 2026	DP		NPP	Dec 04, 2023
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP	U-727		
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023		U-1034		
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023		U-727		
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP	U-727		
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023		U-727		
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP	U-842		
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023		U-842		
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP	U-842		
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023		U-727		
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP	U-842		
	7718619*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023		U-727		
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP	U-727		
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023		U-727		
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023		U-727		
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP	U-727		
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023		U-727		
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP	U-727		
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023		U-727		
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP	U-727		
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP	U-727		
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023		U-727		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10940177	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 001 >A>	8999393	Jan 08, 2034	DP U-3210			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 002 >A>	8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826 003 >A>	8999393	Jan 08, 2034	DP U-3210			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<u>LOTEPREDNOL ETABONATE - LOTE PREDNOL ETABONATE</u>						
A 212450 001					CGT	Nov 02, 2021
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001	11060093	Dec 26, 2034	DS DP U-2995		ODE-339	Nov 23, 2027
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10960009	Dec 03, 2034	U-814			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	10946015	Sep 11, 2026	DP U-1445			
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED)</u>						
N 213135 001	11033498	Aug 04, 2037	U-3164			
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
	10322182	Apr 25, 2032	DP		ODE-348	Feb 26, 2028
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	6992207	Jun 25, 2022	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10940128	Jun 14, 2030	DP U-3086			
	11020363	May 28, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	11007206	Aug 08, 2031	U-3128		NCE	Aug 29, 2022
	8680136	Aug 29, 2031	DS DP		GAIN	Aug 29, 2027
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					ODE*	Apr 08, 2023
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032		U-2357		
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004					M-82	Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005					M-82	Jun 28, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038	006				M-82	Jun 28, 2024
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388	001	11020361	Dec 22, 2029	U-2843		
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844	001	10966990	Jun 20, 2038	DP		
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844	002	10966990	Jun 20, 2038	DP		
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623	001	10874655	May 30, 2038	U-2371		
		10874656	May 30, 2038	U-2371		
		10874657	May 30, 2038	U-2371		
		10925866	Apr 28, 2028	U-2371		
		11033538	Apr 28, 2028	U-2371		
		RE48608	Feb 12, 2029	U-2371		
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269	001	11103517	Apr 07, 2036	DP		
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269	002	11103517	Apr 07, 2036	DP		
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690	001	10946101	Oct 01, 2030	U-1631		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	001	10842780	Sep 28, 2029	DP U-2996	I-777	Apr 27, 2021
		10842780*PED	Mar 28, 2030		I-855	Mar 25, 2024
		6346532	Mar 27, 2022	DS DP	PED	Sep 25, 2024
		6346532*PED	Sep 27, 2022			
		8772315	Oct 30, 2028	U-2300		
		8772315*PED	Apr 30, 2029			
		8835474	Nov 04, 2023	U-1527		
		8835474*PED	May 04, 2024			
		RE44872	Nov 04, 2023	U-1527		
		RE44872*PED	May 04, 2024			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611	002	10842780	Sep 28, 2029	DP U-2996	I-777	Apr 27, 2021
		10842780*PED	Mar 28, 2030		I-855	Mar 25, 2024
		6346532	Mar 27, 2022	DS DP	PED	Sep 25, 2024
		6346532*PED	Sep 27, 2022			
		8772315	Oct 30, 2028	U-2300		
		8772315*PED	Apr 30, 2029			
		8835474	Nov 04, 2023	U-1527		
		8835474*PED	May 04, 2024			
		RE44872	Nov 04, 2023	U-1527		
		RE44872*PED	May 04, 2024			
<u>MIRABEGRON - MYRBETRIO GRANULES</u>						
N 213801	001	10058536	Mar 31, 2036	DP U-3108	NP	Mar 25, 2024
		10058536*PED	Oct 01, 2036		PED	Sep 25, 2024
		6346532	Mar 27, 2022	DS		
		6346532*PED	Sep 27, 2022			
		7342117	Nov 04, 2023	DS		
		7342117*PED	May 04, 2024			
		7982049	Nov 04, 2023	DP		
		7982049*PED	May 04, 2024			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOBOCERTINIB SUCCINATE - EXKIVITY</u>						
N 215310 001	>A> 10227342	May 13, 2035	DS DP U-3220		>A> NCE	Sep 15, 2026
	>A> 9796712	May 13, 2035	DS DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 002					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 002					NPP	Jun 02, 2024
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	10952968	May 13, 2033	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	10722510	Aug 26, 2034	DP U-3110			
	10973814	Aug 26, 2034	DP U-3110			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
	11090280	Mar 03, 2026	DP U-3195			
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 001					>A> PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 002					>A> PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 003					>A> PC	Dec 17, 2021
<u>NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE</u>						
A 203659 004					>A> PC	Dec 17, 2021
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043			
	10035788	Oct 15, 2028	U-3047			
	10035788	Oct 15, 2028	U-3097			
	7982043	Oct 08, 2025	U-2043			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10961195	Sep 25, 2035	DS DP			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					ODE-319	Aug 06, 2027
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	11091459	Mar 27, 2038	DP			
	8071623	Mar 27, 2031	DS DP			
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820 001					CGT	Jun 05, 2021
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
>A>	11103669	Jun 21, 2030	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11052126	Feb 03, 2036	U-2857			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		>A> ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		>A> ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		>A> ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		>A> ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	7132416	Sep 05, 2022	DS DP			
	9694018	Nov 08, 2031	U-3186			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	8420592	Aug 29, 2029	U-3101		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		GAIN	Aug 06, 2024
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEO</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
>A>	11103482	Dec 16, 2039	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	11065250	May 24, 2036	DP			
	RE47739	Mar 05, 2027	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005					>A> NS	Aug 30, 2024
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006					>A> NS	Aug 30, 2024
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 001					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 002					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 003					ODE*	Oct 18, 2023
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A 215003 001					>A> CGT	Mar 12, 2022
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	>A> 11123363	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	>A> 11123363	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	>A> 11123363	Oct 08, 2033	U-1766			
<u>PATISIRAN SODIUM - ONPATTRO</u>						
N 210922 001	10240152	Oct 20, 2029	DS DP U-2378			
	11079379	Aug 27, 2035	DS DP U-2378			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		ODE-351	May 14, 2028
	10875893	Nov 15, 2033	DS	U-3124		
	11040107	Apr 09, 2038	DP	U-3172		
	11040107	Apr 09, 2038	DP	U-3173		
	11040107	Apr 09, 2038	DP	U-3174		
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS	U-3123		
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027		U-2622		
	10391075	Feb 12, 2027		U-3069		
	8778997	May 07, 2027		U-1627		
	8778997	May 07, 2027		U-2622		
	8778997	May 07, 2027		U-3069		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2022	DS DP	U-106		
	6949571	Jun 08, 2022	DS DP	U-2088		
	6949571	Jun 08, 2022	DS DP	U-2089		
	6949571	Jun 08, 2022	DS DP	U-2428		
	6949571	Jun 08, 2022	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2022	DS DP	U-106		
	6949571	Jun 08, 2022	DS DP	U-2088		
	6949571	Jun 08, 2022	DS DP	U-2089		
	6949571	Jun 08, 2022	DS DP	U-2428		
	6949571	Jun 08, 2022	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2022	DS DP	U-106		
	6949571	Jun 08, 2022	DS DP	U-2088		
	6949571	Jun 08, 2022	DS DP	U-2089		
	6949571	Jun 08, 2022	DS DP	U-2428		
	6949571	Jun 08, 2022	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2022	DS DP	U-106		
	6949571	Jun 08, 2022	DS DP	U-2088		
	6949571	Jun 08, 2022	DS DP	U-2089		
	6949571	Jun 08, 2022	DS DP	U-2428		
	6949571	Jun 08, 2022	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2022	DS DP	U-106		
	6949571	Jun 08, 2022	DS DP	U-2088		
	6949571	Jun 08, 2022	DS DP	U-2089		
	6949571	Jun 08, 2022	DS DP	U-2428		
	6949571	Jun 08, 2022	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2022	DS DP	U-106		
	6949571	Jun 08, 2022	DS DP	U-2088		
	6949571	Jun 08, 2022	DS DP	U-2089		
	6949571	Jun 08, 2022	DS DP	U-2428		
	6949571	Jun 08, 2022	DS DP	U-2429		
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2022	DS DP	U-106		
	6949571	Jun 08, 2022	DS DP	U-2088		
	6949571	Jun 08, 2022	DS DP	U-2089		
	6949571	Jun 08, 2022	DS DP	U-2428		
	6949571	Jun 08, 2022	DS DP	U-2429		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					ODE-331	Oct 13, 2027
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					ODE-331	Oct 13, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					M-14 PED	Nov 20, 2023 May 20, 2024
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 001	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP ODE-355	May 31, 2024 Jun 17, 2028
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698		NPP	May 31, 2024
	9023790	Jul 04, 2031	DP U-3160		ODE-355	Jun 17, 2028
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					NP	May 31, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					ODE-340 ODE-341	Dec 01, 2027 Dec 01, 2027
<u>PYRIMETHAMINE - PYRIMETHAMINE</u>						
A 211271 001					>A> CGT	Apr 02, 2022
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	11007208	Sep 16, 2036	U-2984			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11007208	Sep 16, 2036	U-2984			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Oct 06, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11008289	Jul 14, 2030	U-2440			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			
	10456384	Feb 26, 2029	U-2643			
	10456384	Feb 26, 2029	U-2644			
	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
	10709694	Jul 24, 2029	U-2579			
	10765667	Feb 26, 2029	U-2643			
	10765667	Feb 26, 2029	U-2644			
	7045620	Jun 19, 2024	DS			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8829017	Jul 24, 2029	U-1562			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
	9271968	Feb 27, 2026	DP			
	9421195	Jul 24, 2029	U-1481			
	9629828	Jul 24, 2029	U-1994			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3068			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	11083724	Mar 25, 2039	DP U-2718		I-865	May 27, 2024
	11083724	Mar 25, 2039	DP U-3142			
	8314117	Feb 22, 2031	DS DP U-2718			
	8314117	Feb 22, 2031	DS DP U-3142			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	10966966	Aug 12, 2040	U-3153			
	>A> RE48731	Jun 07, 2032	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					ODE-334	Aug 07, 2027
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001					>A> I-867	Aug 23, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002					>A> I-867	Aug 23, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003					>A> I-867	Aug 23, 2024
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004	>A> 10828310	Jan 31, 2039	U-3207		>A> I-867	Aug 23, 2024
	>A> 10828310	Jan 31, 2039	U-3208			
	>A> 9415053	Nov 13, 2024	DP U-2435			
	>A> 9415053	Nov 13, 2024	DP U-3205			
	>A> 9415053	Nov 13, 2024	DP U-3206			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 001					PC	Nov 28, 2021
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 002					PC	Nov 28, 2021
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8101659*PED	Jul 14, 2023				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8101659*PED	Jul 14, 2023				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	>A> 8101659	Jan 15, 2025	DP			
	>A> 8101659*PED	Jul 14, 2023				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8283380	Mar 21, 2031	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8283380	Mar 21, 2031	U-1993			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10849884	Sep 04, 2035	DP U-2583		I-866	Jun 30, 2024
	10849884	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002					NCE	Apr 30, 2024
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003					NCE	Apr 30, 2024
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	7205302	Apr 04, 2023	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001 >A>	11097063	Jul 17, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002 >A>	11097063	Jul 17, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					ODE-336	Nov 25, 2027
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 003	>A> 7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	>A> 8492441	Nov 30, 2030	U-2511			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 214805 001					CGT	Jan 03, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001					ODE*	Aug 28, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	002				ODE*	Apr 07, 2024
					ODE*	Aug 28, 2026
					PED	Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	001	10086011	Jan 30, 2034	U-1470	D-177	Nov 15, 2022
		10086011*PED	Jul 30, 2034		M-264	Jul 14, 2023
	>A>	11116783	Jan 30, 2034	DP U-1470	NPP	Mar 19, 2023
		8575135	Nov 16, 2032	DS DP U-1470	PED	May 15, 2023
		8575135*PED	May 16, 2033		PED	Sep 19, 2023
		8735372	Mar 21, 2028	U-1470	PED	Jan 14, 2024
		8735372*PED	Sep 21, 2028			
		8921341	Nov 16, 2032	DS DP U-1470		
		8921341*PED	May 16, 2033			
		8940718	Nov 16, 2032	DS DP U-1470		
		8940718*PED	May 16, 2033			
		9757406	Jan 30, 2034	DP		
		9757406*PED	Jul 30, 2034			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341	002	10086011	Jan 30, 2034	U-1470	M-264	Jul 14, 2023
		10086011*PED	Jul 30, 2034		NS	Mar 19, 2023
	>A>	11116783	Jan 30, 2034	DP U-1470	PED	Sep 19, 2023
		7964580	Mar 26, 2029	DS DP U-1470	PED	Jan 14, 2024
		7964580*PED	Sep 26, 2029			
		8334270	Mar 21, 2028	DS DP U-1470		
		8334270*PED	Sep 21, 2028			
		8575135	Nov 16, 2032	DS DP U-1470		
		8575135*PED	May 16, 2033			
		8580765	Mar 21, 2028	DS DP U-1470		
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8735372	Mar 21, 2028	U-1470		
		8735372*PED	Sep 21, 2028			
		8889159	Mar 26, 2029	DP U-1470		
		8889159*PED	Sep 26, 2029			
		8921341	Nov 16, 2032	DS DP U-1470		
		8921341*PED	May 16, 2033			
		8940718	Nov 16, 2032	DS DP U-1470		
		8940718*PED	May 16, 2033			
		9085573	Mar 21, 2028	DS DP U-1470		
		9085573*PED	Sep 21, 2028			
		9284342	Sep 13, 2030	DS DP U-1470		
		9284342*PED	Mar 13, 2031			
		9757406	Jan 30, 2034	DP		
		9757406*PED	Jul 30, 2034			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187	001	>A> 11116783	Jan 30, 2034	DP U-1470		
		7964580	Mar 26, 2029	DS DP U-1470		
		7964580*PED	Sep 26, 2029			
		8334270	Mar 21, 2028	DS DP U-1470		
		8334270*PED	Sep 21, 2028			
		8575135	Nov 16, 2032	DS DP U-1470		
		8575135*PED	May 16, 2033			
		8580765	Mar 21, 2028	DS DP U-1470		
		8580765*PED	Sep 21, 2028			
		8618076	Dec 11, 2030	DS DP U-1470		
		8618076*PED	Jun 11, 2031			
		8633309	Mar 26, 2029	DS DP U-1470		
		8633309*PED	Sep 26, 2029			
		8735372	Mar 21, 2028	U-1470		
		8735372*PED	Sep 21, 2028			
		8889159	Mar 26, 2029	DP U-1470		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002 >A>	11116783	Jan 30, 2034	DP U-1470			
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	>A> 11116783	Jan 30, 2034	DP U-2039			
	>A> 11116783	Jan 30, 2034	DP U-2040			
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001	9918970	May 18, 2031	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10799138	Apr 05, 2039	U-3125			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	11013703	Apr 01, 2034	DP			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001					NCE ODE-352	May 28, 2026 May 28, 2028
<u>SPINOSAD - NATROBA</u>						
N 022408 001					I-858	Apr 28, 2024
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP	Jun 25, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP	Jun 25, 2024
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708 002					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708 003					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050709 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003					ODE*	May 24, 2025
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	>A> 11110081	May 30, 2028	U-2678			
	>A> 11123331	May 30, 2028	U-2677			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	>A> 11110081	May 30, 2028	U-2678			
	>A> 11123331	May 30, 2028	U-2677			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	>A> 11110081	May 30, 2028	U-2678			
	>A> 11123331	May 30, 2028	U-2677			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>						
N 210115 001					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 210115 002					ODE-360	Jul 16, 2028
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u>TAFIUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	11007156	Oct 22, 2022	DP U-1178			
	11007156	Oct 22, 2022	DP U-1276			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007		ODE-330	Dec 01, 2027
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	10980770	Jan 25, 2033	U-3106		NP	Dec 01, 2023
					ODE-329	Dec 01, 2027
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					PC	Apr 17, 2021
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10786511	Dec 19, 2035	DP			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-3179			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					NPP	May 19, 2024
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028	U-3077			
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028	U-3078			
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Sep 12, 2026	U-1285		M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001 >A>	11090312	Mar 17, 2034	U-1616			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP	U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP	U-2418		
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP	U-2418		
<u>THEOPHYLLINE - THEOPHYLLINE</u>						
A 212184 002					CGT	Dec 08, 2021
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					I-851	May 28, 2023
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP	U-3015		
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	10905694	Apr 07, 2030	DP			
<u>TORSEMIDE - SOANZ</u>						
N 213218 001	10154963	Oct 06, 2033	DP			
<u>TORSEMIDE - SOANZ</u>						
N 213218 002	10154963	Oct 06, 2033	DP			
<u>TRAMADOL HYDROCHLORIDE - ODOLO</u>						
N 214044 001	>A> 11103452	Sep 01, 2040	DP U-3197			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033			U-3184	
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033			U-3184	
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	10869869	Aug 30, 2033			U-3184	
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024			U-2845	
	7999007	Mar 29, 2029	DP		U-1437	
	8653137	Sep 05, 2028			U-1437	
	8658694	Sep 05, 2028			U-1437	
	9199908	May 24, 2024			U-1771	
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024			U-2036	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					I-856	Mar 31, 2024
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	9498465	May 30, 2033	DP U-1033			
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	10966984	Mar 14, 2034	U-3079			
	10966984	Mar 14, 2034	U-3080			
	11040042	Mar 14, 2034	DP			
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064		ODE-343	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3063		ODE-344	Feb 05, 2028
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			
	10947244	May 26, 2035	U-3064			
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			
	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001 >A>	11090294	Nov 29, 2030	U-3203			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995		NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027	U-1995			
<u>VALSARTAN - DIOVAN</u>						
N 021283 001					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 002					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 004					NPP	Apr 19, 2024
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	>A> 10039804	Nov 06, 2035	DP U-282			
	>A> 10188697	Nov 06, 2035	DP U-282			
	>A> 10849956	Nov 06, 2035	DP			
	>A> 11000567	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10993942	Sep 06, 2033	U-3114			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10993942	Sep 06, 2033	U-3114			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9790183	Sep 02, 2025	U-3109			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP U-3056			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					M-187	Jan 22, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					M-187	Jan 22, 2024
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	DS DP U-2145			
	10927117	Aug 15, 2037	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41ST Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm